ras oncogenes in human cancer: a review

Cancer Research
49, 4682-9

Citation Report

#	Article	IF	Citations
1	Diabetes induced in male transgenic mice by expression of human H-ras oncoprotein in pancreatic beta cells.. Molecular and Cellular Biology, 1990, 10, 1779-1783.	1.1	51
2	Eine neue Dimension in der Proteinkristallographie. Nachrichten Aus Der Chemie, 1990, 38, 842-850.	0.0	4
3	Frequent mutation of the p53 gene in human esophageal cancer.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 9958-9961.	3.3	344
4	Molecules, Cancer, and the Surgeon. Annals of Surgery, 1990, 212, 3-13.	2.1	10
5	Detection of mRNAs of Carcinoembryonic Antigen and Nonspecific Cross-reacting Antigen Genes in Colorectal Adenomas and Carcinomas byin situHybridization. Japanese Journal of Cancer Research, 1990, 81, 1149-1154.	1.7	12
6	Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. British Journal of Cancer, 1990, 62, 398-404.	2.9	51
7	Ha-ras gene codon 12 mutation and DNA ploidy in urinary bladder carcinoma. British Journal of Cancer, 1990, 62, 762-763.	2.9	56
8	V-K-ras transformation induces reversion to an earlier developmental form in adult rat adrenal cells. Differentiation, 1990, 43, 29-36.	1.0	10
9	MOLECULAR MECHANISMS OF ULTRAVIOLET RADIATION CARCINOGENESIS. Photochemistry and Photobiology, 1990, 52, 1119-1136.	1.3	353
10	Sequence specificity in the reaction of benzopyrene diol epoxide with DNA. Chemico-Biological Interactions, 1990, 75, 131-140.	1.7	6
11	Mutational activation of the c-K-ras gene in human pancreatic carcinoma. Bailliere's Clinical Gastroenterology, 1990, 4, 151-169.	0.9	49
12	DNA alkylation damage: consequences and relevance to tumour production. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1990, 233, 247-252.	0.4	18
13	The invasive phenotypes. Cancer and Metastasis Reviews, 1990, 9, 45-62.	2.7	94
14	The current state of oncogenes and cancer: Experimental approaches for analyzing oncogenetic events in human cancer. Cancer and Metastasis Reviews, 1990, 9, 63-80.	2.7	19
15	Detection of preferentialNRAS mutations in human male germ cell tumors by the polymerase chain reaction. Genes Chromosomes and Cancer, 1990, 1, 228-232.	1.5	41
16	Mutational analysis of humanNRAS genes in malignant melanoma: Rapid methods for oligonucleotide hybridization and manual and automated direct sequencing of products generated by the polymerase chain reaction. Genes Chromosomes and Cancer, 1990, 1, 257-269.	1.5	24
17	RAS gene mutations in childhood acute myeloid leukemia: A pediatric oncology group study. Genes Chromosomes and Cancer, 1990, 2, 159-162.	1.5	43
18	Histologic variation among experimental tumors of common origin: Relationships to viral p21 expression and to tumor-derived extracellular matrix. International Journal of Cancer, 1990, 46, 618-625.	2.3	1

#	Article	IF	Citations
19	Pancreatic ductal adenocarcinomas induced in syrian hamsters byN-nitrosobis (2-oxopropyl) amine contain a c-Ki-ras oncogene with a point-mutated codon 12. Molecular Carcinogenesis, 1990, 3, 296-301.	1.3	93
20	Production and Characterization of Anti-RASp21 Monoclonal Antibodies. Hybridoma, 1990, 9, 573-587.	0.9	17
21	Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science, 1990, 249, 796-798.	6.0	231
22	Activation of ras oncogenes preceding the onset of neoplasia. Science, 1990, 248, 1101-1104.	6.0	275
23	Identification of a nucleotide exchange-promoting activity for p21ras.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 5998-6002.	3.3	152
24	K-rasOncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung. New England Journal of Medicine, 1990, 323, 561-565.	13.9	769
25	Yes, But Is It a Human Carcinogen?. Journal of the American College of Toxicology, 1990, 9, 1-18.	0.2	7
26	Two G protein oncogenes in human endocrine tumors. Science, 1990, 249, 655-659.	6.0	1,039
27	Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. Cancer Letters, 1990, 51, 169-174.	3.2	16
28	The ras superfamily of small GTP-binding proteins. Trends in Biochemical Sciences, 1990, 15, 469-472.	3.7	165
29	Cancer genes: current status, future prospects, and applications in radiotherapy/oncology. Radiotherapy and Oncology, 1990, 19, 197-218.	0.3	22
30	Oncogenes, antioncogenes, and the regulation of cell growth. Trends in Endocrinology and Metabolism, 1990, 1, 248-253.	3.1	9
31	The significance of histology in non-small cell lung cancer. Cancer Treatment Reviews, 1990, 17, 409-425.	3.4	22
32	REGULATING ras. Lancet, The, 1990, 336, 1291-1292.	6.3	3
33	Molecular genetics of human multiple myeloma. Clinical Immunology Newsletter, 1990, 10, 79-84.	0.1	0
34	Three-dimensional structures of H-ras p21 mutants: Molecular basis for their inability to function as signal switch molecules. Cell, 1990, 62, 539-548.	13.5	394
35	TGFÎ± overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell, 1990, 61, 1137-1146.	13.5	721
36	The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell, 1990, 63, 843-849.	13.5	949

#	Article	IF	Citations
37	Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell, 1990, 62, 81-88.	13.5	827
38	Molecular genetics of human bladder carcinomas. Cancer Genetics and Cytogenetics, 1990, 49, 143-156.	1.0	39
39	NEW TARGETS FOR CANCER CHEMOTHERAPY â€“ POLY(ADPRIBOSYLATION) PROCESSING AND POLYISOPRENE METABOLISM. Biological Reviews, 1990, 65, 623-641.	4.7	24
40	Enhanced immunoreactivity of ras oncogene p21 protein in urinary bladder epithelium of rats treated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. Cancer Letters, 1991, 59, 95-102.	3.2	5
41	Increased c-Ki-ras expression in hamster lung exposed to N-nitrosodiethylamine and hyperoxia as detected by the polymerase chain reaction. Cancer Letters, 1991, 59, 75-80.	3.2	9
42	K-ras activation in gastric epithelial tumors in Japanese. Cancer Letters, 1991, 58, 107-113.	3.2	43
43	Inhibition of ras-induced germinal vesicle breakdown in Xenopus oocytes by rap-1B. Biochemical and Biophysical Research Communications, 1991, 174, 1-5.	1.0	50
44	Recent advances in the polymerase chain reaction. Science, 1991, 252, 1643-1651.	6.0	1,021
45	The discs-large tumor suppressor gene of Drosophila encodes a guanylate kinase homolog localized at septate junctions. Cell, 1991, 66, 451-464.	13.5	871
46	Leukemia and the disruption of normal hematopoiesis. Cell, 1991, 64, 337-350.	13.5	353
47	Protooncogenes in Endometriotic and Endometrial Tissue. Annals of the New York Academy of Sciences, 1991, 626, 276-283.	1.8	27
48	Evolutionary Genetics of Fish. Advances in Genetics, 1991, 29, 119-228.	0.8	27
49	Correlation of Blood Group Antigen Expression and Oncogene-related Proteins in Malignant Prostatic Tissues. Pathology Research and Practice, 1991, 187, 189-197.	1.0	14
50	Single-base mutational analysis of cancer and genetic diseases using membrane bound modified oligonucleotides. Nucleic Acids Research, 1991, 19, 3929-3933.	6.5	130
51	Three-dimensional structure of p21 in the active conformation and analysis of an oncogenic mutant.. Environmental Health Perspectives, 1991, 93, 11-15.	2.8	25
52	Genetic studies on lung tumor susceptibility and histogenesis in mice.. Environmental Health Perspectives, 1991, 93, 149-159.	2.8	58
53	Genetic Analysis of Germ Cell Tumors: Current Progress and Future Prospects. Hematology/Oncology Clinics of North America, 1991, 5, 1271-1283.	0.9	18
54	Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.. Environmental Health Perspectives, 1991, 93, 125-131.	2.8	185

#	Article	IF	Citations
55	GTP-binding proteins as oncogenes in human tumors.. Environmental Health Perspectives, 1991, 93, 17-18.	2.8	3
56	ras activation in human tumors and in animal model systems.. Environmental Health Perspectives, 1991, 93, 19-25.	2.8	29
57	Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. British Journal of Cancer, 1991, 64, 1076-1082.	2.9	369
58	c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. British Journal of Cancer, 1991, 64, 174-178.	2.9	87
59	Lovastatin selectively inhibits ras activation of the 12-O-tetradecanoylphorbol-13-acetate response element in mammalian cells.. Molecular and Cellular Biology, 1991, 11, 2307-2310.	1.1	10
60	Advances in Molecular Biology: Potential Impact on Diagnosis and Treatment of Disorders of the Thyroid. Medical Clinics of North America, 1991, 75, 41-59.	1.1	4
61	Rapid, nonradioactive screening for activating ras oncogene mutations using PCR-primer introduced restriction analysis (PCR-PIRA). Genome Research, 1991, 1, 146-148.	2.4	36
62	Purification of a plasma membrane-associated GTPase-activating protein specific for rap1/Krev-1 from HL60 cells.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 239-243.	3.3	94
63	Dose-dependent differences in the profile of mutations induced by an ultimate carcinogen from benzo[a]pyrene.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 11227-11230.	3.3	88
64	Association of p21ras with phosphatidylinositol 3-kinase.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7908-7912.	3.3	145
65	Alteration of homeobox gene expression by N-ras transformation of PA-1 human teratocarcinoma cells.. Molecular and Cellular Biology, 1991, 11, 3573-3583.	1.1	24
66	The biochemistry of ras p21. Biochemical Journal, 1991, 279, 609-631.	1.7	181
67	Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology, 1991, 100, 233-238.	0.6	146
68	Analysis of Point Mutations at Codon 12 of K-ras in Human Endometrial Carcinoma and Cervical Adenocarcinoma by Dot Blot Hybridization and Polymerase Chain Reaction.. Tohoku Journal of Experimental Medicine, 1991, 165, 131-136.	0.5	14
69	Evaluation of the DNA-repair host-mediated assay. III. Relationship between metabolic activation of dimethylnitrosamine and organ-specific differential lethality induced in E. coli indicator strains. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1991, 247, 87-96.	0.4	4
70	N-ras gene mutations in childhood acute non-lymphoblastic leukemia. Leukemia Research, 1991, 15, 935-941.	0.4	3
71	How does p21ras transform cells?. Trends in Genetics, 1991, 7, 91-95.	2.9	72
72	Transgenic models for haemopoietic malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 1991, 1072, 9-31.	3.3	16

#	Article	IF	Citations
73	Diagnostic utility of oncogenes and their products in human cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 1991, 1072, 193-214.	3.3	12
74	Ras p21: effects and regulation. Biochimica Et Biophysica Acta: Reviews on Cancer, 1991, 1072, 215-229.	3.3	32
75	Hepatocyte proliferation in stepwise development of experimental liver cell cancer. Digestive Diseases and Sciences, 1991, 36, 973-978.	1.1	73
76	High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. British Journal of Cancer, 1991, 63, 573-578.	2.9	229
77	The detection of alkylation damage in the DNA of human gastrointestinal tissues. British Journal of Cancer, 1991, 64, 59-63.	2.9	66
78	Lack of evidence of Ki-ras codon 12 mutations in melanocytic lesions. Journal of Cutaneous Pathology, 1991, 18, 273-278.	0.7	15
79	Multiâ€Drug Resistance Genes in the Management of Neoplastic Disease. Journal of Veterinary Internal Medicine, 1991, 5, 239-247.	0.6	14
80	Recessive (mediator?) revertants from c-h-ras oncogene-transformed NIH 3T3 cells: Tumorigenicity in nude mice and transient anchorage and serum independence of the recovered tumor cells in culture. Journal of Cellular Physiology, 1991, 149, 214-221.	2.0	1
81	The analysis of restriction fragment length polymorphism in human cancer: A review from an epidemiological perspective. International Journal of Cancer, 1991, 47, 26-30.	2.3	13
82	c-erbB-2 andras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. International Journal of Cancer, 1991, 47, 833-838.	2.3	76
83	Ras mutations in united kingdom examples of oral malignancies are infrequent. International Journal of Cancer, 1991, 48, 409-412.	2.3	94
84	Differential activation ofras genes by point mutation in human colon cancer with metastases to either lung or liver. International Journal of Cancer, 1991, 49, 875-879.	2.3	101
85	Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes and Cancer, 1991, 3, 168-188.	1.5	86
86	Ras-related genes inDictyostelium discoideum. Genesis, 1991, 12, 147-153.	3.1	10
87	The molecular progression of plutonium-239â€“induced rat lung carcinogenesis: Ki-ras expression and activation. Molecular Carcinogenesis, 1991, 4, 43-51.	1.3	28
88	Expression ofras genes in rainbow trout liver. Molecular Carcinogenesis, 1991, 4, 97-102.	1.3	20
89	Structural analysis of the mouse c-HA-ras gene promoter. Molecular Carcinogenesis, 1991, 4, 103-111.	1.3	6
90	Analysis ofras gene mutations in rainbow trout liver tumors initiated by aflatoxin B1. Molecular Carcinogenesis, 1991, 4, 112-119.	1.3	43

#	Article	IF	Citations
91	Analysis of oncogene alterations in human endometrial carcinoma: Prevalence ofras mutations. Molecular Carcinogenesis, 1991, 4, 189-195.	1.3	53
92	Ras gene mutation and amplification in human nonmelanoma skin cancers. Molecular Carcinogenesis, 1991, 4, 196-202.	1.3	250
93	Analysis of N-ras gene mutations in medulloblastomas by polymerase chain reaction and oligonucleotide probes in formalin-fixed, paraffin-embedded tissues. Medical and Pediatric Oncology, 1991, 19, 240-245.	1.0	12
94	The effect of the insecticide heptachlor on ras proto-oncogene expression in human myeloblastic leukemia (ML-1) cells. Toxicology, 1991, 70, 283-292.	2.0	11
95	Molecular and cellular lesions associated with breast cancer progression. Breast Cancer Research and Treatment, 1991, 18, S51-S54.	1.1	3
96	Chromosome rearrangement, oncogene activation, and other clonal events in cancer: Their use in molecular diagnostics. Journal of Pathology, 1991, 163, 7-12.	2.1	3
97	Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour. Journal of Pathology, 1991, 165, 187-201.	2.1	76
98	Transgenic models of tumor development. Science, 1991, 254, 1161-1167.	6.0	302
99	Growth factors and cancer. Science, 1991, 254, 1146-1153.	6.0	1,278
100	The Radiosensitivity of Human Keratinocytes: Influence of ActivatedC-H-rasOncogene Expression and Tumorigenicity. International Journal of Radiation Biology, 1991, 59, 1195-1206.	1.0	25
101	The Biology of Breast Tumor Progression: Acquisition of hormone independence and resistance to cytotoxic drugs. Acta OncolÃ³gica, 1992, 31, 115-123.	0.8	31
102	PCR-based approaches for detection of mutated ras genes.. Genome Research, 1992, 1, 211-216.	2.4	39
103	X-ray crystal structures of transforming p21 ras mutants suggest a transition-state stabilization mechanism for GTP hydrolysis.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3649-3653.	3.3	132
104	Recent Results on the Biology of Hodgkin and Reed-Sternberg Cells. I. Biopsy Material. Leukemia and Lymphoma, 1992, 8, 283-313.	0.6	130
105	A novel blocker-PCR method for detection of rare mutant alleles in the presence of an excess amount of normal DNA. Nucleic Acids Research, 1992, 20, 2493-2496.	6.5	47
106	Oncogenes and Tumor Suppressor Genes: New Biochemical Tests. Critical Reviews in Clinical Laboratory Sciences, 1992, 29, 269-305.	2.7	16
107	Transformation and Radiosensitivity of Human Diploid Skin Fibroblasts Transfected with ActivatedRASOncogene and SV40 T-antigen. International Journal of Radiation Biology, 1992, 62, 201-210.	1.0	22
108	The Polymerase Chain Reaction: Its use in the Molecular Characterization and Diagnosis of Cancers. Cancer Investigation, 1992, 10, 417-429.	0.6	8

#	Article	IF	Citations
111	p53 Gene mutations in gastric and esophageal cancers. Gastroenterology, 1992, 103, 892-896.	0.6	69
112	Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology, 1992, 102, 230-236.	0.6	236
113	Cancer Immunotherapy: are the Results Discouraging? Can They be Improved?. Advances in Cancer Research, 1992, 59, 245-322.	1.9	67
114	Relationship Between myc Oncogene Activation and MHC Class I Expression. Advances in Cancer Research, 1992, 60, 181-246.	1.9	42
115	Regulation of collagen I gene expression by ras.. Molecular and Cellular Biology, 1992, 12, 4714-4723.	1.1	58
116	Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity.. Molecular and Cellular Biology, 1992, 12, 2050-2056.	1.1	282
117	N-ras Mutations in Acute Myelogenous Leukemia: A Review of the Current Literature and an update of the Southwest Oncology Group Experience. Leukemia and Lymphoma, 1992, 6, 325-334.	0.6	13
118	The Neurofibromatosis Type 1 (NF1) Gene: Identification and Partial Characterization of a Putative Tumor Suppressor Gene. Journal of Dermatology, 1992, 19, 881-884.	0.6	14
119	Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 5804-5808.	3.3	92
120	An interaction between p21ras and heat shock protein hsp60, a chaperonin.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 2012-2016.	3.3	64
121	Androgen receptor gene mutations in human prostate cancer.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6319-6323.	3.3	367
122	Isolation of rsp-1, a novel cDNA capable of suppressing v-Ras transformation.. Molecular and Cellular Biology, 1992, 12, 3750-3756.	1.1	82
123	Expression of ras proto-oncogene related protein p21 in normal human skin and cutaneous tumours. Acta Histochemica, 1992, 93, 282-289.	0.9	7
124	Mutations of the Ki-ras oncogene in endometrial carcinoma. American Journal of Obstetrics and Gynecology, 1992, 167, 227-232.	0.7	72
125	Detection of single DNA base mutations with mismatch repair enzymes. Genomics, 1992, 14, 249-255.	1.3	44
126	Detection of Point Mutations in p21ras Genes. Annals of Medicine, 1992, 24, 207-209.	1.5	3
127	Carcinogens leave fingerprints. Nature, 1992, 355, 209-210.	13.7	149
128	A novel compound, depudecin, induces production of transformation to the flat phenotype of NIH3T3 cells transformed by ras-oncogene. Biochemical and Biophysical Research Communications, 1992, 182, 379-387.	1.0	24

#	Article	IF	Citations
129	A point mutation of C-KI-RAS gene was found in human esophageal carcinoma cell lines but not in primary esophageal carcinomas. Biochemical and Biophysical Research Communications, 1992, 187, 515-521.	1.0	11
130	Metal carcinogenesis: Mechanistic implications. , 1992, 53, 31-65.		321
131	Mutations in the ras protooncogenes are rare events in renal cell cancer. European Journal of Cancer, 1992, 28, 333-336.	1.3	26
132	Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. Journal of Hepatology, 1992, 14, 342-346.	1.8	65
133	Stability of K-ras mutations throughout the natural history of human colorectal cancer. European Journal of Cancer, 1992, 28, 1115-1120.	1.3	99
134	Oncogene-transformed granulosa cells as a model system for the study of steroidogenic processes. Journal of Steroid Biochemistry and Molecular Biology, 1992, 43, 875-884.	1.2	16
135	Immunohistochemical Analysis of Ras oncogene p21 Product in Human Gastric Carcinomas and their Adjacent Mucosas. Pathology Research and Practice, 1992, 188, 263-272.	1.0	9
136	T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Human Immunology, 1992, 33, 266-274.	1.2	63
137	Chromosome 11p15 deletions in human malignant astrocytomas and primitive neuroectodermal tumors. Genomics, 1992, 14, 799-801.	1.3	49
138	What are cancer genes, and how do they upset cell behaviour?. European Journal of Cancer, 1992, 28, 251-255.	1.3	2
139	Analysis of expressed N-ras mutations in human melanoma short-term cell lines with allele specific restriction analysis induced by the polymerase chain reaction. European Journal of Cancer, 1992, 28, 9-11.	1.3	25
140	The antiporter in oncology in the light of the Spontaneous Regression of cancer and cell metabolism. Medical Hypotheses, 1992, 39, 229-237.	0.8	24
141	Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Human Pathology, 1992, 23, 1199-1204.	1.1	94
142	Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell, 1992, 69, 275-281.	13.5	365
143	Molecular cloning of cDNAs encoding the GAP-associated protein p190: Implications for a signaling pathway from ras to the nucleus. Cell, 1992, 69, 539-549.	13.5	350
144	Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. European Journal of Cancer Part B, Oral Oncology, 1992, 28, 67-76.	0.9	141
145	The neurofibromatosis 1 gene transcripts expressed in peripheral nerve and neurofibromas bear the additional exon located in the GAP domain. Biochemical and Biophysical Research Communications, 1992, 188, 851-857.	1.0	14
146	Characterization of a Gly19 â†' Val mutant of ram p25, a low Mr GTP-binding protein: Loss of GTP/GDP-binding activity in the mutated ram p25. Biochemical and Biophysical Research Communications, 1992, 189, 330-335.	1.0	2

#	Article	IF	Citations
147	Smoking and cancer. American Journal of Medicine, 1992, 93, S13-S17.	0.6	98
148	Studies of chlorambucilâ€"DNA adducts. Biochemical Pharmacology, 1992, 44, 571-575.	2.0	18
149	Ultraviolet mutagenesis in human lymphocytes: The effect of cellular transformation. Experimental Cell Research, 1992, 201, 462-469.	1.2	19
150	Diagnostic and prognostic molecular markersin cancer. American Journal of Surgery, 1992, 164, 299-306.	0.9	18
151	Detection of ras gene mutations in human lung cancer: comparison of two screening assays based on the polymerase chain reaction.. Environmental Health Perspectives, 1992, 98, 183-185.	2.8	14
152	Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research.. Environmental Health Perspectives, 1992, 98, 167-178.	2.8	82
153	Multiple genetic alterations in human carcinogenesis.. Environmental Health Perspectives, 1992, 98, 5-12.	2.8	81
154	Molecular Genetic Aspects of Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 1992, 6, 557-570.	0.9	43
155	Molecular Biology of Bladder Cancer. Hematology/Oncology Clinics of North America, 1992, 6, 31-39.	0.9	17
156	Ras oncogene point mutations in bladder cancer resistant to cisplatin. Urological Research, 1992, 20, 313-316.	1.5	6
157	InfrequentRAS oncogene mutations in human prostate cancer. Prostate, 1992, 20, 327-338.	1.2	94
158	The molecular biology of urological tumors. Prostate, 1992, 21, 159-169.	1.2	7
159	Genetics of transitional cell carcinoma. Journal of Surgical Oncology, 1992, 8, 260-266.	1.4	2
160	NF is enough of GAP. Nature, 1992, 356, 663-664.	13.7	61
161	rasMutations in Endocrine Tumors: Mutation Detection by Polymerase Chain Reaction-Single Strand Conformation Polymorphism. Japanese Journal of Cancer Research, 1992, 83, 1057-1062.	1.7	70
162	Point mutations in the Ha-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases. Journal of Oral Pathology and Medicine, 1992, 21, 225-229.	1.4	36
163	Hormonal aspects of breast cancer. Critical Reviews in Oncology/Hematology, 1992, 12, 1-23.	2.0	128
164	The biology of colorectal carcinoma. Current Problems in Cancer, 1992, 16, 265-328.	1.0	10

#	Article	IF	Citations
165	A search for activating N-ras mutations in malignant histiocytosis of the bernese mountain dog. Comparative Haematology International, 1992, 2, 103-105.	0.5	0
166	CritÃ¨res histologiques et immunohistochimiques de surveillance de lâ€™endobrachyÅ“sophage. Acta Endoscopica, 1992, 22, 531-540.	0.0	1
167	Analysis of ras oncogene mutations in human squamous cell carcinoma of the head and neck. Surgical Oncology, 1992, 1, 405-411.	0.8	9
168	The gene encoding hypoxanthine-guanine phosphoribosyltransferase as target for mutational analysis: PCR cloning and sequencing of the cDNA from the rat. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 266, 105-116.	0.4	45
169	Biochemical and biological activity of phosphorylated and non-phosphorylated ras p21 mutants. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1992, 1129, 278-286.	2.4	5
170	Sequential assignment of the backbone nuclei (1H,15N and13C) of c-H-ras p21 (1â€“166).GDP using a novel 4D NMR strategy. Journal of Biomolecular NMR, 1992, 2, 639-646.	1.6	31
171	Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World Journal of Surgery, 1992, 16, 576-581.	0.8	101
172	The value of measurement of RAS oncogenes and nuclear DNA analysis in the diagnosis of HÃ¼rthle cell tumors of the thyroid. World Journal of Surgery, 1992, 16, 745-751.	0.8	25
174	IDENTIFICATION OF A TRANSFORMING ras ONCOGENE IN AN ULTRAVIOLET RADIATION-INDUCED CORNEAL TUMOR OF Monodelphis domestica. Photochemistry and Photobiology, 1992, 55, 417-424.	1.3	8
175	Molecular genetic study showing that the IN/157 â€˜oligodendrogliomaâ€™ cell line has been contaminated by rhabdomyosarcoma (RD) cells. Neuropathology and Applied Neurobiology, 1992, 18, 159-169.	1.8	3
176	Regulatory mechanisms forras proteins. BioEssays, 1992, 14, 177-184.	1.2	130
177	Oncogenes as markers for early detection of cancer. Journal of Cellular Biochemistry, 1992, 50, 131-136.	1.2	15
178	Abnormalities of chromosomes 7 and 22 in human malignant pleural mesothelioma: Correlation between southern blot and cytogenetic analyses. Genes Chromosomes and Cancer, 1992, 4, 176-182.	1.5	16
179	Detection ofRAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization. Genes Chromosomes and Cancer, 1992, 5, 109-118.	1.5	45
180	Regulation of natural antibody binding and susceptibility to natural killer cells through Zn++-inducibleras oncogene expression. International Journal of Cancer, 1992, 50, 423-430.	2.3	9
181	K-ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis. International Journal of Cancer, 1992, 52, 30-33.	2.3	75
182	The H-ras oncogene regulates expression of 70- and 45-kDa cell-surface molecules whose expression correlates with tumor-cell immunogenicity. International Journal of Cancer, 1992, 52, 329-335.	2.3	4
183	The p53 tumor-suppressor gene andras oncogene mutations in oral squamous-cell carcinoma. International Journal of Cancer, 1992, 52, 867-872.	2.3	108

#	Article	IF	Citations
184	Elevated expression of the ribosomal protein S2 gene in human tumors. Molecular Carcinogenesis, 1992, 5, 219-231.	1.3	59
185	Characterization of the syrian hamster c-Ha-ras gene and intron-d-exon transcript. Molecular Carcinogenesis, 1992, 5, 254-258.	1.3	8
186	Selective pressures andras activation in carcinogenesis. Molecular Carcinogenesis, 1992, 6, 1-4.	1.3	17
187	Activation of the Ki-ras gene in spontaneous and chemically induced lung tumors in CD-1 mice. Molecular Carcinogenesis, 1992, 6, 68-75.	1.3	22
188	p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Molecular Carcinogenesis, 1992, 6, 148-158.	1.3	74
189	Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma. Cancer, 1992, 69, 1589-1591.	2.0	25
190	Molecular markers for the diagnosis and prognosis of lung cancer. Cancer, 1992, 69, 1592-1599.	2.0	48
191	Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?. Cancer, 1992, 70, 1732-1739.	2.0	69
192	Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer, 1993, 71, 3827-3838.	2.0	212
193	p53 gene mutations and 17p allelic deletions in hepatocellular Carcinoma from Japan. Cancer, 1993, 72, 355-360.	2.0	69
194	Neurofibromatosis type 1 and childhood cancer. Cancer, 1993, 72, 2746-2754.	2.0	174
195	Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clinical Biochemistry, 1993, 26, 439-447.	0.8	35
196	ras Gene mutations and hpv infection are common in human laryngeal carcinoma. International Journal of Cancer, 1993, 53, 22-28.	2.3	54
197	K-ras mutations in human adenocarcinoma of the lung: Association with smoking and occupational exposure to asbestos. International Journal of Cancer, 1993, 53, 250-256.	2.3	143
198	Cellular andIn Vivo characterization of the MCR rat mammary tumor model. International Journal of Cancer, 1993, 53, 486-492.	2.3	0
199	Prevalence of G-TO-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. International Journal of Cancer, 1993, 54, 249-254.	2.3	59
200	p53 Mutations in sporadic adrenocortical tumors. International Journal of Cancer, 1993, 54, 408-410.	2.3	134
201	Possible role of activatedras genes in human esophageal carcinogenesis. International Journal of Cancer, 1993, 54, 978-982.	2.3	14

#	Article	IF	Citations
202	Decreasing the level of translation initiation factor 4E with antisense rna causes reversal ofras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. International Journal of Cancer, 1993, 55, 841-847.	2.3	119
203	Carcinogen biomarkers related to smoking and upper aerodigestive tract cancer. Journal of Cellular Biochemistry, 1993, 53, 27-35.	1.2	45
204	T cell clones specific for p21 ras-derived peptides: Characterization of their fine specificity and HLA restriction. European Journal of Immunology, 1993, 23, 754-760.	1.6	54
205	Overlapping epitopes encompassing a point mutation (12 Gly â†' Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. European Journal of Immunology, 1993, 23, 2687-2691.	1.6	62
206	Comprehensive screening of the humanKRAS2 gene for sequence variants. Genes Chromosomes and Cancer, 1993, 6, 73-85.	1.5	11
207	Carcinogen-induced amplification of SV40 DNA inserted at 9q12-21.1 associated with chromosome breakage, deletions, and translocations in human uroepithelial cell transformation in vitro. Genes Chromosomes and Cancer, 1993, 8, 155-166.	1.5	17
208	Ki-ras mRNA regulation in untransformed mouse lung cells. Molecular Carcinogenesis, 1993, 8, 193-201.	1.3	7
209	Toxicity of phorbol esters for human epithelial cells expressing a mutantras Oncogene. Molecular Carcinogenesis, 1993, 8, 280-289.	1.3	4
210	Drugs acting on the intracellular signalling system. Medicinal Research Reviews, 1993, 13, 1-60.	5.0	10
211	Amplification ofc-myc oncogene and absence ofc-Ha-ras point mutation in human bone sarcoma. Journal of Orthopaedic Research, 1993, 11, 556-563.	1.2	38
212	Methods used for analyses of â€œenvironmentallyâ€•damaged nucleic acids. Biomedical Applications, 1993, 618, 289-314.	1.7	21
213	The effect of H-ras expression on tumorigenicity and immunogenicity of Balb/c 3T3 fibroblasts. Immunology Letters, 1993, 39, 3-8.	1.1	12
214	Expression of nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: an association with lymph node metastasis and tumor invasion. Clinical and Experimental Metastasis, 1993, 11, 151-158.	1.7	69
215	Reassignment of the H-ras-1 gene to the Hbb-terminus region of mouse Chromosome 7. Mammalian Genome, 1993, 4, 220-222.	1.0	2
216	Molecular and cellular markers for metastatic prostate cancer. Cancer and Metastasis Reviews, 1993, 12, 3-10.	2.7	17
217	The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clinical and Experimental Metastasis, 1993, 11, 15-26.	1.7	71
218	The pathway to signal achievement. Nature, 1993, 365, 781-783.	13.7	577
219	The absence of Harvey ras mutations during development and progression of squamous cell carcinomas of the head and neck. British Journal of Cancer, 1993, 68, 617-620.	2.9	35

#	Article	IF	Citations
220	Tumourigenesis associated with the p53 tumour suppressor gene. British Journal of Cancer, 1993, 68, 653-661.	2.9	112
221	Neurofibromatosis type 1 gene mutations in neuroblastoma. Nature Genetics, 1993, 3, 62-66.	9.4	157
222	7,12-Dimethylbenz [a] anthracene-Induced Mouse Keratinocyte Malignant Transformation Independent of Harvey ras Activation. Journal of Investigative Dermatology, 1993, 101, 595-599.	0.3	16
223	Clonal Analysis of Multiple Point Mutations in the N-rasGene in Patients with Acute Myeloid Leukemia. Japanese Journal of Cancer Research, 1993, 84, 379-387.	1.7	38
224	Enhancing Effects of Calcium-deficient Diet on Gastric Carcinogenesis by N-Methyl-Nâ€²-nitro-N-nitrosoguanidine in Wistar Rats. Japanese Journal of Cancer Research, 1993, 84, 945-950.	1.7	9
225	InfrequentrasMutation in Human Stomach Cancers. Japanese Journal of Cancer Research, 1993, 84, 163-167.	1.7	26
226	Epidermal-growth-factor receptors generate Ras . GTP more efficiently than insulin receptors. FEBS Journal, 1993, 212, 477-482.	0.2	23
227	Nucleotide binding and GTP hydrolysis by the 21-kDa product of the c-H-ras gene as monitored by proton-NMR spectroscopy. FEBS Journal, 1993, 213, 781-788.	0.2	4
228	Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukaemia carrying an activating N-ras mutation. British Journal of Haematology, 1993, 84, 443-450.	1.2	11
229	Separation of transforming N-ras mutations in codons 12, 13 and 61 by denaturing gradient gel electrophoresis : investigation based on a set of phagemid constructs. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1993, 285, 287-294.	0.4	7
230	Posttranslational processing of the ras superfamily of small GTP-binding proteins. Biochimica Et Biophysica Acta: Reviews on Cancer, 1993, 1155, 79-96.	3.3	32
231	Mutant H-ras over-expression inhibits a random apoptotic nuclease in myeloid leukemia cells. Leukemia Research, 1993, 17, 703-709.	0.4	26
232	Revisiting the role of mutagenesis in the induction of lung cancers in rats by diesel emissions. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1993, 303, 91-95.	1.2	22
233	The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasma of the pancreas. International Journal of Gastrointestinal Cancer, 1993, 14, 135-143.	0.4	38
234	Sequential changes in MHC antigen expression induced by the v-Ki-ras oncogene. Cancer Immunology, Immunotherapy, 1993, 37, 361-366.	2.0	2
235	Cell proliferation and prevalence of ras gene mutations in 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary tumors. Research in Experimental Medicine, 1993, 193, 143-151.	0.7	11
236	G protein mutations in human disease. Clinical Biochemistry, 1993, 26, 333-338.	0.8	49
237	Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science, 1993, 260, 1934-1937.	6.0	606

#	Article	IF	Citations
238	Comparative clinical evaluation of biochemical and genomic tumor markers. Clinica Chimica Acta, 1993, 217, 39-55.	0.5	4
239	Microinjection of acylphosphatase blocksXenopus laevisoocytes maturation induced byras-p21. FEBS Letters, 1993, 326, 167-170.	1.3	7
240	Neuroendocrine neoplasms of the lung are not associated with point mutations at codon 12 of the Ki-ras gene. Vigiliae Christianae, 1993, 63, 325-329.	0.1	17
241	Chaetomella acutiseta produces chaetomellic acids A and B which are reversible inhibitors of farnesyl-protien transferase. Applied Microbiology and Biotechnology, 1993, 40, 370-4.	1.7	47
242	Oncogenes and onco-suppressor genes in lung cancer. Respiratory Medicine, 1993, 87, 413-420.	1.3	19
243	Molecular genetics of thyroid cancer. Trends in Endocrinology and Metabolism, 1993, 4, 224-232.	3.1	34
244	Mechanism of GTP hydrolysis by p21N-ras catalyzed by GAP: Studies with a fluorescent GTP analog. Biochemistry, 1993, 32, 7451-7459.	1.2	77
245	N-Ras Mutation in acute myeloid leukemia: Incidence, prognostic significance and value as a marker of minimal residual disease. Pathology, 1993, 25, 57-62.	0.3	11
246	Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicology Letters, 1993, 67, 201-210.	0.4	55
247	Effects of signalling transduction modulators on the transformed phenotypes in v-H-ras-transformed NIH 3T3 cells. Cancer Letters, 1993, 74, 197-202.	3.2	3
248	ras Gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mucosal lesions. European Journal of Cancer Part B, Oral Oncology, 1993, 29, 63-67.	0.9	39
249	Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science, 1993, 260, 85-88.	6.0	598
250	ras oncogene activation and the expression of ras-related genes in human lung cancer. Lung Cancer, 1993, 9, 59-67.	0.9	3
251	Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Human Pathology, 1993, 24, 1127-1134.	1.1	203
252	Immunodetection of the p21-ras products in human normal and preneoplastic tissues and solid tumors: A review. Human Pathology, 1993, 24, 1271-1285.	1.1	25
253	Molecular and Biochemical Reprogramming of Oncogenesis through the Activity of Prooxidants and Antioxidants. Annals of the New York Academy of Sciences, 1993, 686, 262-278.	1.8	82
254	T-Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR-ABL. Annals of the New York Academy of Sciences, 1993, 690, 101-112.	1.8	32
255	Characterization of the K-rasgene of the marsupialMonodelphis domestica. DNA Sequence, 1993, 4, 37-42.	0.7	7

#	Article	IF	Citations
256	Mutational Status of Codons 12 and 13 of the N- andK-rasGenes in Tissue and Cell Lines Derived from Primary and Metastatic Prostate Carcinomas. Cancer Investigation, 1993, 11, 25-32.	0.6	41
257	Identification of two human homologues toDrosophilaSOS (Son of Sevenless) localized on two different chromosomes. Nucleic Acids Research, 1993, 21, 4398-4398.	6.5	3
258	Probing the structure and mechanism of Ras protein with an expanded genetic code. Science, 1993, 259, 806-809.	6.0	144
259	Initiators and Promoters of Lung Cancer. Chest, 1993, 103, 4S-11S.	0.4	31
260	Molecular genetics of human malignant melanoma. Cancer Treatment and Research, 1993, 65, 201-255.	0.2	33
261	K-ras point mutations in routinely processed tissues: non-radioactive screening by single strand conformational polymorphism analysis.. Journal of Clinical Pathology, 1993, 46, 621-623.	1.0	13
262	c-N-rasis Activated Infrequently in Canine Malignant Lymphoma. Toxicologic Pathology, 1993, 21, 288-291.	0.9	16
263	Expression of c-myc, c-Ki-ras and c-Ha-ras Oncogene Products in Peripheral Blood Mononuclear Cells from Patients with Myasthenia Gravis.. Internal Medicine, 1993, 32, 519-522.	0.3	3
264	Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology, 1993, 104, 57-64.	0.6	240
265	Over-expression of the c-myc proto-oncogene in colorectal carcinoma. British Journal of Cancer, 1993, 68, 407-413.	2.9	80
266	Biliary papillomatosis with the point mutation of K-ras gene arising in congenital choledochal cyst. Gastroenterology, 1993, 105, 1209-1212.	0.6	66
267	Biochemical Markers for Colorectal Cancer: Diagnostic and Therapeutic Implications. Surgical Clinics of North America, 1993, 73, 85-102.	0.5	3
268	Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology, 1993, 104, 1044-1048.	0.6	182
269	Interventional genetics and cancer treatment.. BMJ: British Medical Journal, 1993, 306, 665-666.	2.4	12
270	Oncogenes and ENT: a review of the molecular biological advances in squamous cell carcinoma of the head and neck. Clinical Otolaryngology, 1993, 18, 4-13.	0.6	5
271	Suppression of oncogenic Ras by mutant neurofibromatosis type 1 genes with single amino acid substitutions.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 6706-6710.	3.3	26
272	Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction.. Molecular and Cellular Biology, 1993, 13, 7311-7320.	1.1	26
273	Molecular Genetic Changes in Human Breast Cancer. Advances in Cancer Research, 1993, 61, 25-56.	1.9	51

#	Article	IF	Citations
274	Overview of Genetic and Molecular Events in the Pathogenesis of Lung Cancer. Chest, 1993, 103, 1S-3S.	0.4	36
275	New Molecular Targets and Therapeutic Strategies against Cancer. International Journal of Biological Markers, 1993, 8, 1-7.	0.7	0
276	Contamination and restoration of groundwater aquifers.. Environmental Health Perspectives, 1993, 100, 237-247.	2.8	17
277	K-ras oncogene codon 12 point mutations in testicular cancer.. Environmental Health Perspectives, 1993, 101, 185-187.	2.8	10
278	Probing the role of loop 2 in Ras function with unnatural amino acids.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10145-10149.	3.3	32
279	Advances in the Diagnosis of Acute Leukemia. Hematology/Oncology Clinics of North America, 1993, 7, 1-46.	0.9	12
280	Molecular Biology of Neoplastic Transformation of the Large Bowel: Identification of Two Etiologic Pathways. Surgical Oncology Clinics of North America, 1994, 3, 449-477.	0.6	8
281	The genetics of human cancer: implications for ecotoxicology.. Environmental Health Perspectives, 1994, 102, 75-80.	2.8	8
282	The role of the cellular antioxidant defense in oxidant carcinogenesis.. Environmental Health Perspectives, 1994, 102, 123-129.	2.8	164
283	Suppression of ras oncogene-mediated transformation. , 1994, 124, 29-92.		7
284	Diagnosis of pancreatic lesions using fine needle aspiration cytology: detection of K-ras point mutations using solid phase minisequencing.. Journal of Clinical Pathology, 1994, 47, 1082-1084.	1.0	10
285	The Binding of Acute Myeloid Leukemia Blast Cells to Human Endothelium. Leukemia and Lymphoma, 1994, 16, 19-29.	0.6	10
286	Mutagenesis in monkey cells of a vector containing a single d(GPG)cis-diamminedichloroplatinum(ll) adduct placed on codon 13 of the humanH-rasproto-oncogen. Nucleic Acids Research, 1994, 22, 2519-2524.	6.5	38
287	Loss of p53 protein during radiation transformation of primary human mammary epithelial cells.. Molecular and Cellular Biology, 1994, 14, 2468-2478.	1.1	81
288	Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.. Journal of Clinical Pathology, 1994, 47, 914-919.	1.0	65
289	N-ras oncogene causes AP-2 transcriptional self-interference, which leads to transformation.. Genes and Development, 1994, 8, 1258-1269.	2.7	89
290	Absence of p53 Gene Mutations in Cutaneous Melanoma. Journal of Investigative Dermatology, 1994, 102, 819-821.	0.3	99
291	High Frequency of RAS Oncogene Mutation in Chronic Myeloid Leukemia Patients with Myeloblastoma. Leukemia and Lymphoma, 1994, 13, 317-322.	0.6	8

#	Article	IF	Citations
292	ras Oncogene Activation Does Not Induce Sensitivity to Natural Killer Cell-Mediated Lysis in Human Melanoma.. Journal of Investigative Dermatology, 1994, 103, 117S-121S.	0.3	5
293	Ras p21 Farnesylation in Ultraviolet B Radiationâ€"Induced Tumors in The Skin of SKH-1 Hairless Mice. Journal of Investigative Dermatology, 1994, 102, 754-758.	0.3	11
294	N- and K-Ras Oncogenes in Plasma Cell Dyscrasias. Leukemia and Lymphoma, 1994, 15, 17-20.	0.6	28
295	Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer. Clinical and Experimental Metastasis, 1994, 12, 55-62.	1.7	80
296	Reflections on viruses and cancer. Veterinary Research Communications, 1994, 18, 43-61.	0.6	5
297	Molecular biology of breast carcinoma. World Journal of Surgery, 1994, 18, 12-20.	0.8	22
298	Point mutations of ras genes in human adrenal cortical tumors: Absence in adrenocortical hyperplasia. World Journal of Surgery, 1994, 18, 455-460.	0.8	42
299	K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 367-73.	1.4	26
300	Genetic analysis of the catalytic domain of the GAP gene in human lung cancer cell lines. Human Genetics, 1994, 93, 27-31.	1.8	6
301	Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate, 1994, 25, 177-188.	1.2	18
302	Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate, 1994, 25, 249-265.	1.2	79
303	Chemoprevention of colon cancer by dietary fatty acids. Cancer and Metastasis Reviews, 1994, 13, 285-302.	2.7	64
304	The Ras signal transduction pathway. Cancer and Metastasis Reviews, 1994, 13, 67-89.	2.7	342
305	Only wild-type c-ki-ras codons 12, 13, and 61 in human pancreatic acinar cell carcinomas. Molecular Carcinogenesis, 1994, 10, 110-114.	1.3	39
306	Clonal variation of tumorigenic potential in v-Ha-ras-transformed human bronchial epithelial cells: Relationship toras oncogene expression and CAD gene amplification. Molecular Carcinogenesis, 1994, 11, 34-41.	1.3	4
307	Far less frequent mutations inras genes than in thep53 gene in skin tumors of xeroderma pigmentosum patients. Molecular Carcinogenesis, 1994, 11, 98-105.	1.3	23
308	Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. Journal of Surgical Oncology, 1994, 57, 57-64.	0.8	64
309	Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer, 1994, 73, 1589-1594.	2.0	140

#	Article	IF	Citations
310	K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. Cancer, 1994, 73, 2727-2733.	2.0	97
311	DNA adduct and mutation analysis in white blood cells of smokers and nonsmokers. Environmental and Molecular Mutagenesis, 1994, 24, 46-50.	0.9	14
312	Establishment of human oral-cancer cell lines (KOSC-2 and -3) carryingp53 andc-myc abnormalities by geneticin treatment. International Journal of Cancer, 1994, 56, 301-308.	2.3	20
313	Multifactorial analysis ofp53 alteration in human cancer: A review. International Journal of Cancer, 1994, 57, 1-9.	2.3	287
314	Association of H-ras mutations with adenocarcinomas of the parotid gland. International Journal of Cancer, 1994, 57, 362-364.	2.3	11
315	A K-ras 13GLY â†' ASP mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation?. International Journal of Cancer, 1994, 58, 506-511.	2.3	36
316	Differential Na+, K+-ATPase activity and cisplatin sensitivity between transformants induced by H-ras and those induced by K-ras. International Journal of Cancer, 1994, 58, 672-677.	2.3	13
317	Regulation of the ras signalling network. BioEssays, 1994, 16, 489-496.	1.2	87
318	Activation of c-fos expression by transforming Ha-ras in HC11 mouse mammary epithelial cells is PKC-dependent and mediated by the serum response element. Cellular Signalling, 1994, 6, 285-297.	1.7	12
319	Colorectal tumourigenesis. Surgical Oncology, 1994, 3, 195-201.	0.8	1
320	Raf: the holy grail of Ras biology?. Trends in Cell Biology, 1994, 4, 347-350.	3.6	28
321	Quantitative determination of the ratio of mutated to normal ras genes in the blood of leukemia patients by allele-specific PCR. Leukemia Research, 1994, 18, 693-702.	0.4	4
322	The neurofibromatosis gene in human pituitary adenomas. Endocrine Pathology, 1994, 5, 229-232.	5.2	2
324	Oncogenes and cell immunogenity: Î½-H-ras suppressing MHC class I expression in mouse fibroblast. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1994, 6, 149-156.	0.7	0
325	Modulation of oncogene and tumor-suppressor gene expression: A novel strategy for cancer prevention and treatment. Annals of Surgical Oncology, 1994, 1, 79-86.	0.7	8
326	Characterization of a newly established human gallbladder carcinoma cell line. In Vitro Cellular and Developmental Biology - Animal, 1994, 30, 729-732.	0.7	14
327	High incidence of H-ras oncogene mutations in squamous cell carcinoma of lip vermilion. Journal of Oral Pathology and Medicine, 1994, 23, 298-301.	1.4	23
328	Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. Journal of Oral Pathology and Medicine, 1994, 23, 342-346.	1.4	44

#	Article	IF	Citations
329	Mutations of Ki-ras oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan. Journal of Oral Pathology and Medicine, 1994, 23, 70-74.	1.4	69
330	Genetic Alterations in Non-Melanoma Skin Cancer. Journal of Investigative Dermatology, 1994, 103, 747-750.	0.3	51
331	K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. British Journal of Cancer, 1994, 69, 367-371.	2.9	127
332	Binding of Ras Oncogene Peptides to Purified HLA-DQ(alphal*0102, ss1*0602) and -DR(alpha, ss1*0101) Molecules. Scandinavian Journal of Immunology, 1994, 39, 607-612.	1.3	9
333	Cytotoxicity of Simvastatin to Pancreatic Adenocarcinoma Cells Containing MutantrasGene. Japanese Journal of Cancer Research, 1994, 85, 633-638.	1.7	28
334	State of Adenomatous Polyposis Coli Gene and ras Oncogenes in Japanese Prostate Cancer. Japanese Journal of Cancer Research, 1994, 85, 847-852.	1.7	44
335	Persistence of an activating Nâ€‹RAS oncogene mutation in clonogenic progenitor cells from an acute myeloid leukaemia patient in remission. British Journal of Haematology, 1994, 86, 298-302.	1.2	6
336	Point mutations of the Nâ€‹ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. British Journal of Haematology, 1994, 86, 774-779.	1.2	365
337	Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis. British Journal of Haematology, 1994, 88, 575-581.	1.2	45
338	RESPIRATORY BURST ACTIVITY IN MDS MPS PATIENTS. British Journal of Haematology, 1994, 88, 663-664.	1.2	0
339	Historical Origins of Current Concepts of Carcinogenesis. Advances in Cancer Research, 1994, 65, 17-111.	1.9	30
340	H-ras Ribozyme-Mediated, Alteration of the Human Melanoma Phenotype. Annals of the New York Academy of Sciences, 1994, 716, 242-256.	1.8	30
342	Damage to DNA by UV light and activation of transcription factors. Biochemical Pharmacology, 1994, 47, 129-136.	2.0	58
343	Isolation and characterization of mutants of human mitogen-activated protein kinase (ERK2). FEBS Letters, 1994, 353, 185-188.	1.3	4
344	The major histocompatibility complex: Its genes and their roles in antigen presentation. Molecular Aspects of Medicine, 1994, 15, 377-503.	2.7	10
345	Dietary modulation of rat colonic cAMP-dependent protein kinase activity. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1224, 51-60.	1.9	4
346	Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. Human Pathology, 1994, 25, 564-571.	1.1	34
347	The mammalian UV response: Mechanism of DNA damage induced gene expression. Advances in Enzyme Regulation, 1994, 34, 381-395.	2.9	93

#	Article	IF	Citations
348	Arsenic-related Bowen's disease and paraquat-related skin cancerous lesions show no detectable ras and p53 gene alterations. Cancer Letters, 1994, 86, 59-65.	3.2	29
349	Gene replacement strategies for the prevention and therapy of cancer. European Journal of Cancer, 1994, 30, 2032-2037.	1.3	8
350	A new tool for studying protein structure and function. Current Opinion in Structural Biology, 1994, 4, 601-607.	2.6	30
351	Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. European Journal of Cancer, 1994, 30, 987-993.	1.3	123
352	K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. Lung Cancer, 1994, 11, 19-27.	0.9	29
353	The genetics of childhood cancer. European Journal of Cancer, 1994, 30, 1942-1946.	1.3	15
354	New approaches in cancer pharmacology: Drug design and development (part 2). European Journal of Cancer, 1994, 30, 1148-1160.	1.3	8
355	Mutation analysis of RASK and the â€˜FLR exonâ€™ of NF1 in sporadic ovarian carcinoma. European Journal of Cancer, 1994, 30, 528-530.	1.3	8
356	Reversion of the transformed phenotypes of v-H-ras NIH3T3 cells by flavonoids through attenuating the content of phosphotyrosine. Cancer Letters, 1994, 87, 91-97.	3.2	36
357	Mutational Spectrum of the P53 Tumor Suppressor Gene: Clues to Cancer Etiology and Molecular Pathogenesis. Drug Metabolism Reviews, 1994, 26, 221-235.	1.5	12
358	Characterization of the prenylated protein methyltransferase in human endometrial carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1994, 1226, 330-336.	1.8	9
359	Malignant liver disease in alpha1-antitrypsin deficiency. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 27-32.	0.7	9
360	FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.. Journal of Antibiotics, 1994, 47, 301-310.	1.0	418
361	Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology, 1994, 106, 1645-1651.	0.6	74
362	Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology, 1994, 107, 1147-1153.	0.6	117
363	The Ras-related protein R-ras interacts directly with Raf-1 in a GTP-dependent manner. Biochemical Journal, 1994, 300, 303-307.	1.7	62
364	Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy. Annual Reports in Medicinal Chemistry, 1994, 29, 165-174.	0.5	9
365	Conserved cis-elements bind a protein complex that regulates Drosophila ras2/rop bidirectional expression. British Journal of Cancer, 1994, 69, 264-273.	2.9	18

#	Article	IF	Citations
366	Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9141-9145.	3.3	280
367	Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation.. Molecular and Cellular Biology, 1994, 14, 4108-4115.	1.1	88
368	The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5124-5128.	3.3	200
369	A human oncogene of the RAS superfamily unmasked by expression cDNA cloning.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7558-7562.	3.3	89
370	The Sixth George Swanson Christie Memorial Lecture: Growth factors and their receptors: new opportunities for cancer treatment. Pathology, 1994, 26, 453-463.	0.3	8
371	Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues.. Molecular and Cellular Biology, 1994, 14, 5318-5325.	1.1	179
372	Ras activation of genes: Mob-1 as a model.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 12515-12519.	3.3	67
373	Suppression of albumin enhancer activity by H-ras and AP-1 in hepatocyte cell lines.. Molecular and Cellular Biology, 1994, 14, 1531-1543.	1.1	20
374	Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 12609-12613.	3.3	251
375	Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 10460-10464.	3.3	166
376	Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 10919-10923.	3.3	30
377	A mechanism for posttranslational modifications of proteins by yeast protein farnesyltransferase.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5008-5011.	3.3	109
378	The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 744-747.	3.3	213
379	Lung pathology: the molecular genetics of non-small cell lung cancer. Pathology, 1995, 27, 295-301.	0.3	7
380	Glutathione Transferase P1â€“1 Expression in Human Melanoma Metastases: Correlation toN-RASmutations and expression. Acta OncolÃ³gica, 1995, 34, 759-765.	0.8	8
381	Molecular Genetics of Exocrine Pancreatic Neoplasms. Surgical Clinics of North America, 1995, 75, 857-869.	0.5	58
382	Induction of intercellular adhesion molecule 1 and class II histocompatibility antigens in colorectal tumour cells expressing activated ras oncogene. Journal of Clinical Pathology, 1995, 48, M326-M332.	2.1	2
383	[38] Inhibition of Ras function in Vitro and in Vivo using inhibitors of farnesyl-protein transferase. Methods in Enzymology, 1995, 255, 378-386.	0.4	7

#	Article	IF	Citations
384	Oncogenes in tumor progression. Advances in Genome Biology, 1995, 3, 17-53.	0.3	1
385	The p53 tumor suppressor gene. Advances in Genome Biology, 1995, 3, 55-141.	0.3	2
386	p21ras. Advances in Genome Biology, 1995, 3, 163-183.	0.3	0
387	Cloning and sequencing of CATR1.3, a human gene associated with tumorigenic conversion.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6409-6413.	3.3	9
388	Colon Carcinogenesis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 1995, 1, 142-158.	0.9	17
389	[1] Refolding and purification of ras proteins. Methods in Enzymology, 1995, 255, 3-13.	0.4	32
390	A role for Rho in Ras transformation.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 11781-11785.	3.3	514
391	Idiopathic macrocytic anaemia in the aged: molecular and cytogenetic findings. British Journal of Haematology, 1995, 90, 797-803.	1.2	22
392	Mammosomatotroph adenoma causing gigantism in an 8â€year old boy: a possible pathogenetic mechanism. Clinical Endocrinology, 1995, 42, 539-549.	1.2	21
393	Untersuchungen von Struktur und Funktion von Proteinen mit einem erweiterten genetischen Code. Angewandte Chemie, 1995, 107, 677-690.	1.6	28
394	Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. Cancer, 1995, 75, 2794-2801.	2.0	65
395	High incidence of point mutation in K-ras codon12 in carcinoma of the fallopian tube. Cancer, 1995, 76, 86-90.	2.0	14
396	Regulatory elements in the first intron of the mouse ha-ras gene. Molecular Carcinogenesis, 1995, 12, 137-145.	1.3	8
397	Partial restoration of pre-transformation levels of lysyl oxidase and transin mRNAs in phenotypicras revertants. Molecular Carcinogenesis, 1995, 12, 198-204.	1.3	16
398	Novel use of a selectable fusion gene as an â€œIn-Outâ€•marker for studying genetic loss in mammalian cells. Molecular Carcinogenesis, 1995, 12, 213-224.	1.3	11
399	N-methylnitrosoureaâ€”Induced Ki-ras codon 12 mutations: Early events in mouse thymic lymphomas. Molecular Carcinogenesis, 1995, 13, 89-95.	1.3	17
400	Effect of increased glucocorticoid responsiveness in transformed mouse lung cells. Molecular Carcinogenesis, 1995, 13, 135-145.	1.3	6
402	Induction of interleukin-2 transcription by the hamster polyomavirus middle T antigen: a role for Fyn in T cell signal transduction. European Journal of Immunology, 1995, 25, 385-393.	1.6	23

#	Article	IF	Citations
403	Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. European Journal of Immunology, 1995, 25, 2588-2597.	1.6	41
404	Colon carcinogenesis in inflammatory bowel disease. Inflammatory Bowel Diseases, 1995, 1, 142-158.	0.9	25
405	Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene. International Journal of Cancer, 1995, 61, 206-213.	2.3	13
406	Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. International Journal of Cancer, 1995, 61, 389-396.	2.3	77
407	High frequency of Kâ€•ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. International Journal of Cancer, 1995, 63, 810-814.	2.3	80
408	Analysis and clinical implications of k-ras gene mutations and infection with human papillomavirus types 16 and 18 in primary adenocarcinoma of the uterine cervix. International Journal of Cancer, 1995, 64, 9-13.	2.3	23
409	TP53 andRAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. International Journal of Cancer, 1995, 64, 229-233.	2.3	25
410	Analysis of the gap-related domain of the neurofibromatosis type 1 (NF1) gene in childhood brain tumors. International Journal of Cancer, 1995, 64, 234-238.	2.3	17
411	BPV E1 protein alters the kinetics of cell cycle entry of serum starved mouse fibroblasts. Cytometry, 1995, 21, 257-264.	1.8	6
412	Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Development Research, 1995, 34, 121-137.	1.4	68
413	Intracellular pH regulation in hep G2 cells: Effects of epidermal growth factor, transforming growth factor-Î±, and insulinlike growth factor-II on Na+/H+ exchange activity. Hepatology, 1995, 22, 588-597.	3.6	21
414	Transcriptional repression of the Î±1(I) collagen gene byras is mediated in part by an intronic AP1 site. Journal of Cellular Biochemistry, 1995, 58, 380-392.	1.2	22
415	Molecular aspects of chemical carcinogenesis: The roles of oncogenes and tumour suppressor genes. Toxicology, 1995, 96, 173-194.	2.0	88
416	Alterations inc-myc, Ha-ras, andKi-ras protooncogenes in experimental rat mesothelioma. Bulletin of Experimental Biology and Medicine, 1995, 120, 1046-1049.	0.3	0
417	Do oncogene and tumor suppressor gene abnormalities vary with type of carcinoma of the pancreas?. Journal of Hepato-Biliary-Pancreatic Surgery, 1995, 2, 1-7.	2.0	3
418	CD8+T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (GLY13?ASP), are cytotoxic towards a carcinoma cell line harbouring the same mutation. Cancer Immunology, Immunotherapy, 1995, 40, 165-172.	2.0	43
419	The expression of CMP-NeuAc: Gal?1,4GlcNAc ?2,6 sialyltransferase [EC 2.4.99.1] and glycoproteins bearing ?2,6-linked sialic acids in human brain tumours. Glycoconjugate Journal, 1995, 12, 848-856.	1.4	12
420	Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Research and Treatment, 1995, 35, 133-144.	1.1	194

#	Article	IF	Citations
421	Frequency and spectrum of p53 mutations in gastric cancer ? a molecular genetic and immunohistochemical study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1995, 426, 447-55.	1.4	32
422	Role of Point Mutation of the K-rasGene in Tumorigenesis of B6C3F1Mouse Lung Lesions Induced by Urethane. Japanese Journal of Cancer Research, 1995, 86, 802-810.	1.7	35
423	Absence ofrasMutations and Low Incidence ofp53Mutations in Renal Cell Carcinomas Induced by Ferric Nitrilotriacetate. Japanese Journal of Cancer Research, 1995, 86, 1143-1149.	1.7	13
424	Immunity to Oncogenic Proteins. Immunological Reviews, 1995, 145, 33-59.	2.8	167
425	Rational cancer therapy. Nature Medicine, 1995, 1, 747-748.	15.2	8
426	Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Medicine, 1995, 1, 792-797.	15.2	523
427	Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. British Journal of Cancer, 1995, 71, 556-561.	2.9	41
428	Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. British Journal of Cancer, 1995, 72, 123-128.	2.9	91
429	Elevated ras p21 expression in oral premalignant lesions and squamous cell carcinomas in Taiwan. Journal of Oral Pathology and Medicine, 1995, 24, 255-260.	1.4	45
430	Detection of point mutations in human tyrosinase gene by improved allele-specific amplification. Experimental Dermatology, 1995, 4, 377-381.	1.4	11
431	Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology, 1995, 19, 183-232.	2.0	2,457
432	Concepts in multistage carcinogenesis. Critical Reviews in Oncology/Hematology, 1995, 21, 105-133.	2.0	29
433	Constrained analogs of KCVFM with improved inhibitory properties against farnesyl transferase. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1779-1784.	1.0	37
434	Mitotic and post mitotic consequences of genomic instability induced by oncogenic Ha-Ras. Somatic Cell and Molecular Genetics, 1995, 21, 241-253.	0.7	41
435	Activation of Ca2+ influx by transforming Ha-ras. Cell Calcium, 1995, 18, 120-134.	1.1	7
436	Upregulation of p21 RAS levels in HL-60 cells during differentiation induction with DMSO, all-trans-retinoic acid and TPA. Leukemia Research, 1995, 19, 291-296.	0.4	9
437	A screen for RAS mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals. Leukemia Research, 1995, 19, 299-301.	0.4	7
438	Neurofibromatosis type 1 and Ras-mediated signaling: filling in the GAPs. Biochimica Et Biophysica Acta: Reviews on Cancer, 1995, 1242, 43-59.	3.3	26

#	Article	IF	Citations
439	Absence of Ki-ras mutations in exocrine pancreatic tumors from male rats chronically exposed to gabapentin. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 327, 151-160.	0.4	10
440	Molecular and genetic toxicology of 1,3-butadiene. Mutation Research - Reviews in Genetic Toxicology, 1995, 339, 121-130.	3.0	18
441	Comparison of DGGE and CDGE in detection of single base changes in the hamster hprt and human N-ras genes. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1995, 334, 357-364.	0.4	13
442	Mutational activation of ras genes is absent in pediatric osteosarcoma. Cancer Genetics and Cytogenetics, 1995, 79, 49-53.	1.0	23
443	Comparison of DNA content in non-Hodgkin's lymphoma as measured by flow cytometry and cytogenetics. Cancer Genetics and Cytogenetics, 1995, 80, 124-128.	1.0	3
444	Analysis of mutations of neurofibromatosis type 1 gene and Nâ€•ras gene in acute myelogenous leukemia. Stem Cells, 1995, 13, 556-563.	1.4	19
445	Chapter 8: Perspectives for the use of biological indicators for the assessment of radiation induced responses and impairments: Biologic indicators of exposure: Are markers associated with oncogenesis useful as biologic markers of effect?. Stem Cells, 1995, 13, 326-338.	1.4	5
446	On the role of cholecystokinin in pancreatic cancer. International Journal of Gastrointestinal Cancer, 1995, 17, 121-138.	0.4	13
447	K-ras mutation and pancreatic adenocarcinoma. International Journal of Gastrointestinal Cancer, 1995, 18, 1-6.	0.4	127
448	La citogenetica e la genetica molecolare nella prognosi del carcinoma della vescica: Cytogenetics and molecular genetics in bladder carcinoma prognosis. Urologia, 1995, 62, 196-208.	0.3	0
449	Section Review: Oncologic, Endocrine & Metabolic: Future directions for the treatment of human pancreatic carcinoma. Expert Opinion on Investigational Drugs, 1995, 4, 1273-1279.	1.9	2
450	Spontaneous Mutation of Cell Oncogenes Plays a Minor Role in Neoplastic Transformation of Virus-Induced Murine T-Cell Lymphomas. Tumori, 1995, 81, 268-272.	0.6	0
451	Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K-ras mutants for malignant progression?. Cancer, 1995, 75, 1527-1533.	2.0	58
452	Detection of Circulating Tumor Cells in Colorectal Cancer by Immunobead-PCR Is a Sensitive Prognostic Marker for Relapse of Disease. Molecular Medicine, 1995, 1, 789-794.	1.9	107
453	Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes.. Genes and Development, 1995, 9, 1953-1964.	2.7	171
454	Negative Feedback Regulation and Desensitization of Insulin- and Epidermal Growth Factor-stimulated p21ras Activation. Journal of Biological Chemistry, 1995, 270, 25320-25323.	1.6	160
455	Nutritional factors and colon cancer. Critical Reviews in Food Science and Nutrition, 1995, 35, 175-190.	5.4	88
456	Neoplastic Transformation of Normal Rat Embryo Fibroblasts by a Mutated p53 and an Activated ras Oncogene Induces Parathyroid Hormone-related Peptide Gene Expression and Causes Hypercalcemia in Nude Mice. Journal of Biological Chemistry, 1995, 270, 30857-30861.	1.6	15

#	Article	IF	Citations
457	Rational design of point mutation-selective antisense DNA targeted to codon 12 of Ha-rasmRNA in human cells. Nucleic Acids Research, 1995, 23, 3411-3418.	6.5	31
458	Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product.. Journal of Clinical Pathology, 1995, 48, 218-222.	1.0	39
459	DISEASE PROGRESSION IN STAGE A PROSTATE CANCER. International Journal of Urology, 1995, 2, 39-43.	0.5	3
460	Ras Gene Mutation: A Rare Event in Nonmetastatic Primary Malignant Melanoma. Journal of Investigative Dermatology, 1995, 104, 868-871.	0.3	33
461	Inhibition of Human Mammary Cell Line Proliferation by Membrane Lectin-Mediated Uptake of Ha-rasAntisense Oligodeoxynucleotide. Drug Delivery, 1995, 2, 63-72.	2.5	5
462	Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3333-3337.	3.3	105
463	A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expressionin vivo. Nucleic Acids Research, 1995, 23, 1495-1501.	6.5	99
464	p21 as a Common Signaling Target of Reactive Free Radicals and Cellular Redox Stress. Journal of Biological Chemistry, 1995, 270, 21195-21198.	1.6	347
465	p21ras: An oncoprotein functioning in growth factor-induced signal transduction. European Journal of Cancer, 1995, 31, 1051-1054.	1.3	64
466	The role of inducible transcription factors in apoptotic nerve cell death. Brain Research Reviews, 1995, 21, 1-28.	9.1	174
467	A rapid and convenient filter-binding assay for ras p21 processing enzyme farnesyltransferase. Journal of Proteomics, 1995, 30, 133-144.	2.4	19
468	About the large fluctuations observed using gas-phase molecular dynamics in the K-ras gene containing a mismatch. Biochimie, 1995, 77, 835-839.	1.3	1
469	Mutations of the Ki-ras protooncogene in 3-methylcholanthrene and urethan-induced and butylated hydroxytoluene-promoted lung tumors of strain A/J and SWR mice. Cancer Letters, 1995, 91, 33-39.	3.2	26
470	Frequent ras gene mutations in squamous cell cervical cancer. Cancer Letters, 1995, 95, 29-32.	3.2	20
471	N-ras mRNA expression is unaffected in glutathione-depleted cells of hematopoietic origin. Cancer Letters, 1995, 95, 105-112.	3.2	1
472	Analysis of a family of ypt genes and their products from Chlamydomonas reinhardtii. Gene, 1995, 158, 41-50.	1.0	37
473	Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. Biochemical Pharmacology, 1995, 50, 1987-1993.	2.0	6
474	Ras binding to a C-terminal region of GAP. FEBS Letters, 1995, 368, 297-303.	1.3	3

#	Article	IF	Citations
475	Cell-specific effects of RAS oncogene and protein kinase C agonist TPA on P-glycoprotein function. FEBS Letters, 1995, 368, 373-376.	1.3	18
476	A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog ofrheb. FEBS Letters, 1995, 377, 221-226.	1.3	60
477	The clinical and genetic manifestations of hereditary nonpolyposis colorectal carcinoma. American Journal of Surgery, 1995, 169, 368-372.	0.9	15
478	Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with dna ploidy. Urology, 1995, 46, 334-340.	0.5	44
479	Reversion of human prostate tumorigenic growth by azatyrosine. Urology, 1995, 46, 370-377.	0.5	4
480	Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology, 1995, 108, 434-440.	0.6	140
481	Aberrant crypt foci and k-ras mutations: Earliest recognized players or innocent bystanders in colon carcinogenesis?. Gastroenterology, 1995, 108, 600-603.	0.6	49
482	K-ras-2 G-C and G-T transversions correlate with DNA aneuploidy in colorectal adenomas. Gastroenterology, 1995, 108, 1040-1047.	0.6	49
483	Endoscopic Diagnosis in the Era of Molecular Biology. Digestive Endoscopy, 1995, 7, 14-18.	1.3	1
484	Analysis of mutagenesis in UV-sensitive mouse lymphoma L5178Y-R cells with a polyomavirus-based shuttle vector. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1995, 344, 31-39.	1.2	3
485	Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemotherapy and Pharmacology, 1995, 35, 423-431.	1.1	27
486	New fungal metabolites as potential antihypercholesterolemics and anticancer agents. Canadian Journal of Botany, 1995, 73, 898-906.	1.2	25
487	The Role of the Immune System in Anti-Tumour Responses. Drugs and Aging, 1995, 7, 266-277.	1.3	4
488	Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet, The, 1995, 345, 1257-1259.	6.3	284
489	Ras signaling and NF1. Current Opinion in Genetics and Development, 1995, 5, 51-55.	1.5	100
490	ETIOLOGY AND PATHOGENESIS OF AIDS-RELATED NON-HODGKIN'S LYMPHOMA. Hematology/Oncology Clinics of North America, 1996, 10, 1081-1109.	0.9	67
491	Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces. International Journal of Cancer, 1996, 67, 876-882.	2.3	26
492	p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Letters, 1996, 105, 105-112.	3.2	23

#	Article	IF	Citations
493	Molecular and genetic events in schistosomiasis-associated human bladder cancer: role of oncogenes and tumor suppressor genes. Cancer Letters, 1996, 105, 123-138.	3.2	49
494	Detection of rare circulating human colon tumor cells in a nude mouse xenograft model. Cancer Letters, 1996, 106, 139-144.	3.2	1
495	The activation of K-ras gene at an early stage of lung tumorigenesis in mice. Cancer Letters, 1996, 107, 165-170.	3.2	28
496	Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Letters, 1996, 107, 241-247.	3.2	52
497	Phytohemagglutinin-L (PHA-L) lectin surface binding of N-linked Î²1â€“6 carbohydrate and its relationship to activated mutant ras in human pancreatic cancer cell lines. Cancer Letters, 1996, 107, 285-291.	3.2	17
498	C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. European Journal of Cancer, 1996, 32, 491-497.	1.3	66
499	Stage of disease confounds apparent relationship between levels of N-ras and duration of survival in head and neck tumours. European Journal of Cancer Part B, Oral Oncology, 1996, 32, 73-75.	0.9	2
500	T cell responses against mutant ras: a basis for novel cancer vaccines. Immunotechnology: an International Journal of Immunological Engineering, 1996, 2, 3-9.	2.4	2
501	Unfarnesylated transforming Ras mutant inhibits the Ras-signaling pathway by forming a stable RasÂ·Raf complex in the cytosol. FEBS Letters, 1996, 378, 15-18.	1.3	30
502	Mammalian microsomal and soluble Ras-processing peptidase activities are distinct. FEBS Letters, 1996, 391, 310-312.	1.3	2
503	Alteration of glycerolipid and sphingolipid-derived second messenger kinetics in ras transformed 3T3 cells. Lipids and Lipid Metabolism, 1996, 1299, 146-154.	2.6	17
504	Failure to Detect Mutations in the Retinoblastoma Protein-binding Domain of the Transcription Factor E2F-1 in Human Cancers. Japanese Journal of Cancer Research, 1996, 87, 1204-1209.	1.7	4
505	Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet, The, 1996, 347, 649-653.	6.3	365
506	Loss of heterozygosity and microsatellite alterations in p53 and RB genes in adenoid cystic carcinoma of the salivary glands. Human Pathology, 1996, 27, 1204-1210.	1.1	57
507	Minimal Residual Epithelial Cancer: Diagnostic Approaches and Prognostic Relevance. Progress in Histochemistry and Cytochemistry, 1996, 30, iii-60.	5.1	29
508	Activation of ras oncogenes during hepatocarcinogenesis induced by N-nitrosodiethylamine: possible involvement of PKC and GAP. Cancer Letters, 1996, 109, 149-154.	3.2	7
509	Differential expression of c-jun and c-myc in N-nitroso diethylamine-induced hepatic oncogenesis in AKR mice. Cancer Letters, 1996, 109, 121-127.	3.2	10
510	Compensatory modulation of GAP activity in response to oncogenic stimulation. Cancer Letters, 1996, 109, 211-215.	3.2	3

#	Article	IF	Citations
511	Potential role of DNA polymerase beta in gene therapy against cancer: A case for colorectal cancer. Medical Hypotheses, 1996, 47, 1-9.	0.8	10
512	Neurofibromatosis and Associated Tumour Suppressor Genes. Pathology Research and Practice, 1996, 192, 647-657.	1.0	23
513	p21ras in Carcinogenesis. Pathology Research and Practice, 1996, 192, 658-668.	1.0	12
514	Endocrine disorders associated with mutations in guanine nucleotide binding proteins. Bailliere's Clinical Endocrinology and Metabolism, 1996, 10, 177-187.	1.0	5
515	Targeting signal transduction for disease therapy. Current Opinion in Cell Biology, 1996, 8, 239-244.	2.6	111
516	Chapter 8 Ras: Processor of vital signals. Advances in Oncobiology, 1996, 1, 159-177.	0.0	1
517	Fish models for environmental carcinogenesis: the rainbow trout.. Environmental Health Perspectives, 1996, 104, 5-21.	2.8	180
518	Ras Oncogene Mutations in Thyroid Tumors. Diagnostic Molecular Pathology, 1996, 5, 45-52.	2.1	65
519	Identification of a Novel Human Rho Protein with Unusual Properties: GTPase Deficiency and In Vivo Farnesylation. Molecular and Cellular Biology, 1996, 16, 2689-2699.	1.1	275
520	RREB-1, a Novel Zinc Finger Protein, Is Involved in the Differentiation Response to Ras in Human Medullary Thyroid Carcinomas. Molecular and Cellular Biology, 1996, 16, 5335-5345.	1.1	133
521	Epidemiology and Mechanisms Relating Diet to Risk of Colorectal Cancer. Nutrition Research Reviews, 1996, 9, 197-239.	2.1	41
522	Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4454-4458.	3.3	149
523	Differential sensitivity of normal and H-ras oncogene-transformed ratkidney epithelial cells to okadaic acid-induced apoptosis. Toxicology and Applied Pharmacology, 1996, 141, 93-101.	1.3	34
524	Chapter 18. Ras Farnesyltransferase Inhibitors. Annual Reports in Medicinal Chemistry, 1996, 31, 171-180.	0.5	12
525	The melanoma differentiation associated gene mda-7 suppresses cancer cell growth.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9160-9165.	3.3	276
526	Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Diseases of the Colon and Rectum, 1996, 39, 1238-1244.	0.7	40
527	Malignant rhabdoid tumor of the colon. Diseases of the Colon and Rectum, 1996, 39, 1322-1326.	0.7	40
528	Frequent K-ras mutations in small bowel adenocarcinomas. Digestive Diseases and Sciences, 1996, 41, 115-118.	1.1	54

#	Article	IF	Citations
529	C-erbB-2, p53, N-ras expression in hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1996, 8, 178-182.	0.7	0
530	The study on relationship between cigarette smoking and the p53 protein and P21 protein expression in non-small lung cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 1996, 8, 187-191.	0.7	1
531	Representativeness of microorgans from human colorectal tumors. In Vitro Cellular and Developmental Biology - Animal, 1996, 32, 189-191.	0.7	0
532	ras oncoproteins in human plasma from lung cancer patients and healthy controls. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 349, 121-126.	0.4	13
533	Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Trends in Molecular Medicine, 1996, 2, 468-475.	2.6	79
534	Distribution of Gs-? activating mutations in human thyroid tumors measured by subcloning. Journal of Cancer Research and Clinical Oncology, 1996, 122, 453-457.	1.2	9
535	Immunohistochemical expression of N-ras oncogene is a late event in head and neck carcinomas. Pathology and Oncology Research, 1996, 2, 30-33.	0.9	4
536	Lack of mutations in K-ras codons 12 and 13 in human atherosclerotic lesions. Chemico-Biological Interactions, 1996, 102, 55-62.	1.7	5
537	c-Ki-ras mutations in peripheral blood of pancreatic cancer patients: A marker for early tumor metastasis. International Journal of Radiation Oncology Biology Physics, 1996, 34, 161-166.	0.4	8
538	Animal models of breast cancer: Their diversity and role in biomedical research. Breast Cancer Research and Treatment, 1996, 39, 1-6.	1.1	55
539	Early Diagnosis of Colon Cancer in Ulcerative Colitis. Digestive Endoscopy, 1996, 8, 53-56.	1.3	0
540	METACHRONOUS COLORECTAL AND BILIARY CARCINOMA: THE AETIOLOGICAL IMPLICATIONS OF Kâ€RAS ONCOGENES. ANZ Journal of Surgery, 1996, 66, 572-574.	0.3	0
541	Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutation Research - Reviews in Genetic Toxicology, 1996, 366, 23-44.	3.0	138
542	Future approaches to genetic toxicology risk assessment. Mutation Research - Reviews in Genetic Toxicology, 1996, 365, 191-204.	3.0	12
543	Gene replacement strategies for lung cancer. Seminars in Radiation Oncology, 1996, 6, 105-109.	1.0	6
544	Identification of overlapping epitopes in mutantras oncogene peptides that activate CD4+ and CD8+ T cell responses. European Journal of Immunology, 1996, 26, 435-443.	1.6	56
545	Hereditary nonpolyposis colorectal cancer: Review of clinical, molecular genetics, and counseling aspects. , 1996, 62, 353-364.		79
546	Ki-ras MUTATIONS IN ADENOMAS: A CHARACTERISTIC OF CANCER-BEARING COLORECTAL MUCOSA. Journal of Pathology, 1996, 180, 357-363.	2.1	39

#	Article	IF	Citations
547	Intravenous vs. intraprostatic administration of N-methyl-N-nitrosourea to induce prostate cancer in rats. , 1996, 28, 32-43.		11
548	Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. , 1996, 77, 507-513.		89
549	K-ras point mutations in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. , 1996, 77, 1752-1757.		75
550	Regional chemotherapy plus hemofiltration for the treatment of regionally advanced malignancy. , 1996, 78, 941-943.		5
551	Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. , 1996, 66, 332-336.		89
552	Three-dimensional cell culture induces novel proliferative and metabolic alterations associated with oncogenic transformation. , 1996, 66, 578-586.		47
553	A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors. , 1996, 66, 753-759.		2
554	A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. , 1996, 69, 241-245.		89
555	An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. , 1996, 67, 264-268.		37
556	Hypersensitivity of NIH3T3 cells transformed by H-RAS gene to DNA-topoisomerase-I inhibitors. , 1996, 67, 702-708.		6
557	N-ras oncogene expression changes the growth characteristics of human melanoma in two independent SCID-hu mouse models. , 1996, 67, 821-825.		7
558	Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: An analysis of specific T-cell-receptor gene usage. , 1996, 68, 471-478.		19
559	Oncogene alterations in primary, recurrent, and metastatic human bone tumors. Journal of Cellular Biochemistry, 1996, 63, 37-50.	1.2	91
560	Identification of a potential physiological substrate for oncogenic Ras-activated protein kinases in activatedXenopus egg extracts: Correlation with oncogenic RAS-induced cell cycle arrest. Journal of Cellular Physiology, 1996, 169, 149-158.	2.0	1
561	Ethnic difference in the pattern of K-ras oncogene mutations in human colorectal cancers. , 1996, 8, 258-261.		15
562	ras effector loop mutations that dissociate p120GAP and neurofibromin interactions. , 1996, 15, 64-69.		3
563	Mutations inras oncogenes: Rare events in ultraviolet B radiation-induced mouse skin tumorigenesis. , 1996, 15, 96-103.		12
564	Frequency of Ki-ras mutations and DNA alkylation in colorectal tissue from individuals living in Manchester. , 1996, 16, 12-19.		25

#	Article	IF	Citations
565	Stimulation of ras GTPase activity by an anti-ras monoclonal antibody. , 1996, 16, 132-138.		1
566	Protection against malignant conversion in SENCAR mouse skin by allTrans retinoic acid: Inhibition of theras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization. , 1996, 17, 13-22.		5
567	Expression of humanKrev-1 gene in lungs of transgenic mice and subsequent reduction in multiplicity of ethyl carbamate-induced lung adenomas. , 1996, 17, 84-91.		8
568	A cembranolide diterpene farnesyl protein transferase inhibitor from the marine soft coral Lobophytum cristagalli. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 909-912.	1.0	48
569	Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1291-1296.	1.0	11
570	Inhibitors of farnesyl:protein transferaseâ€"A possible cancer chemotherapeutic. Bioorganic and Medicinal Chemistry, 1996, 4, 1537-1543.	1.4	20
571	Novel tricyclic aminoacetyl and sulfonamide inhibitors of Ras farnesyl protein transferase. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2977-2982.	1.0	13
572	Pancreatic adenocarcinoma. Current Problems in Cancer, 1996, 20, 281-328.	1.0	35
573	Analysis of microsatellite instability in chronic lymphoproliferative disorders. Annals of Hematology, 1996, 72, 67-71.	0.8	30
574	Positive and negative modulation of H-ras transforming potential by mutations of phenylalanine-28. Molecular Biology Reports, 1996, 23, 109-117.	1.0	1
575	Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. Cancer and Metastasis Reviews, 1996, 15, 53-76.	2.7	48
576	Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. Journal of Oral Pathology and Medicine, 1996, 25, 232-238.	1.4	48
577	Effects of K-rasGene Mutations in the Development of Lung Lesions Induced by 4-(N-Methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone in A/J Mice. Japanese Journal of Cancer Research, 1996, 87, 44-50.	1.7	28
578	Detection of Gastric Cancer Micrometastases in Lymph Nodes by Amplification of Keratin 19 mRNA with Reverse Transcriptase-Polymerase Chain Reaction. Japanese Journal of Cancer Research, 1996, 87, 650-654.	1.7	77
579	Molecular genetic approaches to non-melanoma and melanoma skin cancer. Clinical and Experimental Dermatology, 1996, 21, 253-262.	0.6	15
580	Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo. Nature Structural Biology, 1996, 3, 244-251.	9.7	139
581	Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Medicine, 1996, 2, 668-675.	15.2	455
582	Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. British Journal of Cancer, 1996, 74, 936-941.	2.9	23

#	Article	IF	Citations
583	Codon 12 Ki-ras mutation in non-small-cell lung cancer: comparative evaluation in tumoural and non-tumoural lung. British Journal of Cancer, 1996, 74, 1051-1055.	2.9	14
584	Suppression of the Malignant Phenotype of Melanoma Cells by Anti-Oncogene Ribozymes. Journal of Investigative Dermatology, 1996, 106, 275-280.	0.3	43
585	TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells.. Genes and Development, 1996, 10, 2462-2477.	2.7	612
586	Antisense Oligonucleotides Demonstrate a Dominant Role of c-Ki-RAS Proteins in Regulating the Proliferation of Diploid Human Fibroblasts. Journal of Biological Chemistry, 1996, 271, 28259-28265.	1.6	63
587	Molecular genetics of neurofibromatosis type 1 (NF1).. Journal of Medical Genetics, 1996, 33, 2-17.	1.5	311
588	Simple and Sensitive Detection of Mutations in the Ras Proto-Oncogenes Using PNA-Mediated PCR Clamping. Nucleic Acids Research, 1996, 24, 983-984.	6.5	113
589	Pancreatic adenocarcinoma: epidemiology and genetics.. Journal of Medical Genetics, 1996, 33, 889-898.	1.5	75
590	Necessity of Biotherapeutic Treatments Inducing TH1 Cell Functions in Colorectal Cancer. Cancer Biotherapy and Radiopharmaceuticals, 1996, 11, 373-383.	0.7	12
591	Inhibitors of the Ras Signal Transduction Pathway as Potential Antitumour Agentsx. Journal of Enzyme Inhibition and Medicinal Chemistry, 1996, 11, 77-95.	0.5	7
592	Clinical significance of K-ras oncogene activation in ampullary neoplasms.. Journal of Clinical Pathology, 1996, 49, 460-464.	1.0	52
593	Equilibrium and Kinetic Measurements Reveal Rapidly Reversible Binding of Ras to Raf. Journal of Biological Chemistry, 1996, 271, 6713-6719.	1.6	52
594	Biochemical Characterization of a Novel KRAS Insertion Mutation from a Human Leukemia. Journal of Biological Chemistry, 1996, 271, 32491-32494.	1.6	54
595	The Ca2+-dependent Lipid Binding Domain of P120GAP Mediates Protein-Protein Interactions with Ca2+-dependent Membrane-binding Proteinss. Journal of Biological Chemistry, 1996, 271, 24333-24336.	1.6	60
596	Oncogenes and Antioncogenes in Lung Tumorigenesis. Chest, 1996, 109, 130S-134S.	0.4	35
597	Sporadic Acute Lymphocytic Leukemia Arising in a Patient with Neurofibromatosis and Xanthogranulomatosis. Cancer Investigation, 1996, 14, 109-111.	0.6	5
598	Laboratory Probing of Oncogenes from Human Liquid and Solid Specimens as Markers of Exposure to Toxicants. Critical Reviews in Toxicology, 1996, 26, 483-549.	1.9	4
599	Homozygous Inactivation of theNF1Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders. New England Journal of Medicine, 1997, 336, 1713-1720.	13.9	285
600	Ara-C: Cellular and Molecular Pharmacology. Advances in Cancer Research, 1997, 72, 197-233.	1.9	226

#	Article	IF	Citations
601	Transformation by Ras Suppresses Expression of the Neurotrophic Growth Factor Pleiotrophin. Journal of Biological Chemistry, 1997, 272, 24696-24702.	1.6	11
602	Induction of Cytosolic Phospholipase A2 by Oncogenic Ras in Human Non-small Cell Lung Cancer. Journal of Biological Chemistry, 1997, 272, 14501-14504.	1.6	144
603	Mechanisms of Apoptosis. Advances in Molecular and Cell Biology, 1997, 20, 183-229.	0.1	3
604	K-ras mutations in patients with early colorectal cancers. Gut, 1997, 41, 323-329.	6.1	39
605	K-ras is an essential gene in the mouse with partial functional overlap withâ€‰N-ras. Genes and Development, 1997, 11, 2468-2481.	2.7	475
606	Heat Shock Factor 1 Represses Ras-induced Transcriptional Activation of the c-fos Gene. Journal of Biological Chemistry, 1997, 272, 26803-26806.	1.6	73
607	Growth-inhibitory Activity and Downregulation of the Class II Tumor-suppressor Gene H-rev107 in Tumor Cell Lines and Experimental Tumors. Journal of Cell Biology, 1997, 136, 935-944.	2.3	103
608	Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I. Journal of Biological Chemistry, 1997, 272, 10232-10239.	1.6	177
609	A Raf-independent Epidermal Growth Factor Receptor Autocrine Loop Is Necessary for Ras Transformation of Rat Intestinal Epithelial Cells. Journal of Biological Chemistry, 1997, 272, 18926-18931.	1.6	101
610	Specific Hammerhead Ribozyme-mediated Cleavage of Mutant N-ras mRNA in Vitro and ex Vivo. Journal of Biological Chemistry, 1997, 272, 14304-14313.	1.6	49
611	Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations. Gut, 1997, 41, 320-322.	6.1	17
612	Interaction of Activated Ras with Raf-1 Alone May Be Sufficient for Transformation of rat2 Cells. Molecular and Cellular Biology, 1997, 17, 3047-3055.	1.1	25
613	Phosphorylation of Raf-1 Serine 338-Serine 339 Is an Essential Regulatory Event for Ras-Dependent Activation and Biological Signaling. Molecular and Cellular Biology, 1997, 17, 4509-4516.	1.1	185
614	Rapid Phosphorylation of Ets-2 Accompanies Mitogen-Activated Protein Kinase Activation and the Induction of Heparin-Binding Epidermal Growth Factor Gene Expression by Oncogenic Raf-1. Molecular and Cellular Biology, 1997, 17, 2401-2412.	1.1	161
615	Signaling through Mitogen-Activated Protein Kinase and Rac/Rho Does Not Duplicate the Effects of Activated Ras on Skeletal Myogenesis. Molecular and Cellular Biology, 1997, 17, 3547-3555.	1.1	82
616	Analysis of the Allele-specific PCR Method for the Detection of Neoplastic Disease. Diagnostic Molecular Pathology, 1997, 6, 49-57.	2.1	39
617	Raf-Induced Proliferation or Cell Cycle Arrest Is Determined by the Level of Raf Activity with Arrest Mediated by p21^{Cip1}. Molecular and Cellular Biology, 1997, 17, 5598-5611.	1.1	643
618	Anti-oncogene Ribozymes for Cancer Gene Therapy. Advances in Pharmacology, 1997, 40, 207-257.	1.2	18

#	Article	IF	Citations
619	Cloning and Characterization of Ras-GRF2, a Novel Guanine Nucleotide Exchange Factor for Ras. Molecular and Cellular Biology, 1997, 17, 1396-1406.	1.1	140
620	Increasing Complexity of Ras Signal Transduction: Involvement of Rho Family Proteins. Advances in Cancer Research, 1997, 72, 57-107.	1.9	150
621	Ras1-Mediated Photoreceptor Development in Drosophila. Advances in Developmental Biology (1992), 1997, , 1-41.	1.1	11
622	The Role of Low Molecular Weight GTP-Binding Proteins in Human Platelets. Advances in Molecular and Cell Biology, 1997, 18, 197-251.	0.1	0
623	Prognostic significance of ras/p21 alterations in human ovarian cancer. British Journal of Cancer, 1997, 75, 1547-1553.	2.9	21
624	Physical modulation of intracellular signaling processes by locational regulation. Biophysical Journal, 1997, 72, 2014-2031.	0.2	72
625	Pituitary Tumor Pathogenesis1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1675-1681.	1.8	121
626	Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts. Science, 1997, 275, 1649-1652.	6.0	1,505
627	Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer, 1997, 17, S37-S58.	0.9	66
628	Overexpression of SAP-1, a Transmembrane-Type Protein Tyrosine Phosphatase, in Human Colorectal Cancers. Biochemical and Biophysical Research Communications, 1997, 231, 705-711.	1.0	51
629	Geranylgeranyl as Well as Farnesyl Moiety Is Transferred to Ras p21 Overproduced in Adrenocortical Cells Transformed by c-Ha-rasEJOncogene. Biochemical and Biophysical Research Communications, 1997, 231, 789-792.	1.0	7
630	Human Colorectal Carcinogenesis Is Associated with Deregulation of Homeobox Gene Expression. Biochemical and Biophysical Research Communications, 1997, 232, 742-748.	1.0	96
631	Genomic Structure and Assignment of theRhoH/TTFSmall GTPase Gene (ARHH) to 4p13 byin SituHybridization. Genomics, 1997, 43, 89-94.	1.3	39
632	Characterization of Human Homologs of theDrosophila seven in absentia(sina) Gene. Genomics, 1997, 46, 103-111.	1.3	129
633	Molecular Characterization of Adenocarcinoma of the Cervix. Gynecologic Oncology, 1997, 64, 242-251.	0.6	48
634	Analysis of Ki-ras, p53, and MDM2 Genes in Uterine Leiomyomas and Leiomyosarcomas. Gynecologic Oncology, 1997, 65, 330-335.	0.6	76
635	Activation of Raf-1 in Human Pancreatic Adenocarcinoma. Journal of Surgical Research, 1997, 69, 199-204.	0.8	18
636	Detection of K-raspoint mutation by enriched PCRâ€“colorimetric plate assay. Molecular and Cellular Probes, 1997, 11, 33-38.	0.9	21

#	Article	IF	Citations
637	The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. European Journal of Cancer, 1997, 33, 1572-1577.	1.3	46
638	Ras p21 protein immunoreactivity and its relationship to p53 expression and prognosis in gallbladder and extrahepatic biliary carcinoma. European Journal of Surgical Oncology, 1997, 23, 233-237.	0.5	12
639	A newly identified pattern of K-ras mutations at codons 12 and 13 is associated with long-term survival in colorectal cancer. Surgery, 1997, 122, 765-770.	1.0	11
640	A rat model of pancreatic ductal adenocarcinoma: Targeting chemical carcinogens. Surgery, 1997, 122, 82-90.	1.0	49
641	KRAS oncogene mutations suggest a common histogenetic origin for pleomorphic giant cell tumor of the pancreas, osteoclastoma of the pancreas, and pancreatic duct adenocarcinoma. Human Pathology, 1997, 28, 80-83.	1.1	41
642	Positive autoregulation ofrasgenes expression in fibroblasts. FEBS Letters, 1997, 416, 317-323.	1.3	5
643	Abnormal cholesterol metabolism in a malignant Ras-mutated rat fibroblast line. Pathophysiology, 1997, 4, 235-240.	1.0	0
644	Clinical applications of tumor suppressor genes and oncogenes in cancer. Clinica Chimica Acta, 1997, 257, 157-180.	0.5	9
645	CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. Trends in Pharmacological Sciences, 1997, 18, 437-444.	4.0	29
646	Synergistic effect of MNU and DMBA in mammary carcinogenesis and H-ras activation in female Sprague‚Äì"Dawley rats. Cancer Letters, 1997, 120, 87-93.	3.2	20
647	Meat, starch and non-starch polysaccharides, are epidemiological and experimental findings consistent with acquired genetic alterations in sporadic colorectal cancer?. Cancer Letters, 1997, 114, 25-34.	3.2	14
648	Meat consumption and preparation, and genetic susceptibility in relation to colorectal adenomas. Cancer Letters, 1997, 114, 309-311.	3.2	5
649	Differential Binding to Frequent HLA-A Alleles of p21 RAS Derived Peptides Bearing Oncogenic Substitutions at Position 12 or 13. Human Immunology, 1997, 55, 117-126.	1.2	3
650	Rapid and large-scale method to detect K-ras gene mutations in tumor samples. Clinical Chemistry, 1997, 43, 936-942.	1.5	26
651	Prognostic Factors in Colorectal Carcinoma. Surgical Oncology Clinics of North America, 1997, 6, 463-494.	0.6	4
652	HLA Binding Characteristics and Generation of Cytotoxic Lymphocytes against Peptides Derived from Oncogenic Proteins. Tumori, 1997, 83, 847-855.	0.6	4
653	12th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals: susceptibility to environmental hazards.. Environmental Health Perspectives, 1997, 105, 699-737.	2.8	38
654	The Multistep Nature of Cancer. , 1997, , 54-60.		0

#	Article	IF	Citations
655	A Tyrosine-Phosphorylated Protein of 140 kD Is Constitutively Associated With the Phosphotyrosine Binding Domain of Shc and the SH3 Domains of Grb2 in Acute Myeloid Leukemia Cells. Blood, 1997, 89, 2024-2035.	0.6	14
656	Genetic factors in lung disease Part II: Lung cancer and angiotensin converting enzyme gene. Respirology, 1997, 2, 81-90.	1.3	1
657	Ribozyme-Mediated Cancer Gene Therapy. International Journal of Urology, 1997, 4, 329-337.	0.5	8
658	K-RAS MUTATION AND LOSS OF HETEROZYGOSITY OF CHROMOSOME 17P AND SURVIVAL IN COLORECTAL CANCER. ANZ Journal of Surgery, 1997, 67, 239-244.	0.3	7
659	Molecular genetics of colorectal cancer (part 2). Clinical Oncology, 1997, 9, 79-82.	0.6	1
660	K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. British Journal of Cancer, 1997, 75, 1125-1130.	2.9	125
661	Reduced expression of neurofibromin in human meningiomas. British Journal of Cancer, 1997, 76, 747-756.	2.9	8
662	Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. British Journal of Cancer, 1997, 76, 1293-1299.	2.9	150
663	The molecular biology of oral carcinogenesis: Toward a tumor progression model. Journal of Oral and Maxillofacial Surgery, 1997, 55, 613-623.	0.5	85
664	Dbl family proteins. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1332, F1-F23.	3.3	140
665	Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, F51-F71.	3.3	125
666	Ras-like GTPases. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, M19-M31.	3.3	77
667	Oncoprotein Signalling and Mitosis. Cellular Signalling, 1997, 9, 249-255.	1.7	47
668	Modulation of RAS expression in human malignant cells by dietary supplements. Nutrition, 1997, 13, 921-923.	1.1	5
669	Molecular advances in the etiology and treatment of colorectal cancer. Surgical Oncology, 1997, 6, 143-156.	0.8	9
670	Mucinâ€producing adenocarcinoma of the lung, with special reference to goblet cell type adenocarcinoma: Immunohistochemical observation and Kiâ€ras gene mutation. Pathology International, 1997, 47, 454-460.	0.6	33
671	Detection of colorectal cancer K-ras mutations using a simplified oligonucleotide ligation assay. Journal of Immunological Methods, 1997, 206, 11-19.	0.6	23
672	Genetic changes in lung cancer: Potential biomarkers for early detection and prevention. Translational Research, 1997, 130, 550-557.	2.4	9

#	Article	IF	Citations
673	Mutations of the p53 tumor suppressor gene as clonal marker for multiple primary lung cancers. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 354-360.	0.4	55
674	UV-induced mutations affecting codon 12 of the K-ras gene are suppressed by interferon-Î± in human RSa cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 373, 251-256.	0.4	7
675	Oligonucleotides as modulators of cancer gene expression. , 1997, 74, 317-332.		30
676	Oncogenic RAS genes impair erythroid differentiation of erythroleukaemia cells. Leukemia Research, 1997, 21, 635-640.	0.4	11
677	Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. Leukemia Research, 1997, 21, 697-701.	0.4	45
678	Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth. BioFactors, 1997, 6, 359-366.	2.6	16
679	Generation of Stable CD4+and CD8+T Cell Lines from Patients Immunized withrasOncogene-Derived Peptides Reflecting Codon 12 Mutations. Cellular Immunology, 1997, 182, 137-151.	1.4	88
680	Expression of the Farnesyltransferase Î²-Subunit Gene in Human Ovarian Carcinoma: Correlation to K-rasMutation. Gynecologic Oncology, 1997, 66, 308-312.	0.6	12
681	Molecular and cellular biology of prostate cancer. Cancer and Metastasis Reviews, 1997, 16, 29-66.	2.7	67
682	Signal transduction pathways and their relevance in human astrocytomas. Journal of Neuro-Oncology, 1997, 35, 223-248.	1.4	71
683	The cell and molecular biological approach to biomaterial research: a perspective. Journal of Materials Science: Materials in Medicine, 1997, 8, 131-141.	1.7	69
684	K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers. International Journal of Gastrointestinal Cancer, 1997, 21, 205-217.	0.4	32
685	Topographic genotyping of colorectal carcinoma: From a molecular carcinogenesis model to clinical relevance. Annals of Surgical Oncology, 1997, 4, 269-278.	0.7	4
686	Targeting signal transduction for disease therapy. Medical Oncology, 1997, 14, 83-89.	1.2	14
687	Regulation of cellular signals by G-proteins. Journal of Biosciences, 1997, 22, 375-397.	0.5	2
688	A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines. Journal of Cancer Research and Clinical Oncology, 1997, 123, 91-99.	1.2	15
689	HERâ€2/ neu Signal Transduction in Human Breast and Ovarian Cancer. Stem Cells, 1997, 15, 1-8.	1.4	185
690	Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA-in vitro and in vivo studies. Journal of Cancer Research and Clinical Oncology, 1997, 123, 25-33.	1.2	25

#	Article	IF	Citations
691	Expression of ras proto-oncogenes: regulation and implications in the development of human tumors. Critical Reviews in Oncology/Hematology, 1997, 26, 65-75.	2.0	55
692	Chemoá¹•revention of human cancer: biology and therapy. Critical Reviews in Oncology/Hematology, 1997, 25, 139-174.	2.0	61
693	Discovery of novel nonpeptide tricyclic inhibitors of ras farnesyl protein transferase. Bioorganic and Medicinal Chemistry, 1997, 5, 101-113.	1.4	50
694	Mouse lung epithelial cell linesâ€"tools for the study of differentiation and the neoplastic phenotype. Toxicology, 1997, 123, 53-100.	2.0	118
695	Molecular diagnosis of pancreas carcinoma. , 1997, 11, 225-231.		18
696	Calculation of pathways for the conformational transition between the GTP- and GDP-bound states of the Ha-ras-p21 protein: Calculations with explicit solvent simulations and comparison with calculations in vacuum. Proteins: Structure, Function and Bioinformatics, 1997, 28, 434-451.	1.5	55
697	Chemopreventive effect of perillyl alcohol on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in (C3H/HeJ X A/J)F1 mouse lung. , 1997, 67, 20-25.		36
698	Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia. Genes Chromosomes and Cancer, 1997, 19, 250-255.	1.5	15
699	Epidemiology and molecular biology of Barrett's adenocarcinoma. , 1997, 13, 270-280.		66
700	Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function. Molecular Carcinogenesis, 1997, 18, 221-231.	1.3	13
701	Ha-ras oncogeneâ€"induced transcription of human papillomavirus type 18E6 andE7 oncogenes. , 1997, 19, 83-90.		14
702	Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. , 1997, 79, 462-467.		45
703	Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. , 1997, 79, 900-905.		78
704	K-ras mutations in mucinous ovarian tumors. , 1997, 79, 1581-1586.		200
705	Mutations of the Ki-ras, p53 andAPC genes in adenocarcinomas of the human small intestine. , 1997, 70, 390-395.		75
706	Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. , 1997, 74, 162-170.		17
707	N-ras protein: Frequent quantitative and qualitative changes occur in human colorectal carcinomas. , 1997, 71, 767-775.		10
708	Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. , 1997, 72, 784-790.		147

#	Article	IF	Citations
709	In vivo effects of activated H-ras oncogene expressed in the liver and in urogenital tissues. , 1997, 73, 749-756.		29
710	Farnesyltransferase as a target for anticancer drug design. , 1997, 43, 25-41.		74
711	Detection of Infrequent and Multiple K-rasMutations in Human Tumors and Tumor-Adjacent Tissues. Analytical Biochemistry, 1997, 247, 394-403.	1.1	31
712	Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Research and Treatment, 1998, 52, 201-216.	1.1	57
713	Analysis of signaling protein kinases in human colon or colorectal carcinomas. Digestive Diseases and Sciences, 1998, 43, 1454-1464.	1.1	47
714	The Use of Molecular Technology in the Differentiation of Pancreatic Cancer and Chronic Pancreatitis. International Journal of Gastrointestinal Cancer, 1998, 23, 83-100.	0.4	17
715	All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. EMBO Journal, 1998, 17, 6776-6782.	3.5	327
716	Recent advances in the understanding of interleukin-2 signal transduction. Journal of Clinical Immunology, 1998, 18, 307-320.	2.0	62
717	Alterations of thep53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. International Journal of Cancer, 1998, 78, 695-698.	2.3	45
718	Identification of a Human CD8+T Lymphocyte Neo-epitope Created by arasCodon 12 Mutation Which Is Restricted by the HLA-A2 Allele. Cellular Immunology, 1998, 187, 103-116.	1.4	31
719	Prognostic significance of proliferative activity, DNAâ€ploidy, p53 and Kiâ€ras point mutations in colorectal liver metastases. Cell Proliferation, 1998, 31, 139-153.	2.4	22
720	Differentially Expressed Genes in Head and Neck Cancer. Laryngoscope, 1998, 108, 639-644.	1.1	5
721	Mutations of K-ras oncogene in human adrenal tumours in Taiwan. British Journal of Cancer, 1998, 77, 1060-1065.	2.9	48
722	The detection of K-ras mutations in colorectal cancer using the amplification-refractory mutation system. British Journal of Cancer, 1998, 77, 1267-1274.	2.9	35
723	Facile synthesis of 5â€²-deoxy- and 2â€²,5â€²-dideoxy-6-thiopurine nucleosides by nucleoside phosphorylases. Tetrahedron, 1998, 54, 8661-8670.	1.0	11
724	Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillaryelectrophoresis and allele specific polymerase chain reaction. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 403, 103-112.	0.4	49
725	Ras p21 protein levels in human plasma from patients with chronic obstructive pulmonary disease (COPD) compared with lung cancer patients and healthy controls. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 403, 229-235.	0.4	12
726	Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia. Leukemia Research, 1998, 22, 631-637.	0.4	19

#	Article	IF	Citations
727	Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. Cell Proliferation, 1998, 31, 139-153.	2.4	20
728	Determination of pancreatic ductal carcinoma histogenesis by analysis of mucous quality and K-ras mutation. , 1998, 82, 651-660.		26
729	K-ras mutations in nonmucinous ovarian epithelial tumors. Cancer, 1998, 82, 1088-1095.	2.0	72
730	Generation and characterization of GP-100 peptide-specific NK-T cell clones. , 1998, 75, 794-803.		11
731	Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells. , 1998, 76, 601-608.		12
732	Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. , 1998, 69, 119-124.		29
733	Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. , 1998, 185, 130-138.		114
734	Clinical application of K-ras oncogene mutations in pancreatic carcinoma: Detection of micrometastases. , 1998, 15, 40-46.		10
735	Overexpression of CD44: A useful independent predictor of prognosis in patients with colorectal carcinomas. Annals of Surgical Oncology, 1998, 5, 495-501.	0.7	47
736	Oncogens in ENT and head and neck â€" a review. Indian Journal of Otolaryngology, 1998, 50, 320-325.	0.1	0
737	Prognostic factors in colorectal cancer. Diseases of the Colon and Rectum, 1998, 41, 1033-1049.	0.7	124
738	Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids. Lipids, 1998, 33, 39-46.	0.7	23
739	Comparative genomic in situ hybridization discloses chromosomal copy number changes in a transplanted brain tumor line of the rat (Rattus norvegicus). Mammalian Genome, 1998, 9, 193-197.	1.0	14
740	Preparation of aromatic farnesol analogues via a Cu(I)-mediated Grignard coupling of THP ethers. Tetrahedron Letters, 1998, 39, 783-786.	0.7	14
741	Inhibitors of farnesyl protein transferase. synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2521-2526.	1.0	16
742	Synthesis of Isomeric 3-Piperidinyl and 3-Pyrrolidinyl Benzo[5,6]cyclohepta[1,2-b]pyridines: Sulfonamido Derivatives as Inhibitors of Ras Prenylation. Bioorganic and Medicinal Chemistry, 1998, 6, 673-686.	1.4	13
743	The Significance of ras Oncogene Mutation for the Development of Human Breast Cancer. Breast Journal, 1998, 4, 112-115.	0.4	0
744	Genetic alterations in endometrial carcinomas. International Journal of Gynecological Cancer, 1998, 8, 415-422.	1.2	3

#	Article	IF	Citations
745	Clear cell carcinoma of the pancreas: an adenocarcinoma with ductal phenotype. Histopathology, 1998, 32, 444-448.	1.6	42
746	Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. Alimentary Pharmacology and Therapeutics, 1998, 12, 937-948.	1.9	13
747	Tumourigenicity ofMTG8, a leukaemiaâ€related gene, in concert with vâ€Haâ€rasgene in BALB/3T3 cells. British Journal of Haematology, 1998, 101, 737-742.	1.2	14
748	Genomic organization and cloning of the human homologue of murine Sipa-1. Gene, 1998, 214, 215-221.	1.0	1
749	K-ras mutations in sinonasal adenocarcinomas in patients occupationally exposed to wood or leather dust. Cancer Letters, 1998, 126, 59-65.	3.2	66
750	Role of K-ras mutations in colorectal carcinoma. Cancer Letters, 1998, 126, 179-185.	3.2	20
751	Inhibition of K-ras-transformed rodent and human cancer cell growth via induction of apoptosis by irreversible inhibitors of ras endoprotease1This work was presented in part at the 1997 meeting on Biology of Proteolysis, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA, 23â€“27 April 1997.1. Cancer Letters, 1998, 131, 191-200.	3.2	24
752	Retention of intracellular fibronectin expression in primary and metastatic thyroid carcinoma: an immunohistochemical study. Cancer Letters, 1998, 133, 215-222.	3.2	10
753	Points of convergence between Ca2+ and Ras signalling pathways. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1448, 171-182.	1.9	26
754	The promise of cancer genetics. Lancet, The, 1998, 351, SII1-SII8.	6.3	68
755	Osteoclast-like Giant Cell Tumor of the Pancreas with Metastases to Gallbladder and Lymph Nodes. A Case Report. Pathology Research and Practice, 1998, 194, 587-594.	1.0	18
756	Therapeutic intervention and signaling. Current Opinion in Cell Biology, 1998, 10, 284-288.	2.6	53
757	Ras versus cyclin-dependent kinase inhibitors. Current Opinion in Genetics and Development, 1998, 8, 43-48.	1.5	60
758	Ras signalling and apoptosis. Current Opinion in Genetics and Development, 1998, 8, 49-54.	1.5	508
759	Oncogenic ras modulates epidermal growth factor responsiveness in endometrial carcinomas. European Journal of Cancer, 1998, 34, 737-744.	1.3	18
760	The Drosophila Gene hid Is a Direct Molecular Target of Ras-Dependent Survival Signaling. Cell, 1998, 95, 331-341.	13.5	462
761	A novel human RasGAP-like gene that maps within the prostate cancer susceptibility locus at chromosome 1q25. FEBS Letters, 1998, 441, 127-131.	1.3	20
762	J-104,871, a Novel Farnesyltransferase Inhibitor, Blocks Ras Farnesylation In Vivo in a Farnesyl Pyrophosphate-Competitive Manner. Molecular Pharmacology, 1998, 54, 1-7.	1.0	36

#	Article	IF	Citations
763	NEW TUMOR MARKERS OF TESTIS CANCER. Urologic Clinics of North America, 1998, 25, 365-373.	0.8	7
764	Nucleotide Sequence of Exon 2 to 4 of theR-rasGene in the Hermaphroditic FishRivulus marmorafus. DNA Sequence, 1998, 8, 229-234.	0.7	6
765	Dendritic cell-based approaches to cancer immunotherapy. Expert Opinion on Investigational Drugs, 1998, 7, 1617-1627.	1.9	4
766	Additional Evidence That the K-rasProtooncogene is a Candidate for the Major Mouse Pulmonary Adenoma Susceptibility (Pas-1) Gene. Experimental Lung Research, 1998, 24, 481-497.	0.5	60
767	Increasing Complexity of the Ras Signaling Pathway. Journal of Biological Chemistry, 1998, 273, 19925-19928.	1.6	504
768	Molecular Comparison of Human and Mouse Pulmonary Adenocarcinomas. Experimental Lung Research, 1998, 24, 541-555.	0.5	141
769	Identification and Cloning of Human G-Protein Î³ 7, Down-regulated in Pancreatic Cancer. Biochemical and Biophysical Research Communications, 1998, 246, 205-209.	1.0	33
770	Role of Far Upstream Repressor Elements Controlling Proto-Ha-ras Gene Transcription. Biochemical and Biophysical Research Communications, 1998, 252, 716-722.	1.0	6
771	Involvement of H-rasin Erythroid Differentiation of TF1 and Human Umbilical Cord Blood CD34+++Cells. Blood Cells, Molecules, and Diseases, 1998, 24, 124-136.	0.6	8
772	Non-radioactive detection of K-rasmutations by nested allele specific PCR and oligonucleotide hybridization. Molecular and Cellular Probes, 1998, 12, 309-315.	0.9	7
773	Restriction Endonuclease-Mediated Selective Polymerase Chain Reaction. American Journal of Pathology, 1998, 153, 373-379.	1.9	79
774	Specific K-ras2 Mutations in Human Sporadic Colorectal Adenomas Are Associated with DNA Near-Diploid Aneuploidy and Inhibition of Proliferation. American Journal of Pathology, 1998, 153, 1201-1209.	1.9	37
775	The Type of K-ras Mutation Determines Prognosis in Colorectal Cancer. American Journal of Surgery, 1998, 175, 198-202.	0.9	79
776	Reovirus Therapy of Tumors with Activated Ras Pathway. , 1998, 282, 1332-1334.		651
777	Increased Cyclin D1 in Human Pancreatic Cancer Is Associated with Decreased Postoperative Survival. Oncology, 1998, 55, 363-369.	0.9	88
778	N-ras Mutations are Common in Melanomas from Sun-Exposed Skin of Humans but Rare in Mucosal Membranes or Unexposed Skin. Journal of Investigative Dermatology, 1998, 111, 757-761.	0.3	131
779	The Hyaluronan Receptor RHAMM Regulates Extracellular-regulated Kinase. Journal of Biological Chemistry, 1998, 273, 11342-11348.	1.6	187
780	Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 13221-13226.	3.3	432

#	Article	IF	Citations
781	The Cytogenesis and Pathogenesis of Pituitary Adenomas*. Endocrine Reviews, 1998, 19, 798-827.	8.9	285
782	Radicicol Leads to Selective Depletion of Raf Kinase and Disrupts K-Ras-activated Aberrant Signaling Pathway. Journal of Biological Chemistry, 1998, 273, 822-828.	1.6	87
783	Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines. Journal of Experimental Medicine, 1998, 187, 1893-1902.	4.2	140
784	Induction of Cyclooxygenase-2 by Activated Ha-rasOncogene in Rat-1 Fibroblasts and the Role of Mitogen-activated Protein Kinase Pathway. Journal of Biological Chemistry, 1998, 273, 22120-22127.	1.6	161
785	Activation of the Rap1 GTPase by the B Cell Antigen Receptor. Journal of Biological Chemistry, 1998, 273, 29218-29223.	1.6	76
786	Differential regulation of neurofibromin and p120 GTPaseâ€activating protein by nutritionally relevant fatty acids. Nutrition and Cancer, 1998, 30, 97-107.	0.9	10
787	Early Steps in Insulin Action. Archives of Physiology and Biochemistry, 1998, 106, 269-289.	1.0	8
788	Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase. Journal of Biological Chemistry, 1998, 273, 24052-24056.	1.6	393
789	Molecular Oncology: Diagnostic and Prognostic Assessment of Human Cancers in the Clinical Laboratory. Cancer Investigation, 1998, 16, 485-502.	0.6	5
790	Regulation of Exit from Quiescence by p27 and Cyclin D1-CDK4. Molecular and Cellular Biology, 1998, 18, 6605-6615.	1.1	88
791	Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 1126-1130.	3.3	64
792	p21^{WAF1/CIP1} Is Upregulated by the Geranylgeranyltransferase I Inhibitor GGTI-298 through a Transforming Growth Factor Î²- and Sp1-Responsive Element: Involvement of the Small GTPase RhoA. Molecular and Cellular Biology, 1998, 18, 6962-6970.	1.1	122
793	Ras Signals to the Cell Cycle Machinery via Multiple Pathways To Induce Anchorage-Independent Growth. Molecular and Cellular Biology, 1998, 18, 2586-2595.	1.1	63
794	Sequence-Directed Base Mispairing in Human Oncogenes. Molecular and Cellular Biology, 1998, 18, 4659-4669.	1.1	4
795	A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis. Molecular and Cellular Biology, 1998, 18, 85-92.	1.1	164
796	The Peripheral Cannabinoid Receptor, Cb2, in Retrovirally-Induced Leukemic Transformation and Normal Hematopoiesis. Leukemia and Lymphoma, 1998, 32, 29-43.	0.6	27
797	Neurofibromatosis Type 1: Piecing the Puzzle Together. Canadian Journal of Neurological Sciences, 1998, 25, 181-191.	0.3	67
798	Ras Activation in Astrocytomas and Neurofibromas. Canadian Journal of Neurological Sciences, 1998, 25, 267-281.	0.3	63

#	Article	IF	Citations
799	Genetic predispositions and childhood cancer.. Environmental Health Perspectives, 1998, 106, 801-806.	2.8	6
800	Sensitive Methods for the Detection of ras Mutations in Lung Cancer: Some Answers, More Questions. Clinical Chemistry, 1998, 44, 1376-1378.	1.5	4
801	In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.. Environmental Health Perspectives, 1998, 106, 71-80.	2.8	40
802	Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.. Environmental Health Perspectives, 1998, 106, 57-69.	2.8	115
803	Relationship between Schistosomiasis and Bladder Cancer. Clinical Microbiology Reviews, 1999, 12, 97-111.	5.7	417
804	DIET AND CANCER. , 1999, , 879-928.		0
805	RasMutation, Irrespective of Cell Type and p53 Status, Determines a Cellâ€™s Destiny to Undergo Apoptosis by Okadaic Acid, an Inhibitor of Protein Phosphatase 1 and 2A. Molecular Pharmacology, 1999, 56, 515-525.	1.0	46
806	Oncogene-mediated downregulation of RECK, a novel transformation suppressor gene. Brazilian Journal of Medical and Biological Research, 1999, 32, 891-895.	0.7	20
807	Genetic alterations in Ki-ras and Ha-ras genes in Juvenile Nasopharyngeal Angiofibromas and head and neck cancer. Sao Paulo Medical Journal, 1999, 117, 113-120.	0.4	25
808	Inhibition of Ras and Related Guanosine Triphosphate-dependent Proteins as a Therapeutic Strategy for Blocking Malignant Glioma Growth: II-Preclinical Studies in a Nude Mouse Model. Neurosurgery, 1999, 45, 1208-1215.	0.6	38
809	Expression of Activated Epidermal Growth Factor Receptors, Ras-Guanosine Triphosphate, and Mitogen-activated Protein Kinase in Human Glioblastoma Multiforme Specimens. Neurosurgery, 1999, 45, 1442-1453.	0.6	206
810	Diagnosis of Childhood Acute Myeloid Leukemia. Clinics in Laboratory Medicine, 1999, 19, 187-238.	0.7	12
811	M-Ras, a Widely Expressed 29-kD Homologue of p21 Ras: Expression of a Constitutively Active Mutant Results in Factor-Independent Growth of an Interleukin-3â€“Dependent Cell Line. Blood, 1999, 94, 2433-2444.	0.6	51
812	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells. Blood, 1999, 94, 2469-2476.	0.6	81
813	Mutant N-ras Induces Myeloproliferative Disorders and Apoptosis in Bone Marrow Repopulated Mice. Blood, 1999, 93, 2043-2056.	0.6	103
814	Role of Amplified Genes in the Production of Autoantibodies. Blood, 1999, 93, 2158-2166.	0.6	40
815	Concepts in Ras-directed therapy. Expert Opinion on Investigational Drugs, 1999, 8, 2121-2140.	1.9	49
816	Activation of K-p21ras and N-p21ras, but Not H-p21ras, Is Necessary for Mitogen-Induced Human Airway Smooth-Muscle Proliferation. American Journal of Respiratory Cell and Molecular Biology, 1999, 21, 719-727.	1.4	37

#	Article	IF	Citations
817	A Relationship between K-ras Gene Mutations and Some Clinical and Histologic Variables in Patients with Primary Colorectal Carcinoma. Clinical Chemistry and Laboratory Medicine, 1999, 37, 723-7.	1.4	9
818	The relationship between 1,2-dimethylhydrazine dose and the induction of colon tumours: tumour development in female SWR mice does not require a K-ras mutational event. Carcinogenesis, 1999, 20, 509-513.	1.3	34
819	Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture. Nucleic Acids Research, 1999, 27, 2737-2744.	6.5	27
820	Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7065-7070.	3.3	131
821	High-level expression, purification, kinetic characterization and crystallization of protein farnesyltransferase Î²-subunit C-terminal mutants. Protein Engineering, Design and Selection, 1999, 12, 341-348.	1.0	10
822	Internalized Epidermal Growth Factor Receptors Participate in the Activation of p21 in Fibroblasts. Journal of Biological Chemistry, 1999, 274, 34350-34360.	1.6	134
823	Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility. Journal of Biological Chemistry, 1999, 274, 17164-17170.	1.6	245
824	Oncogenic Ras Sensitizes Cells to Apoptosis by Par-4. Journal of Biological Chemistry, 1999, 274, 29976-29983.	1.6	91
825	The ras Oncogene-Mediated Sensitization of Human Cells to Topoisomerase II Inhibitor-Induced Apoptosis. Journal of the National Cancer Institute, 1999, 91, 236-244.	3.0	36
826	Frequency and Clinicopathology Associations of K-ras Mutations in Colorectal Cancer in a Northeast Mexican Population. Digestive Diseases, 1999, 17, 225-229.	0.8	30
827	Therapeutic Efficacy of an Adenovirus-Mediated Anti-H-ras Ribozyme in Experimental Bladder Cancer. Oligonucleotides, 1999, 9, 341-349.	4.4	36
828	The Molecular Perspective: The ras Oncogene. Stem Cells, 1999, 17, 235-236.	1.4	49
829	Paradoxical activation of Raf by a novel Raf inhibitor. Chemistry and Biology, 1999, 6, 559-568.	6.2	232
830	Solid-phase synthesis of novel inhibitors of Farnesyl Transferase. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 623-626.	1.0	23
831	Potent inhibitors of protein farnesyltransferase: Heteroarenes as cysteine replacements. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 703-708.	1.0	16
832	Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1069-1074.	1.0	31
833	Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1875-1880.	1.0	2
834	Î±-Cyanocinnamide derivatives: a new family of non-peptide, non-sulfhydryl inhibitors of ras farnesylation. Bioorganic and Medicinal Chemistry, 1999, 7, 1727-1736.	1.4	11

#	Article	IF	Citations
835	ADP-ribosylation of oncogenic Ras proteins by Pseudomonas aeruginosa exoenzyme S in vivo. Molecular Microbiology, 1999, 32, 1054-1064.	1.2	45
836	Analogues of 1-(3,10-Dibromo-8-chloro-6,11-dihydro-5 H -benzo[5,6]-cyclohepta[1,2- b) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 7 Chemistry, 1999, 7, 1845-1855.	1.4	9
837	Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. Bioorganic and Medicinal Chemistry, 1999, 7, 3011-3024.	1.4	30
838	Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nature Cell Biology, 1999, 1, 98-105.	4.6	411
839	Squalene, Olive Oil, and Cancer Risk: Review and Hypothesis. Annals of the New York Academy of Sciences, 1999, 889, 193-203.	1.8	112
840	Farnesyltransferase Inhibitors: Preclinical Development. Annals of the New York Academy of Sciences, 1999, 886, 91-102.	1.8	15
841	Selective Inhibition of ras-Transformed Cell Growth by a Novel Fatty Acid-Based Chloromethyl Ketone Designed to Target Ras Endoprotease. Annals of the New York Academy of Sciences, 1999, 886, 103-108.	1.8	17
842	SCH 51344, An Inhibitor of RAS/RAC-Mediated Cell Morphology Pathway. Annals of the New York Academy of Sciences, 1999, 886, 122-131.	1.8	4
843	Immortalized Pancreatic Duct Cells in vitro and in vivo. Annals of the New York Academy of Sciences, 1999, 880, 50-65.	1.8	18
844	Molecular Pathology of Invasive Carcinoma. Annals of the New York Academy of Sciences, 1999, 880, 74-82.	1.8	13
845	Myelodysplasia and myeloproliferative disorders in childhood: an update. British Journal of Haematology, 1999, 105, 852-863.	1.2	76
846	Antitumor Efficacy of Hypothemycin, A New Ras-signaling Inhibitor. Japanese Journal of Cancer Research, 1999, 90, 1139-1145.	1.7	59
847	A role for intracellular immunization in chemosensitization of tumor cells?. Gene Therapy, 1999, 6, 1202-1209.	2.3	7
848	The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress. Oncogene, 1999, 18, 689-701.	2.6	21
849	Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene, 1999, 18, 1807-1817.	2.6	50
850	TC21 and Ras share indistinguishable transforming and differentiating activities. Oncogene, 1999, 18, 2107-2116.	2.6	60
851	Anchorage-dependent expression of cyclin A in primary cells requires a negative DNA regulatory element and a functional Rb. Oncogene, 1999, 18, 1819-1825.	2.6	18
852	Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene, 1999, 18, 2281-2290.	2.6	241

#	Article	IF	Citations
853	A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene, 1999, 18, 2579-2588.	2.6	111
854	Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene, 1999, 18, 3104-3113.	2.6	131
855	Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms. Oncogene, 1999, 18, 4336-4347.	2.6	29
856	Suppression of anchorage-independent growth of human cancer cell lines by the drs gene. Oncogene, 1999, 18, 4777-4787.	2.6	38
857	Activation of mitogen-activated protein kinase is necessary but not sufficient for proliferation of human thyroid epithelial cells induced by mutant Ras. Oncogene, 1999, 18, 4819-4832.	2.6	45
858	Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Oncogene, 1999, 18, 5268-5277.	2.6	73
859	Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene, 1999, 18, 7514-7526.	2.6	107
860	Ras stimulates DNA topoisomerase IIÎ± through MEK: A link between oncogenic signaling and a therapeutic target. Oncogene, 1999, 18, 7149-7160.	2.6	25
861	Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene, 1999, 18, 7115-7123.	2.6	69
862	Signal transduction pathways regulated by arsenate and arsenite. Oncogene, 1999, 18, 7794-7802.	2.6	80
863	Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes. British Journal of Cancer, 1999, 80, 526-535.	2.9	139
864	Targeted disruption of the K-Ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. British Journal of Cancer, 1999, 80, 1884-1891.	2.9	49
865	c-Ki-ras mutations in colorectal adenocarcinomas from a country with a rapidly changing colorectal cancer incidence. British Journal of Cancer, 1999, 81, 237-241.	2.9	12
866	Differential regulation of MAP kinase cascade in human colorectal tumorigenesis. British Journal of Cancer, 1999, 81, 1116-1121.	2.9	15
867	Differences in K-ras Codon 12 Mutation Frequency between â€œHigh-Riskâ€•and â€œLow-Riskâ€•HPV-Infected Samples. Gynecologic Oncology, 1999, 75, 108-112.	0.6	11
868	Tumor Suppressor Genes in Rodent Lung Carcinogenesisâ€”Mutation ofp53Does Not Appear to be an Early Lesion in Lung Tumor Pathogenesis. Toxicology and Applied Pharmacology, 1999, 156, 70-77.	1.3	10
869	Janus faces of ras: anti or pro-apoptotic?. , 1999, 4, 383-388.		8
870	Proteins of the Ras pathway as novel potential anticancer therapeutic targets. , 1999, 15, 345-358.		8

#	Article	IF	Citations
871	Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum. Digestive Diseases and Sciences, 1999, 44, 2014-2019.	1.1	24
872	Micrometastatic bone marrow involvement: detection and prognostic significance. Medical Oncology and Tumor Pharmacotherapy, 1999, 16, 154-165.	1.0	72
873	Educational Review Cellular and Biological Therapies of Gastrointestinal Tumors: Overview of Clinical Trials. Annals of Surgical Oncology, 1999, 6, 218-223.	0.7	3
874	H-ras-transformed NRK-52E renal epithelial cells have altered growth, morphology, and cytoskeletal structure that correlates with renal cell carcinoma in vivo. In Vitro Cellular and Developmental Biology - Animal, 1999, 35, 205-214.	0.7	14
875	Prognostic Markers in Resected Nonâ€“Small-Cell Lung Cancer: An Patients with 5 Year Follow-Up. Clinical Lung Cancer, 1999, 1, 59-67.	1.1	28
876	Antisense Oligonucleotide Inhibition of Serine/Threonine Kinases. , 1999, 82, 437-449.		22
877	Function and biological applications of catalytic nucleic acids. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1445, 1-20.	2.4	8
878	Cloning, expression and characterization of a novel human Ras-related protein that is regulated by glucocorticoid hormone. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1489, 452-456.	2.4	44
879	Cytogenetic damage and ras p21 oncoprotein levels from patients with chronic obstructive pulmonary disease (COPD), untreated lung cancer and healthy controls. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 431, 123-131.	0.4	7
880	Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leukemia Research, 1999, 23, 115-126.	0.4	115
881	Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Experimental Hematology, 1999, 27, 1599-1608.	0.2	35
882	Kâ€rasgene point mutation in neogenetic lesions of subpleural fibrotic lesions: Either an early genetic event in lung cancer development or a nonâ€specific genetic change during the inflammatory reparative process. Pathology International, 1999, 49, 411-418.	0.6	11
883	A Scintillation Proximity Assay for the Raf/MEK/ERK Kinase Cascade: High-Throughput Screening and Identification of Selective Enzyme Inhibitors. Analytical Biochemistry, 1999, 268, 318-329.	1.1	70
884	Reduced receptor expression for platelet-derived growth factor and epidermal growth factor in dividing mouse lung epithelial cells. , 1999, 25, 285-294.		9
885	Characterization of six cell lines established from human pancreatic adenocarcinomas. , 1999, 85, 832-840.		29
886	The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer, 1999, 85, 1703-1710.	2.0	146
887	Transient monosomy 7. , 1999, 85, 2655-2661.		51
888	K-ras and p53 mutations in the pathogenesis of classical and goblet cell carcinoids of the appendix. , 1999, 86, 14-21.		87

#	Article	IF	Citations
889	ras Gene mutations in ethmoid sinus adenocarcinoma. , 1999, 86, 255-264.		40
890	K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma. , 1999, 86, 1441-1448.		40
891	Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. , 1999, 80, 553-558.		71
892	v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. , 1999, 80, 731-737.		51
893	Establishment and characterization of 12 human colorectal-carcinoma cell lines. , 1999, 81, 902-910.		40
894	New approaches to cancer therapies. Journal of Pathology, 1999, 187, 138-146.	2.1	19
895	Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. , 1999, 187, 433-438.		95
896	Gene therapy for carcinoma of the breast: Genetic toxins. Breast Cancer Research, 1999, 2, 22-7.	2.2	4
897	Pharmaceutical Perspectives of Nonviral Gene Therapy. Advances in Genetics, 1999, 41, 95-156.	0.8	126
898	BRCA1 Partially Reverses the Transforming Activity of the ras Oncogene. Neoplasia, 1999, 1, 417-423.	2.3	1
899	Chemoprevention: Insights into biological mechanisms and promising food factors. Food Reviews International, 1999, 15, 335-395.	4.3	27
900	Macrophage Stimulating Protein. Advances in Cancer Research, 1999, 77, 139-167.	1.9	29
901	Proteasome inhibitors as potential novel anticancer agents. Drug Resistance Updates, 1999, 2, 215-223.	6.5	142
902	Control of the cell cycle and apoptosis. European Journal of Cancer, 1999, 35, 531-539.	1.3	224
903	Non steroidal anti-inflammatory drugs and colorectal cancer: is there a way forward?. European Journal of Cancer, 1999, 35, 892-901.	1.3	17
904	Control of the cell cycle and apoptosis. European Journal of Cancer, 1999, 35, 1886-1894.	1.3	215
905	Genetic Analysis in Fine-needle Aspiration of the Thyroid: A New Tool for the Clinic. Trends in Endocrinology and Metabolism, 1999, 10, 280-285.	3.1	25
906	Needle-in-a-haystack detection and identification of base substitution mutations in human tissues. Mutation Research - Mutation Research Genomics, 1999, 406, 79-100.	1.2	22

#	Article	IF	Citations
907	Ras caught in another affair: the exchange factors for Ral. Current Opinion in Genetics and Development, 1999, 9, 112-117.	1.5	144
909	The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Brain Research Reviews, 1999, 29, 232-249.	9.1	48
910	Susceptibility to urethane carcinogenesis of transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) and its modification by butylhydroxytoluene. Cancer Letters, 1999, 145, 101-106.	3.2	19
911	Low-level transforming activity of an activated Ras gene under the control of a vaccinia virus p40 promoter is abrogated by truncation of the Ras cDNA. Vaccine, 1999, 17, 2275-2283.	1.7	0
912	Perspectives on Cancer Chemoprevention Research and Drug Development. Advances in Cancer Research, 1999, 78, 199-334.	1.9	234
913	Selection of phage-displayed Fab antibodies on the active conformation of Ras yields a high affinity conformation-specific antibody preventing the binding of c-Raf kinase to Ras. FEBS Letters, 1999, 463, 115-120.	1.3	19
914	The role of p21ras in pancreatic neoplasia and chronic pancreatitis. Human Pathology, 1999, 30, 602-610.	1.1	17
915	Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the ras pathway. World Neurosurgery, 1999, 51, 211-218.	1.3	48
916	Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factorâ€“related peptides. Gastroenterology, 1999, 117, 567-576.	0.6	37
917	Inhibition of benzo[a]pyrene-induced mutagenesis by (â€“)-epigallocatechin gallate in the lung of rpsL transgenic mice. Carcinogenesis, 1999, 20, 421-424.	1.3	55
918	Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. Journal of Endocrinological Investigation, 1999, 22, 781-789.	1.8	45
919	Development of Keratoacanthomas and Squamous Cell Carcinomas in Transgenic Rabbits with Targeted Expression of EJras. Oncogene in Epidermis. American Journal of Pathology, 1999, 155, 315-324.	1.9	19
920	Urinary Bladder Transitional Cell Carcinogenesis Is Associated with Down-Regulation of NF1 Tumor Suppressor Gene in Vivo and in Vitro. American Journal of Pathology, 1999, 154, 755-765.	1.9	38
921	Molecular Genetic Alterations in Radiation-Induced Astrocytomas. American Journal of Pathology, 1999, 154, 1431-1438.	1.9	101
922	Malignant Transformation and Antineoplastic Actions of Nonsteroidal Antiinflammatory Drugs (Nsaids) on Cyclooxygenase-Null Embryo Fibroblasts. Journal of Experimental Medicine, 1999, 190, 451-460.	4.2	254
923	Ras and Rap1: Two Highly Related Small GTPases with Distinct Function. Experimental Cell Research, 1999, 253, 157-165.	1.2	157
924	Identification and Chromosomal Location of Two Human Genes Encoding Enzymes Potentially Involved in Proteolytic Maturation of Farnesylated Proteins. Genomics, 1999, 58, 270-280.	1.3	55
925	Cell Signaling Defects and Human Disease. Molecular Genetics and Metabolism, 1999, 66, 143-171.	0.5	4

#	Article	IF	Citations
926	Detection of DNA Abnormalities by Arbitrarily Primed PCR Fingerprinting: Amplification of theMDM2Gene in a Mediastinum Fibrosarcoma. Biochemical and Biophysical Research Communications, 1999, 258, 271-277.	1.0	2
927	Involvement of the Sp1 Site in ras-Mediated Downregulation of the RECK Metastasis Suppressor Gene. Biochemical and Biophysical Research Communications, 1999, 264, 668-675.	1.0	94
928	Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations. Journal of Clinical Pathology, 1999, 52, 64-67.	2.1	6
929	Farnesyl transferase inhibitors. Advances in Medicinal Chemistry, 1999, 4, 273-314.	0.8	10
930	High-meat diets and cancer risk. Proceedings of the Nutrition Society, 1999, 58, 243-248.	0.4	110
931	Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Annals of Oncology, 1999, 10, 449-453.	0.6	26
932	Complementation of Defective Colony-Stimulating Factor 1 Receptor Signaling and Mitogenesis by Raf and v-Src. Molecular and Cellular Biology, 1999, 19, 1101-1115.	1.1	53
933	Benzo[A]Pyrene and Dibenzo[A, L]Pyrene do not Alter gap Junction Communication in Rat Liver Epithelial Cells. Polycyclic Aromatic Compounds, 1999, 17, 53-62.	1.4	1
934	K-Ras Point Mutations in Spontaneously Occurring Endometrial Adenocarcinomas in the Donryu Rat.. Tohoku Journal of Experimental Medicine, 1999, 189, 87-93.	0.5	11
935	Recent studies of the mechanism of protein prenylation (1992 to 1998). Natural Product Reports, 2000, 17, 137-144.	5.2	27
936	TAN-1813, a Novel Ras-Farnesyltransferase Inhibitor Produced by Phoma sp. Taxonomy, Fermentation, Isolation and Biological Activities In Vitro and In Vivo.. Journal of Antibiotics, 2000, 53, 765-778.	1.0	23
937	Whatâ€™s New with Tumor Markers for Colorectal Cancer?. Digestive Surgery, 2000, 17, 209-215.	0.6	23
938	Acinarâ€“Islet Cell Tumor of the Pancreas. Journal of Clinical Gastroenterology, 2000, 31, 175-178.	1.1	16
939	Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1. , 2000, 88, 2010-2021.		13
940	Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. International Journal of Cancer, 2000, 85, 438-445.	2.3	137
941	Human hemangiosarcomas have a common polymorphism but no mutations in the connexin37 gene. , 2000, 86, 67-70.		20
942	Molecular interactions in the Vogelstein model of colorectal carcinoma. , 2000, 190, 412-416.		148
943	Disrupting the geranylgeranylation at the C-termini of the shrimp Ras by depriving guanine nucleotide binding at the N-terminal. , 2000, 286, 441-449.		10

#	Article	IF	Citations
944	Genetic changes in solid tumors. , 2000, 18, 358-370.		6
945	Frequent codon 12 Ki-ras mutations in mouse skin tumors initiated byN-methyl-N?-nitro-N-nitrosoguanidine and promoted by mezerein. Molecular Carcinogenesis, 2000, 27, 298-307.	1.3	25
946	Down-regulation of drs mRNA in human colon adenocarcinomas. International Journal of Cancer, 2000, 87, 5-11.	2.3	19
947	Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. International Journal of Cancer, 2000, 87, 155-164.	2.3	37
948	Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification ofp53 and K-ras genes in patients with colorectal cancer. International Journal of Cancer, 2000, 89, 337-344.	2.3	91
949	Expression and regulation of neuropilin-1 in human astrocytomas. International Journal of Cancer, 2000, 88, 584-592.	2.3	69
950	Neurofibromatosis type 1 I. General overview. Journal of Neuroscience Research, 2000, 62, 755-763.	1.3	48
951	Mediation of cell-substratum adhesion by RasG inDictyostelium. Journal of Cellular Biochemistry, 2000, 79, 139-149.	1.2	12
952	Human Ras-Converting Enzyme (hRCE1) Endoproteolytic Activity on K-Ras-Derived Peptides. Analytical Biochemistry, 2000, 286, 129-137.	1.1	38
953	New comprehensive denaturing-gradient-gel- electrophoresis assay forKRAS mutation detection applied to paraffin-embedded tumours. Genes Chromosomes and Cancer, 2000, 29, 309-314.	1.5	17
954	Substrate-assisted catalysis: Implications for biotechnology and drug design. Drug Development Research, 2000, 50, 250-257.	1.4	2
955	Damage to DNA and activity of nuclear DNA repair and replicative enzymes followingN-nitrosodiethylamine treatment to rats. Journal of Biochemical and Molecular Toxicology, 2000, 14, 277-282.	1.4	4
956	Expression of Activated N-ras in a Primary Melanoma Cell Line Counteracts Growth Inhibition by Transforming Growth Factor-Î². Journal of Investigative Dermatology, 2000, 114, 1200-1204.	0.3	19
957	Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Proliferation, 2000, 33, 1-18.	2.4	105
958	LUCA15, a putative tumour suppressor gene encoding an RNA-binding nuclear protein, is down-regulated in ras-transformed Rat-1 cells. Genes To Cells, 2000, 5, 849-858.	0.5	54
959	Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. FEBS Journal, 2000, 267, 3248-3254.	0.2	61
960	Overexpression of c-H-ras p21 is correlated with vascular endothelial growth factor expression and neovascularization in advanced gastric carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 1393-1399.	1.4	9
961	Development of a Tripeptide Mimetic Strategy for the Inhibition of Protein Farnesyltransferase. Tetrahedron, 2000, 56, 9833-9841.	1.0	15

#	Article	IF	Citations
962	Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. Current Opinion in Immunology, 2000, 12, 85-91.	2.4	22
963	3-Imidazolylmethylaminophenylsulfonyltetrahydroquinolines, a novel series of farnesyltransferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 273-275.	1.0	32
964	2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization. Bioorganic and Medicinal Chemistry, 2000, 8, 2729-2737.	1.4	23
965	A genome-wide survey of RAS transformation targets. Nature Genetics, 2000, 24, 144-152.	9.4	265
966	Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia, 2000, 14, 312-315.	3.3	41
967	Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia, 2000, 14, 602-611.	3.3	83
968	Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras. Oncogene, 2000, 19, 115-123.	2.6	36
969	[Lys61]N-Ras is able to induce full activation and nuclear accumulation of Cdk4 in NIH3T3 cells. Oncogene, 2000, 19, 690-699.	2.6	5
970	R-Ras3, a brain-specific Ras-related protein, activates Akt and promotes cell survival in PC12 cells. Oncogene, 2000, 19, 2014-2022.	2.6	50
971	PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene, 2000, 19, 2269-2276.	2.6	61
972	Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene, 2000, 19, 2930-2942.	2.6	101
973	Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene, 2000, 19, 3013-3020.	2.6	348
974	Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras. Oncogene, 2000, 19, 3245-3255.	2.6	34
975	Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation. Oncogene, 2000, 19, 4582-4591.	2.6	60
976	Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling. Oncogene, 2000, 19, 5367-5376.	2.6	13
977	Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene, 2000, 19, 5338-5347.	2.6	85
978	Disruption of TGF-Î² growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene, 2000, 19, 5926-5935.	2.6	57
979	Small-molecule inhibitors of cell signaling. Current Opinion in Biotechnology, 2000, 11, 593-597.	3.3	27

#	Article	IF	Citations
980	RAS inhibitors: potential for cancer therapeutics. Trends in Molecular Medicine, 2000, 6, 398-402.	2.6	82
981	Tumor suppressors and oncogenes in cellular senescenceâ˜†. Experimental Gerontology, 2000, 35, 317-329.	1.2	344
982	The importance of being K-Ras. Cellular Signalling, 2000, 12, 425-434.	1.7	145
983	Understanding Ras: â€˜it ainâ€™t over â€™til itâ€™s overâ€™. Trends in Cell Biology, 2000, 10, 147-154.	3.6	739
984	H-RAS, K-RAS, and N-RAS Gene Activation in Human Bladder Cancers. Cancer Genetics and Cytogenetics, 2000, 121, 73-77.	1.0	56
985	The human RGL (RalGDS-like) gene: cloning, expression analysis and genomic organization. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2000, 1491, 285-288.	2.4	11
986	Genetic analysis of Raf1, Mdm2, c-Myc, Cdc25a and Cdc25b proto-oncogenes in 2â€²,3â€²-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000, 452, 19-26.	0.4	4
987	Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochemical Pharmacology, 2000, 60, 1061-1068.	2.0	57
988	Combination analysis of genetic alterations and cell proliferation in small intestinal carcinomas. Digestive Diseases and Sciences, 2000, 45, 2022-2028.	1.1	22
989	Genes that regulate metastasis and angiogenesis. , 2000, 50, 71-87.		79
990	Ras activation in human breast cancer. Breast Cancer Research and Treatment, 2000, 62, 51-62.	1.1	163
991	Increased apoptosis and increased clonogenic survival of 12V-H-ras transformed rat fibroblasts in response to cisplatin. Apoptosis: an International Journal on Programmed Cell Death, 2000, 5, 355-367.	2.2	8
992	Identification of a ras Oncogene Peptide That Contains Both CD4+ and CD8+ T Cell Epitopes in a Nested Configuration and Elicits Both T Cell Subset Responses by Peptide or DNA Immunization. Cellular Immunology, 2000, 205, 73-83.	1.4	29
993	ras Gene Activation and Infrequent Mutation in Papillary Serous Carcinoma of the Peritoneum. Gynecologic Oncology, 2000, 77, 105-111.	0.6	4
994	Detection of codon 12 K- ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung adenocarcinomas. British Journal of Cancer, 2000, 82, 412-417.	2.9	11
995	Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumourcells. British Journal of Cancer, 2000, 82, 905-912.	2.9	33
996	Ribozyme as an Approach for Growth Suppression of Human Pancreatic Cancer. Molecular Biotechnology, 2000, 14, 59-72.	1.3	21
997	Fluorescent Oligonucleotide Ligation Technology for Identification of ras Oncogene Mutations. Molecular Biotechnology, 2000, 14, 223-233.	1.3	8

#	Article	IF	Citations
998	Molecular staging of colorectal cancer. Diseases of the Colon and Rectum, 2000, 43, 155-159.	0.7	33
999	Inhibition ofras oncogene: A novel approach to antineoplastic therapy. Journal of Biomedical Science, 2000, 7, 292-298.	2.6	14
1000	Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood, 2000, 95, 639-645.	0.6	59
1001	Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood, 2000, 96, 1655-1669.	0.6	277
1002	Early Detection of Leptomeningeal Metastasis by PCR Examination of Tumor-derived K-ras DNA in Cerebrospinal Fluid. Clinical Chemistry, 2000, 46, 132-133.	1.5	39
1003	Long Term Pulmonary Toxicity of Indium Arsenide and Indium Phosphide Instilled Intratracheally in Hamsters. Journal of Occupational Health, 2000, 42, 169-178.	1.0	45
1004	Molecular Detection of Codon 12 K-RAS Mutations in Circulating DNA from Serum of Colorectal Cancer Patients. International Journal of Biological Markers, 2000, 15, 300-307.	0.7	16
1005	Full Oncogenic Activities of v-Src Are Mediated by Multiple Signaling Pathways. Journal of Biological Chemistry, 2000, 275, 24096-24105.	1.6	59
1006	Future Treatment Modalities for Meningiomas. Neurosurgery Clinics of North America, 2000, 11, 717-733.	0.8	0
1007	Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway. Journal of Cell Biology, 2000, 151, 1179-1192.	2.3	26
1008	The p38 Pathway Provides Negative Feedback for Ras Proliferative Signaling. Journal of Biological Chemistry, 2000, 275, 38973-38980.	1.6	153
1009	Ras Inactivation of the Retinoblastoma Pathway by Distinct Mechanisms in NIH 3T3 Fibroblast and RIE-1 Epithelial Cells. Journal of Biological Chemistry, 2000, 275, 40916-40924.	1.6	28
1010	Transforming Growth Factor-Î²1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA. Journal of Biological Chemistry, 2000, 275, 6628-6635.	1.6	175
1011	Evidence for a Telomere-Independent â€œClockâ€•Limiting RAS Oncogene-Driven Proliferation of Human Thyroid Epithelial Cells. Molecular and Cellular Biology, 2000, 20, 5690-5699.	1.1	80
1012	Induced Expression of Rnd3 Is Associated with Transformation of Polarized Epithelial Cells by the Rafâ€“MEKâ€“Extracellular Signal-Regulated Kinase Pathway. Molecular and Cellular Biology, 2000, 20, 9364-9375.	1.1	96
1013	Ras Oncoprotein Induces CD44 Cleavage through Phosphoinositide 3-OH Kinase and the Rho Family of Small G Proteins. Journal of Biological Chemistry, 2000, 275, 29628-29635.	1.6	62
1014	Membrane Localization of Raf Assists Engagement of Downstream Effectors. Journal of Biological Chemistry, 2000, 275, 31318-31324.	1.6	10
1015	RAS-Mediated Radiation Resistance is not Linked to MAP Kinase Activation in Two Bladder Carcinoma Cell Lines. Radiation Research, 2000, 154, 64-72.	0.7	36

#	Article	IF	Citations
1016	The C-terminal Polylysine Region and Methylation of K-Ras Are Critical for the Interaction between K-Ras and Microtubules. Journal of Biological Chemistry, 2000, 275, 41251-41257.	1.6	78
1017	Molecular markers for early cancer detection. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2000, 18, 75-125.	2.9	12
1018	Inhibition of Cell Growth by Antisense Oligonucleotides Targeting the Growth-Related Protein Kinase c-raf. , 2000, 35, 167-188.		0
1019	Novel non-operative treatment and treatment strategies in pancreatic cancer. Expert Opinion on Investigational Drugs, 2000, 9, 1179-1195.	1.9	7
1020	Molecular Abnormalities of p53, MDM2, and H-ras in Synovial Sarcoma. Modern Pathology, 2000, 13, 994-1004.	2.9	62
1021	Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic. Expert Opinion on Therapeutic Patents, 2000, 10, 1711-1724.	2.4	9
1022	Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis, 2000, 21, 371-377.	1.3	124
1023	Restoration of Tight Junction Structure and Barrier Function by Down-Regulation of the Mitogen-activated Protein Kinase Pathway in Ras-transformed Madin-Darby Canine Kidney Cells. Molecular Biology of the Cell, 2000, 11, 849-862.	0.9	250
1024	Elevated levels of the pro-carcinogenic adduct, O6-methylguanine, in normal DNA from the cancer prone regions of the large bowel. Gut, 2000, 47, 362-365.	6.1	73
1025	K-ras Gene Mutations in Liver Carcinomas from a Mediterranean Area of Spain. International Journal of Surgical Pathology, 2000, 8, 267-270.	0.4	1
1026	Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures. Gut, 2000, 47, 357-361.	6.1	22
1027	Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment. Toxicologic Pathology, 2000, 28, 482-499.	0.9	73
1028	Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis. Journal of Biological Chemistry, 2000, 275, 35669-35672.	1.6	252
1029	Point Mutants of c-Raf-1 RBD with Elevated Binding to v-Ha-Ras. Journal of Biological Chemistry, 2000, 275, 30363-30371.	1.6	35
1030	Oncogenic Ras Mediates Apoptosis in Response to Protein Kinase C Inhibition through the Generation of Reactive Oxygen Species. Journal of Biological Chemistry, 2000, 275, 39001-39011.	1.6	50
1031	Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS1. Radiation Research, 2000, 154, 125-132.	0.7	66
1032	Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia. Molecular and Cellular Biology, 2000, 20, 8655-8666.	1.1	98
1033	Dissection of Ras-Dependent Signaling Pathways Controlling Aggressive Tumor Growth of Human Fibrosarcoma Cells: Evidence for a Potential Novel Pathway. Molecular and Cellular Biology, 2000, 20, 9294-9306.	1.1	47

#	Article	IF	Citations
1034	Both Farnesylated and Geranylgeranylated RhoB Inhibit Malignant Transformation and Suppress Human Tumor Growth in Nude Mice. Journal of Biological Chemistry, 2000, 275, 17974-17978.	1.6	165
1035	Oncogenic Ras-mediated Cell Growth Arrest and Apoptosis are Associated with Increased Ubiquitin-dependent Cyclin D1 Degradation. Journal of Biological Chemistry, 2000, 275, 22916-22924.	1.6	70
1036	Beef induces and rye bran prevents the formation of intestinal polyps in ApcMin mice: relation to Î²-catenin and PKC isozymes. Carcinogenesis, 2000, 21, 1167-1173.	1.3	91
1037	Prevention of v-Ha-Ras-Dependent Apoptosis by PDGF Coordinates in Phosphorylation of ERK and Akt. Biochemical and Biophysical Research Communications, 2000, 267, 33-39.	1.0	18
1038	A Novel Activating Mutation of the K-ras Gene in Human Primary Colon Adenocarcinoma. Biochemical and Biophysical Research Communications, 2000, 278, 653-658.	1.0	32
1039	DNA Adducts, Mutations, and Cancer 2000. Regulatory Toxicology and Pharmacology, 2000, 32, 264-275.	1.3	77
1040	Intercellular junctions: downstream and upstream of Ras?. Seminars in Cell and Developmental Biology, 2000, 11, 309-314.	2.3	15
1041	Ras protein signalling. Seminars in Immunology, 2000, 12, 63-73.	2.7	100
1042	Ras-induced cellular events. Molecular Membrane Biology, 2000, 17, 65-73.	2.0	43
1043	Analysis of mutations in the p53 tumor suppressor gene and Ki- and Ha-ras proto-oncogenes in hepatic tumors of European flounder (Platichthys flesus). Marine Environmental Research, 2000, 50, 251-255.	1.1	17
1044	cDNA cloning and expression of two Ki-ras genes in the flounder, Platichthys flesus, and analysis of hepatic neoplasms. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2000, 126, 17-27.	0.7	6
1045	Ras oncogenes and p53 tumor suppressor gene analysis in cardiac myxomas. Pathology Research and Practice, 2000, 196, 601-605.	1.0	7
1046	Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathology Research and Practice, 2000, 196, 1-7.	1.0	96
1047	Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor alpha mutation in advanced stage human breast cancer. Pathology Research and Practice, 2000, 196, 817-826.	1.0	15
1048	Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treatment Reviews, 2000, 26, 29-52.	3.4	81
1049	Farnesyl transferase inhibitors: current developments and future perspectives. Cancer Treatment Reviews, 2000, 26, 319-332.	3.4	17
1050	Role of Ras and Mapks in TGFÎ² signaling. Cytokine and Growth Factor Reviews, 2000, 11, 23-35.	3.2	400
1051	Association between activated K-ras and c-erbB-2 oncogenes with â€œhigh-riskâ€•and â€œlow-riskâ€•Human Papilloma Virus types in preinvasive cervical lesions. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2000, 469, 127-134.	0.9	17

#	Article	IF	Citations
1052	Evaluation of fecal mutagenicity and colorectal cancer risk. Mutation Research - Reviews in Mutation Research, 2000, 463, 53-101.	2.4	99
1053	Nf1 and Gmcsf Interact in Myeloid Leukemogenesis. Molecular Cell, 2000, 5, 189-195.	4.5	132
1054	Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. European Journal of Cancer, 2000, 36, 1161-1170.	1.3	16
1055	Opposing Effects of Ras on p53. Cell, 2000, 103, 321-330.	13.5	346
1056	The molecular biology of cancer. Molecular Aspects of Medicine, 2000, 21, 167-223.	2.7	392
1057	Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Letters, 2000, 481, 31-36.	1.3	63
1058	Co-expression of epidermal growth factor receptor and transforming growth factor-Î± is independent of ras mutations in lung adenocarcinoma. Lung Cancer, 2000, 29, 151-157.	0.9	59
1059	A Subclass of Ras Proteins That Regulate the Degradation of IB. Science, 2000, 287, 869-873.	6.0	102
1060	Leukemia Relapse Reconsidered from the Molecular Aspect. Leukemia and Lymphoma, 2000, 37, 527-534.	0.6	1
1061	H-ras but Not K-ras Traffics to the Plasma Membrane through the Exocytic Pathway. Molecular and Cellular Biology, 2000, 20, 2475-2487.	1.1	397
1062	The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases. Expert Opinion on Emerging Drugs, 2000, 5, 161-199.	1.1	12
1063	Antisense Approaches for the Treatment of Cancer. Cancer Investigation, 2000, 18, 635-650.	0.6	37
1064	Inhibitors of protein prenylation 2000. Expert Opinion on Therapeutic Patents, 2000, 10, 1813-1831.	2.4	32
1065	Impact of Kras and Tp53 Mutations on Survival in Patients With Left- and Right-Sided Dukes' C Colon Cancer. American Journal of Gastroenterology, 2000, 95, 2953-2957.	0.2	59
1066	Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-ras mutations. Carcinogenesis, 2000, 21, 827-831.	1.3	31
1067	SCREENING FOR EARLY PANCREATIC DUCTAL ADENOCARCINOMA IN HEREDITARY PANCREATITIS. Medical Clinics of North America, 2000, 84, 719-738.	1.1	23
1068	Molecular pathogenesis of thyroid nodules and cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2000, 14, 517-539.	2.2	48
1069	Clinical Relevance of Occult Metastatic Cells in the Bone Marrow of Patients with Different Stages of Breast Cancer. Clinical Breast Cancer, 2000, 1, 217-225.	1.1	8

#	Article	IF	Citations
1070	Kinase Inhibitors in Cancer Therapy. Drugs, 2000, 59, 435-476.	4.9	76
1071	Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology, 2000, 118, 1045-1050.	0.6	99
1072	Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. Journal of Hepatology, 2000, 32, 374-380.	1.8	79
1073	Farnesyltransferase Inhibitors. Drugs, 2001, 61, 723-732.	4.9	56
1074	Downregulation of Akt1 Inhibits Anchorage-Independent Cell Growth and Induces Apoptosis in Cancer Cells. Neoplasia, 2001, 3, 278-286.	2.3	37
1075	The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 â†' M or G1 Pause in Sensitive Human Tumor Cell Lines. Experimental Cell Research, 2001, 262, 17-27.	1.2	113
1076	Neurofibromin, a Tumor Suppressor in the Nervous System. Experimental Cell Research, 2001, 264, 19-28.	1.2	75
1077	Transforming Growth Factor-Î²1 Promotes Invasiveness after Cellular Transformation with Activated Ras in Intestinal Epithelial Cells. Experimental Cell Research, 2001, 266, 239-249.	1.2	74
1078	Controlling Tumor-Derived and Vascular Endothelial Cell Growth. American Journal of Pathology, 2001, 159, 165-178.	1.9	10
1079	Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene. American Journal of Pathology, 2001, 159, 1635-1643.	1.9	260
1080	Hydrophobicity and functionality maps of farnesyltransferase. Journal of Molecular Graphics and Modelling, 2001, 19, 307-317.	1.3	3
1081	Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model. Oncogene, 2001, 20, 2854-2858.	2.6	34
1082	Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes and Development, 2001, 15, 859-876.	2.7	520
1083	Current prospects for controlling cancer growth with non-cytotoxic agents â€“ nutrients, phytochemicals, herbal extracts, and available drugs. Medical Hypotheses, 2001, 56, 137-154.	0.8	30
1084	DNA vaccination against v-src oncogene-induced tumours in congenic chickens. Vaccine, 2001, 19, 4526-4535.	1.7	11
1085	K-ras exon 2 point mutations in human endometrial cancer. Cancer Letters, 2001, 164, 207-212.	3.2	21
1086	Ras gene mutations in 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat sarcomas. Cancer Letters, 2001, 166, 47-53.	3.2	10
1087	Reinitiated expression of EJras transgene in targeted epidermal cells of transgenic rabbits by cottontail rabbit papillomavirus infection. Cancer Letters, 2001, 171, 193-200.	3.2	8

#	Article	IF	Citations
1088	Fluorescence spectroscopy for detection of malignancy: H-ras overexpressing fibroblasts as a model. Journal of Proteomics, 2001, 50, 53-63.	2.4	24
1089	Structure, expression and activation of fish ras genes. Aquatic Toxicology, 2001, 55, 1-21.	1.9	44
1090	Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncology, The, 2001, 2, 18-26.	5.1	138
1091	Host determinants of DNA alkylation and DNA repair activity in human colorectal tissue: O6-methylguanine levels are associated with GSTT1 genotype and O6-alkylguanine-DNA alkyltransferase activity with CYP2D6 genotype. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2001, 495, 103-115.	0.9	6
1092	Antisense therapy in oncology: new hope for an old idea?. Lancet, The, 2001, 358, 489-497.	6.3	223
1093	TARGETING APOPTOSIS IN PROSTATE CANCER. Hematology/Oncology Clinics of North America, 2001, 15, 509-524.	0.9	35
1094	Molecular Biology of Pancreatic Cancer. BioDrugs, 2001, 15, 439-452.	2.2	22
1095	Lack of Association Between N-ras Gene Mutations and Clinical Prognosis in Brazilian Children with Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 2001, 42, 473-479.	0.6	4
1096	Oncolytic viruses as therapeutic agents. Annals of Medicine, 2001, 33, 291-304.	1.5	31
1098	Prognostic Significance of DNA Aneuploidy and p21ras Oncoprotein Expression in Colorectal Cancer and Their Role in the Determination of Treatment Modalities. International Journal of Biological Markers, 2001, 16, 97-104.	0.7	8
1099	k-ras Mutation May Be an Early Event in Mucinous Ovarian Tumorigenesis. International Journal of Gynecological Pathology, 2001, 20, 244-251.	0.9	66
1100	Blocking Oncogenic Ras Signaling for Cancer Therapy. Journal of the National Cancer Institute, 2001, 93, 1062-1074.	3.0	776
1101	4 Farnesyltransferase inhibitors. The Enzymes, 2001, , 81-103.	0.7	0
1102	Phosphate-binding loop and Rab GTPase function: mutations at Ser29 and Ala30 of Rab5 lead to loss-of-function as well as gain-of-function phenotype. Biochemical Journal, 2001, 355, 681-689.	1.7	32
1103	Cell-cycleâ€“dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood, 2001, 97, 1823-1834.	0.6	120
1104	Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. Blood, 2001, 98, 1914-1921.	0.6	35
1105	Suppressor and oncogenic roles of transforming growth factor-Î² and its signaling pathways in tumorigenesis. Advances in Cancer Research, 2001, 83, 1-54.	1.9	88
1106	Identification of ras-regulated genes by representational difference analysis. Methods in Enzymology, 2001, 332, 221-232.	0.4	4

#	Article	IF	Citations
1107	Dominant negative mutants of mitogen-activated protein kinase pathway. Methods in Enzymology, 2001, 332, 353-367.	0.4	10
1108	Animal models for Ras-induced metastasis. Methods in Enzymology, 2001, 333, 318-329.	0.4	3
1109	Immunocytochemical assay for Ras activity. Methods in Enzymology, 2001, 333, 348-356.	0.4	6
1110	Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Diseases of the Colon and Rectum, 2001, 44, 523-533.	0.7	48
1111	Prognostic value of K- ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Diseases of the Colon and Rectum, 2001, 44, 549-557.	0.7	54
1112	Therapeutic targets in radiotherapy. International Journal of Radiation Oncology Biology Physics, 2001, 49, 319-326.	0.4	70
1113	Ras mutations are rare in solitary cold and toxic thyroid nodules. Clinical Endocrinology, 2001, 55, 241-248.	1.2	34
1114	Frequent multiple câ€kiâ€•ras oncogene activation in pancreatic juice from patients with benign pancreatic cysts. Digestive Endoscopy, 2001, 13, 77-81.	1.3	3
1115	Alanine scan mutagenesis of the switch I domain of the Caulobacter crescentus CgtA protein reveals critical amino acids required for in vivo function. Molecular Microbiology, 2001, 39, 924-934.	1.2	23
1116	Synthetic peptide conjugatesâ€"tailor-made probes for the biology of protein modification and protein processing. Tetrahedron, 2001, 57, 2247-2277.	1.0	50
1117	MEK (MAPKK) inhibitors. Part 2: structureâ€"activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1407-1410.	1.0	29
1118	Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2775-2778.	1.0	84
1119	3-Aryl-4-aryloyl-1-(1H-imidazol-5-yl)methylpyrrole, a novel class of farnesyltransferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2963-2965.	1.0	13
1120	A novel class of highly potent, selective, and non-peptidic inhibitor of ras farnesyltransferase (FTase). Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3069-3072.	1.0	69
1121	Gene mutation as a target for early detection in cancer diagnosis. Critical Reviews in Oncology/Hematology, 2001, 40, 195-213.	2.0	13
1122	Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Critical Reviews in Oncology/Hematology, 2001, 38, 177-192.	2.0	106
1123	Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. Journal of Pathology, 2001, 195, 543-548.	2.1	31
1124	Differences inin vitro invasive capacity induced by differences in Ki-Ras protein mutations. Journal of Pathology, 2001, 195, 549-556.	2.1	30

#	Article	IF	Citations
1125	Absence of activating mutations in ras and gsp oncogenes in a cohort of nine patients with sporadic pediatric thyroid tumors. Medical and Pediatric Oncology, 2001, 36, 630-634.	1.0	9
1126	Regulation of the differentiation-related geneDrg-1during mouse skin carcinogenesis. Molecular Carcinogenesis, 2001, 32, 100-109.	1.3	34
1127	Disrupting the transforming activity of shrimpras(Q61K) by deleting the CAAX box at the C-terminus. The Journal of Experimental Zoology, 2001, 289, 441-448.	1.4	4
1128	GTPase stimulation in shrimp Ras(Q61K) with geranylgeranyl pyrophosphate but not mammalian GAP. The Journal of Experimental Zoology, 2001, 290, 642-651.	1.4	5
1129	Correlation between microsatellite instability and metachronous disease recurrence after endoscopic mucosal resection in patients with early stage gastric carcinoma. Cancer, 2001, 91, 339-345.	2.0	16
1130	The association of k-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer, 2001, 92, 488-499.	2.0	50
1131	Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer, 2001, 92, 822-829.	2.0	65
1132	A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer, 2001, 92, 1265-1271.	2.0	106
1133	Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer, 2001, 92, 1525-1530.	2.0	381
1134	Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant. International Journal of Cancer, 2001, 92, 712-717.	2.3	23
1135	High-Performance Liquid Chromatography/Mass Spectrometry Characterization of Ki4B-Ras in PSN-1 Cells Treated with the Prenyltransferase Inhibitor L-778,123. Analytical Biochemistry, 2001, 290, 126-137.	1.1	31
1136	Occupational cancer genetics: infrequentras oncogenes point mutations in lung cancer samples from chromate workers. American Journal of Industrial Medicine, 2001, 40, 92-97.	1.0	30
1137	Ras-Mediated Cleavage of a GTP Analogue by a Novel Mechanism. ChemBioChem, 2001, 2, 570-575.	1.3	11
1138	The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model. Seminars in Cancer Biology, 2001, 11, 201-218.	4.3	34
1139	K-RAS mutation in transitional cell carcinoma of urinary bladder. International Urology and Nephrology, 2001, 33, 363-367.	0.6	15
1140	Signal transduction targets in androgen-independent prostate cancer. Cancer and Metastasis Reviews, 2001, 20, 351-362.	2.7	21
1141	Molecular mechanisms of metal toxicity and carcinogenesis. Molecular and Cellular Biochemistry, 2001, 222, 3-9.	1.4	197
1142	The ras signaling pathway in mammary tumorigenesis and metastasis. , 2001, 6, 101-113.		77

#	Article	IF	Citations
1143	Differences in carcinogenesis by the length of carcinogen exposure period in rat colon. Digestive Diseases and Sciences, 2001, 46, 109-117.	1.1	10
1144	Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO Journal, 2001, 20, 755-766.	3.5	353
1145	DOC-2/hDab2 Expression Is Up-Regulated in Primary Pancreatic Cancer but Reduced in Metastasis. Laboratory Investigation, 2001, 81, 863-873.	1.7	26
1146	c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nature Medicine, 2001, 7, 235-239.	15.2	391
1147	A new verdict for an old convict. Nature Genetics, 2001, 29, 3-4.	9.4	15
1148	Molecular signals in anti-apoptotic survival pathways. Leukemia, 2001, 15, 21-34.	3.3	60
1149	The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism. Oncogene, 2001, 20, 1816-1824.	2.6	24
1150	Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene, 2001, 20, 1973-1980.	2.6	144
1151	Immediate early genes induced by H-Ras in thyroid cells. Oncogene, 2001, 20, 2281-2290.	2.6	5
1152	P21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene, 2001, 20, 4354-4364.	2.6	45
1153	hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors. Oncogene, 2001, 20, 5155-5163.	2.6	29
1154	Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene, 2001, 20, 6551-6558.	2.6	190
1155	Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene, 2001, 20, 6724-6730.	2.6	16
1156	Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene, 2001, 20, 7486-7493.	2.6	366
1157	Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 2001, 410, 1111-1116.	13.7	1,060
1158	PI3-kinase p85Î± Is a Target Molecule of Proline-rich Antimicrobial Peptide to Suppress Proliferation of ras-Transformed Cells. Japanese Journal of Cancer Research, 2001, 92, 959-967.	1.7	46
1159	Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leukemia Research, 2001, 25, 651-660.	0.4	58
1160	Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a JNK independent pathway. Leukemia Research, 2001, 25, 801-811.	0.4	14

#	Article	IF	Citations
1161	P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency, and P450 binding spectra in human liver microsomes 1 1Abbreviations: FTI, farnesyl-protein transferase inhibitor; FTase, farnesyl-protein transferase; and LC-MS, liquid chromatography-mass spectrometry.. Biochemical Pharmacology, 2001, 62, 773-776.	2.0	17
1162	Hereditary breast cancer. Current Problems in Surgery, 2001, 38, 387-480.	0.6	124
1163	Ras inhibitors and radiation therapy. Seminars in Radiation Oncology, 2001, 11, 328-337.	1.0	48
1164	Expression of ras (p21) protein in plasma from exposed workers and from patients with lung disease. International Journal of Hygiene and Environmental Health, 2001, 204, 55-60.	2.1	5
1165	Substrate assisted catalysis â€“ application to G proteins. Trends in Biochemical Sciences, 2001, 26, 161-166.	3.7	45
1166	Regulation of the p53 pathway by Ras, the plot thickens. Biochimica Et Biophysica Acta: Reviews on Cancer, 2001, 1471, M63-M71.	3.3	17
1167	The rasH2 Transgenic Mouse: Nature of the Model and Mechanistic Studies on Tumorigenesis. Toxicologic Pathology, 2001, 29, 81-89.	0.9	80
1168	The arginine finger of RasGAP helps Gln-61 align the nucleophilic water in GAP-stimulated hydrolysis of GTP. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6033-6038.	3.3	47
1169	Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10722-10727.	3.3	94
1170	Differential Activation of the Rac Pathway by Ha-Ras and K-Ras. Journal of Biological Chemistry, 2001, 276, 15609-15615.	1.6	148
1171	Animal Models Used in Identifying Gender-Related Differences. International Journal of Toxicology, 2001, 20, 153-160.	0.6	31
1172	Calmodulin Binds to K-Ras, but Not to H- or N-Ras, and Modulates Its Downstream Signaling. Molecular and Cellular Biology, 2001, 21, 7345-7354.	1.1	185
1173	A Ras by Any Other Name. Molecular and Cellular Biology, 2001, 21, 1441-1443.	1.1	79
1174	Induction of Î²3-Integrin Gene Expression by Sustained Activation of the Ras-Regulated Rafâ€“MEKâ€“Extracellular Signal-Regulated Kinase Signaling Pathway. Molecular and Cellular Biology, 2001, 21, 3192-3205.	1.1	121
1175	Melting Temperature Analysis as Quantitative Method for Detection of Point Mutations. Clinical Chemistry and Laboratory Medicine, 2001, 39, 501-4.	1.4	1
1176	Bladder Cancer. European Urology, 2001, 39, 491-497.	0.9	76
1177	Understanding the Interaction Between Environmental Exposures and Molecular Events in Colorectal Carcinogenesis. Cancer Investigation, 2001, 19, 524-539.	0.6	10
1178	H-rasOncogene Mutation in Dedifferentiated Liposarcoma. American Journal of Clinical Pathology, 2001, 115, 235-242.	0.4	13

#	Article	IF	Citations
1179	Akt/PKB Activity Is Required for Ha-Ras-mediated Transformation of Intestinal Epithelial Cells. Journal of Biological Chemistry, 2001, 276, 14498-14504.	1.6	91
1180	CAC3 (MSI1) Suppression of RAS2 G19V Is Independent of Chromatin Assembly Factor I and Mediated by NPR1. Molecular and Cellular Biology, 2001, 21, 1784-1794.	1.1	28
1181	Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy. Expert Review of Anticancer Therapy, 2001, 1, 247-257.	1.1	8
1182	Searching new targets for anticancer drug design: The families of Ras and Rho GTPases and their effectors. Progress in Molecular Biology and Translational Science, 2001, 67, 193-234.	1.9	36
1183	Acute Myeloid Leukemia. Hematology American Society of Hematology Education Program, 2001, 2001, 62-86.	0.9	95
1184	Suppression of Colorectal Cancer Growth Using an Adenovirus Vector Expressing an Antisense K-ras RNA. Molecular Therapy, 2001, 3, 491-499.	3.7	20
1185	Rac1 mediates STAT3 activation by autocrine IL-6. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9014-9019.	3.3	140
1186	Regulation of glut1 mRNA by Hypoxia-inducible Factor-1. Journal of Biological Chemistry, 2001, 276, 9519-9525.	1.6	633
1187	Analysis of the transcriptional program induced by Raf in epithelial cells. Genes and Development, 2001, 15, 981-994.	2.7	222
1188	Control by the endogenous cannabinoid system of ras oncogeneâ€dependent tumor growth. FASEB Journal, 2001, 15, 1-17.	0.2	123
1189	Targeted Genomic Disruption of H- ras and N- ras , Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and Development. Molecular and Cellular Biology, 2001, 21, 1444-1452.	1.1	265
1190	Retrovirus-Induced Ovine Pulmonary Adenocarcinoma, an Animal Model for Lung Cancer. Journal of the National Cancer Institute, 2001, 93, 1603-1614.	3.0	130
1191	Oncogenic Ras Blocks Anoikis by Activation of a Novel Effector Pathway Independent of Phosphatidylinositol 3-Kinase. Molecular and Cellular Biology, 2001, 21, 5488-5499.	1.1	109
1192	Murine Leukemia Virus Proviral Insertions between the N- ras and unr Genes in B-Cell Lymphoma DNA Affect the Expression of N- ras Only. Journal of Virology, 2001, 75, 11907-11912.	1.5	18
1193	Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cellsâœª. Journal of Experimental Medicine, 2001, 194, 1625-1638.	4.2	823
1194	H-ras Oncogene Mutation in Dedifferentiated Chondrosarcoma: Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Analysis. Modern Pathology, 2001, 14, 343-349.	2.9	21
1195	Detection of minimal residual disease. Advances in Cancer Research, 2001, 82, 133-185.	1.9	48
1196	Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes and Development, 2002, 16, 1587-1609.	2.7	1,053

#	Article	IF	Citations
1197	Loss of Transgelin in Breast and Colon Tumors and in RIE-1 Cells by Ras Deregulation of Gene Expression through Raf-independent Pathways. Journal of Biological Chemistry, 2002, 277, 9790-9799.	1.6	118
1198	CCAAT/enhancer binding protein-Â is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 207-212.	3.3	179
1199	APC-dependent suppression of colon carcinogenesis by PPARÂ. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13771-13776.	3.3	252
1200	Proline Reverses the Abnormal Phenotypes of Colletotrichum trifolii Associated with Expression of Endogenous Constitutively Active Ras. Applied and Environmental Microbiology, 2002, 68, 1647-1651.	1.4	15
1201	A ras-Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion. Journal of Immunology, 2002, 168, 4802-4808.	0.4	82
1202	A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Annals of Oncology, 2002, 13, 1067-1071.	0.6	93
1203	Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9433-9438.	3.3	425
1204	A Case of Pancreatic Adenocarcinoma With Novel K -Ras Mutation and Long Term Survival. American Journal of Gastroenterology, 2002, 97, 1852-1853.	0.2	0
1205	Skeletal Myopathy in Transgenic Mice Carrying Human Prototype c-Ha-ras Gene. Toxicologic Pathology, 2002, 30, 501-506.	0.9	7
1206	p53 Is Necessary for the Apoptotic Response Mediated by a Transient Increase of Ras Activity. Molecular and Cellular Biology, 2002, 22, 2928-2938.	1.1	17
1207	Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression. Carcinogenesis, 2002, 23, 943-948.	1.3	17
1208	Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor. Journal of Biological Chemistry, 2002, 277, 27643-27650.	1.6	186
1209	Farnesyltransferase Inhibitors in Breast Cancer Therapy. Cancer Investigation, 2002, 20, 30-37.	0.6	13
1210	Aberrant G protein signaling in nervous system tumors. Journal of Neurosurgery, 2002, 97, 627-642.	0.9	28
1211	Prenylation of CaaX-type proteins: Basic principles through clinical applications. Current Topics in Membranes, 2002, , 531-550.	0.5	7
1212	Novel treatments and therapies in development for pancreatic cancer. Expert Opinion on Investigational Drugs, 2002, 11, 769-786.	1.9	21
1213	The Genetics of Hereditary Nonmedullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2455-2459.	1.8	47
1214	Dendritic Cell-based Immunization for Cancer Therapy. Advances in Experimental Medicine and Biology, 2002, 465, 335-346.	0.8	9

#	Article	IF	Citations
1215	Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis, 2002, 23, 521-528.	1.3	81
1216	The structural basis for the transition from Ras-GTP to Ras-GDP. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12138-12142.	3.3	136
1217	R-Ras3/M-Ras Induces Neuronal Differentiation of PC12 Cells through Cell-Type-Specific Activation of the Mitogen-Activated Protein Kinase Cascade. Molecular and Cellular Biology, 2002, 22, 5946-5961.	1.1	48
1218	Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells. Journal of Cell Biology, 2002, 157, 865-872.	2.3	207
1219	The RASputin effect. Genes and Development, 2002, 16, 2033-2038.	2.7	25
1220	Interaction between Active Pak1 and Raf-1 Is Necessary for Phosphorylation and Activation of Raf-1. Journal of Biological Chemistry, 2002, 277, 4395-4405.	1.6	105
1221	Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes and Development, 2002, 16, 2045-2057.	2.7	373
1222	Contribution of Estrogen Receptor Î± to Oncogenic K-Ras-mediated NIH3T3 Cell Transformation and Its Implication for Escape from Senescence by Modulating the p53 Pathway. Journal of Biological Chemistry, 2002, 277, 11217-11224.	1.6	30
1223	Twenty-Six-Week Carcinogenicity Study of Chloroform in CB6F1 rasH2-Transgenic Mice. Toxicologic Pathology, 2002, 30, 328-338.	0.9	4
1224	Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Annals of Oncology, 2002, 13, 1438-1446.	0.6	196
1225	Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 14398-14403.	3.3	140
1226	Mechanisms and Biological Markers of Carcinogenesis. , 2002, , 7-19.		0
1227	Raf-independent Deregulation of p38 and JNK Mitogen-activated Protein Kinases Are Critical for Ras Transformation. Journal of Biological Chemistry, 2002, 277, 31808-31817.	1.6	73
1228	Ras processing as a therapeutic target in hematologic malignancies. Current Opinion in Hematology, 2002, 9, 308-315.	1.2	33
1229	Ecdysone-inducible expression of oncogenic Ha-Ras in NIH 3T3 cells leads to transient nuclear localization of activated extracellular signal-regulated kinase regulated by mitogen-activated protein kinase phosphatase-1. Biochemical Journal, 2002, 362, 305.	1.7	10
1230	Protein kinase C mediates mutant N-Rasâ€“induced developmental abnormalities in normal human erythroid cells. Blood, 2002, 100, 4185-4192.	0.6	27
1231	DNA Alkylation and Repair in the Large Bowel: Animal and Human Studies. Journal of Nutrition, 2002, 132, 3518S-3521S.	1.3	52
1232	Downstream Targets of let-60 Ras in Caenorhabditis elegans. Developmental Biology, 2002, 247, 127-136.	0.9	25

#	Article	IF	Citations
1233	Oncogenic Î²-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology, 2002, 122, 60-71.	0.6	129
1234	Activation of the ras/raf-1 signal transduction pathway in carcinoid tumor cells results in morphologic transdifferentiation. Surgery, 2002, 132, 1035-1039.	1.0	26
1235	Strategies for Gene Therapy. , 2002, , 331-341.		0
1236	Rho GTPases in transformation and metastasis. Advances in Cancer Research, 2002, 84, 57-80.	1.9	236
1237	Oncogenic H-Ras Enhances DNA Repair through the Ras/Phosphatidylinositol 3-Kinase/Rac1 Pathway in NIH3T3 Cells. Journal of Biological Chemistry, 2002, 277, 19358-19366.	1.6	54
1238	Induction of apoptosis in cancer: new therapeutic opportunities. Annals of Medicine, 2002, 34, 451-469.	1.5	45
1239	Glutathione S-Transferase and O6-Methylguanine DNA Methyl Transferase Activities in Patients with Thyroid Papillary Carcinoma. Cancer Investigation, 2002, 20, 965-971.	0.6	7
1240	Benzene and Leukemia. Critical Reviews in Toxicology, 2002, 32, 155-210.	1.9	134
1241	Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways. Biochemical and Biophysical Research Communications, 2002, 298, 805-814.	1.0	16
1242	Rac1 prevents cisplatin-induced apoptosis through down-regulation of p38 activation in NIH3T3 cells. FEBS Letters, 2002, 518, 129-134.	1.3	27
1243	Prostaglandin E2reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Letters, 2002, 518, 154-158.	1.3	58
1244	A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. Clinica Chimica Acta, 2002, 318, 107-112.	0.5	36
1245	Observation of Slow Dynamic Exchange Processes in Ras Protein Crystals by 31P Solid State NMR Spectroscopy. Journal of Molecular Biology, 2002, 323, 899-907.	2.0	22
1246	Ras-MAP Kinase Signaling Pathways and Control of Cell Proliferation: Relevance to Cancer Therapy. Critical Reviews in Clinical Laboratory Sciences, 2002, 39, 285-330.	2.7	93
1247	Future developments in the treatment of lung cancer. Lung Cancer, 2002, 38, 81-85.	0.9	6
1248	Expression of drs mRNA in human lung adenocarcinomas. Human Pathology, 2002, 33, 615-619.	1.1	12
1249	Antisense therapy for cancerâ€"the time of truth. Lancet Oncology, The, 2002, 3, 672-683.	5.1	160
1250	Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. European Journal of Cancer, 2002, 38, 2272-2278.	1.3	53

#	Article	IF	Citations
1251	An allele of HRAS1 3â€²variable number of tandem repeats is a frailty allele: implication for an evolutionarily-conserved pathway involved in longevity. Gene, 2002, 286, 121-126.	1.0	34
1252	Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways. Cancer Letters, 2002, 175, 89-94.	3.2	18
1253	Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. Cancer Letters, 2002, 179, 185-195.	3.2	30
1254	Inhibitors of the ras oncogene as therapeutic targets. Hematology/Oncology Clinics of North America, 2002, 16, 1065-1088.	0.9	27
1255	Ras Proteins. , 2002, , 41-48.		0
1256	Diagnostic Biochip Array for Fast and Sensitive Detection of K-ras Mutations in Stool. Clinical Chemistry, 2002, 48, 428-435.	1.5	49
1257	Signal transduction targets in androgen-independent prostate cancer. , 2002, , 215-226.		0
1258	Loss of Rb overrides the requirement for ERK activity for cell proliferation. Journal of Cell Science, 2002, 115, 4607-4616.	1.2	33
1259	The Role of Farnesyltransferase Inhibitors in Lung Cancer Therapy. Clinical Lung Cancer, 2002, 4, 57-62.	1.1	3
1260	Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. Seminars in Oncology, 2002, 29, 2-8.	0.8	9
1261	N-ras Mutation in a Feline Lymphoma. Low Frequency of N-ras Mutations in a Series of Feline, Canine and Bovine Lymphomas. Veterinary Journal, 2002, 163, 326-328.	0.6	14
1262	Gene expression profiling in RAS oncogene-transformed cell lines and in solid tumors using subtractive suppression hybridization and cDNA arrays. Advances in Enzyme Regulation, 2002, 42, 63-82.	2.9	19
1263	Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2002, 2, 243-247.	7.7	1,067
1264	Blocking oncogenes in malignant cells by RNA interferenceâ€"New hope for a highly specific cancer treatment?. Cancer Cell, 2002, 2, 167-168.	7.7	58
1265	Identification of a Novel Ras-Regulated Proapoptotic Pathway. Current Biology, 2002, 12, 253-265.	1.8	343
1266	Clonal evolution in marrows of patients with Shwachman-Diamond syndrome. Experimental Hematology, 2002, 30, 659-669.	0.2	79
1267	GTPase activating proteins: critical regulators of intracellular signaling. Biochimica Et Biophysica Acta: Reviews on Cancer, 2002, 1602, 23-45.	3.3	117
1268	Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detection and Prevention, 2002, 26, 435-443.	2.1	49

#	Article	IF	Citations
1269	Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncology, 2002, 38, 468-474.	0.8	57
1270	Modulation of the Ras/Raf/MEK/ERK pathway by Ca2+, and Calmodulin. Cellular Signalling, 2002, 14, 649-654.	1.7	369
1271	Clinical relevance of molecular markers in lung cancer. Surgical Oncology, 2002, 11, 167-179.	0.8	30
1272	v-Ha-ras mitogenic signaling through superoxide and derived reactive oxygen species. Molecular Carcinogenesis, 2002, 33, 206-218.	1.3	48
1273	Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. Journal of Surgical Oncology, 2002, 81, 45-53.	0.8	84
1274	High-Efficiency Solid-Phase Capture Using Glass Beads Bonded to Microcentrifuge Tubes: Immunoprecipitation of Proteins from Cell Extracts and Assessment of Ras Activation. Analytical Biochemistry, 2002, 302, 298-304.	1.1	4
1275	Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. International Journal of Cancer, 2002, 98, 514-522.	2.3	46
1276	Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. International Journal of Cancer, 2002, 100, 43-48.	2.3	85
1277	Ras family genes: An interesting link between cell cycle and cancer. Journal of Cellular Physiology, 2002, 192, 125-130.	2.0	132
1278	Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2). Journal of Cellular Physiology, 2002, 193, 42-54.	2.0	23
1279	Chemistry and biology of ras farnesyltransferase. Archives of Pharmacal Research, 2002, 25, 759-769.	2.7	15
1280	Molecular pathogenesis of MDS. International Journal of Hematology, 2002, 76, 213-221.	0.7	39
1281	Prospects for anti-ras drugs. British Journal of Haematology, 2002, 116, 511-518.	1.2	23
1282	Dematin interacts with the Ras-guanine nucleotide exchange factor Ras-GRF2 and modulates mitogen-activated protein kinase pathways. FEBS Journal, 2002, 269, 638-649.	0.2	16
1283	Lipid rafts and little caves. FEBS Journal, 2002, 269, 737-752.	0.2	215
1284	Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1269-1273.	1.0	23
1285	Ras as a target in cancer therapy. Critical Reviews in Oncology/Hematology, 2002, 44, 109-120.	2.0	35
1286	The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution. BMC Pharmacology, 2002, 2, 2.	0.4	8

#	Article	IF	Citations
1287	Molecular technology and pancreatic cancer. British Journal of Surgery, 2002, 87, 840-853.	0.1	15
1288	The colorectal adenomaâ€“carcinoma sequence. British Journal of Surgery, 2002, 89, 845-860.	0.1	553
1289	Cyclin D1 overexpression in colorectal carcinomain vivo is dependent on ?-catenin protein dysregulation, but notk-ras mutation. Journal of Pathology, 2002, 197, 128-135.	2.1	36
1290	Differential Mechanisms of Constitutive Akt/PKB Activation and Its Influence on Gene Expression in Pancreatic Cancer Cells. Japanese Journal of Cancer Research, 2002, 93, 1317-1326.	1.7	17
1291	Down-regulation ofdrsmRNA in Colorectal Neoplasms. Japanese Journal of Cancer Research, 2002, 93, 888-893.	1.7	10
1292	Impaired expression of a human septin family gene Bradeion inhibits the growth and tumorigenesis of colorectal cancer in vitro and in vivo. Cancer Gene Therapy, 2002, 9, 483-488.	2.2	34
1293	Regulation of choline kinase activity by Ras proteins involves Ralâ€“GDS and PI3K. Oncogene, 2002, 21, 937-946.	2.6	114
1294	Endonuclein is a cell cycle regulated WD-repeat protein that is up-regulated in adenocarcinoma of the pancreas. Oncogene, 2002, 21, 1123-1129.	2.6	21
1295	RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene, 2002, 21, 2713-2720.	2.6	104
1296	Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene, 2002, 21, 4200-4211.	2.6	70
1297	K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene, 2002, 21, 3792-3795.	2.6	168
1298	Frequent mutations of the Trp53, Hras1 and Î²-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice. Oncogene, 2002, 21, 5643-5648.	2.6	18
1299	Loss of the cell cycle inhibitors p21Cip1 and p27Kip1 enhances tumorigenesis in knockout mouse models. Oncogene, 2002, 21, 8486-8497.	2.6	75
1300	On the offensive. Nature, 2002, 416, 470-474.	13.7	26
1301	Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nature Cell Biology, 2002, 4, 487-494.	4.6	348
1302	Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nature Medicine, 2002, 8, 979-986.	15.2	506
1303	PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Medicine, 2002, 8, 1153-1160.	15.2	880
1304	Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2002, 2, 563-572.	12.8	3,414

#	Article	IF	Citations
1305	The Molecular and Genetic Basis of Neurological Tumours. Nature Reviews Cancer, 2002, 2, 616-626.	12.8	280
1306	Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras. British Journal of Cancer, 2002, 86, 436-442.	2.9	23
1307	High-performance liquid chromatographic assay validation of Manumycin A in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 776, 177-182.	1.2	2
1308	7,12-DMBA-induced rat leukemia: a review with insights into future research. Leukemia Research, 2002, 26, 1053-1068.	0.4	29
1309	Decrease in K-ras p21 and Increase in Raf1 and Activated Erk 1 and 2 in Murine Lung Tumors Initiated by N-Nitrosodimethylamine and Promoted by 2,3,7,8-Tetrachlorodibenzo-p-dioxin. Toxicology and Applied Pharmacology, 2002, 179, 21-34.	1.3	30
1310	Sequential Activation of the MEK-Extracellular Signal-Regulated Kinase and MKK3/6-p38 Mitogen-Activated Protein Kinase Pathways Mediates Oncogenic ras-Induced Premature Senescence. Molecular and Cellular Biology, 2002, 22, 3389-3403.	1.1	346
1311	Signaling inhibitors in the treatment of prostate cancer. Investigational New Drugs, 2002, 20, 159-172.	1.2	13
1312	Nucleoside diphosphate kinase (NDPK/NM23) and the waltz with multiple partners: possible consequences in tumor metastasis. Clinical and Experimental Metastasis, 2002, 19, 465-476.	1.7	62
1313	Involvement of Ras in survival responsiveness to nitric oxide toxicity in pheochromocytoma cells. Journal of Neuro-Oncology, 2002, 60, 97-107.	1.4	5
1314	Pancreatic cancer. Current Problems in Cancer, 2002, 26, 176-275.	1.0	268
1315	Chemokines: New, Key Players in the Pathobiology of Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2002, 31, 23-30.	0.4	21
1316	Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer and Metastasis Reviews, 2003, 22, 405-422.	2.7	76
1317	The Protective Role of p53 in Ras-Induced Transformation of REF52 Cells. Molecular Biology, 2003, 37, 392-403.	0.4	5
1318	Detection of oncogenes in chronic pancreatitis. Hpb, 2003, 5, 214-225.	0.1	3
1319	Ras promotes p21Waf1/Cip1 protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO Journal, 2003, 22, 2036-2046.	3.5	133
1320	Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell Lines. Breast Cancer Research and Treatment, 2003, 78, 59-67.	1.1	31
1321	Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clinical and Experimental Metastasis, 2003, 20, 77-84.	1.7	84
1322	Pyrazino[1,2- a]indole-1,4-diones, simple analogues of gliotoxin, as selective inhibitors of geranylgeranyltransferase I. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3661-3663.	1.0	17

#	Article	IF	Citations
1323	4-Methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the Farnesyltransferase inhibitor ZARNESTRA â„¢. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4361-4364.	1.0	17
1324	Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Current Oncology Reports, 2003, 5, 489-497.	1.8	13
1325	Antisense oligonucleotide therapy for urologic tumors. Current Urology Reports, 2003, 4, 60-69.	1.0	7
1327	Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Seminars in Cancer Biology, 2003, 13, 191-202.	4.3	58
1328	Ras interference as cancer therapy. Seminars in Cancer Biology, 2003, 13, 267-273.	4.3	44
1329	Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells. Cancer Cell, 2003, 3, 471-482.	7.7	103
1330	Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell, 2003, 4, 111-120.	7.7	518
1331	GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochimica Et Biophysica Acta: Reviews on Cancer, 2003, 1603, 47-82.	3.3	206
1332	Autophagy: a barrier or an adaptive response to cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2003, 1603, 113-128.	3.3	165
1333	Raf proteins and cancer: B-Raf is identified as a mutational target. Biochimica Et Biophysica Acta: Reviews on Cancer, 2003, 1653, 25-40.	3.3	236
1334	Inhibition of DNA synthesis by Carvacrol in mouse myoblast cells bearing a human N-RAS oncogene. Phytomedicine, 2003, 10, 292-299.	2.3	79
1335	Immunotherapy of melanoma. Seminars in Cancer Biology, 2003, 13, 391-400.	4.3	48
1336	Dissection of signal-regulated transcriptional modules by signaling pathway interference in oncogene-transformed cells. Advances in Enzyme Regulation, 2003, 43, 379-391.	2.9	8
1337	Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)â¨†. Gynecologic Oncology, 2003, 89, 129-133.	0.6	73
1338	p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecologic Oncology, 2003, 88, 318-325.	0.6	97
1339	K-ras alterations in Danish ovarian tumour patients.. Gynecologic Oncology, 2003, 89, 31-36.	0.6	25
1340	Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecologic Oncology, 2003, 90, 378-381.	0.6	211
1341	Current status of the molecular genetics of human prostatic adenocarcinomas. International Journal of Cancer, 2003, 103, 285-293.	2.3	67

#	Article	IF	Citations
1342	Roles of JNK-1 and p38 in selective induction of apoptosis by capsaicin inras-transformed human breast epithelial cells. International Journal of Cancer, 2003, 103, 475-482.	2.3	90
1343	Allelic imbalance at 11p15.5-15.4 correlated withc-Ha-ras mutation during radiation-induced neoplastic transformation of human breast epithelial cells. International Journal of Cancer, 2003, 103, 730-737.	2.3	34
1344	A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. International Journal of Cancer, 2003, 104, 527-532.	2.3	312
1345	Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. International Journal of Cancer, 2003, 105, 165-175.	2.3	97
1346	Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. International Journal of Cancer, 2003, 106, 789-798.	2.3	41
1347	High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. International Journal of Cancer, 2003, 107, 387-393.	2.3	19
1348	Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. Arthritis and Rheumatism, 2003, 48, 2682-2692.	6.7	54
1349	Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4365-4369.	1.0	28
1350	Stable analogues of geranylgeranyl diphosphate possessing improved geranylgeranyl versus farnesyl protein transferase inhibitory selectivity. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4405-4408.	1.0	5
1351	Molecular targets in acute myelogenous leukemia. Blood Reviews, 2003, 17, 15-23.	2.8	35
1352	Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. International Journal of Radiation Oncology Biology Physics, 2003, 56, 846-853.	0.4	178
1353	Targeted therapies: focus on a new strategy for gastrointestinal tumors. Critical Reviews in Oncology/Hematology, 2003, 47, 261-271.	2.0	6
1354	5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1543-1547.	1.0	31
1355	Simultaneous genotyping of multiplex single nucleotide polymorphisms of the K-ras gene with a home-made kit. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 795, 55-60.	1.2	5
1356	Human Ras converting enzyme endoproteolytic specificity at the P2â€² and P3â€² positions of K-Ras-derived peptides. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1649, 24-29.	1.1	10
1357	Oncogenes in thyroid cancer. Clinical Otolaryngology, 2003, 28, 386-395.	0.0	19
1358	Role of tissue stroma in cancer cell invasion. Journal of Pathology, 2003, 200, 429-447.	2.1	878
1359	Lack of effect of human c-Ha-ras proto-oncogene overexpression on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Science, 2003, 94, 1042-1045.	1.7	1

#	Article	IF	Citations
1360	Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers. British Journal of Cancer, 2003, 88, 530-536.	2.9	24
1361	BRAF mutations in non-Hodgkin's lymphoma. British Journal of Cancer, 2003, 89, 1958-1960.	2.9	64
1362	Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia, 2003, 17, 1508-1520.	3.3	35
1363	Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia, 2003, 17, 1482-1498.	3.3	38
1364	LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene, 2003, 22, 1243-1246.	2.6	54
1365	Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes. Oncogene, 2003, 22, 2689-2697.	2.6	55
1366	Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene, 2003, 22, 3806-3812.	2.6	168
1367	Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene, 2003, 22, 6257-6265.	2.6	34
1368	BRAF and KRAS mutations in stomach cancer. Oncogene, 2003, 22, 6942-6945.	2.6	131
1369	Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer. Oncogene, 2003, 22, 5694-5701.	2.6	110
1370	Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nature Medicine, 2003, 9, 1267-1268.	15.2	56
1371	RAS oncogenes: the first 30 years. Nature Reviews Cancer, 2003, 3, 459-465.	12.8	1,597
1372	Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer, 2003, 3, 11-22.	12.8	2,800
1373	Ras proteins: different signals from different locations. Nature Reviews Molecular Cell Biology, 2003, 4, 373-385.	16.1	778
1374	Global optimization of conformational constraint on non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain. Bioorganic and Medicinal Chemistry, 2003, 11, 3929-3936.	1.4	23
1375	RASSF1A Promoter Methylation and Kras2 Mutations in Non Small Cell Lung Cancer. Neoplasia, 2003, 5, 362-366.	2.3	29
1376	Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Review of Anticancer Therapy, 2003, 3, 595-614.	1.1	99
1377	Pharmacogenetic candidate genes for melanoma. Pharmacogenomics, 2003, 4, 753-765.	0.6	2

#	Article	IF	Citations
1378	Mutation analysis of vinyl carbamate or urethane induced lung tumors in rasH2 transgenic mice. Toxicology Letters, 2003, 142, 111-117.	0.4	22
1379	Molecular responses to hypoxia in tumor cells. Molecular Cancer, 2003, 2, 23.	7.9	162
1380	Farnesyltransferase Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Clinical Lymphoma and Myeloma, 2003, 4, S30-S35.	2.1	15
1381	Glucocorticoid Receptor-like Zn(Cys)4 Motifs in BslI Restriction Endonuclease. Journal of Molecular Biology, 2003, 334, 595-603.	2.0	8
1382	Expression profiles of pancreatic cancer cell lines infected with antisense K-ras-expressing adenoviral vector. Biochemical and Biophysical Research Communications, 2003, 309, 798-803.	1.0	16
1383	K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China11We dedicate this work to the late Dr Marc Mass who passed away during the preparation of this manuscript.. Lung Cancer, 2003, 41, 21-27.	0.9	26
1384	An overview of farnesyltransferase inhibitors and their role in lung cancer therapy. Lung Cancer, 2003, 41, 55-62.	0.9	23
1385	Structural Fingerprints of the Ras-GTPase Activating Proteins Neurofibromin and p120GAP. Journal of Molecular Biology, 2003, 329, 699-710.	2.0	58
1386	GTPase Catalysis by Ras and Other G-proteins: Insights from Substrate Directed SuperImposition. Journal of Molecular Biology, 2003, 331, 1157-1170.	2.0	17
1387	Control of Ras cycling by Ca2+. FEBS Letters, 2003, 546, 6-10.	1.3	36
1388	Ca2+/calmodulin binds and dissociates K-RasB from membrane. Biochemical and Biophysical Research Communications, 2003, 304, 655-660.	1.0	48
1389	Absence of point mutation in codons 12 and 13 of K-RAS oncogene in HPV-associated high grade dysplasia and squamous cell cervical carcinoma. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2003, 111, 68-73.	0.5	17
1390	Selective reovirus killing of bladder cancer in a co-culture spheroid model. Virus Research, 2003, 93, 1-12.	1.1	40
1391	Capillary Malformationâ€“Arteriovenous Malformation, a New Clinical and Genetic Disorder Caused by RASA1 Mutations. American Journal of Human Genetics, 2003, 73, 1240-1249.	2.6	647
1392	Ras redux: rethinking how and where Ras acts. Current Opinion in Genetics and Development, 2003, 13, 6-13.	1.5	80
1393	Clinicopathologic and genetic studies of nasal NK/T-cell lymphoma. International Congress Series, 2003, 1240, 1141-1144.	0.2	0
1394	ras oncogene mutations in diethylnitrosamine-induced hepatic tumors in medaka (Oryzias latipes), a teleost fish. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2003, 539, 43-53.	0.9	22
1395	Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematology/Oncology Clinics of North America, 2003, 17, 785-820.	0.9	148

#	Article	IF	Citations
1396	Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opinion on Therapeutic Targets, 2003, 7, 663-677.	1.5	17
1397	Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukesâ€™ B colorectal cancer patients: how much evidence is enough?. Annals of Oncology, 2003, 14, 1026-1038.	0.6	114
1398	Direct visualization of Ras proteins in spatially distinct cell surface microdomains. Journal of Cell Biology, 2003, 160, 165-170.	2.3	699
1399	c-mycDown-Regulation Induces Apoptosis in Human Cancer Cell Lines Exposed to RPR-115135 (C31H29NO4), a Non-Peptidomimetic Farnesyltransferase Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 37-47.	1.3	23
1400	Increased Expression of TATA-Binding Protein, the Central Transcription Factor, Can Contribute to Oncogenesis. Molecular and Cellular Biology, 2003, 23, 3043-3051.	1.1	62
1401	Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK Pathway. Journal of Biological Chemistry, 2003, 278, 42409-42418.	1.6	105
1402	A Novel Strategy for Specifically Down-regulating Individual Rho GTPase Activity in Tumor Cells. Journal of Biological Chemistry, 2003, 278, 44617-44625.	1.6	73
1403	Ligation of high-melting-temperature 'clamp' sequence extends the scanning range of rare point-mutational analysis by constant denaturant capillary electrophoresis (CDCE) to most of the human genome. Nucleic Acids Research, 2003, 31, 97e-97.	6.5	8
1404	Suprachiasmatic Nucleus Circadian Oscillatory Protein, a Novel Binding Partner of K-Ras in the Membrane Rafts, Negatively Regulates MAPK Pathway. Journal of Biological Chemistry, 2003, 278, 14920-14925.	1.6	83
1405	Farnesyl transferase inhibitors in clinical development. Expert Opinion on Investigational Drugs, 2003, 12, 943-954.	1.9	89
1406	Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. Journal of Cell Science, 2003, 116, 4957-4963.	1.2	107
1407	Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes and Development, 2003, 17, 629-637.	2.7	127
1408	Src-CrkII-C3G-dependent Activation of Rap1 Switches Growth Hormone-stimulated p44/42 MAP Kinase and JNK/SAPK Activities. Journal of Biological Chemistry, 2003, 278, 27301-27311.	1.6	40
1409	Lysyl Oxidase Inhibits Ras-Mediated Transformation by Preventing Activation of NF-Î²B. Molecular and Cellular Biology, 2003, 23, 2251-2263.	1.1	95
1410	Clinical, Cellular, and Molecular Aspects of Cancer Invasion. Physiological Reviews, 2003, 83, 337-376.	13.1	447
1411	Farnesyl transferase inhibitors in the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2003, 12, 413-421.	1.9	29
1412	K-Ras Regulates the Steady-state Expression of Matrix Metalloproteinase 2 in Fibroblasts. Journal of Biological Chemistry, 2003, 278, 31871-31878.	1.6	55
1413	Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6529-6534.	3.3	140

#	Article	IF	Citations
1414	High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors. Journal of Biological Chemistry, 2003, 278, 41718-41727.	1.6	80
1415	Differences on the Inhibitory Specificities of H-Ras, K-Ras, and N-Ras (N17) Dominant Negative Mutants Are Related to Their Membrane Microlocalization. Journal of Biological Chemistry, 2003, 278, 4572-4581.	1.6	102
1416	Astroglial c-Myc Overexpression Predisposes Mice to Primary Malignant Gliomas. Journal of Biological Chemistry, 2003, 278, 8300-8308.	1.6	47
1417	Elevated Phospholipase D Activity in H-Ras- but Not K-Ras-Transformed Cells by the Synergistic Action of RalA and ARF6. Molecular and Cellular Biology, 2003, 23, 645-654.	1.1	49
1418	Differential Î±v integrinâ€“mediated Ras-ERK signaling during two pathways of angiogenesis. Journal of Cell Biology, 2003, 162, 933-943.	2.3	248
1419	Emerging drugs for non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2003, 8, 179-192.	1.0	13
1420	Oncoprotein Suppression of Tumor Necrosis Factor-induced NFÎºB Activation Is Independent of Raf-controlled Pathways. Journal of Biological Chemistry, 2003, 278, 34910-34917.	1.6	24
1421	Lovastatin Induces Apoptosis of Anaplastic Thyroid Cancer Cells via Inhibition of Protein Geranylgeranylation and de Novo Protein Synthesis. Endocrinology, 2003, 144, 3852-3859.	1.4	95
1423	Using Mice to Decipher the Molecular Genetics of Brain Tumors. Neurosurgery, 2003, 53, 685-695.	0.6	44
1424	Serous Tumors of the Ovary (Borderline Tumors and Carcinomas) With and Without Micropapillary Features. International Journal of Gynecological Pathology, 2003, 22, 25-28.	0.9	20
1425	{tf1ansiansicpg1250deff0deflang1038deflangfe1038deftab708{onttbl{0romanprq2charset238{*name Times New Roman;}Times New Roman CE;}} viewkind4uc1pard0s24 N-ras mutation in a canine lymphoma: Short communication par}. Acta Veterinaria Hungarica, 2003, 51, 91-94.	0.2	8
1426	Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, 101, 1692-1697.	0.6	210
1427	Hematologic effects of inactivating the Ras processing enzymeRce1. Blood, 2003, 101, 2250-2252.	0.6	20
1428	Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood, 2003, 102, 1474-1479.	0.6	144
1429	Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometryâ€“based novel culture system. Blood, 2003, 102, 3938-3946.	0.6	365
1430	Characterization of human palmitoyl-acyl transferase activity using peptides that mimic distinct palmitoylation motifs. Biochemical Journal, 2003, 373, 91-99.	1.7	33
1431	Rb and N- ras Function Together To Control Differentiation in the Mouse. Molecular and Cellular Biology, 2003, 23, 5256-5268.	1.1	49
1432	The role of transgenic mouse models in carcinogen identification.. Environmental Health Perspectives, 2003, 111, 444-454.	2.8	126

#	Article	IF	Citations
1433	Prognostic Value of Mutations in TP53 and RAS Genes in Breast Cancer. International Journal of Biological Markers, 2003, 18, 49-53.	0.7	5
1434	Methotrexate and Ras Methylation: A New Trick for an Old Drug?. Science Signaling, 2004, 2004, pe13-pe13.	1.6	16
1435	Ras Signaling, Deregulation of Gene Expression and Oncogenesis. , 2004, , 189-208.		26
1436	Activation of Ras-Ral Pathway Attenuates p53-independent DNA Damage G2 Checkpoint. Journal of Biological Chemistry, 2004, 279, 36382-36389.	1.6	16
1437	Novel targeted agents in the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2004, 13, 609-629.	1.9	2
1438	Identification and Characterization of Rain, a Novel Ras-interacting Protein with a Unique Subcellular Localization. Journal of Biological Chemistry, 2004, 279, 22353-22361.	1.6	63
1439	Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. British Journal of Cancer, 2004, 91, 980-984.	2.9	117
1440	BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer. Clinical Cancer Research, 2004, 10, 191-195.	3.2	378
1441	Cooperative Regulation of the Cell Division Cycle by the Protein Kinases RAF and AKT. Molecular and Cellular Biology, 2004, 24, 10868-10881.	1.1	109
1442	Ras Activation in Jurkat T cells following Low-Grade Stimulation of the T-Cell Receptor Is Specific to N-Ras and Occurs Only on the Golgi Apparatus. Molecular and Cellular Biology, 2004, 24, 3485-3496.	1.1	137
1443	Oncogenic H-Ras Up-Regulates Expression of ERCC1 to Protect Cells from Platinum-Based Anticancer Agents. Cancer Research, 2004, 64, 4849-4857.	0.4	96
1444	Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes and Development, 2004, 18, 1317-1330.	2.7	100
1445	Mammary Epithelial-Mesenchymal Interaction Regulates Fibronectin Alternative Splicing via Phosphatidylinositol 3-Kinase. Journal of Biological Chemistry, 2004, 279, 21029-21037.	1.6	48
1446	Human Papillomavirus Type 16 E6 Amino Acid 83 Variants Enhance E6-Mediated MAPK Signaling and Differentially Regulate Tumorigenesis by Notch Signaling and Oncogenic Ras. Journal of Virology, 2004, 78, 5934-5945.	1.5	115
1447	Signaling Specificity by Ras Family GTPases Is Determined by the Full Spectrum of Effectors They Regulate. Molecular and Cellular Biology, 2004, 24, 4943-4954.	1.1	287
1448	Normal Human Fibroblasts Are Resistant to RAS-Induced Senescence. Molecular and Cellular Biology, 2004, 24, 2842-2852.	1.1	100
1449	A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2004, 10, 5447-5454.	3.2	73
1450	B-Raf Acts via the ROCKII/LIMK/Cofilin Pathway To Maintain Actin Stress Fibers in Fibroblasts. Molecular and Cellular Biology, 2004, 24, 5937-5952.	1.1	91

#	Article	IF	Citations
1451	Activation of Antioxidant Pathways in Ras-Mediated Oncogenic Transformation of Human Surface Ovarian Epithelial Cells Revealed by Functional Proteomics and Mass Spectrometry. Cancer Research, 2004, 64, 4577-4584.	0.4	120
1452	Roles of Phosphatidylinositol 3â€²-Kinase and Mammalian Target of Rapamycin/p70 Ribosomal Protein S6 Kinase in K-Ras-Mediated Transformation of Intestinal Epithelial Cells. Cancer Research, 2004, 64, 229-235.	0.4	63
1453	Conditional Expression of K-ras in an Epithelial Compartment that Includes the Stem Cells Is Sufficient to Promote Squamous Cell Carcinogenesis. Cancer Research, 2004, 64, 8804-8807.	0.4	127
1454	Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia1. Clinical Cancer Research, 2004, 10, 994-1002.	3.2	53
1455	The Transcriptional Response to Raf Activation Is Almost Completely Dependent on Mitogen-activated Protein Kinase Kinase Activity and Shows a Major Autocrine Component. Molecular Biology of the Cell, 2004, 15, 3450-3463.	0.9	63
1456	Crucial Role of Phospholipase CÎµ in Chemical Carcinogen-Induced Skin Tumor Development. Cancer Research, 2004, 64, 8808-8810.	0.4	195
1457	H-Ras and Phosphoinositide 3-Kinase Cooperate to Induce Î±(1,3)-Fucosyltransferase VII Expression in Jurkat T Cells. Journal of Biological Chemistry, 2004, 279, 39495-39504.	1.6	10
1458	Higher Farnesyl Diphosphate Synthase Activity in Human Colorectal Cancer Inhibition of Cellular Apoptosis. Oncology, 2004, 67, 351-358.	0.9	41
1459	Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Research, 2004, 32, e53-e53.	6.5	31
1460	Protein kinase CÎ¹ is required for Ras transformation and colon carcinogenesis in vivo. Journal of Cell Biology, 2004, 164, 797-802.	2.3	129
1461	A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2004, 10, 2636-2644.	3.2	20
1462	The Thyroid Hormone Receptor Is a Suppressor of ras -Mediated Transcription, Proliferation, and Transformation. Molecular and Cellular Biology, 2004, 24, 7514-7523.	1.1	97
1463	The Nuclear Factor ÎºB Subunits RelA/p65 and c-Rel Potentiate but Are Not Required for Ras-Induced Cellular Transformation. Cancer Research, 2004, 64, 7248-7255.	0.4	52
1464	K-Ras and H-Ras Activation Promote Distinct Consequences on Endometrial Cell Survival. Cancer Research, 2004, 64, 2759-2765.	0.4	35
1465	The Membrane-Anchored Matrix Metalloproteinase (MMP) Regulator RECK in Combination with MMP-9 Serves as an Informative Prognostic Indicator for Colorectal Cancer. Clinical Cancer Research, 2004, 10, 5572-5579.	3.2	102
1466	Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 597-602.	3.3	279
1467	High Intensity ras Signaling Induces Premature Senescence by Activating p38 Pathway in Primary Human Fibroblasts. Journal of Biological Chemistry, 2004, 279, 1050-1059.	1.6	152
1468	Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis. Cancer Research, 2004, 64, 4585-4592.	0.4	184

#	Article	IF	Citations
1469	Hematopoietic Cell Fate and the Initiation of Leukemic Properties in Primitive Primary Human Cells Are Influenced by Ras Activity and Farnesyltransferase Inhibition. Molecular and Cellular Biology, 2004, 24, 6993-7002.	1.1	37
1470	The role of protein tyrosine phosphatase 1B in Ras signaling. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1834-1839.	3.3	134
1471	Differentiation Induction of Human Keratinocytes by Phosphatidylethanolamine-binding Protein. Journal of Biological Chemistry, 2004, 279, 32191-32195.	1.6	26
1472	Role of osteopontin in tumour progression. British Journal of Cancer, 2004, 90, 1877-1881.	2.9	385
1473	p19â€ŠArf Suppresses Growth, Progression, and Metastasis of Hras-Driven Carcinomas through p53-Dependent and -Independent Pathways. PLoS Biology, 2004, 2, e242.	2.6	74
1474	A New Look at an Old Problem: The Survival and Organ-Specific Growth of Metastases. Science Signaling, 2004, 2004, pe3-pe3.	1.6	11
1475	Synergistic activation of signalling to extracellular signal-regulated kinases 1 and 2 by epidermal growth factor and 4Î²-phorbol 12-myristate 13-acetate. FEBS Journal, 2004, 271, 3905-3913.	0.2	15
1476	Principles behind the multifarious control of signal transduction. FEBS Journal, 2004, 272, 244-258.	2.2	135
1477	Preferential mammary carcinogenic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in human c-Ha-ras proto-oncogene transgenic rats. Cancer Science, 2004, 95, 399-403.	1.7	6
1478	Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. Apmis, 2004, 112, 233-238.	0.9	32
1479	Kâ€Ras gene status and expression of Ras/mitogenâ€activated protein kinase (MAPK) signaling molecules in ameloblastomas. Journal of Oral Pathology and Medicine, 2004, 33, 360-367.	1.4	41
1480	Neuronal activation of Ras regulates synaptic connectivity. European Journal of Neuroscience, 2004, 19, 2953-2966.	1.2	63
1481	Cancer genes and the pathways they control. Nature Medicine, 2004, 10, 789-799.	15.2	3,689
1482	The art and design of genetic screens: mammalian culture cells. Nature Reviews Genetics, 2004, 5, 179-189.	7.7	101
1483	Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein binding. Cancer Gene Therapy, 2004, 11, 465-476.	2.2	29
1484	RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia, 2004, 18, 685-692.	3.3	99
1485	Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways. Oncogene, 2004, 23, 9-20.	2.6	54
1486	Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene, 2004, 23, 1-8.	2.6	289

#	Article	IF	Citations
1487	Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene, 2004, 23, 2431-2441.	2.6	108
1488	Enhanced tenascin-C expression and matrix deposition during Ras/TGF-Î²-induced progression of mammary tumor cells. Oncogene, 2004, 23, 3622-3633.	2.6	45
1489	Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 2004, 23, 2838-2849.	2.6	1,361
1490	Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis. Oncogene, 2004, 23, 5994-5999.	2.6	17
1491	Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice. Oncogene, 2004, 23, 6639-6646.	2.6	46
1492	Ha-RasG12V induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction. Oncogene, 2004, 23, 6760-6768.	2.6	44
1493	Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research. Oncogene, 2004, 23, 8359-8365.	2.6	46
1494	Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways. Oncogene, 2004, 23, 7839-7845.	2.6	13
1495	Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. British Journal of Cancer, 2004, 91, 795-802.	2.9	55
1496	Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor. British Journal of Pharmacology, 2004, 143, 318-330.	2.7	13
1497	Thumbs up for inactivation. Nature, 2004, 429, 138-139.	13.7	3
1498	Molecular biology of prostate cancer. Prostate Cancer and Prostatic Diseases, 2004, 7, 6-20.	2.0	38
1499	Oncogenic Ras dominates overexpression of E-cadherin in malignant transformation of intestinal epithelial cells. Surgery, 2004, 136, 303-309.	1.0	12
1500	Toxic effects of ultraviolet radiation on the skin. Toxicology and Applied Pharmacology, 2004, 195, 298-308.	1.3	1,006
1501	Oncogenic Ras and its role in tumor cell invasion and metastasis. Seminars in Cancer Biology, 2004, 14, 105-114.	4.3	246
1502	Notch and T cell malignancy. Seminars in Cancer Biology, 2004, 14, 329-340.	4.3	45
1503	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell, 2004, 5, 375-387.	7.7	710
1504	Future Directions: Oncolytic Viruses. Clinical Lung Cancer, 2004, 5, 226-230.	1.1	4

#	Article	IF	Citations
1505	Adenoviral gene therapy for pancreatic adenocarcinoma. Journal of Surgical Education, 2004, 61, 351-358.	0.7	3
1506	Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse. Experimental Hematology, 2004, 32, 852-860.	0.2	25
1507	Stable propylphosphonic acid analogues of geranylgeranyl diphosphate possessing inhibitory activity on geranylgeranyl protein transferase. Il Farmaco, 2004, 59, 857-861.	0.9	1
1508	Stimulation of angiogenesis by Ras proteins. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1654, 23-37.	3.3	81
1509	Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces cell cycle arrest in ras-transformed human mammary epithelial cells. Biochemical Pharmacology, 2004, 68, 1081-1087.	2.0	57
1510	Species- and cell type-specific requirements for cellular transformation. Cancer Cell, 2004, 6, 171-183.	7.7	491
1511	Guilty as charged. Cancer Cell, 2004, 6, 313-319.	7.7	736
1512	Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell, 2004, 6, 447-458.	7.7	741
1513	Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detection and Prevention, 2004, 28, 127-142.	2.1	108
1514	Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cellular Signalling, 2004, 16, 1319-1327.	1.7	45
1515	Terminal Endbuds and Acini as the Respective Major Targets for Chemical and Sporadic Carcinogenesis in the Mammary Glands of Human c-Ha-ras Protooncogene Transgenic Rats. Breast Cancer Research and Treatment, 2004, 83, 43-56.	1.1	11
1516	Gliotoxin Is a Dual Inhibitor of Farnesyltransferase and Geranylgeranyltransferase I with Antitumor Activity Against Breast Cancer In Vivo. Medical Oncology, 2004, 21, 21-30.	1.2	89
1517	The influence of Ras pathway signaling on tumor radiosensitivity. Cancer and Metastasis Reviews, 2004, 23, 227-236.	2.7	30
1518	Role of reactive oxygen species and Cr(VI) in Ras-mediated signal transduction. Molecular and Cellular Biochemistry, 2004, 255, 119-127.	1.4	28
1519	Diagnostic Impact of Ornithine Decarboxylase in Meningiomas. Journal of Neuro-Oncology, 2004, 66, 59-64.	1.4	2
1520	In Vitro and in Vivo Metabolism of the Anti-Cancer Agent CI-1040, a MEK Inhibitor, in Rat, Monkey, and Human. Pharmaceutical Research, 2004, 21, 1670-1679.	1.7	16
1521	Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathologica, 2004, 108, 467-470.	3.9	136
1522	Deregulated expression of KRAP, a novel gene encoding actin-interacting protein, in human colon cancer cells. Journal of Human Genetics, 2004, 49, 46-52.	1.1	25

#	Article	IF	Citations
1523	Overexpressions of Ha-ras and p53 predict the prognosis of patients with non-small-cell lung carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2004, 16, 40-44.	0.7	0
1524	Capsaicin-Induced apoptosis of h-ras-transformed human breast epithelial cells is rac-dependentvia ros generation. Archives of Pharmacal Research, 2004, 27, 845-849.	2.7	42
1525	Why does the Ras switch â€œbreakâ€•by oncogenic mutations?. Proteins: Structure, Function and Bioinformatics, 2004, 55, 1-10.	1.5	94
1526	Meat-related mutagens/carcinogens in the etiology of colorectal cancer. Environmental and Molecular Mutagenesis, 2004, 44, 44-55.	0.9	371
1527	Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. International Journal of Cancer, 2004, 109, 377-384.	2.3	133
1528	Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. International Journal of Cancer, 2004, 110, 368-373.	2.3	75
1529	Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. International Journal of Cancer, 2004, 112, 190-199.	2.3	41
1530	Ras signaling in prostate cancer progression. Journal of Cellular Biochemistry, 2004, 91, 13-25.	1.2	146
1531	Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. Journal of Cellular Physiology, 2004, 198, 277-294.	2.0	18
1532	A 32 kDa protein?whose phosphorylation correlates with oncogenic Ras-induced cell cycle arrest in activatedXenopus egg extracts?is identified as ribosomal protein S6. Journal of Cellular Physiology, 2004, 201, 305-319.	2.0	8
1533	Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Molecular Carcinogenesis, 2004, 39, 91-102.	1.3	62
1534	The chemopreventive agent ?-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells. Molecular Carcinogenesis, 2004, 39, 221-233.	1.3	45
1535	Synthesis of GTP-Derived Ras Ligands. ChemBioChem, 2004, 5, 1448-1453.	1.3	6
1536	The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. International Journal of Radiation Oncology Biology Physics, 2004, 58, 927-931.	0.4	121
1537	Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3957-3962.	1.0	22
1538	Deficiencies in Mouse Myh and Ogg1 Result in Tumor Predisposition and G to T Mutations in Codon 12 of the K-Ras Oncogene in Lung Tumors. Cancer Research, 2004, 64, 3096-3102.	0.4	271
1539	Reactive Oxygen Species And Lung Tumorigenesis By Mutant K-ras: A Working Hypothesis. Experimental Lung Research, 2004, 31, 83-104.	0.5	10
1540	Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action. Leukemia and Lymphoma, 2004, 45, 2187-2195.	0.6	30

#	Article	IF	Citations
1541	Phase II Study of Antineoplaston A10 and AS2-1 in Children with Recurrent and Progressive Multicentric Glioma. Drugs in R and D, 2004, 5, 315-326.	1.1	3
1542	Spontaneous nucleotide exchange in low molecular weight GTPases by fluorescently labeled Â-phosphate-linked GTP analogs. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2800-2805.	3.3	31
1543	Ki-ras mutational analysis in rat follicular-cell proliferative lesions of the thyroid gland induced by radioactive iodine and potassium perchlorate. Journal of Endocrinological Investigation, 2004, 27, 12-17.	1.8	16
1544	Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis. Cancer Research, 2004, 64, 6461-6468.	0.4	202
1545	Novel treatments in nonâ€“small cell lung cancer. Hematology/Oncology Clinics of North America, 2004, 18, 245-267.	0.9	14
1546	Malignant peripheral nerve sheath tumors. Neurosurgery Clinics of North America, 2004, 15, 203-216.	0.8	83
1547	A NOVEL INTRAVESICAL THERAPY FOR SUPERFICIAL BLADDER CANCER IN AN ORTHOTOPIC MODEL: ONCOLYTIC REOVIRUS THERAPY. Journal of Urology, 2004, 172, 2018-2022.	0.2	34
1548	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opinion on Investigational Drugs, 2004, 13, 1-19.	1.9	48
1549	Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas. British Journal of Cancer, 2004, 90, 1591-1593.	2.9	68
1550	Multimutated Herpes Simplex Virus G207 Is a Potent Inhibitor of Angiogenesis. Neoplasia, 2004, 6, 725-735.	2.3	49
1551	JunD Reduces Tumor Angiogenesis by Protecting Cells from Oxidative Stress. Cell, 2004, 118, 781-794.	13.5	530
1552	Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer. DNA Repair, 2004, 3, 1057-1062.	1.3	37
1553	Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Cancer Letters, 2004, 214, 115-120.	3.2	36
1554	Do aberrant crypt foci have predictive value for the occurrence of colorectal tumours? Potential of gene expression profiling in tumours. Food and Chemical Toxicology, 2004, 42, 1629-1639.	1.8	22
1555	Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. European Journal of Cancer, 2004, 40, 298-307.	1.3	147
1556	Involvement of Ras in extraembryonic endoderm differentiation of embryonic stem cells. Biochemical and Biophysical Research Communications, 2004, 313, 475-481.	1.0	79
1557	Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins. Biochemical and Biophysical Research Communications, 2004, 313, 654-665.	1.0	55
1558	Ras inhibition amplifies cisplatin sensitivity of human glioblastoma. Biochemical and Biophysical Research Communications, 2004, 320, 493-500.	1.0	16

#	Article	IF	Citations
1559	Potentiated caspase-3 in Ras-transformed 10T1/2 cells. Biochemical and Biophysical Research Communications, 2004, 322, 557-564.	1.0	10
1560	Identifying specific kinase substrates through engineered kinases and ATP analogs. Methods, 2004, 32, 389-397.	1.9	9
1561	PTC gene mutations and expression of SHH, PTC, SMO, and GLI-1 in odontogenic keratocysts. International Journal of Oral and Maxillofacial Surgery, 2004, 33, 584-592.	0.7	72
1562	Fluoride as an essential element in the prevention of disease. Medical Hypotheses, 2004, 62, 710-717.	0.8	11
1563	The role of Osteopontin in tumor metastasis. Journal of Surgical Research, 2004, 121, 228-241.	0.8	330
1564	GTP Hydrolysis Mechanism of Ras-like GTPases. Journal of Molecular Biology, 2004, 340, 921-932.	2.0	76
1565	Oncogenic Mutations in B-Raf. Cell, 2004, 116, 764-766.	13.5	28
1566	Mechanism Targeted Discovery of Antitumor Marine Natural Products. Current Medicinal Chemistry, 2004, 11, 1725-1756.	1.2	64
1567	C<scp>onnective</scp> T<scp>issue</scp> M<scp>etabolism and</scp> G<scp>ingival</scp> O<scp>vergrowth</scp>. Critical Reviews in Oral Biology and Medicine, 2004, 15, 165-175.	4.4	123
1568	Too much ERK, not enough erythrocytes. Blood, 2004, 104, 1591-1592.	0.6	0
1569	Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood, 2004, 103, 4243-4250.	0.6	162
1570	RLP, a novel Ras-like protein, is an immediate-early transforming growth factor-Î² (TGF-Î²) target gene that negatively regulates transcriptional activity induced by TGF-Î². Biochemical Journal, 2004, 383, 187-199.	1.7	15
1571	Pancreatic Carcinoma: An Introduction. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2005, 3, 279-304.	0.0	0
1573	Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines. Cancer Research, 2005, 65, 7902-7910.	0.4	169
1574	Deciphering Cancer Complexities in Genetically Engineered Mice. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 283-290.	2.0	8
1575	7, 12-DMBA-induced Rat Leukemia as a Model of Chemical Carcinogenesis. Proceedings of the Japanese Society of Animal Models for Human Diseases, 2005, 21, 37-44.	0.1	1
1576	Signal transduction in prostate cancer progression. Clinical Science, 2005, 108, 293-308.	1.8	103
1577	N-Nitrosamines. Chromatographic Science, 2005, , 419-452.	0.1	1

#	Article	IF	Citations
1578	Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leukemia Research, 2005, 29, 527-533.	0.4	34
1579	Spectroscopic study of fluorescent peptides for prenyl transferase assays. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 417-422.	1.4	9
1580	Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 153-158.	1.0	16
1581	Design, synthesis, and structureâ€“activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1895-1899.	1.0	21
1582	Alterations of the <I>BRAF</I> Gene in Thyroid Tumors. Endocrine Pathology, 2005, 16, 163-172.	5.2	101
1583	Understanding the Genotype of Follicular Thyroid Tumors. Endocrine Pathology, 2005, 16, 311-322.	5.2	26
1584	Flavonoid Compounds in Maintenance of Prostate Health and Prevention and Treatment of Cancer. Molecular Biotechnology, 2005, 30, 253-270.	1.3	38
1585	Oncogenic Ras in tumour progression and metastasis. Biological Chemistry, 2005, 386, 193-205.	1.2	240
1586	Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver International, 2005, 25, 380-388.	1.9	68
1587	FREQUENT K-RAS MUTATIONS AMONG LATERALLY SPREADING TUMORS WITH GRANULAR COMPONENTS AND THEIR SIGNIFICANCE FOR RECTAL CARCINOMAS. Digestive Endoscopy, 2005, 17, 69-72.	1.3	3
1588	Antimutagenic and anti-oxidant activities of the non-steroidal anti-inflammatory drug celecoxib. Clinical and Experimental Pharmacology and Physiology, 2005, 32, 888-893.	0.9	14
1589	High susceptibility of human c-Ha-ras proto-oncogene transgenic rats to carcinogenesis: A cancer-prone animal model. Cancer Science, 2005, 96, 309-316.	1.7	25
1590	Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nature Structural and Molecular Biology, 2005, 12, 1037-1044.	3.6	211
1591	H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells. British Journal of Cancer, 2005, 92, 80-88.	2.9	20
1592	The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nature Cell Biology, 2005, 7, 1074-1082.	4.6	515
1593	Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nature Genetics, 2005, 37, 1038-1040.	9.4	597
1594	Nature and nurture â€“ lessons from chemical carcinogenesis. Nature Reviews Cancer, 2005, 5, 113-125.	12.8	362
1595	Mechanisms of BCRâ€“ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews Cancer, 2005, 5, 172-183.	12.8	896

#	Article	IF	Citations
1596	Post-prenylation-processing enzymes as new targets in oncogenesis. Nature Reviews Cancer, 2005, 5, 405-412.	12.8	315
1597	Immunotherapy for pancreatic cancer â€" science driving clinical progress. Nature Reviews Cancer, 2005, 5, 459-467.	12.8	180
1598	Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. Leukemia, 2005, 19, 18-26.	3.3	38
1599	RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia, 2005, 19, 415-419.	3.3	51
1600	Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia, 2005, 19, 1536-1542.	3.3	227
1601	The small G-protein RalA stimulates metastasis of transformed cells. Oncogene, 2005, 24, 329-335.	2.6	38
1602	AP-1 dimers regulate transcription of the p14/p19ARF tumor suppressor gene. Oncogene, 2005, 24, 2298-2306.	2.6	43
1603	Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras. Oncogene, 2005, 24, 2330-2342.	2.6	20
1604	Paired-like homeoprotein ESXR1 acts as a sequence-specific transcriptional repressor of the human K-ras gene. Oncogene, 2005, 24, 5878-5887.	2.6	7
1605	Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene, 2005, 24, 6174-6184.	2.6	32
1606	Control of MAPK signalling: from complexity to what really matters. Oncogene, 2005, 24, 5533-5542.	2.6	175
1607	Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene, 2005, 24, 7720-7728.	2.6	83
1608	Molecular dynamics structures of peptide nucleic acidÂ·DNA hybrid in the wild-type and mutated alleles of Ki-ras proto-oncogene. FEBS Journal, 2005, 272, 4055-4070.	2.2	18
1609	Harvey-ras Gene Expression and Epidermal Cell Proliferation in Dibenzo[a,l]Pyrene-Treated Early Preneoplastic SENCAR Mouse Skin. Journal of Investigative Dermatology, 2005, 125, 567-574.	0.3	5
1610	Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genetics and Cytogenetics, 2005, 158, 55-60.	1.0	20
1611	Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell, 2005, 7, 533-545.	7.7	330
1612	Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell, 2005, 8, 381-392.	7.7	168
1613	Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2â€²-O-methyl phosphodiester oligonucleotides in normal rats. European Journal of Pharmaceutical Sciences, 2005, 26, 26-38.	1.9	57

#	Article	IF	Citations
1614	Viral oncolysis: Tumor-tailored therapy. Journal of Surgical Education, 2005, 62, 25-30.	0.7	1
1615	Ras signaling from plasma membrane and endomembrane microdomains. Biochimica Et Biophysica Acta - Molecular Cell Research, 2005, 1746, 274-283.	1.9	113
1616	Mouse models of K-ras-initiated carcinogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2005, 1756, 145-154.	3.3	19
1617	The KRAS oncogene: Past, present, and future. Biochimica Et Biophysica Acta: Reviews on Cancer, 2005, 1756, 81-82.	3.3	156
1618	Effects of HRAS Oncogene on Cell Cycle Progression in a Cervical Cancer-Derived Cell Line. Archives of Medical Research, 2005, 36, 311-316.	1.5	22
1619	Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discovery Today, 2005, 10, 847-855.	3.2	56
1620	Gene-expression analysis after alcohol exposure in the developing mouse. Translational Research, 2005, 145, 47-54.	2.4	60
1621	E-cadherin is regulated by the transcriptional repressor SLUG during Ras-mediated transformation of intestinal epithelial cells. Surgery, 2005, 138, 306-312.	1.0	31
1622	Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicology and Applied Pharmacology, 2005, 206, 288-298.	1.3	155
1623	Ral GTPases: corrupting the exocyst in cancer cells. Trends in Cell Biology, 2005, 15, 327-332.	3.6	105
1624	G-protein-directed ligand discovery with peptide combinatorial libraries. Trends in Biochemical Sciences, 2005, 30, 318-324.	3.7	25
1625	Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer, 2005, 5, 160.	1.1	53
1626	Detection of single-base mutation by affinity capillary electrophoresis using a DNA-polyacrylamide conjugate. Electrophoresis, 2005, 26, 3076-3080.	1.3	17
1627	A novel high-specificity approach for colorectal neoplasia: Detection of K-ras2 oncogene mutation in normal mucosa. International Journal of Cancer, 2005, 113, 1015-1021.	2.3	13
1628	Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-Î±-tocotrienol, a redox-silent derivative of Î±-tocotrienol. International Journal of Cancer, 2005, 115, 839-846.	2.3	43
1629	Suppression of oncogenicNRAS by RNA interference induces apoptosis of human melanoma cells. International Journal of Cancer, 2005, 115, 65-73.	2.3	83
1630	BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. International Journal of Cancer, 2005, 115, 943-950.	2.3	48
1631	New approaches in the treatment of myelofibrosis. Cancer, 2005, 103, 32-43.	2.0	20

#	Article	IF	Citations
1632	Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer, 2005, 104, 561-569.	2.0	106
1633	Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers. Molecular Carcinogenesis, 2005, 43, 59-63.	1.3	15
1634	Dietary fibre and colorectal cancer: A model for environment - gene interactions. Molecular Nutrition and Food Research, 2005, 49, 571-584.	1.5	130
1635	Imaging Activation of Two Ras Isoforms Simultaneously in a Single Cell. ChemBioChem, 2005, 6, 78-85.	1.3	62
1636	Solid-Phase Synthesis of Lipidated Peptides. Chemistry - A European Journal, 2005, 11, 7405-7415.	1.7	51
1637	Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathologica, 2005, 109, 207-210.	3.9	85
1638	Unraveling the mechanism of the farnesyltransferase enzyme. Journal of Biological Inorganic Chemistry, 2005, 10, 3-10.	1.1	39
1639	In vitro anti-tumor immune response induced by dendritic cells transfected with recombinant adenovirus carrying mutant k-ras genes. Journal of Huazhong University of Science and Technology [Medical Sciences], 2005, 25, 378-381.	1.0	1
1640	Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy. Bioscience Reports, 2005, 25, 107-125.	1.1	119
1641	Codon 12 Region of Mouse K-ras Gene Is the Site for in vitro Binding of Transcription Factors GATA-6 and NF-Y. Biochemistry (Moscow), 2005, 70, 1180-1184.	0.7	4
1642	Recognition and binding of mismatch repair proteins at an oncogenic hot spot. BMC Molecular Biology, 2005, 6, 6.	3.0	8
1643	Differences in Effects of Oncogenes on Sensitivity to Anticancer Drugs. Journal of Radiation Research, 2005, 46, 197-203.	0.8	5
1644	Reversal of the phenotype byK-rasval12silencing mediated by adenovirus-delivered siRNA in human pancreatic cancer cell line Panc-1. World Journal of Gastroenterology, 2005, 11, 831.	1.4	26
1646	Microarray analysis and RNA silencing to determine genes functionally important in mesothelioma. , 2005, , 447-469.		0
1647	Magnetic Resonance Spectroscopy Monitoring of Mitogen-Activated Protein Kinase Signaling Inhibition. Cancer Research, 2005, 65, 3356-3363.	0.4	80
1648	Development of Farnesyl Transferase Inhibitors: A Review. Oncologist, 2005, 10, 565-578.	1.9	256
1649	A Diacylglycerol-Protein Kinase C-RasGRP1 Pathway Directs Ras Activation upon Antigen Receptor Stimulation of T Cells. Molecular and Cellular Biology, 2005, 25, 4426-4441.	1.1	180
1650	NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut, 2005, 54, 1129-1135.	6.1	41

#	Article	IF	Citations
1651	Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models. Clinical Cancer Research, 2005, 11, 3045-3054.	3.2	21
1652	Oncogenic H-Ras Up-regulates Expression of Ku80 to Protect Cells from Î³-Ray Irradiation in NIH3T3 Cells. Cancer Research, 2005, 65, 6811-6819.	0.4	22
1653	International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences. Pharmacological Reviews, 2005, 57, 27-77.	7.1	869
1654	Getting at MYC through RAS. Clinical Cancer Research, 2005, 11, 4278-4281.	3.2	36
1655	Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors. Clinical Cancer Research, 2005, 11, 4151-4159.	3.2	14
1656	Calcium-activated RAF/MEK/ERK Signaling Pathway Mediates p53-dependent Apoptosis and Is Abrogated by Î±B-Crystallin through Inhibition of RAS Activation. Molecular Biology of the Cell, 2005, 16, 4437-4453.	0.9	173
1657	Ras-mediated Loss of the Pro-apoptotic Response Protein Par-4 Is Mediated by DNA Hypermethylation through Raf-independent and Raf-dependent Signaling Cascades in Epithelial Cells. Journal of Biological Chemistry, 2005, 280, 23363-23370.	1.6	87
1658	Caenorhabditis elegans CNK-1 promotes Raf activation but is not essential for Ras/Raf signaling. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11757-11762.	3.3	23
1659	Expression of Endogenous Oncogenic V600EB-raf Induces Proliferation and Developmental Defects in Mice and Transformation of Primary Fibroblasts. Cancer Research, 2005, 65, 11493-11500.	0.4	147
1660	Genotyping of Patients with Sporadic and Radiation-Associated Meningiomas. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 969-976.	1.1	76
1661	Disruption of Cooperation Between Ras and MycN in Human Neuroblastoma Cells Promotes Growth Arrest. Clinical Cancer Research, 2005, 11, 4321-4330.	3.2	61
1662	Future of Early Detection of Lung Cancer: The Role of Mouse Models. Clinical Cancer Research, 2005, 11, 4999s-5003s.	3.2	20
1663	Transformation by Oncogenic RAS Sensitizes Human Colon Cells to TRAIL-induced Apoptosis by Up-regulating Death Receptor 4 and Death Receptor 5 through a MEK-dependent Pathway. Journal of Biological Chemistry, 2005, 280, 22856-22867.	1.6	74
1664	A Ras Homologue Member I Directly Inhibits Signal Transducers and Activators of Transcription 3 Translocation and Activity in Human Breast and Ovarian Cancer Cells. Cancer Research, 2005, 65, 6701-6710.	0.4	42
1665	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut, 2005, 54, 1283-1286.	6.1	203
1666	Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer. Cancer Research, 2005, 65, 4562-4567.	0.4	335
1667	Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Therapy, 2005, 12, 147-159.	2.3	32
1668	Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Annals of Oncology, 2005, 16, 1688-1694.	0.6	270

#	Article	IF	Citations
1669	Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 1638-1642.	3.3	62
1670	Genetic Modeling of Human Rhabdomyosarcoma. Cancer Research, 2005, 65, 4490-4495.	0.4	79
1671	A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4336-4341.	3.3	168
1672	From The Cover: Proline suppresses apoptosis in the fungal pathogen Colletotrichum trifolii. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3459-3464.	3.3	415
1673	Pathway- and Expression Level-Dependent Effects of Oncogenic N-Ras: p27Kip1 Mislocalization by the Ral-GEF Pathway and Erk-Mediated Interference with Smad Signaling. Molecular and Cellular Biology, 2005, 25, 8239-8250.	1.1	52
1674	Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time?. Oncologist, 2005, 10, 480-492.	1.9	19
1675	DHHC9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras. Journal of Biological Chemistry, 2005, 280, 31141-31148.	1.6	295
1676	Mutations That Rescue the Paralysis of Caenorhabditis elegans ric-8 (Synembryn) Mutants Activate the GÎ±s Pathway and Define a Third Major Branch of the Synaptic Signaling Network. Genetics, 2005, 169, 631-649.	1.2	112
1677	Epstein-Barr Virus Latent Membrane Protein 1 (CAO) Up-regulates VEGF and TGFÎ± Concomitant with Hyperlasia, with Subsequent Up-regulation of p16 and MMP9. Cancer Research, 2005, 65, 8826-8835.	0.4	57
1678	Rit Contributes to Nerve Growth Factor-Induced Neuronal Differentiation via Activation of B-Raf-Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Cascades. Molecular and Cellular Biology, 2005, 25, 830-846.	1.1	67
1679	Effect of the Farnesyl Transferase Inhibitor L-744,832 on the Colon Cancer Cell Line DLD-1 and Its Combined Use with Radiation and 5-FU. Chemotherapy, 2005, 51, 319-323.	0.8	4
1680	Thematic Review Series: Lipid Posttranslational Modifications. Prelamin A, Zmpste24, misshapen cell nuclei, and progeriaâ€"new evidence suggesting that protein farnesylation could be important for disease pathogenesis. Journal of Lipid Research, 2005, 46, 2531-2558.	2.0	193
1681	Farnesyltransferase Inhibitor SCH66336 Induces Rapid Phosphorylation of Eukaryotic Translation Elongation Factor 2 in Head and Neck Squamous Cell Carcinoma Cells. Cancer Research, 2005, 65, 5841-5847.	0.4	20
1682	The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase. Cancer Research, 2005, 65, 3883-3893.	0.4	101
1683	The Ability of E1A to Rescue ras-Induced Premature Senescence and Confer Transformation Relies on Inactivation of Both p300/CBP and Rb Family Proteins. Cancer Research, 2005, 65, 8298-8307.	0.4	40
1684	Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors. Clinical Cancer Research, 2005, 11, 5472-5480.	3.2	332
1685	H-Ras-specific Activation of Rac-MKK3/6-p38 Pathway. Journal of Biological Chemistry, 2005, 280, 14675-14683.	1.6	170
1686	Diacylglycerol kinase Â regulates Ras guanyl-releasing protein 3 and inhibits Rap1 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7595-7600.	3.3	75

#	Article	IF	Citations
1687	A Novel Function for Galectin-7: Promoting Tumorigenesis by Up-regulating MMP-9 Gene Expression. Cancer Research, 2005, 65, 5205-5210.	0.4	92
1689	Dissection of the GTPase mechanism of Ras protein by MD analysis of Ras mutants. Proteins: Structure, Function and Bioinformatics, 2005, 59, 528-533.	1.5	4
1690	Gene targeting approach to selectively kill colon cancer cells, with hyperactive K-Ras pathway. Biomedicine and Pharmacotherapy, 2005, 59, S370-S374.	2.5	9
1691	The characteristics of disseminated tumor cells in pancreatic cancer: A black box needs to be explored. Pancreatology, 2005, 5, 316-324.	0.5	19
1692	Medullary Thyroid Cancer: The Functions of raf-1 and Human Achaete-scute Homologue-1. Thyroid, 2005, 15, 511-521.	2.4	43
1693	Prostaglandin E2 Enhances Intestinal Adenoma Growth via Activation of the Ras-Mitogen-Activated Protein Kinase Cascade. Cancer Research, 2005, 65, 1822-1829.	0.4	166
1694	Oncogenes as Novel Targets for Cancer Therapy (Part II). Molecular Diagnosis and Therapy, 2005, 5, 247-257.	3.3	14
1695	Accommodation of a 1S-(â˜)-Benzo[c]phenanthrenyl-N6-dA Adduct in the Y-Family Dpo4 DNA Polymerase Active Site:â€‰ Structural Insights through Molecular Dynamics Simulations. Chemical Research in Toxicology, 2005, 18, 441-456.	1.7	15
1696	Gender-dependent hepatic alterations in H-ras12V transgenic mice. Journal of Hepatology, 2005, 43, 836-844.	1.8	56
1697	Regulation of Raf-1 by Direct Feedback Phosphorylation. Molecular Cell, 2005, 17, 215-224.	4.5	539
1698	Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. Journal of Clinical Neuroscience, 2005, 12, 1-5.	0.8	38
1699	P120-GAP associated with syndecan-2 to function as an active switch signal for Src upon transformation with oncogenic ras. Biochemical and Biophysical Research Communications, 2005, 329, 855-862.	1.0	22
1700	Trap RACK1 with Ras to mobilize Src signaling at syndecan-2/p120-GAP upon transformation with oncogenic ras. Biochemical and Biophysical Research Communications, 2005, 330, 1087-1094.	1.0	15
1701	Dimerize RACK1 upon transformation with oncogenic ras. Biochemical and Biophysical Research Communications, 2005, 330, 474-482.	1.0	11
1702	RASA1: variable phenotype with capillary and arteriovenous malformations. Current Opinion in Genetics and Development, 2005, 15, 265-269.	1.5	240
1703	A Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and Tumorigenicity. Cell, 2005, 121, 849-858.	13.5	257
1704	Intracellular signalling and cancer: complex pathways lead to multiple targets. European Journal of Cancer, 2005, 41, 206-215.	1.3	18
1705	The potential of statins as part of anti-cancer treatment. European Journal of Cancer, 2005, 41, 516-522.	1.3	92

#	Article	IF	Citations
1706	Distinct roles of the ERK pathway in modulating apoptosis of Ras-transformed and non-transformed cells induced by anticancer agent FR901228. FEBS Letters, 2005, 579, 90-94.	1.3	17
1707	Peroxisome proliferator-activated receptor Î´ as a molecular target to regulate lung cancer cell growth. FEBS Letters, 2005, 579, 3829-3836.	1.3	63
1708	The lesswright mutation activates Rel-related proteins, leading to overproduction of larval hemocytes in Drosophila melanogaster. Developmental Biology, 2005, 280, 407-420.	0.9	58
1709	Electron microscopic imaging of Ras signaling domains. Methods, 2005, 37, 165-172.	1.9	49
1710	Theoretical IR Spectroscopy Based on QM/MM Calculations Provides Changes in Charge Distribution, Bond Lengths, and Bond Angles of the GTP Ligand Induced by the Ras-Protein. Biophysical Journal, 2005, 88, 3829-3844.	0.2	62
1711	The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochemistry and Cell Biology, 2005, 83, 1-14.	0.9	201
1712	The Ras Effector RASSF2 Is a Novel Tumor-Suppressor Gene in Human Colorectal Cancer. Gastroenterology, 2005, 129, 156-169.	0.6	132
1713	Oncogenic Potential of MEK1 in Rat Intestinal Epithelial Cells Is Mediated via Cyclooxygenase-2. Gastroenterology, 2005, 129, 577-590.	0.6	23
1714	Gene-Expression Profiling Predicts Recurrence in Dukesâ€™ C Colorectal Cancer. Gastroenterology, 2005, 129, 874-884.	0.6	119
1715	Biologie des cancers bronchiques. EMC - Pneumologie, 2005, 2, 9-31.	0.2	0
1716	Biochip for K-ras Mutation Screening in Ovarian Cancer. Clinical Chemistry, 2005, 51, 784-787.	1.5	15
1717	A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040. Neoplasia, 2005, 7, 336-347.	2.3	46
1718	Molecular Mechanisms in Gliomagenesis. Advances in Cancer Research, 2005, 94, 1-27.	1.9	63
1719	The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells. Breast Cancer Research, 2006, 8, R46.	2.2	65
1720	Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Research, 2006, 8, R21.	2.2	25
1721	A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY. , 2006, , 1-35.		0
1722	Mechanisms of Gliomagenesis. , 2006, , 449-462.		1
1723	Glioma Oncogenesis and Animal Models of Glioma Formation. Hematology/Oncology Clinics of North America, 2006, 20, 1193-1214.	0.9	3

#	Article	IF	Citations
1724	Drug Insight: statins and gastrointestinal cancer. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 552-562.	1.7	8
1725	Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006). American Journal of Pathology, 2006, 169, 1875-1885.	1.9	139
1726	ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Experimental Cell Research, 2006, 312, 2066-2073.	1.2	70
1727	Involvement of H- and N-Ras isoforms in transforming growth factor-Î²1-induced proliferation and in collagen and fibronectin synthesis. Experimental Cell Research, 2006, 312, 2093-2106.	1.2	44
1728	Novel Targeted Therapies for Nonâ€“Small Cell Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 353-366.	0.4	1
1729	CD24 Is a New Oncogene, Early at the Multistep Process of Colorectal Cancer Carcinogenesis. Gastroenterology, 2006, 131, 630-639.	0.6	102
1730	Germline Missense Mutations Affecting KRAS Isoform B Are Associated with a Severe Noonan Syndrome Phenotype. American Journal of Human Genetics, 2006, 79, 129-135.	2.6	205
1731	Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Molecular Cancer, 2006, 5, 31.	7.9	129
1732	Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Molecular Cancer, 2006, 5, 63.	7.9	12
1733	The New Era in Cancer Research. Science, 2006, 312, 1162-1165.	6.0	278
1734	Tumorigenesis: Modeling Kras in cells and mice. Drug Discovery Today: Disease Models, 2006, 3, 161-166.	1.2	0
1735	Chemopreventive effect of punicalagin, a novel tannin component isolated from Terminalia catappa, on H-ras-transformed NIH3T3 cells. Toxicology Letters, 2006, 163, 44-53.	0.4	52
1736	A Genetically Defined Normal Human Somatic Cell System to Study Ras Oncogenesis In Vivo and In Vitro. Methods in Enzymology, 2006, 407, 637-647.	0.4	44
1737	Detailed Map of Oxidative Post-Translational Modifications of Human P21Ras Using Fourier Transform Mass Spectrometry. Analytical Chemistry, 2006, 78, 5134-5142.	3.2	32
1738	Mechanisms of Disease: the pathogenesis of pituitary tumors. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 220-230.	2.9	85
1739	Silencing of the Metastasis Suppressor RECK by RAS Oncogene Is Mediated by DNA Methyltransferase 3bâ€“Induced Promoter Methylation. Cancer Research, 2006, 66, 8413-8420.	0.4	89
1740	Shift syndecan-2 from RACK1 to caveolin-2 upon transformation with oncogenic ras. Biochemical and Biophysical Research Communications, 2006, 350, 227-232.	1.0	11
1741	Chronic renal failure rats are highly sensitive to aristolochic acids, which are nephrotoxic and carcinogenic agents. Cancer Letters, 2006, 232, 236-242.	3.2	30

#	Article	IF	Citations
1742	Anti-proliferative effects of green tea polyphenol EGCG on Ha-Ras-induced transformation of intestinal epithelial cells. Cancer Letters, 2006, 238, 260-270.	3.2	33
1743	Aurora-A overexpression associates with Ha-ras codon-12 mutation and blackfoot disease endemic area in bladder cancer. Cancer Letters, 2006, 241, 93-101.	3.2	15
1744	Perspectives for targeted therapies in cancer of unknown primary site. Cancer Treatment Reviews, 2006, 32, 637-644.	3.4	18
1745	Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years. European Journal of Cancer, 2006, 42, 1357-1361.	1.3	27
1746	Dehydrotrametenolic acid selectively inhibits the growth of H-ras transformed rat2 cells and induces apoptosis through caspase-3 pathway. Life Sciences, 2006, 78, 607-613.	2.0	29
1747	Orchiectomy reduces hepatotumorigenesis of H-ras12V transgenic mice via the MAPK pathway. Life Sciences, 2006, 79, 1974-1980.	2.0	8
1748	The role of ras gene in the development of haemic neoplasia in Mytilus trossulus. Marine Environmental Research, 2006, 62, S147-S150.	1.1	26
1749	MAP-quest: Could we produce constitutively active variants of MAP kinases?. Molecular and Cellular Endocrinology, 2006, 252, 231-240.	1.6	18
1750	PKC Regulates a Farnesyl-Electrostatic Switch on K-Ras that Promotes its Association with Bcl-Xl on Mitochondria and Induces Apoptosis. Molecular Cell, 2006, 21, 481-493.	4.5	421
1751	Ras Signaling Pathways and Farnesyltransferase Inhibitors. , 2006, , 173-184.		1
1752	Prognostic Value of Circulating KRAS2 Gene Mutations in Colorectal Cancer with Distant Metastases. International Journal of Biological Markers, 2006, 21, 223-228.	0.7	26
1753	Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood, 2006, 108, 2349-2357.	0.6	79
1754	Neuronal nitric oxide synthase-induced S-nitrosylation of H-Ras inhibits calcium ionophore-mediated extracellular-signal-regulated kinase activity. Biochemical Journal, 2006, 397, 329-336.	1.7	40
1755	Sorafenib. Current Opinion in Oncology, 2006, 18, 615-621.	1.1	66
1756	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. Topics in Medicinal Chemistry, 2006, , 83-132.	0.4	1
1757	Farnesylation or geranylgeranylation? Efficient assays for testing protein prenylation in vitro and in vivo. BMC Biochemistry, 2006, 7, 6.	4.4	36
1758	ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. Journal of Biology, 2006, 5, 14.	2.7	185
1759	Oligonucleotide microarrays for studying the effects of Ras signal transduction on the genetic program. Signal Transduction, 2006, 6, 209-218.	0.7	3

#	Article	IF	Citations
1760	Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatric Blood and Cancer, 2006, 46, 745-754.	0.8	39
1761	Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood and Cancer, 2006, 46, 579-585.	0.8	103
1762	Proteomic analysis of p38Î± mitogen-activated protein kinase-regulated changes in membrane fractions of RAS-transformed fibroblasts. Proteomics, 2006, 6, S262-S271.	1.3	23
1763	A proteomic approach for dissecting H-Ras signaling networks in NIH/3T3 mouse embryonic fibroblast cells. Proteomics, 2006, 6, 2433-2443.	1.3	7
1764	Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. International Journal of Gynecological Cancer, 2006, 16, 200-206.	1.2	11
1765	Analysis of Lowâ€Molecularâ€Weight GTPâ€Binding Proteins in Two Functionally Different Intestinal Epithelial Cell Lines. Annals of the New York Academy of Sciences, 2000, 915, 223-230.	1.8	1
1766	Diagnostic Value of Kâ€ras Mutations in Serum of Pancreatic Cancer Patients. Annals of the New York Academy of Sciences, 2000, 906, 19-24.	1.8	7
1767	Enrichment Methods for Mutation Detection. Annals of the New York Academy of Sciences, 2000, 906, 31-38.	1.8	8
1768	RTâ€PCRâ€Based Detection of Occult Disseminated Tumor Cells in Peripheral Blood and Bone Marrow of Patients with Solid Tumors: An Overview. Annals of the New York Academy of Sciences, 2000, 906, 110-123.	1.8	69
1769	Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Science, 2006, 97, 546-553.	1.7	260
1770	Rapid induction of skin tumors in human but not mouse c-Ha-ras proto-oncogene transgenic mice by chemical carcinogenesis. Cancer Science, 2006, 97, 842-847.	1.7	7
1771	Germline KRAS mutations cause Noonan syndrome. Nature Genetics, 2006, 38, 331-336.	9.4	670
1772	Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery, 2006, 5, 835-844.	21.5	1,525
1773	Frequent of ribosomal protein S6 hyperphosphorylation in lymphangioleiomyomatosis-associated angiomyolipomas. Modern Pathology, 2006, 19, 839-846.	2.9	31
1774	Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras. EMBO Journal, 2006, 25, 1093-1103.	3.5	46
1775	Absence of Classical MAP Kinase Pathway Signalling in Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2006, 126, 1135-1142.	0.3	54
1776	Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia, 2006, 20, 1496-1510.	3.3	250
1777	The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene, 2006, 25, 1743-1752.	2.6	102

#	Article	IF	Citations
1778	H-RAS 81 polymorphism is significantly associated with aneuploidy in follicular tumors of the thyroid. Oncogene, 2006, 25, 4620-4627.	2.6	34
1779	Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene, 2006, 25, 4890-4903.	2.6	61
1780	Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene, 2006, 25, 6574-6581.	2.6	55
1781	Solid-phase synthesis andÂpharmacological evaluation ofÂaÂlibrary ofÂpeptidomimetics asÂpotential farnesyltransferase inhibitors: anÂapproach toÂnew lead compounds. European Journal of Medicinal Chemistry, 2006, 41, 745-755.	2.6	16
1782	3D-QSAR studies of farnesyltransferase inhibitors: A comparative molecular field analysis approach. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1821-1827.	1.0	28
1783	Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 6281-6287.	1.0	61
1784	A systems biology approach for the study of cumulative oncogenes with applications to the MAPK signal transduction pathway. Biophysical Chemistry, 2006, 119, 49-60.	1.5	8
1785	Non-cross-linking gold nanoparticle aggregation for sensitive detection of single-nucleotide polymorphisms: Optimization of the particle diameter. Analytical Biochemistry, 2006, 350, 162-164.	1.1	73
1786	Application of a lanthanide fluorescent chelate label for detection of single-nucleotide mutations with peptide nucleic acid probes. Analytical Biochemistry, 2006, 355, 278-284.	1.1	12
1787	Artepillin C isoprenomics: Design and synthesis of artepillin C isoprene analogues as lipid peroxidation inhibitor having low mitochondrial toxicity. Bioorganic and Medicinal Chemistry, 2006, 14, 5721-5728.	1.4	26
1788	Affinity capillary electrophoresis of DNA for detection of single-nucleotide polymorphisms and point mutations. Journal of Chromatography A, 2006, 1111, 120-126.	1.8	18
1789	PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leukemia Research, 2006, 30, 1085-1089.	0.4	61
1790	Genetic Abnormalities as Targets for Molecular Therapies in Myelodysplastic Syndromes. Annals of the New York Academy of Sciences, 2006, 1089, 411-423.	1.8	8
1791	Antisense Therapy in Clinical Oncology: Preclinical and Clinical Experiences. Molecular Biotechnology, 2006, 33, 221-238.	1.3	19
1792	A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens. Cell Biology and Toxicology, 2006, 22, 269-274.	2.4	14
1793	Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-ÎºB p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1025-1037.	2.2	17
1794	Cloning and characterization of a novel small monomeric GTPase, RasL10B, with tumor suppressor potential. Biotechnology Letters, 2006, 28, 1901-1908.	1.1	17
1795	Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemotherapy and Pharmacology, 2006, 58, 577-584.	1.1	42

#	Article	IF	Citations
1796	The impact and role of EGFR gene mutation on non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 25-31.	1.1	7
1797	Effective tailor-made force field parameterization of the several Zn coordination environments in the puzzling FTase enzyme: opening the door to the full understanding of its elusive catalytic mechanism. Theoretical Chemistry Accounts, 2006, 117, 171-181.	0.5	26
1798	Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Critical Reviews in Oncology/Hematology, 2006, 57, 145-164.	2.0	100
1799	Reovirus and other oncolytic viruses for the targeted treatment of cancer. Targeted Oncology, 2006, 1, 130-150.	1.7	11
1800	Molecular genetics of colorectal cancer: An overview. Current Colorectal Cancer Reports, 2006, 2, 53-59.	1.0	27
1801	Differential functions of ras for malignant phenotypic conversion. Archives of Pharmacal Research, 2006, 29, 113-122.	2.7	26
1802	c-Myc substitutes for Notch1-CBF1 functions in cooperative transformation with papillomavirus oncogenes. Virology, 2006, 347, 191-198.	1.1	15
1803	Dobesilate diminishes activation of the mitogen - activated protein kinase ERK1/2 in glioma cells. Journal of Cellular and Molecular Medicine, 2006, 10, 225-230.	1.6	15
1804	Lactobacillus delbrueckii subsp lactis strain CIDCA 133 inhibits nitrate reductase activity of Escherichia coli. International Journal of Food Microbiology, 2006, 111, 191-196.	2.1	17
1805	Ras signaling on the Golgi. Current Opinion in Cell Biology, 2006, 18, 162-167.	2.6	55
1806	Recent advances in Ca2+-dependent Ras regulation and cell proliferation. Cell Calcium, 2006, 39, 101-112.	1.1	68
1807	RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cellular Signalling, 2006, 18, 349-358.	1.7	41
1808	Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cellular Signalling, 2006, 18, 1156-1168.	1.7	51
1809	Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells. Current Biology, 2006, 16, 2385-2394.	1.8	212
1810	Role of svp in Drosophila Pericardial Cell Growth. Journal of Genetics and Genomics, 2006, 33, 32-40.	0.3	1
1811	The Angiogenic Switch Molecule, Secreted FGF-Binding Protein, an Indicator of Early Stages of Pancreatic and Colorectal Adenocarcinoma. Seminars in Oncology, 2006, 33, 50-56.	0.8	172
1812	The Genetic and Molecular Pathogenesis of NF1 and NF2. Seminars in Pediatric Neurology, 2006, 13, 21-26.	1.0	69
1813	Structure of a Transient Intermediate for GTP Hydrolysis by Ras. Structure, 2006, 14, 427-436.	1.6	51

#	Article	IF	Citations
1814	The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells. Toxicology and Applied Pharmacology, 2006, 215, 317-329.	1.3	8
1815	Mutation analysis of ras gene in the liver of European eel (Anguilla anguilla L.) exposed to benzo[a]pyrene. Marine Pollution Bulletin, 2006, 52, 1611-1616.	2.3	39
1816	No association between N7-methyldeoxyguanosine and 8-oxodeoxyguanosine levels in human lymphocyte DNA. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006, 600, 125-130.	0.4	5
1817	Coexistence of K-ras mutations and HPV infection in colon cancer. BMC Cancer, 2006, 6, 115.	1.1	53
1818	Mutations in PIK3CAare infrequent in neuroblastoma. BMC Cancer, 2006, 6, 177.	1.1	29
1819	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer, 2006, 6, 295.	1.1	254
1820	Prevention of farnesylation of c-Ha-Ras protein enhances synergistically the cytotoxic action of doxorubicin in cycling but not in quiescent cells. Journal of Cellular Biochemistry, 2006, 99, 1664-1676.	1.2	4
1821	Synthesis of Stable Analogues of Geranylgeranyl Diphosphate Possessing a (Z,E,E)-Geranylgeranyl Side Chain, Docking Analysis, and Biological Assays for Prenyl Protein Transferase Inhibition. ChemMedChem, 2006, 1, 218-224.	1.6	5
1822	K-ras mutations in incident sporadic colorectal adenomas. Cancer, 2006, 106, 1036-1040.	2.0	31
1823	CommonEGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. International Journal of Cancer, 2006, 118, 521-522.	2.3	53
1824	Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. International Journal of Cancer, 2006, 118, 616-627.	2.3	35
1825	E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to ras inhibition. International Journal of Cancer, 2006, 119, 527-538.	2.3	26
1826	Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas. International Journal of Cancer, 2006, 119, 398-405.	2.3	47
1827	RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells. International Journal of Cancer, 2006, 120, 961-969.	2.3	7
1828	Relationship between chemically induced ha-ras mutation and transformation of BALB/c 3T3 cells: Evidence for chemical-specific activation and cell type-specific recruitment of oncogene in transformation. Molecular Carcinogenesis, 2006, 3, 202-209.	1.3	27
1829	Point mutation in codons 12 and 61 of the ha-ras gene in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. Molecular Carcinogenesis, 2006, 3, 210-215.	1.3	6
1830	Effects of MAP kinase inhibitors on epidermal growth factor-induced neoplastic transformation of human keratinocytes. Molecular Carcinogenesis, 2006, 45, 1-9.	1.3	15
1831	HRAS mutations in Costello syndrome: Detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. American Journal of Medical Genetics, Part A, 2006, 140A, 8-16.	0.7	157

#	Article	IF	Citations
1832	Spatial Segregation of Ras Signalingâ€"New Evidence from Fission Yeast. Cell Cycle, 2006, 5, 1936-1939.	1.3	27
1833	Development of a novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS). Nucleic Acids Research, 2006, 34, e150-e150.	6.5	4
1834	Regulation of Parâ€4 by Oncogenic Ras. Methods in Enzymology, 2006, 407, 422-442.	0.4	4
1836	Activation of Ras Proteins by Ras Guanine Nucleotide Releasing Protein Family Members. Methods in Enzymology, 2006, 407, 82-98.	0.4	5
1837	Harnessing RNAi for Analyses of Ras Signaling and Transformation. Methods in Enzymology, 2006, 407, 259-268.	0.4	0
1838	Analysis of Ras Transformation of Human Thyroid Epithelial Cells. Methods in Enzymology, 2006, 407, 648-660.	0.4	4
1839	Lonafarnib in cancer therapy. Expert Opinion on Investigational Drugs, 2006, 15, 709-719.	1.9	44
1840	Ras Upâ€Regulation of Cyclooxygenaseâ€2. Methods in Enzymology, 2006, 407, 401-410.	0.4	14
1841	Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Molecular Cancer Therapeutics, 2006, 5, 187-196.	1.9	84
1842	Is BRAF the Achilles' Heel of Thyroid Cancer?. Clinical Cancer Research, 2006, 12, 1661-1664.	3.2	23
1843	Transcriptional and Posttranscriptional Down-Regulation of the Imprinted Tumor Suppressor Gene ARHI (DRAS3) in Ovarian Cancer. Clinical Cancer Research, 2006, 12, 2404-2413.	3.2	52
1844	Lack of BRAF mutations in hyalinizing trabecular neoplasm. CytoJournal, 2006, 3, 17.	0.8	26
1845	Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets. Carcinogenesis, 2006, 27, 1420-1431.	1.3	13
1846	Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer. Acta OncolÃ³gica, 2006, 45, 1115-1119.	0.8	25
1847	Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells. Cancer Research, 2006, 66, 2116-2128.	0.4	247
1848	The Role of Statins in Cancer Therapy. Oncologist, 2006, 11, 306-315.	1.9	251
1849	Activation of Sterile20-Like Kinase 1 in Proteasome Inhibitor Bortezomibâ€"Induced Apoptosis in Oncogenic K-ras-Transformed Cells. Cancer Research, 2006, 66, 6072-6079.	0.4	19
1850	Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations. Molecular Cancer Therapeutics, 2006, 5, 1073-1078.	1.9	17

#	Article	IF	Citations
1851	Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. Human Molecular Genetics, 2006, 15, 1087-1098.	1.4	89
1852	A Ras Inhibitor Tilts the Balance between Rac and Rho and Blocks Phosphatidylinositol 3-Kinaseâ€"Dependent Glioblastoma Cell Migration. Cancer Research, 2006, 66, 11709-11717.	0.4	112
1853	An animal model for the rapid induction of tongue neoplasms in human c-Ha- ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies. Carcinogenesis, 2006, 27, 619-630.	1.3	42
1854	APC inhibits ERK pathway activation and cellular proliferation induced by RAS. Journal of Cell Science, 2006, 119, 819-827.	1.2	66
1855	Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1070-1080.	1.3	97
1856	Ral Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras. Molecular and Cellular Biology, 2006, 26, 3966-3975.	1.1	19
1857	Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering RNA. Cancer Research, 2006, 66, 9736-9743.	0.4	74
1858	Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen. Journal of Biomolecular Screening, 2006, 11, 145-154.	2.6	19
1859	RASâ€Mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB Journal, 2006, 20, 497-499.	0.2	32
1860	RhoA Mediates Cyclooxygenase-2 Signaling to Disrupt the Formation of Adherens Junctions and Increase Cell Motility. Cancer Research, 2006, 66, 11700-11708.	0.4	46
1861	Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors. Journal of Lipid Research, 2006, 47, 15-31.	2.0	273
1862	Regulation of the Nucleotide State of Oncogenic Ras Proteins by Nucleoside Diphosphate Kinase. Methods in Enzymology, 2006, 407, 33-45.	0.4	3
1863	Molecular Biology of Human Gliomas. Technology in Cancer Research and Treatment, 2006, 5, 185-194.	0.8	27
1864	Red Meat Enhances the Colonic Formation of the DNA Adduct O6-Carboxymethyl Guanine: Implications for Colorectal Cancer Risk. Cancer Research, 2006, 66, 1859-1865.	0.4	197
1865	Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models. Cancer Research, 2006, 66, 999-1006.	0.4	204
1866	A Novel Mechanism for Integrin-Mediated Ras Activation in Breast Carcinoma Cells: The Î±6Î²4 Integrin Regulates ErbB2 Translation and Transactivates Epidermal Growth Factor Receptor/ErbB2 Signaling. Cancer Research, 2006, 66, 2732-2739.	0.4	69
1867	The Retinoblastoma Protein Is Required for Ras-Induced Oncogenic Transformation. Molecular and Cellular Biology, 2006, 26, 1170-1182.	1.1	53
1868	The Growth and Tumor Suppressor NORE1A Is a Cytoskeletal Protein That Suppresses Growth by Inhibition of the ERK Pathway*. Journal of Biological Chemistry, 2006, 281, 8143-8152.	1.6	44

#	Article	IF	Citations
1869	Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. , 2006, , 223-268.		61
1870	Statin Use and Cancer Risk: An Epidemiologic Review. Cancer Investigation, 2006, 24, 413-424.	0.6	24
1871	Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. Journal of Medical Genetics, 2006, 44, 131-135.	1.5	170
1872	Docosahexaenoic acid selectively inhibits plasma membrane targeting of lipidated proteins. FASEB Journal, 2006, 20, 770-772.	0.2	58
1873	Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17390-17395.	3.3	207
1874	Compartmentalized signaling of Ras in fission yeast. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9045-9050.	3.3	96
1875	Malignant melanoma: genetics and therapeutics in the genomic era. Genes and Development, 2006, 20, 2149-2182.	2.7	436
1876	A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes and Development, 2006, 20, 236-252.	2.7	120
1877	Oncogenic RAS Induces Accelerated Transition through G2/M and Promotes Defects in the G2 DNA Damage and Mitotic Spindle Checkpoints. Journal of Biological Chemistry, 2006, 281, 3800-3809.	1.6	84
1878	KRAS variation and risk of endometriosis. Molecular Human Reproduction, 2006, 12, 671-676.	1.3	43
1879	The connection between splicing and cancer. Journal of Cell Science, 2006, 119, 2635-2641.	1.2	318
1880	Network Analysis of Oncogenic Ras Activation in Cancer. Science, 2007, 318, 463-467.	6.0	114
1881	Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor. Clinical Cancer Research, 2007, 13, 1576-1583.	3.2	530
1882	K-ras Is Critical for Modulating Multiple c-kit-Mediated Cellular Functions in Wild-Type and Nf1+/â^' Mast Cells. Journal of Immunology, 2007, 178, 2527-2534.	0.4	36
1883	Direct Binding of PP2A to Sprouty2 and Phosphorylation Changes Are a Prerequisite for ERK Inhibition Downstream of Fibroblast Growth Factor Receptor Stimulation. Journal of Biological Chemistry, 2007, 282, 9117-9126.	1.6	50
1884	Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells*. Journal of Biological Chemistry, 2007, 282, 14048-14055.	1.6	256
1885	Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha- RAS -transformed human colon cells. Carcinogenesis, 2007, 28, 1021-1031.	1.3	115
1886	Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors. Clinical Cancer Research, 2007, 13, 576-583.	3.2	20

#	Article	IF	Citations
1887	An Activating Mutation in sos-1 Identifies Its Dbl Domain as a Critical Inhibitor of the Epidermal Growth Factor Receptor Pathway during Caenorhabditis elegans Vulval Development. Molecular and Cellular Biology, 2007, 27, 3695-3707.	1.1	9
1888	Plexin-B1 mutations in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19040-19045.	3.3	81
1889	Wild-Type NRas and KRas Perform Distinct Functions during Transformation. Molecular and Cellular Biology, 2007, 27, 6742-6755.	1.1	46
1890	Axin Inhibits Extracellular Signal-regulated Kinase Pathway by Ras Degradation via Î²-Catenin. Journal of Biological Chemistry, 2007, 282, 14482-14492.	1.6	63
1891	Modulation of Intracellular Signaling Pathways to Induce Apoptosis in Prostate Cancer Cells. Journal of Biological Chemistry, 2007, 282, 24364-24372.	1.6	8
1892	Inhibitory Effect of Triptolide on Glioblastoma Multiforme In Vitro. Journal of International Medical Research, 2007, 35, 490-496.	0.4	12
1893	Inhibition of farnesyltransferase: A rational approach to treat cancer?. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 127-140.	2.5	6
1894	Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Review of Anticancer Therapy, 2007, 7, 503-518.	1.1	30
1895	Inhibition of RAS-Mediated Transformation and Tumorigenesis by Targeting the Downstream E3 Ubiquitin Ligase Seven in Absentia Homologue. Cancer Research, 2007, 67, 11798-11810.	0.4	68
1896	Molecular mechanisms of pancreatic cancer and potential targets of treatment. Scandinavian Journal of Gastroenterology, 2007, 42, 279-296.	0.6	9
1897	In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathwayâ€“ and microtubule-targeting inhibitors. Molecular Cancer Therapeutics, 2007, 6, 898-906.	1.9	29
1898	The RAS/Raf1/MEK/ERK Signaling Pathway Facilitates VSV-mediated Oncolysis: Implication for the Defective Interferon Response in Cancer Cells. Molecular Therapy, 2007, 15, 1531-1536.	3.7	74
1899	Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine, 2007, 4, 33-43.	0.8	4
1900	Ras Transformation Mediates Reovirus Oncolysis by Enhancing Virus Uncoating, Particle Infectivity, and Apoptosis-dependent Release. Molecular Therapy, 2007, 15, 1522-1530.	3.7	142
1901	Active Rap1, a small GTPase that induces malignant transformation of hematopoietic progenitors, localizes in the nucleus and regulates protein expression. Leukemia and Lymphoma, 2007, 48, 987-1002.	0.6	12
1902	Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9410-9415.	3.3	165
1903	Knock-in of Mutant K-ras in Nontumorigenic Human Epithelial Cells as a New Model for Studying K-rasâ€“Mediated Transformation. Cancer Research, 2007, 67, 8460-8467.	0.4	85
1904	Suppression of PTEN Expression Is Essential for Antiapoptosis and Cellular Transformation by Oncogenic Ras. Cancer Research, 2007, 67, 10343-10350.	0.4	63

#	Article	IF	Citations
1905	Mutant-Enriched PCR and Allele-Specific Hybridization Reaction to Detect K-ras Mutations in Stool DNA: High Prevalence in a Large Sample of Older Adults. Clinical Chemistry, 2007, 53, 787-790.	1.5	29
1906	Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes and Development, 2007, 21, 694-707.	2.7	120
1907	Repression of Sestrin Family Genes Contributes to Oncogenic Ras-Induced Reactive Oxygen Species Up-regulation and Genetic Instability. Cancer Research, 2007, 67, 4671-4678.	0.4	123
1908	Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. Genes and Development, 2007, 21, 361-366.	2.7	7
1909	Prognostic Factors and Riskâ€Based Therapy in Pediatric Acute Myeloid Leukemia. Oncologist, 2007, 12, 341-355.	1.9	83
1910	Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines. Molecular Cancer Research, 2007, 5, 195-201.	1.5	271
1911	Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Molecular Cancer Therapeutics, 2007, 6, 1099-1111.	1.9	32
1912	Endometrial carcinoma: pathology and genetics. Pathology, 2007, 39, 72-87.	0.3	172
1913	Transcriptional Control of the Human High Mobility Group A1 Gene: Basal and Oncogenic Ras-Regulated Expression. Cancer Research, 2007, 67, 4620-4629.	0.4	59
1914	Oncogenic NRAS, KRAS, and HRAS Exhibit Different Leukemogenic Potentials in Mice. Cancer Research, 2007, 67, 7139-7146.	0.4	76
1915	The Survival Kinase Mirk/Dyrk1B Is a Downstream Effector of Oncogenic K-ras in Pancreatic Cancer. Cancer Research, 2007, 67, 7247-7255.	0.4	50
1916	Histological and proteomic analysis of reversible H-Ras V12G expression in transgenic mouse skin. Carcinogenesis, 2007, 28, 2244-2252.	1.3	5
1917	Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. Human Molecular Genetics, 2007, 16, 374-379.	1.4	46
1918	p66 Shc Tumor Levels Show a Strong Prognostic Correlation with Disease Outcome in Stage IIA Colon Cancer. Clinical Cancer Research, 2007, 13, 5798-5804.	3.2	40
1919	RKIP does not contribute to MAP kinase pathway silencing in the Merkel Cell Carcinoma cell line UISO. Journal of Carcinogenesis, 2007, 6, 16.	2.5	9
1920	Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Molecular Systems Biology, 2007, 3, 151.	3.2	128
1921	Dietary meat, endogenous nitrosation and colorectal cancer. Biochemical Society Transactions, 2007, 35, 1355-1357.	1.6	70
1922	Rce1 deficiency accelerates the development of K-RASâ€“induced myeloproliferative disease. Blood, 2007, 109, 763-768.	0.6	60

#	Article	IF	Citations
1923	Ras Pathway Activation in Malignant Mesothelioma. Journal of Thoracic Oncology, 2007, 2, 789-795.	0.5	31
1924	K-ras Mutation and p16 and Preproenkephalin Promoter Hypermethylation in Plasma DNA of Pancreatic Cancer Patients. Pancreas, 2007, 34, 55-62.	0.5	87
1925	Inhibitors of Raf kinase and MEK signaling. Update on Cancer Therapeutics, 2007, 2, 111-118.	0.9	16
1926	Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?. European Journal of Cancer, 2007, 43, 2580-2589.	1.3	38
1927	Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochemical and Biophysical Research Communications, 2007, 352, 728-732.	1.0	45
1928	Superoxide anion: Oncogenic reactive oxygen species?. International Journal of Biochemistry and Cell Biology, 2007, 39, 1297-1304.	1.2	143
1929	Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). Cancer Letters, 2007, 245, 242-251.	3.2	35
1930	Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Letters, 2007, 258, 268-275.	3.2	63
1931	BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications. Endocrine Reviews, 2007, 28, 742-762.	8.9	857
1932	Inhibiting kinases in malignant gliomas. Expert Opinion on Therapeutic Targets, 2007, 11, 473-496.	1.5	41
1933	Molecular Pathogenesis of Adult Brain Tumors and the Role of Stem Cells. Neurologic Clinics, 2007, 25, 891-924.	0.8	34
1934	Ras as a therapeutic target in hematologic malignancies. Expert Opinion on Emerging Drugs, 2007, 12, 271-284.	1.0	23
1935	An update on mouse brain tumor models in cancer drug discovery. Expert Opinion on Drug Discovery, 2007, 2, 1435-1451.	2.5	2
1936	Response to ALA-based PDT in an immortalised normal breast cell line and its counterpart transformed with the Ras oncogene. Photochemical and Photobiological Sciences, 2007, 6, 1306.	1.6	16
1937	Notch Signaling in Development and Cancer. Endocrine Reviews, 2007, 28, 339-363.	8.9	474
1938	DNA mutation detection with chip-based temperature gradient capillary electrophoresis using a slantwise radiative heating system. Lab on A Chip, 2007, 7, 1162.	3.1	28
1939	Structure of the 1,4-Bis(2â€˜-deoxyadenosin-N6-yl)-2S,3S-butanediol Intrastrand DNA Cross-Link Arising from Butadiene Diepoxide in the Human N-ras Codon 61 Sequence. Chemical Research in Toxicology, 2007, 20, 187-198.	1.7	4
1940	Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors. Cancer Investigation, 2007, 25, 347-365.	0.6	16

#	Article	IF	Citations
1941	Growth Factors and Oncogenes as Targets in Melanoma: Lost inÂTranslation?. Advances in Dermatology, 2007, 23, 99-129.	2.0	16
1943	Some Aspects of Medicinal Chemistry at the Schering-Plough Research Institute. , 2007, , 29-51.		1
1944	The Effect of Statins in Colorectal Cancer Is Mediated Through the Bone Morphogenetic Protein Pathway. Gastroenterology, 2007, 133, 1272-1281.	0.6	71
1945	Molecular genetics of papillary thyroid carcinoma: great expectations.... Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 643-653.	1.3	28
1946	Aberrant Promoter Methylation Can be Useful as a Marker of Recurrent Disease in Patients with Cervical Intraepithelial Neoplasia Grade III. Tumori, 2007, 93, 572-579.	0.6	28
1947	Diversity, parental germline origin, and phenotypic spectrum of de novoHRASmissense changes in Costello syndrome. Human Mutation, 2007, 28, 265-272.	1.1	123
1948	Fraâ€1 regulates vimentin during Haâ€RASâ€induced epithelial mesenchymal transition in human colon carcinoma cells. International Journal of Cancer, 2008, 122, 1745-1756.	2.3	64
1949	p21â€rasâ€peptideâ€specific Tâ€cell responses in a patient with colorectal cancer. CD4⁺ and CD8⁺ T cells recognize a peptide corresponding to a common mutation (13Gly â†' Asp). International Journal of Cancer, 1994, 56, 40-45.	2.3	79
1950	OncogenicKRASprovides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. Journal of Cellular Physiology, 2007, 210, 740-749.	2.0	36
1951	Analysis of Ras-induced oncogenic transformation of NIH-3T3 cells using differential-display 2-DE proteomics. Electrophoresis, 2007, 28, 1997-2008.	1.3	22
1952	Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling. Molecular Carcinogenesis, 2007, 46, 958-970.	1.3	13
1953	Cooperation of Ha-ras and Bcl-2 during multistep skin carcinogenesis. Molecular Carcinogenesis, 2007, 46, 949-957.	1.3	9
1954	Farnesyltransferase inihibitors in hematologic malignancies. Blood Reviews, 2007, 21, 173-182.	2.8	26
1955	Synthesis and evaluation of antitumor activity of novel N-acyllavendamycin analogues and quinoline-5,8-diones. Bioorganic and Medicinal Chemistry, 2007, 15, 495-510.	1.4	40
1956	Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 243-249.	1.0	11
1957	Design, synthesis and biological evaluation of substituted dioxodibenzothiazepines and dibenzocycloheptanes as farnesyltransferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5465-5471.	1.0	31
1958	DNA-damage sensitizers: Potential new therapeutical tools to improve chemotherapy. Critical Reviews in Oncology/Hematology, 2007, 63, 160-171.	2.0	20
1959	Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the ZarnestraÂ® series. European Journal of Medicinal Chemistry, 2007, 42, 702-714.	2.6	10

#	Article	IF	Citations
1960	Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. Oncogene, 2007, 26, 733-744.	2.6	23
1961	Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses. Oncogene, 2007, 26, 917-933.	2.6	31
1962	Genetic induction of tumorigenesis in Swine. Oncogene, 2007, 26, 1038-1045.	2.6	65
1963	Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression. Oncogene, 2007, 26, 2058-2070.	2.6	7
1964	Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex. Oncogene, 2007, 26, 3051-3059.	2.6	31
1965	A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene, 2007, 26, 3777-3788.	2.6	68
1966	Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nature Cell Biology, 2007, 9, 493-505.	4.6	412
1967	Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nature Genetics, 2007, 39, 70-74.	9.4	534
1968	Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer, 2007, 7, 295-308.	12.8	1,422
1969	Maximizing mouse cancer models. Nature Reviews Cancer, 2007, 7, 654-658.	12.8	617
1970	Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews Drug Discovery, 2007, 6, 541-555.	21.5	400
1971	Activation of the MAP Kinase Pathway Induces Apoptosis in the Merkel Cell Carcinoma Cell Line UISO. Journal of Investigative Dermatology, 2007, 127, 2116-2122.	0.3	27
1972	Search for Protein Farnesyltransferase Inhibitors of Microbial Origin: Our Strategy and Results as well as the Results Obtained by Other Groups. Journal of Antibiotics, 2007, 60, 1-12.	1.0	18
1973	HRAS and the Costello syndrome. Clinical Genetics, 2007, 71, 101-108.	1.0	104
1974	Low prevalence of p53, p16INK4aand Ha-ras tumour-specific mutations in low-graded actinic keratosis. British Journal of Dermatology, 2007, 156, 34-39.	1.4	24
1975	Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Science, 2007, 98, 169-173.	1.7	56
1976	Decreased c-kit function inhibits enhanced skin carcinogenesis in c-Ha-ras protooncogene transgenic mice. Cancer Science, 2007, 98, 1549-1556.	1.7	6
1977	Key Signaling Pathways and Targets in Lung Cancer Therapy. Clinical Lung Cancer, 2007, 8, S52-S60.	1.1	12

#	Article	IF	Citations
1978	MAP kinase pathways: The first twenty years. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1150-1160.	1.9	236
1979	Clinical experience of MEK inhibitors in cancer therapy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1248-1255.	1.9	153
1980	Ras oncogenes and their downstream targets. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1177-1195.	1.9	369
1981	p38Î± MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis. Cancer Cell, 2007, 11, 191-205.	7.7	358
1982	Activated Ras induces cytoplasmic vacuolation and non-apoptotic death in glioblastoma cells via novel effector pathways. Cellular Signalling, 2007, 19, 1034-1043.	1.7	34
1983	Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling. Cellular Signalling, 2007, 19, 1279-1289.	1.7	94
1984	Transcriptomal profiling of site-specific Ras signals. Cellular Signalling, 2007, 19, 2264-2276.	1.7	26
1985	The tandem PDZ domains of syntenin promote cell invasion. Experimental Cell Research, 2007, 313, 1790-1804.	1.2	34
1986	Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin?proteasome system and Cox-2. Journal of Cellular and Molecular Medicine, 2007, 11, 252-285.	1.6	69
1987	Astrocyte elevated gene-1: Recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. , 2007, 114, 155-170.		149
1988	Increased ROS generation in subsets of OGG1 knockout fibroblast cells. Mechanisms of Ageing and Development, 2007, 128, 637-649.	2.2	37
1989	CANCER CHEMOPREVENTIVE EFFECTS OF CURCUMIN. , 2007, 595, 149-172.		104
1990	Functional transcriptomics: An experimental basis for understanding the systems biology for cancer cells. Advances in Enzyme Regulation, 2007, 47, 41-62.	2.9	0
1992	An unexpected new role of mutant Ras: perturbation of human embryonic development. Journal of Molecular Medicine, 2007, 85, 227-235.	1.7	54
1993	Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells. Cancer Chemotherapy and Pharmacology, 2007, 60, 449-457.	1.1	27
1994	Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemotherapy and Pharmacology, 2007, 61, 89-96.	1.1	60
1995	Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cellular and Molecular Life Sciences, 2007, 64, 2575-2589.	2.4	110
1996	Melittin: a Membrane-active Peptide with Diverse Functions. Bioscience Reports, 2007, 27, 189-223.	1.1	536

#	Article	IF	Citations
1997	Rho GTPases: functions and association with cancer. Clinical and Experimental Metastasis, 2007, 24, 657-672.	1.7	243
1998	Whatâ€™s new in the neuro-cardio-facial-cutaneous syndromes?. European Journal of Pediatrics, 2007, 166, 1091-1098.	1.3	33
1999	RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathologica, 2007, 114, 121-133.	3.9	105
2000	Osteopontin: regulation in tumor metastasis. Cancer and Metastasis Reviews, 2008, 27, 103-118.	2.7	287
2001	Biological Treatment for Liver Tumor and New Potential Biomarkers. Digestive Diseases and Sciences, 2008, 53, 836-843.	1.1	15
2002	Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies. Targeted Oncology, 2008, 3, 235-243.	1.7	3
2003	Evaluation of comparative and combined antimutagenic potential of vitamin C and vitamin E using histidine mutant Salmonella typhimurium strains. Indian Journal of Clinical Biochemistry, 2008, 23, 24-28.	0.9	2
2004	Mutational analysis of SOS1 gene in acute myeloid leukemia. International Journal of Hematology, 2008, 88, 460-462.	0.7	7
2005	The small GTPase RhoH is an atypical regulator of haematopoietic cells. Cell Communication and Signaling, 2008, 6, 6.	2.7	29
2006	Molecular dynamics analysis of farnesyltransferase: A closer look into the amino acid behavior. International Journal of Quantum Chemistry, 2008, 108, 1939-1950.	1.0	10
2007	15â€hydroxyprostaglandin dehydrogenase suppresses Kâ€Ras^{V12}â€dependent tumor formation in Nu/Nu mice. Molecular Carcinogenesis, 2008, 47, 466-477.	1.3	13
2008	Mutation analysis in Costello syndrome: functional and structural characterization of theHRASp.Lys117Arg mutation. Human Mutation, 2008, 29, 232-239.	1.1	48
2009	Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused byRASA1 mutations. Human Mutation, 2008, 29, 959-965.	1.1	382
2010	Nox1 is overâ€expressed in human colon cancers and correlates with activating mutations in Kâ€Ras. International Journal of Cancer, 2008, 123, 100-107.	2.3	141
2011	Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. Journal of Cellular Biochemistry, 2008, 104, 1124-1149.	1.2	186
2012	Difference gel electrophoresis analysis of Rasâ€transformed fibroblast cellâ€derived exosomes. Electrophoresis, 2008, 29, 2660-2671.	1.3	62
2013	Design of alleleâ€specific primers and detection of the human ABO genotyping to avoid the pseudopositive problem. Electrophoresis, 2008, 29, 4130-4140.	1.3	28
2014	H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway. Glia, 2008, 56, 917-924.	2.5	23

#	Article	IF	Citations
2015	Genetic alterations in juvenile nasopharyngeal angiofibromas. Head and Neck, 2008, 30, 390-400.	0.9	80
2016	Binding of calcium ions to Ras promotes Ras guanine nucleotide exchange under emulated physiological conditions. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 1560-1569.	1.1	6
2017	The biological properties of cetuximab. Critical Reviews in Oncology/Hematology, 2008, 68, 93-106.	2.0	113
2018	Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor. European Journal of Medicinal Chemistry, 2008, 43, 1519-1524.	2.6	62
2019	Mechanisms by which docosahexaenoic acid and related fatty acids reduce colon cancer risk and inflammatory disorders of the intestine. Chemistry and Physics of Lipids, 2008, 153, 14-23.	1.5	100
2020	Reovirus: Viral Therapy for Cancer â€˜as Nature Intendedâ€™. Clinical Oncology, 2008, 20, 548-554.	0.6	46
2021	PIK3CA Cooperates with Other Phosphatidylinositol 3â€²-Kinase Pathway Mutations to Effect Oncogenic Transformation. Cancer Research, 2008, 68, 8127-8136.	0.4	159
2022	Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO Journal, 2008, 27, 2181-2193.	3.5	77
2023	Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia, 2008, 22, 1335-1342.	3.3	118
2024	Ras isoform abundance and signalling in human cancer cell lines. Oncogene, 2008, 27, 2754-2762.	2.6	92
2025	Partial functional overlap of the three ras genes in mouse embryonic development. Oncogene, 2008, 27, 2961-2968.	2.6	35
2026	Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. Oncogene, 2008, 27, 3729-3738.	2.6	22
2027	Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nature Genetics, 2008, 40, 1240-1244.	9.4	113
2028	Kras and Hrasâ€”what is the difference?. Nature Genetics, 2008, 40, 1149-1150.	9.4	10
2029	Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nature Reviews Cancer, 2008, 8, 361-375.	12.8	600
2030	p14ARF Hypermethylation Is Common but INK4a-ARF Locus or p53 Mutations Are Rare in Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2008, 128, 1788-1796.	0.3	58
2031	Involvement of miltefosineâ€mediated ERK activation in glioma cell apoptosis through Fas regulation. Journal of Neurochemistry, 2008, 107, 616-627.	2.1	45
2032	Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Science, 2008, 99, 1492-1498.	1.7	110

#	Article	IF	Citations
2033	Purple corn color suppresses Ras protein level and inhibits 7,12â€dimethylbenz[a]anthraceneâ€induced mammary carcinogenesis in the rat. Cancer Science, 2008, 99, 1841-1846.	1.7	30
2034	Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. British Journal of Haematology, 1993, 85, 469-476.	1.2	46
2035	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer, 2008, 8, 142.	1.1	184
2036	TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation. BMC Cancer, 2008, 8, 189.	1.1	48
2037	Signalâ€Transduction Therapy. FEBS Journal, 1994, 226, 1-13.	0.2	16
2038	Mutated D4-guanine diphosphateâ€“dissociation inhibitor is found in human leukemic cells and promotes leukemic cell invasion. Experimental Hematology, 2008, 36, 37-50.	0.2	6
2039	Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chemico-Biological Interactions, 2008, 171, 89-95.	1.7	87
2040	The Signaling Adaptor p62 Is an Important NF-ÎºBÂMediator in Tumorigenesis. Cancer Cell, 2008, 13, 343-354.	7.7	512
2041	Interactions of Ras proteins with the plasma membrane and their roles in signaling. Cellular Signalling, 2008, 20, 31-39.	1.7	49
2042	New developments in medulloblastoma treatment: the potential of a cyclopamineâ€“lovastatin combination. Expert Opinion on Investigational Drugs, 2008, 17, 185-195.	1.9	20
2043	Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Molecular Oncology, 2008, 1, 395-405.	2.1	228
2044	Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. Translational Research, 2008, 152, 203-212.	2.2	17
2045	Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone. Clinical Colorectal Cancer, 2008, 7, 184-190.	1.0	147
2046	Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Annals of Oncology, 2008, 19, 2033-2038.	0.6	34
2048	The Rho-activating CNF1 toxin from pathogenic E. coli: A risk factor for human cancer development?. Infectious Agents and Cancer, 2008, 3, 4.	1.2	40
2049	Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis. Journal of Hematology and Oncology, 2008, 1, 5.	6.9	22
2050	Intragenic Mutations in Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2008, 37, 333-362.	1.2	87
2051	KrÃ¼ppel-Like Factor 5 Mediates Cellular Transformation During Oncogenic KRAS-Induced Intestinal Tumorigenesis. Gastroenterology, 2008, 134, 120-130.	0.6	118

#	Article	IF	Citations
2052	Genetically engineered mouse models for skin research: Taking the next step. Journal of Dermatological Science, 2008, 52, 1-12.	1.0	18
2053	Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. , 2008, , 224-244.		1
2054	Epithelial Morphogenesis and Intestinal Cancer: New Insights in Signaling Mechanisms. Advances in Cancer Research, 2008, 100, 85-111.	1.9	15
2055	Melanoma Biology and the Promise of Zebrafish. Zebrafish, 2008, 5, 247-255.	0.5	58
2056	K-ras Inhibitors and Pancreatic Cancer. , 2008, , 601-607.		1
2057	Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGAP interaction. Biological Chemistry, 2008, 389, 1163-1171.	1.2	47
2058	The role of polycyclic aromatic hydrocarbonâ€"DNA adducts in inducing mutations in mouse skin. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008, 649, 161-178.	0.9	35
2059	An enhanced association of RACK1 with Abl in cells transfected with oncogenic ras. International Journal of Biochemistry and Cell Biology, 2008, 40, 423-431.	1.2	8
2060	Redox signaling and cancer: The role of â€œlabileâ€•iron. Cancer Letters, 2008, 266, 21-29.	3.2	270
2061	Inflammation and cancer: The oncogene-driven connection. Cancer Letters, 2008, 267, 262-270.	3.2	105
2062	Anti-tumor activity of ESX1 on cancer cells harboring oncogenic K-ras mutation. Biochemical and Biophysical Research Communications, 2008, 370, 189-194.	1.0	4
2063	Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells. Biochemical and Biophysical Research Communications, 2008, 372, 845-849.	1.0	17
2064	Predictive Markers in Colorectal Cancer. Seminars in Colon and Rectal Surgery, 2008, 19, 231-238.	0.2	0
2065	Reovirus therapy in cancer: has the orphan virus found a home?. Expert Opinion on Investigational Drugs, 2008, 17, 1925-1935.	1.9	17
2066	High-Fidelity DNA Polymerase Enhances the Sensitivity of a Peptide Nucleic Acid Clamp PCR Assay for K-ras Mutations. Journal of Molecular Diagnostics, 2008, 10, 325-331.	1.2	37
2067	Targeted therapies for pancreatic cancer. British Medical Bulletin, 2008, 87, 97-130.	2.7	26
2068	Insights into the oncogenic effects of /PIK3CA/ mutations from the structure of p110α/p85α. Cell Cycle, 2008, 7, 1151-1156.	1.3	73
2069	Nicht-invasive Diagnostik kolorektaler Tumore â€“ Hat der Guaiac-Test ausgedient? / Non-invasive detection of colorectal cancer â€“ do we still need the guaiac-based fecal occult blood test?. Laboratoriums Medizin, 2008, 32, 158-167.	0.1	2

#	Article	IF	Citations
2070	Suppression of Colorectal Oncogenesis by Selenium-Enriched Milk Proteins: Apoptosis and K-ras Mutations. Cancer Research, 2008, 68, 4936-4944.	0.4	48
2071	Bobel-24 and Derivatives Induce Caspase-Independent Death in Pancreatic Cancer Regardless of Apoptotic Resistance. Cancer Research, 2008, 68, 6313-6323.	0.4	16
2072	RAS Pathway Mutations in Juvenile Myelomonocytic Leukemia. Acta Haematologica, 2008, 119, 207-211.	0.7	12
2073	Silent Assassin: Oncogenic Ras Directs Epigenetic Inactivation of Target Genes. Science Signaling, 2008, 1, pe14.	1.6	6
2074	Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. Hematology, 2008, 13, 1-12.	0.7	2
2075	Mouse Model for NRASâ€Induced Leukemogenesis. Methods in Enzymology, 2008, 439, 15-24.	0.4	5
2076	Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3903-3908.	3.3	808
2077	PAR-4 tees off lung cancer. Science-Business EXchange, 2008, 1, 640-640.	0.0	0
2078	Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. British Journal of Cancer, 2008, 98, 410-417.	2.9	56
2079	Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. British Journal of Cancer, 2008, 98, 1951-1958.	2.9	17
2080	Ras Modifies Proliferation and Invasiveness of Cells Expressing Human Papillomavirus Oncoproteins. Journal of Virology, 2008, 82, 8820-8827.	1.5	21
2081	Allogeneic Granulocyte Macrophage Colony-Stimulating Factorâ€“Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research, 2008, 14, 1455-1463.	3.2	309
2082	Identification of Essential Interacting Elements in K-Ras/Calmodulin Binding and Its Role in K-Ras Localization. Journal of Biological Chemistry, 2008, 283, 10621-10631.	1.6	64
2083	A Novel Binding Factor of 14-3-3Î² Functions as a Transcriptional Repressor and Promotes Anchorage-independent Growth, Tumorigenicity, and Metastasis. Journal of Biological Chemistry, 2008, 283, 18753-18764.	1.6	69
2084	Differential Interference of Chlorpromazine with the Membrane Interactions of Oncogenic K-Ras and Its Effects on Cell Growth. Journal of Biological Chemistry, 2008, 283, 27279-27288.	1.6	28
2085	Phorbol Ester Up-regulates Phospholipase D1 but Not Phospholipase D2 Expression through a PKC/Ras/ERK/NFÎºB-dependent Pathway and Enhances Matrix Metalloproteinase-9 Secretion in Colon Cancer Cells. Journal of Biological Chemistry, 2008, 283, 4094-4104.	1.6	64
2086	DLC1: a significant GAP in the cancer genome. Genes and Development, 2008, 22, 1724-1730.	2.7	78
2087	Noonan, Costello and cardioâ€“facioâ€“cutaneous syndromes: dysregulation of the Rasâ€“MAPK pathway. Expert Reviews in Molecular Medicine, 2008, 10, e37.	1.6	94

#	Article	IF	Citations
2088	Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation. Current Genomics, 2008, 9, 349-360.	0.7	39
2089	Oncogenes and Signal Transduction. , 2008, , 17-30.		0
2090	Apoptosis and tumor resistance conferred by Par-4. Cancer Biology and Therapy, 2008, 7, 1867-1874.	1.5	47
2091	Activated Kras, but Not Hras or Nras, May Initiate Tumors of Endodermal Origin via Stem Cell Expansion. Molecular and Cellular Biology, 2008, 28, 2659-2674.	1.1	81
2092	Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin. Clinical Cancer Research, 2008, 14, 6478-6486.	3.2	77
2093	The Genomics of Colorectal Cancer: State of the Art. Current Genomics, 2008, 9, 1-10.	0.7	14
2094	Altered Detoxification Status and Increased Resistance to Oxidative Stress by K-Ras Transformation. Cancer Research, 2008, 68, 10086-10093.	0.4	45
2095	Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 2008, 26, 4603-4609.	0.8	138
2096	Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells. Biological Chemistry, 2008, 389, 757-764.	1.2	41
2097	Non-invasive detection of colorectal cancer â€“ do we still need the guaiac-based fecal occult blood test? 1. Laboratoriums Medizin, 2008, 32, -.	0.1	0
2098	Tnk1/Kos1 Knockout Mice Develop Spontaneous Tumors. Cancer Research, 2008, 68, 8723-8732.	0.4	33
2099	8-Oxoguanine-mediated transcriptional mutagenesis causes Ras activation in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18877-18882.	3.3	111
2100	Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy. Clinical Cancer Research, 2008, 14, 912-923.	3.2	93
2101	High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. Oncologist, 2008, 13, 1270-1275.	1.9	218
2102	A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer. Clinical Cancer Research, 2008, 14, 7127-7137.	3.2	205
2103	TATA Box-Binding Proteinâ€“Associated Factor 12 Is Important for RAS-Induced Transformation Properties of Colorectal Cancer Cells. Molecular Cancer Research, 2008, 6, 1071-1083.	1.5	18
2104	K-Ras Nanoclustering Is Subverted by Overexpression of the Scaffold Protein Galectin-3. Cancer Research, 2008, 68, 6608-6616.	0.4	123
2105	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics, 2008, 9, 55-69.	0.6	12

#	Article	IF	Citations
2106	Targeting important pathways in head and neck cancer: from the bench to the clinic. Expert Review of Anticancer Therapy, 2008, 8, 1819-1835.	1.1	2
2107	The Hominoid-specific Oncogene TBC1D3 Activates Ras and Modulates Epidermal Growth Factor Receptor Signaling and Trafficking. Journal of Biological Chemistry, 2008, 283, 13233-13242.	1.6	57
2108	A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood, 2008, 111, 2589-2596.	0.6	117
2109	Inactivating Icmt ameliorates K-RASâ€“induced myeloproliferative disease. Blood, 2008, 112, 1357-1365.	0.6	77
2110	Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics: Targets and Therapy, 2008, 2, 223.	3.0	31
2111	Molecular Predictors of EGFR-TKI Sensitivity in Advanced Nonâ€“small Cell Lung Cancer. International Journal of Medical Sciences, 2008, 5, 209-217.	1.1	67
2112	Sorafenib, a systemic therapy for hepatocellular carcinoma. Annals of Hepatology, 2008, 7, 46-51.	0.6	28
2113	Precursor Lesions of Pancreatic Cancer. Gut and Liver, 2008, 2, 137-154.	1.4	72
2114	Surgical Considerations for the Familial Cancer Syndrome, Neurofibromatosis 1: A Comprehensive Review. American Surgeon, 2009, 75, 120-128.	0.4	10
2115	Use of Virtual Patient Populations for Rescuing Discontinued Drug Candidates and for Reducing the Number of Patients in Clinical Trials. ATLA Alternatives To Laboratory Animals, 2009, 37, 39-45.	0.7	10
2116	BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis. Cancer Growth and Metastasis, 2009, 2, CGM.S3982.	3.5	11
2117	Biophysical Mechanism for Ras-Nanocluster Formation and Signaling in Plasma Membrane. PLoS ONE, 2009, 4, e6148.	1.1	36
2118	Reovirus-based therapy for cancer. Expert Opinion on Biological Therapy, 2009, 9, 817-830.	1.4	52
2119	Oncogenic NRAS Cooperates withp53Loss to Generate Melanoma in Zebrafish. Zebrafish, 2009, 6, 397-404.	0.5	121
2120	H-Ras is degraded by Wnt/Î²-catenin signaling via Î²-TrCP-mediated polyubiquitylation. Journal of Cell Science, 2009, 122, 842-848.	1.2	83
2121	Xenobiotic Metabolizing Gene Variants, Dietary Heterocyclic Amine Intake, and Risk of Prostate Cancer. Cancer Research, 2009, 69, 1877-1884.	0.4	33
2122	p38Î± and p38Î³ Mediate Oncogenic ras-induced Senescence through Differential Mechanisms. Journal of Biological Chemistry, 2009, 284, 11237-11246.	1.6	69
2123	Ha-rasOncogeneâ€“Induced Stat3 Phosphorylation Enhances Oncogenicity of the Cell. DNA and Cell Biology, 2009, 28, 131-139.	0.9	15

#	Article	IF	Citations
2124	Pancreatic cancer: advances in medical therapy. Expert Review of Clinical Pharmacology, 2009, 2, 173-180.	1.3	0
2125	Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Nonâ€"Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. International Journal of Surgical Pathology, 2009, 17, 206-218.	0.4	84
2126	Review Article: Targeted Therapy: Comprehensive Review. American Journal of Hospice and Palliative Medicine, 2009, 26, 137-146.	0.8	7
2127	Identification and Characterization of RBEL1 Subfamily of GTPases in the Ras Superfamily Involved in Cell Growth Regulation. Journal of Biological Chemistry, 2009, 284, 18129-18142.	1.6	36
2128	Thinking Outside the Box about Ras. Journal of Biological Chemistry, 2009, 284, 10993-10994.	1.6	17
2129	Protein Kinase CÎ¶ Represses the Interleukin-6 Promoter and Impairs Tumorigenesis In Vivo. Molecular and Cellular Biology, 2009, 29, 104-115.	1.1	76
2130	KRAS and TP53 mutations in colorectal carcinoma. Saudi Journal of Gastroenterology, 2009, 15, 217.	0.5	17
2131	A Computational Approach for the Identification of Small GTPases Based on Preprocessed Amino Acid Sequences. Technology in Cancer Research and Treatment, 2009, 8, 333-341.	0.8	17
2132	Mutations and Response to Epidermal Growth Factor Receptor Inhibitors: Fig. 1.. Clinical Cancer Research, 2009, 15, 1133-1139.	3.2	120
2133	Protein hnRNP A1 and its derivative Up1 unfold quadruplex DNA in the human KRAS promoter: implications for transcription. Nucleic Acids Research, 2009, 37, 2841-2853.	6.5	128
2134	Theoretical and experimental analysis links isoformâ€•specific ERK signalling to cell fate decisions. Molecular Systems Biology, 2009, 5, 334.	3.2	72
2135	Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line. Molecular Cancer Research, 2009, 7, 1456-1465.	1.5	66
2136	Nucleophosmin and Nucleolin Regulate K-Ras Plasma Membrane Interactions and MAPK Signal Transduction. Journal of Biological Chemistry, 2009, 284, 28410-28419.	1.6	61
2137	Oncolytic Reovirus Effectively Targets Breast Cancer Stem Cells. Molecular Therapy, 2009, 17, 972-979.	3.7	77
2138	Development of Extracellular Signal-Regulated Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2009, 9, 678-689.	1.0	30
2139	Regulation of proto-oncogene transcription, cell proliferation, and tumorigenesis in mice by PSF protein and a VL30 noncoding RNA. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16794-16798.	3.3	64
2140	Molecular-targeted therapy in malignant melanoma. Expert Review of Anticancer Therapy, 2009, 9, 567-581.	1.1	13
2141	The Logic of EGFR/ErbB Signaling: Theoretical Properties and Analysis of High-Throughput Data. PLoS Computational Biology, 2009, 5, e1000438.	1.5	164

#	Article	IF	Citations
2142	The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Annals of Oncology, 2009, 20, 879-884.	0.6	72
2143	ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis, 2009, 30, 1841-1847.	1.3	31
2144	Oncogenic K-ras â€œaddictionâ€•and synthetic lethality. Cell Cycle, 2009, 8, 2676-2678.	1.3	34
2145	Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy. Cancer Research, 2009, 69, 1924-1932.	0.4	32
2146	Chemokines in tumor-associated angiogenesis. Biological Chemistry, 2009, 390, 1213-1223.	1.2	60
2147	In vitro and In vivo Activity of Novel Small-Molecule Inhibitors Targeting the Pleckstrin Homology Domain of Protein Kinase B/AKT. Cancer Research, 2009, 69, 5073-5081.	0.4	51
2148	The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis, 2009, 30, 953-959.	1.3	186
2149	Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K-ras and p53 Two-Hit Carcinogenesis Model. Cancer Research, 2009, 69, 4159-4166.	0.4	79
2150	Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncology, 2009, 45, 324-334.	0.8	317
2151	KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer, 2009, 9, 111.	1.1	80
2152	Fast simultaneous detection of K-RASmutations in colorectal cancer. BMC Cancer, 2009, 9, 179.	1.1	38
2153	Aurora-A overexpression enhances cell-aggregation of Ha-rastransformants through the MEK/ERK signaling pathway. BMC Cancer, 2009, 9, 435.	1.1	24
2154	Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway. BMC Systems Biology, 2009, 3, 100.	3.0	54
2155	Version control of pathway models using XML patches. BMC Systems Biology, 2009, 3, 34.	3.0	7
2156	Beyond Doublet Chemotherapy for Advanced Nonâ€“Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy. Clinical Lung Cancer, 2009, 10, 20-27.	1.1	17
2157	A synthetic peptide corresponding to a sequence in the GTPase activating protein inhibits p21^{ras} stimulation and promotes guanine nucleotide exchange. International Journal of Peptide and Protein Research, 1991, 38, 47-53.	0.1	8
2158	Rasâ€dependent maturation of Xenopus oocytes is blocked by modified peptides of GTPase activating protein (GAP). International Journal of Peptide and Protein Research, 1995, 45, 194-199.	0.1	5
2159	Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Experimental and Molecular Pathology, 2009, 86, 174-179.	0.9	335

#	Article	IF	Citations
2160	NRAS mutations are rare in acute myeloid leukaemias with t(8;21) or inv(16). European Journal of Haematology, 1996, 56, 68-71.	1.1	5
2161	Restriction of Src Activity by Cullin-5. Current Biology, 2009, 19, 157-162.	1.8	49
2162	Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 971-978.	1.9	63
2163	RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Experimental Hematology, 2009, 37, 65-77.	0.2	47
2164	IQGAPs in cancer: A family of scaffold proteins underlying tumorigenesis. FEBS Letters, 2009, 583, 1817-1824.	1.3	263
2165	PKCÎ´ survival signaling in cells containing an activated p21Ras protein requires PDK1. Cellular Signalling, 2009, 21, 502-508.	1.7	31
2166	Phylogeny of the CDC25 homology domain reveals rapid differentiation of Ras pathways between early animals and fungi. Cellular Signalling, 2009, 21, 1579-1585.	1.7	21
2167	Down-regulation of Cdx2 in colorectal carcinoma cells by the Rafâ€“MEKâ€“ERK 1/2 pathway. Cellular Signalling, 2009, 21, 1846-1856.	1.7	23
2168	OncogenicHRASmutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome. Human Mutation, 2009, 30, 352-362.	1.1	29
2169	Genomic instability and histone H3 phosphorylation induction by the Rasâ€mitogen activated protein kinase pathway in pancreatic cancer cells. International Journal of Cancer, 2009, 124, 562-567.	2.3	14
2170	Constitutively active MEK1 is sufficient to induce epithelialâ€toâ€mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. International Journal of Cancer, 2009, 125, 1575-1586.	2.3	74
2171	Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRYâ€142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. International Journal of Cancer, 2009, 125, 2332-2341.	2.3	125
2172	Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. International Journal of Cancer, 2009, 125, 2711-2720.	2.3	12
2173	TGFâ€Î² inactivation and TGFâ€Î± overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer. International Journal of Cancer, 2010, 127, 1060-1071.	2.3	22
2174	Investigating the role of Aurora kinases in RAS signaling. Journal of Cellular Biochemistry, 2009, 106, 33-41.	1.2	7
2175	PI3K Acts in synergy with loss of PKC to elicit apoptosis via the UPR. Journal of Cellular Biochemistry, 2009, 107, 76-85.	1.2	8
2176	RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes and Cancer, 2009, 48, 975-982.	1.5	88
2177	Mutational spectra of human cancer. Human Genetics, 2009, 125, 493-506.	1.8	160

#	Article	IF	Citations
2178	Recurring G12S Mutation of HRAS in a Chinese Child with Costello Syndrome with High Alkaline Phosphatase Level. Biochemical Genetics, 2009, 47, 868-872.	0.8	3
2179	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. Critical Reviews in Oncology/Hematology, 2009, 72, 21-44.	2.0	24
2180	Sodium phenylacetate inhibits the Ras/MAPK signaling pathway to induce reduction of the c-Raf-1 protein in human and canine breast cancer cells. Breast Cancer Research and Treatment, 2009, 118, 281-291.	1.1	8
2181	Resistance mechanisms of tumour cells to EGFR inhibitors. Clinical and Translational Oncology, 2009, 11, 270-275.	1.2	19
2182	Inhibiting PI3K as a therapeutic strategy against cancer. Clinical and Translational Oncology, 2009, 11, 572-579.	1.2	28
2183	Small RNA: A Large Contributor to Carcinogenesis?. Journal of Gastrointestinal Surgery, 2009, 13, 1379-1388.	0.9	34
2184	Hematopoietic- and Neurologic-Expressed Sequence 1 Expression in the Murine GL261 and High-Grade Human Gliomas. Pathology and Oncology Research, 2009, 15, 437-44.	0.9	19
2185	A novel mechanism for inflammation-associated carcinogenesis; an important role of activation-induced cytidine deaminase (AID) in mutation induction. Journal of Molecular Medicine, 2009, 87, 1023-1027.	1.7	29
2186	Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2009, 64, 657-663.	1.1	69
2187	Effect of sulfur dioxide on expression of protoâ€oncogenes and tumor suppressor genes from rats. Environmental Toxicology, 2010, 25, 272-283.	2.1	9
2188	Prognostic significance of alterations in KRAS isoforms KRASâ€4A/4B and KRAS mutations in colorectal carcinoma. Journal of Pathology, 2009, 219, 435-445.	2.1	78
2189	Artepillin C (ARC) in Brazilian green propolis selectively blocks oncogenic PAK1 signaling and suppresses the growth of NF tumors in mice. Phytotherapy Research, 2009, 23, 423-427.	2.8	88
2190	Determining protein stability in cell lysates by pulse proteolysis and Western blotting. Protein Science, 2009, 18, 1051-1059.	3.1	32
2191	Identification and characterization of endonuclein binding proteins: evidence of modulatory effects on signal transduction and chaperone activity. BMC Biochemistry, 2009, 10, 34.	4.4	5
2192	Increasingly transformed MCF-10A cells have a progressively tumor-like phenotype in three-dimensional basement membrane culture. Cancer Cell International, 2009, 9, 7.	1.8	75
2193	Tumor biology and cancer therapy â€“ an evolving relationship. Cell Communication and Signaling, 2009, 7, 19.	2.7	11
2194	Isolation of ORCTL3 in a novel genetic screen for tumor-specific apoptosis inducers. Cell Death and Differentiation, 2009, 16, 890-898.	5.0	15
2195	Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition. Cancer Gene Therapy, 2009, 16, 693-702.	2.2	16

#	Article	IF	Citations
2196	Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications. Nature Protocols, 2009, 4, 1350-1362.	5.5	453
2197	Visualization of small GTPase activity with fluorescence resonance energy transfer-based biosensors. Nature Protocols, 2009, 4, 1623-1631.	5.5	127
2198	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British Journal of Cancer, 2009, 101, 715-721.	2.9	509
2199	The Emerging Role of the RAB25 Small GTPase in Cancer. Traffic, 2009, 10, 1561-1568.	1.3	78
2200	Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogeneâ€targeted therapeutics. FEBS Journal, 2009, 276, 6050-6062.	2.2	90
2201	Functional foods for health promotion: microbes and healthâ€Extended abstracts from the 11th Annual Conference on Functional Foods for Health Promotion, April 2008. Nutrition Reviews, 2009, 67, 40-48.	2.6	9
2202	Construction of an N-nitroso database for assessing dietary intake. Journal of Food Composition and Analysis, 2009, 22, S42-S47.	1.9	47
2203	Synthesis of antisense oligonucleotides containing 2â€²-O-psoralenylmethoxyalkyl adenosine for photodynamic regulation of point mutations in RNA. Bioorganic and Medicinal Chemistry, 2009, 17, 475-483.	1.4	47
2204	Molecular dynamics simulations on the critical states of the farnesyltransferase enzyme. Bioorganic and Medicinal Chemistry, 2009, 17, 3369-3378.	1.4	28
2205	Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Analytical Biochemistry, 2009, 391, 166-168.	1.1	72
2206	Squalene: A natural triterpene for use in disease management and therapy. Advanced Drug Delivery Reviews, 2009, 61, 1412-1426.	6.6	281
2207	Levothyroxine therapy in preventing nodular recurrence after hemithyroidectomy: A retrospective study. Journal of Endocrinological Investigation, 2009, 32, 330-334.	1.8	6
2208	Characterization of a Ras Mutant with Identical GDP- and GTP-Bound Structures,. Biochemistry, 2009, 48, 11449-11457.	1.2	29
2209	RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer. Cancer Research, 2009, 69, 6839-6847.	0.4	173
2210	2â€²-Benzoyloxycinnamaldehyde Inhibits Tumor Growth in H-ras12V Transgenic Mice via Downregulation of Metallothionein. Nutrition and Cancer, 2009, 61, 723-734.	0.9	7
2211	Transition State Structures and the Roles of Catalytic Residues in GAP-Facilitated GTPase of Ras As Elucidated by¹⁸O Kinetic Isotope Effects. Biochemistry, 2009, 48, 4538-4547.	1.2	23
2212	15-Lipoxygenase-1 in Colorectal Cancer: A Review. Tumor Biology, 2009, 30, 185-199.	0.8	28
2213	Imaging oncogene expression. European Journal of Radiology, 2009, 70, 265-273.	1.2	15

#	Article	IF	Citations
2214	High glucose induced endothelial cell growth inhibition is associated with an increase in TGFÎ²1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway. International Journal of Biochemistry and Cell Biology, 2009, 41, 561-569.	1.2	4
2215	P120-Ras GTPase activating protein (RasGAP): A multi-interacting protein in downstream signaling. Biochimie, 2009, 91, 320-328.	1.3	102
2216	Cellâ€“cell junction formation: The role of Rap1 and Rap1 guanine nucleotide exchange factors. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 790-796.	1.4	134
2217	Modelling oncogenic Ras/Raf signalling in the mouse. Current Opinion in Genetics and Development, 2009, 19, 4-11.	1.5	55
2218	The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Current Opinion in Genetics and Development, 2009, 19, 230-236.	1.5	640
2219	Thyroid receptor: roles in cancer. Trends in Endocrinology and Metabolism, 2009, 20, 318-324.	3.1	89
2220	Malignant Melanomaâ€“a Genetic Overview. Actas Dermo-sifiliogrÃ¡ficas, 2009, 100, 38-51.	0.2	16
2221	Solubility survey of fragments of the neurofibromatosis type 1 protein neurofibromin. Protein Expression and Purification, 2009, 65, 30-37.	0.6	24
2222	Insights into the role of genetic alterations in adrenocortical tumorigenesis. Molecular and Cellular Endocrinology, 2009, 300, 169-174.	1.6	11
2223	C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E. Molecular Cell, 2009, 36, 477-486.	4.5	61
2224	Detection of K-ras mutations in azoxymethane-induced aberrant crypt foci in mice using LNA-mediated real-time PCR clamping and mutant-specific probes. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2009, 677, 27-32.	0.9	19
2225	Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: Etiopathogenic similarities, differences and paradoxes. Mutation Research - Reviews in Mutation Research, 2009, 682, 83-93.	2.4	76
2226	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nature Reviews Clinical Oncology, 2009, 6, 519-527.	12.5	391
2227	Molecular Targets for Tumor Radiosensitization. Chemical Reviews, 2009, 109, 2974-2988.	23.0	49
2228	Ras/MAPK signaling from endomembranes. Molecular Oncology, 2009, 3, 297-307.	2.1	124
2230	Decreased Expression of the RAS-GTPase Activating Protein RASAL1 Is Associated With Colorectal Tumor Progression. Gastroenterology, 2009, 136, 206-216.	0.6	80
2231	KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. Clinical Colorectal Cancer, 2009, 8, 135-140.	1.0	4
2232	Senescence induction; a possible cancer therapy. Molecular Cancer, 2009, 8, 3.	7.9	76

#	Article	IF	Citations
2233	Oncolytic Viral Therapy Using Reovirus. Methods in Molecular Biology, 2009, 542, 607-634.	0.4	38
2234	Tyrosine Protein Kinases and Adaptive Immunity: TCR, BCR, Soluble Tyrosine Kinases and NFAT. , 2009, , 513-542.		0
2235	Targeting Cancer-initiating Cells With Oncolytic Viruses. Molecular Therapy, 2009, 17, 1677-1682.	3.7	80
2236	Genetic and Pathogenetic Aspects of Noonan Syndrome and Related Disorders. Hormone Research, 2009, 72, 57-63.	1.8	51
2237	Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells. Science, 2009, 325, 1555-1559.	6.0	797
2238	Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptorâ€“Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2009, 101, 1308-1324.	3.0	486
2239	MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Review of Molecular Diagnostics, 2009, 9, 423-440.	1.5	64
2240	Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncology, The, 2009, 10, 508-515.	5.1	314
2241	How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer: Table 1. Journal of Clinical Pathology, 2009, 62, 414-421.	1.0	25
2242	BRAFV600E Efficient Transformation and Induction of Microsatellite Instability Versus KRASG12V Induction of Senescence Markers in Human Colon Cancer Cells. Neoplasia, 2009, 11, 1116-IN2.	2.3	36
2243	BRAF Signaling and Targeted Therapies in Melanoma. Hematology/Oncology Clinics of North America, 2009, 23, 529-545.	0.9	159
2244	Applications of Genomics in Melanoma Oncogene Discovery. Hematology/Oncology Clinics of North America, 2009, 23, 397-414.	0.9	26
2245	Advances in the Treatment of Metastatic Colorectal Cancer. American Journal of Therapeutics, 2009, 16, 412-420.	0.5	37
2246	Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood, 2009, 113, 1304-1314.	0.6	91
2247	High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood, 2009, 113, 1749-1755.	0.6	119
2248	Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood, 2009, 113, 2478-2487.	0.6	47
2249	BRAF^{V600E}mutation in papillary thyroid carcinoma: a potential target for therapy?. Expert Review of Endocrinology and Metabolism, 2009, 4, 467-480.	1.2	0
2250	MicroRNA: Biogenesis, Function and Role in Cancer. Current Genomics, 2010, 11, 537-561.	0.7	1,372

#	Article	IF	Citations
2251	FK228 and oncogenic H-Ras synergistically induce Mek1/2 and Nox-1 to generate reactive oxygen species for differential cell death. Anti-Cancer Drugs, 2010, 21, 831-840.	0.7	15
2252	KRAS Status in Patients With Colorectal Cancer Peritoneal Carcinomatosis and Its Impact on Outcome. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 456-460.	0.6	22
2253	Detection of Occult Metastases in Sentinel Lymph Nodes From Colon Cancer Patients by K-ras Mutation Peptide Nucleic Acid Clamp PCR. Annals of Surgery, 2010, 251, 1087-1091.	2.1	10
2254	Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Molecular Medicine Reports, 2010, 3, 581-7.	1.1	13
2255	Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood, 2010, 116, 5991-6002.	0.6	109
2256	Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood, 2010, 115, 3598-3605.	0.6	72
2257	Enhancing Detection of Circulating Tumor Cells with Activating KRAS Oncogene in Patients with Colorectal Cancer by Weighted Chemiluminescent Membrane Array Method. Annals of Surgical Oncology, 2010, 17, 624-633.	0.7	50
2258	Role of RAS in the Regulation of PI 3-Kinase. Current Topics in Microbiology and Immunology, 2010, 346, 143-169.	0.7	99
2259	Molecular pathogenesis of follicular cell derived thyroid cancers. International Journal of Surgery, 2010, 8, 186-193.	1.1	50
2260	The use of network analyses for elucidating mechanisms in cardiovascular disease. Molecular BioSystems, 2010, 6, 289-304.	2.9	81
2261	Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. Cancer Immunology, Immunotherapy, 2010, 59, 183-193.	2.0	15
2262	Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 65, 235-241.	1.1	38
2263	Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. International Journal of Clinical Oncology, 2010, 15, 242-255.	1.0	30
2264	Human Papillomavirus DNA and Oncogene Alterations in Colorectal Tumors. Pathology and Oncology Research, 2010, 16, 461-468.	0.9	22
2265	Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted Oncology, 2010, 5, 19-28.	1.7	27
2267	Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Research and Treatment, 2010, 121, 227-231.	1.1	33
2268	microRNAs and lung cancer: tumors and 22-mers. Cancer and Metastasis Reviews, 2010, 29, 109-122.	2.7	74
2269	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer and Metastasis Reviews, 2010, 29, 49-60.	2.7	191

#	Article	IF	Citations
2270	ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration. Clinical and Experimental Metastasis, 2010, 27, 481-491.	1.7	41
2271	Cathepsin L increased level upon Ras mutants expression: the role of p38 and p44/42 MAPK signaling pathways. Molecular and Cellular Biochemistry, 2010, 343, 49-57.	1.4	11
2272	Intravenous administration of ReolysinÂ®, a live replication competent RNA virus is safe in patients with advanced solid tumors. Investigational New Drugs, 2010, 28, 641-649.	1.2	123
2273	Retrotransposition and mutation events yield Rap1 GTPases with differential signalling capacity. BMC Evolutionary Biology, 2010, 10, 55.	3.2	6
2274	Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts. BMC Cancer, 2010, 10, 13.	1.1	14
2275	KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer, 2010, 10, 660.	1.1	66
2276	Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer, 2010, 10, 99.	1.1	52
2277	Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discovery Today, 2010, 15, 502-516.	3.2	38
2278	Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 314-323.	0.5	119
2279	Mitochondrial respiratory chain super-complex Iâ€“III in physiology and pathology. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 633-640.	0.5	107
2280	Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 202, 67-69.	1.0	19
2281	Deletion mapping of chromosome region 12q13-24 in colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 201, 32-38.	1.0	12
2282	Oxidative stress, inflammation, and cancer: How are they linked?. Free Radical Biology and Medicine, 2010, 49, 1603-1616.	1.3	3,991
2283	Unmasking the complexities of mucinous ovarian carcinoma. Gynecologic Oncology, 2010, 117, 491-496.	0.6	85
2284	High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer, 1992, 69, 1115-1118.	2.0	77
2285	Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. International Journal of Cancer, 2010, 126, 2268-2281.	2.3	21
2286	Cancer models in Caenorhabditis elegans. Developmental Dynamics, 2010, 239, 1413-1448.	0.8	63
2287	Identification and Characterization of a Peptidic Ligand for Ras. ChemBioChem, 2010, 11, 517-522.	1.3	15

#	Article	IF	Citations
2291	Oriented Immobilization of Farnesylated Proteins by the Thiolâ€Ene Reaction. Angewandte Chemie - International Edition, 2010, 49, 1252-1257.	7.2	93
2292	Stabilizing a Weak Binding State for Effectors in the Human Ras Protein by Cyclen Complexes. Angewandte Chemie - International Edition, 2010, 49, 3830-3833.	7.2	97
2293	Synthesis of the Rheb and Kâ€Ras4B GTPases. Angewandte Chemie - International Edition, 2010, 49, 6090-6095.	7.2	73
2294	Statins can modulate effectiveness of antitumor therapeutic modalities. Medicinal Research Reviews, 2010, 30, 102-135.	5.0	37
2295	Mutational analysis of K-ras codon 12 in blood samples of patients with acute myeloid leukemia. Leukemia Research, 2010, 34, 883-891.	0.4	4
2296	Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy. Journal of Molecular Graphics and Modelling, 2010, 28, 513-523.	1.3	28
2297	Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. Clinical Biochemistry, 2010, 43, 296-301.	0.8	28
2298	Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. Bioorganic and Medicinal Chemistry, 2010, 18, 3448-3456.	1.4	37
2299	Andrographolide Sensitizes Ras-Transformed Cells to Radiation in vitro and in vivo. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1232-1239.	0.4	24
2300	Duodenal carcinoma at the ligament of Treitz. A molecular and clinical perspective. BMC Gastroenterology, 2010, 10, 109.	0.8	11
2301	Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. BMC Medical Genetics, 2010, 11, 34.	2.1	23
2302	Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. Journal of Molecular Signaling, 2010, 5, 2.	0.5	34
2303	p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. Journal of Pathology, 2010, 222, 129-137.	2.1	77
2304	Vaccines based on whole recombinant Saccharomyces cerevisiae cells. FEMS Yeast Research, 2010, 10, 1060-1069.	1.1	69
2305	Oncogenic Rasâ€mediated downregulation of Clast1/LR8 is involved in Rasâ€mediated neoplastic transformation and tumorigenesis in NIH3T3 cells. Cancer Science, 2010, 101, 1990-1996.	1.7	8
2306	Epidermal growth factorâ€™s activation of Ras is inhibited by four cardiac hormones. European Journal of Clinical Investigation, 2010, 40, 408-413.	1.7	16
2307	Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context. Oncogene, 2010, 29, 68-80.	2.6	13
2308	Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene, 2010, 29, 139-149.	2.6	85

#	Article	IF	Citations
2309	Ras-induced invasion and metastasis are regulated by a leukotriene B4 receptor BLT2-linked pathway. Oncogene, 2010, 29, 1167-1178.	2.6	51
2310	Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene, 2010, 29, 3873-3880.	2.6	76
2311	The activating mutation R201C in GNAS promotes intestinal tumourigenesis in ApcMin/+ mice through activation of Wnt and ERK1/2 MAPK pathways. Oncogene, 2010, 29, 4567-4575.	2.6	98
2312	K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function. Oncogene, 2010, 29, 5911-5922.	2.6	66
2313	Analysis of the genome to personalize therapy for melanoma. Oncogene, 2010, 29, 5545-5555.	2.6	125
2314	Oncogenic mutations as predictive factors in colorectal cancer. Oncogene, 2010, 29, 3033-3043.	2.6	98
2315	Spatial cycles in G-protein crowd control. EMBO Journal, 2010, 29, 2689-2699.	3.5	33
2316	Disorders of dysregulated signal traffic through the RASâ€MAPK pathway: phenotypic spectrum and molecular mechanisms. Annals of the New York Academy of Sciences, 2010, 1214, 99-121.	1.8	167
2317	Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway. Pediatrics International, 2010, 52, 557-562.	0.2	8
2318	The Roles of Ras Family Small GTPases in Breast Cancer. , 2010, , 2763-2772.		2
2319	Ras and Cancer. , 2010, , 1741-1743.		0
2320	Bisubstrate Analog Inhibitors. , 2010, , 689-717.		1
2321	Analysis ofKRASMutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing. Gastroenterology Research and Practice, 2010, 2010, 1-5.	0.7	27
2322	Multistage Carcinogenesis: Cell and Animal Models. , 2010, , 11-33.		0
2323	Ionizing Radiation as a Carcinogen*. , 2010, , 181-228.		2
2324	VRK2 Inhibits Mitogen-Activated Protein Kinase Signaling and Inversely Correlates with ErbB2 in Human Breast Cancer. Molecular and Cellular Biology, 2010, 30, 4687-4697.	1.1	37
2325	Sec5 and Exo84 Foster Oncogenic Ras-Mediated Tumorigenesis. Molecular Cancer Research, 2010, 8, 223-231.	1.5	34
2326	A Tagging-via-substrate Approach to Detect the Farnesylated Proteome Using Two-dimensional Electrophoresis Coupled with Western Blotting. Molecular and Cellular Proteomics, 2010, 9, 742-751.	2.5	47

#	Article	IF	Citations
2327	Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro-Oncology, 2010, 12, 1014-1023.	0.6	47
2328	NRAS Mutations Are Rare in Colorectal Cancer. Diagnostic Molecular Pathology, 2010, 19, 157-163.	2.1	159
2329	Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation. Human Molecular Genetics, 2010, 19, 790-802.	1.4	38
2330	Ras activation of Erk restores impaired tonic BCR signaling and rescues immature B cell differentiation. Journal of Experimental Medicine, 2010, 207, 607-621.	4.2	77
2331	ÎºB-Ras Is a Nuclear-Cytoplasmic Small GTPase That Inhibits NF-ÎºB Activation through the Suppression of Transcriptional Activation of p65/RelA. Journal of Biological Chemistry, 2010, 285, 30622-30633.	1.6	20
2332	Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis, 2010, 31, 1003-1009.	1.3	46
2333	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4706-4713.	0.8	909
2334	Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. Carcinogenesis, 2010, 31, 1523-1530.	1.3	96
2335	The Use of DNA Transposons for Cancer Gene Discovery in Mice. Methods in Enzymology, 2010, 477, 91-106.	0.4	1
2336	Novel biomarkers of metastatic cancer. Expert Review of Molecular Diagnostics, 2010, 10, 581-590.	1.5	17
2337	REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research, 2010, 16, 5564-5572.	3.2	120
2338	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression. Journal of Clinical Pharmacology, 2010, 50, 1397-1405.	1.0	8
2339	Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis. Molecular Syndromology, 2010, 1, 2-26.	0.3	197
2340	Activating K-Ras mutations outwith â€˜hotspotâ€™ codons in sporadic colorectal tumours â€“ implications for personalised cancer medicine. British Journal of Cancer, 2010, 102, 693-703.	2.9	156
2341	Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6471-6476.	3.3	108
2342	A Mouse Model of Melanoma Driven by Oncogenic KRAS. Cancer Research, 2010, 70, 5549-5557.	0.4	72
2343	Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA. Molecular and Cellular Biology, 2010, 30, 508-523.	1.1	100
2344	Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. Expert Review of Molecular Diagnostics, 2010, 10, 75-87.	1.5	18

#	Article	IF	Citations
2345	New and potential clinical applications ofKRASas a cancer biomarker. Expert Opinion on Medical Diagnostics, 2010, 4, 383-395.	1.6	7
2346	ERK1/2 activation by theC. elegansmuscarinic acetylcholine receptor GAR-3 in cultured mammalian cells involves multiple signaling pathways. Animal Cells and Systems, 2010, 14, 155-160.	0.8	1
2347	The Scaffold Protein Shoc2/SUR-8 Accelerates the Interaction of Ras and Raf. Journal of Biological Chemistry, 2010, 285, 7818-7826.	1.6	54
2348	The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies. International Journal of Cell Biology, 2010, 2010, 1-21.	1.0	345
2349	Gene Expression Profile Associated with Oncogenic Ras-induced Senescence, Cell Death, and Transforming Properties in Human Cells. Cancer Investigation, 2010, 28, 563-587.	0.6	6
2352	p53 Regulates the Ras Circuit to Inhibit the Expression of a Cancer-Related Gene Signature by Various Molecular Pathways. Cancer Research, 2010, 70, 2274-2284.	0.4	66
2353	Novel insights into the molecular origins and treatment of lung cancer. Cell Cycle, 2010, 9, 4098-4105.	1.3	19
2354	Nucleophosmin and nucleolin regulate K-Ras signaling. Communicative and Integrative Biology, 2010, 3, 188-190.	0.6	14
2355	Analysis of the Inhibitory Effect of Flavonoids on H-Ras Protein: An Anticancer Drug Target. Journal of Nutrigenetics and Nutrigenomics, 2010, 3, 127-135.	1.8	1
2356	Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas. Current Cancer Drug Targets, 2010, 10, 840-848.	0.8	82
2357	Predictive Genomic Biomarkers. Current Topics in Microbiology and Immunology, 2010, 355, 173-188.	0.7	1
2358	Targeted Therapeutic Agents for Colorectal Cancer. Gastroenterology Clinics of North America, 2010, 39, 601-613.	1.0	22
2360	Forces During Cell Adhesion and Spreading: Implications for Cellular Homeostasis. Studies in Mechanobiology, Tissue Engineering and Biomaterials, 2010, , 29-69.	0.7	14
2361	Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. Expert Opinion on Investigational Drugs, 2010, 19, 1205-1216.	1.9	14
2362	Overview of the Molecular Genetics and Molecular Chemotherapy of GBM. , 2010, , 1-42.		3
2363	Influence of the Lipid Anchor Motif of N-Ras on the Interaction with Lipid Membranes: A Surface Plasmon Resonance Study. Biophysical Journal, 2010, 98, 2226-2235.	0.2	17
2364	Interplay of RhoA and Motility in the Programmed Spreading of Daughter Cells Postmitosis. Biophysical Journal, 2010, 99, 3526-3534.	0.2	15
2365	A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients. Lung Cancer, 2010, 68, 51-57.	0.9	20

#	Article	IF	Citations
2366	Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1Î± and HIF-2Î± target genes. Molecular Cancer, 2010, 9, 293.	7.9	92
2367	KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice. Clinical Colorectal Cancer, 2010, 9, 22-30.	1.0	22
2368	Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells. Gastroenterology, 2010, 138, 2357-2367.	0.6	130
2369	Usefulness of Peptide Nucleic Acid (PNA)-Clamp Smart Amplification Process Version 2 (SmartAmp2) for Clinical Diagnosis of KRAS Codon12 Mutations in Lung Adenocarcinoma. Journal of Molecular Diagnostics, 2010, 12, 118-124.	1.2	33
2370	Phosphorylation of the Transcription Factor Ets-1 by ERK2: Rapid Dissociation of ADP and Phospho-Ets-1. Biochemistry, 2010, 49, 3619-3630.	1.2	26
2371	Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis, 2010, 31, 37-49.	1.3	559
2372	AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncology, 2010, 6, 457-470.	1.1	338
2373	Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. Biomedicine and Pharmacotherapy, 2010, 64, 550-558.	2.5	13
2374	Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Letters, 2010, 297, 117-125.	3.2	28
2375	Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics. Cytokine and Growth Factor Reviews, 2010, 21, 91-98.	3.2	83
2376	Advances in the Treatment of Metastatic Colorectal Cancer. Disease-a-Month, 2010, 56, 187-203.	0.4	1
2377	The long road to colorectal cancer therapy: Searching for the right signals. Drug Resistance Updates, 2010, 13, 44-56.	6.5	25
2378	An invertebrate mdm homolog interacts with p53 and is differentially expressed together with p53 and ras in neoplastic Mytilus trossulus haemocytes. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2010, 156, 298-308.	0.7	34
2379	Store-Independent Activation of Orai1 by SPCA2 in Mammary Tumors. Cell, 2010, 143, 84-98.	13.5	254
2380	Rap1, a mercenary among the Ras-like GTPases. Developmental Biology, 2010, 340, 1-9.	0.9	103
2381	The CRAL/TRIO and GOLD domain protein TAP-1 regulates RAF-1 activation. Developmental Biology, 2010, 341, 464-471.	0.9	13
2382	The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors. Methods, 2010, 52, 301-306.	1.9	3
2383	Oxidation in the nucleotide pool, the DNA damage response and cellular senescence: Defective bricks build a defective house. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2010, 703, 71-81.	0.9	50

#	Article	IF	Citations
2384	Carcinogenic Polycyclic Aromatic Hydrocarbons. , 2010, , 85-123.		16
2385	Gefitinib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 1343-1357.	0.9	20
2386	Specific Regulation of Point-Mutated K-ras-Immortalized Cell Proliferation by a Photodynamic Antisense Strategy. Oligonucleotides, 2010, 20, 37-44.	2.7	17
2387	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treatment Reviews, 2010, 36, S21-S29.	3.4	128
2388	Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treatment Reviews, 2010, 36, S56-S61.	3.4	103
2389	Role of ES Cell-Expressed Ras (ERas) in Tumorigenicity of Gastric Cancer. American Journal of Pathology, 2010, 177, 955-963.	1.9	29
2390	Gene Dysregulations Driven by Somatic Copy Number Aberrations-Biological and Clinical Implications in Colon Tumors. Journal of Molecular Diagnostics, 2010, 12, 552-561.	1.2	23
2391	Sensitive and Specific KRAS Somatic Mutation Analysis on Whole-Genome Amplified DNA from Archival Tissues. Journal of Molecular Diagnostics, 2010, 12, 27-34.	1.2	31
2392	Detection ofKRASmutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics, 2010, 11, 1169-1179.	0.6	41
2393	Methylation determines fibroblast activation and fibrogenesis in the kidney. Nature Medicine, 2010, 16, 544-550.	15.2	537
2394	Structure-Based Design and Synthesis of Potent, Ethylenediamine-Based, Mammalian Farnesyltransferase Inhibitors as Anticancer Agents. Journal of Medicinal Chemistry, 2010, 53, 6867-6888.	2.9	38
2395	Chemokines. Recent Results in Cancer Research, 2010, 180, 35-50.	1.8	6
2396	Selective Suicide Gene Therapy of Colon Cancer Exploiting the Urokinase Plasminogen Activator Receptor Promoter. BioDrugs, 2010, 24, 131-146.	2.2	16
2397	Sulforaphane Potentiates the Efficacy of 17-Allylamino 17-Demethoxygeldanamycin Against Pancreatic Cancer Through Enhanced Abrogation of Hsp90 Chaperone Function. Nutrition and Cancer, 2011, 63, 1151-1159.	0.9	34
2398	A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer. Cancer Investigation, 2011, 29, 617-625.	0.6	10
2399	Probabilistic Methods in Cancer Biology. European Journal of Control, 2011, 17, 483-511.	1.6	9
2400	Importance of Domain Closure for the Autoactivation of ERK2. Biochemistry, 2011, 50, 8038-8048.	1.2	29
2401	Colon Cancer: A Civilization Disorder. Digestive Diseases, 2011, 29, 222-228.	0.8	210

#	Article	IF	Citations
2402	Gd-EOB-DTPA Enhanced Micro-MR Imaging of Hepatic Tumors in H-ras 12V Transgenic Mice. Academic Radiology, 2011, 18, 13-19.	1.3	4
2403	Targeted Therapies for Thymic Malignancies. Thoracic Surgery Clinics, 2011, 21, 115-123.	0.4	9
2404	Ha-ras Oncogene and Anticancer Drug Resistance. Genomic Medicine, Biomarkers, and Health Sciences, 2011, 3, 39-48.	0.3	3
2405	Rasopathies: Developmental Disorders That Predispose to Cancer and Skin Manifestations. Actas Dermo-sifiliogrÃ¡ficas, 2011, 102, 402-416.	0.2	19
2408	Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nature Chemical Biology, 2011, 7, 942-949.	3.9	231
2409	Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. Journal of Molecular Signaling, 2011, 6, 2.	0.5	21
2410	Polyamines in cancer. Advances in Clinical Chemistry, 2011, 54, 45-70.	1.8	29
2412	Importance of Molecular Features of Nonâ€“Small Cell Lung Cancer for Choice of Treatment. American Journal of Pathology, 2011, 178, 1940-1948.	1.9	42
2414	Aliphatic acetogenin constituents of avocado fruits inhibit human oral cancer cell proliferation by targeting the EGFR/RAS/RAF/MEK/ERK1/2 pathway. Biochemical and Biophysical Research Communications, 2011, 409, 465-469.	1.0	55
2415	EGFR and KRAS mutations in metastatic lung adenocarcinomas. Human Pathology, 2011, 42, 1447-1453.	1.1	57
2416	The GAPs between hepatocellular carcinoma and RAS. Journal of Hepatology, 2011, 54, 191-192.	1.8	3
2417	Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends in Pharmacological Sciences, 2011, 32, 644-651.	4.0	60
2418	Actin on disease â€“ Studying the pathobiology of cell motility using Dictyostelium discoideum. Seminars in Cell and Developmental Biology, 2011, 22, 82-88.	2.3	21
2419	Oncogenic KâEŘas decouples glucose and glutamine metabolism to support cancer cell growth. Molecular Systems Biology, 2011, 7, 523.	3.2	404
2420	Impact of oncogenic K-RASon YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Research, 2011, 13, R28.	2.2	49
2421	p53 and Ras Mutations in Cancer and Experimental Carcinogenesis. , 2011, , 401-422.		0
2422	Farnesyl Transferase Inhibitors. The Enzymes, 2011, , 275-303.	0.7	3
2423	Geranylgeranyltransferase-1 Inhibitors. The Enzymes, 2011, , 129-163.	0.7	0

#	Article	IF	Citations
2424	Metabolic alterations in cancer cells and therapeutic implications. Chinese Journal of Cancer, 2011, 30, 508-525.	4.9	82
2425	Death pathways triggered by activated Ras in cancer cells. Frontiers in Bioscience - Landmark, 2011, 16, 1693.	3.0	53
2426	A Melanoma Molecular Disease Model. PLoS ONE, 2011, 6, e18257.	1.1	77
2427	Ras Inhibition Induces Insulin Sensitivity and Glucose Uptake. PLoS ONE, 2011, 6, e21712.	1.1	22
2428	Both the C-Terminal Polylysine Region and the Farnesylation of K-RasB Are Important for Its Specific Interaction with Calmodulin. PLoS ONE, 2011, 6, e21929.	1.1	30
2429	Live-Cell Microscopy Reveals Small Molecule Inhibitor Effects on MAPK Pathway Dynamics. PLoS ONE, 2011, 6, e22607.	1.1	13
2430	A Gain-of-Function Germline Mutation in Drosophila ras1 Affects Apoptosis and Cell Fate during Development. PLoS ONE, 2011, 6, e23535.	1.1	6
2431	G4-DNA Formation in the HRAS Promoter and Rational Design of Decoy Oligonucleotides for Cancer Therapy. PLoS ONE, 2011, 6, e24421.	1.1	93
2432	Galectin-3 Mediates Cross-Talk between K-Ras and Let-7c Tumor Suppressor microRNA. PLoS ONE, 2011, 6, e27490.	1.1	35
2433	Overexpression of GLUT1 in Colorectal Cancer is Independently Associated with Poor Prognosis. International Journal of Biological Markers, 2011, 26, 166-172.	0.7	41
2434	Pancreatic Hypertrophy in Ki-ras-Induced Actin-Interacting Protein Gene Knockout Mice. Pancreas, 2011, 40, 79-83.	0.5	9
2435	Differential Regulation of RasGAPs in Cancer. Genes and Cancer, 2011, 2, 288-297.	0.6	48
2436	Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood, 2011, 117, 2022-2032.	0.6	132
2437	Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood, 2011, 118, 368-379.	0.6	90
2438	PI3K/AKT/mTOR Pathway in Angiogenesis. Frontiers in Molecular Neuroscience, 2011, 4, 51.	1.4	1,002
2439	Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 15-20.	0.5	48
2440	Greater expression of TC21/Râ€ras2 in highly aggressive malignant skin cancer. International Journal of Dermatology, 2011, 50, 956-960.	0.5	20
2441	Differential antiproliferation effect of 2â€²â€benzoyloxycinnamaldehyde in Kâ€rasâ€transformed cells via downregulation of thiol antioxidants. Cancer Science, 2011, 102, 212-218.	1.7	11

#	Article	IF	Citations
2442	Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome. British Journal of Dermatology, 2011, 164, no-no.	1.4	74
2443	Ras gene mutation is not related to tumour invasion during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. Journal of Oral Pathology and Medicine, 2011, 40, 325-333.	1.4	18
2444	RAS oncogenes: weaving a tumorigenic web. Nature Reviews Cancer, 2011, 11, 761-774.	12.8	1,467
2445	Targeting protein prenylation for cancer therapy. Nature Reviews Cancer, 2011, 11, 775-791.	12.8	497
2446	Thyroid hormone receptor Î²1 domains responsible for the antagonism with the ras oncogene: role of corepressors. Oncogene, 2011, 30, 854-864.	2.6	23
2447	The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral. Oncogene, 2011, 30, 3661-3671.	2.6	8
2448	Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology, 2011, 58, 679-692.	1.6	78
2449	MicroRNA in lung cancer diagnostics and treatment. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 25-31.	0.4	52
2450	Promising Targets and Drugs in Development for Colorectal Cancer. Seminars in Oncology, 2011, 38, 588-597.	0.8	3
2451	Effect of human activated NRAS on replication of delNS1 H5N1 influenza virus in MDCK cells. Virology Journal, 2011, 8, 240.	1.4	3
2452	The enhanced host-cell permissiveness of human cytomegalovirus is mediated by the Ras signaling pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1872-1882.	1.9	7
2453	Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis. Cancer Cell, 2011, 20, 635-648.	7.7	203
2454	mTOR signaling in disease. Current Opinion in Cell Biology, 2011, 23, 744-755.	2.6	409
2455	Guanine nucleotide exchange factors for RhoGTPases: Good therapeutic targets for cancer therapy?. Cellular Signalling, 2011, 23, 969-979.	1.7	93
2457	A vertically stacked, polymer, microfluidic point mutation analyzer: Rapid high accuracy detection of low-abundance K-ras mutations. Analytical Biochemistry, 2011, 417, 211-219.	1.1	18
2458	Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Investigational New Drugs, 2011, 29, 481-488.	1.2	46
2459	A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. Journal of Neuro-Oncology, 2011, 105, 601-606.	1.4	20
2460	Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 487-493.	1.4	20

#	Article	IF	Citations
2461	Update of prognostic and predictive biomarkers in oropharyngeal squamous cell carcinoma: a review. European Archives of Oto-Rhino-Laryngology, 2011, 268, 5-16.	0.8	19
2462	Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor. Cancer Chemotherapy and Pharmacology, 2011, 67, 137-145.	1.1	5
2463	The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 2011, 67, 481-487.	1.1	22
2464	Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2011, 67, 455-463.	1.1	18
2465	Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemotherapy and Pharmacology, 2011, 67, 729-739.	1.1	26
2466	Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunologic Research, 2011, 49, 248-268.	1.3	82
2467	d-Limonene: a bioactive food component from citrus and evidence for a potential role in breast cancer prevention and treatment. Oncology Reviews, 2011, 5, 31-42.	0.8	67
2468	Tumour-associated antigens: considerations for their use in tumour immunotherapy. International Journal of Hematology, 2011, 93, 263-273.	0.7	14
2469	Predictive and Prognostic Markers in Colorectal Cancer. Current Oncology Reports, 2011, 13, 206-215.	1.8	48
2470	Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer, 2011, 11, 406.	1.1	83
2471	KRAS and BRAF: drug targets and predictive biomarkers. Journal of Pathology, 2011, 223, 220-230.	2.1	133
2472	Acute sensitivity of the oral mucosa to oncogenic Kâ€ras. Journal of Pathology, 2011, 224, 22-32.	2.1	12
2473	Factors determining electrostatic fields in molecular dynamics simulations of the ras/effector interface. Proteins: Structure, Function and Bioinformatics, 2011, 79, 3511-3524.	1.5	19
2474	Cutaneous melanoma: A model to study cancer metastasis. Journal of Surgical Oncology, 2011, 103, 538-549.	0.8	38
2475	Costello and cardioâ€facioâ€cutaneous syndromes: Moving toward clinical trials in RASopathies. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2011, 157, 136-146.	0.7	41
2476	Smallâ€Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics. ChemMedChem, 2011, 6, 38-48.	1.6	67
2477	Farnesyl transferase expression determines clinical response to the docetaxelâ€lonafarnib combination in patients with advanced malignancies. Cancer, 2011, 117, 4049-4059.	2.0	16
2478	Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer, 2011, 117, 4257-4266.	2.0	56

#	Article	IF	Citations
2479	Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Human Mutation, 2011, 32, 33-43.	1.1	126
2480	DNAâ€Binding Smallâ€Ligandâ€Immobilized Surface Plasmon Resonance Biosensor for Detecting Thymineâ€Related Singleâ€Nucleotide Polymorphisms. Chemistry - A European Journal, 2011, 17, 14104-14110.	1.7	14
2481	Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1795-1801.	1.0	70
2482	Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1315-1319.	1.0	108
2483	Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical Reviews in Oncology/Hematology, 2011, 79, 224-250.	2.0	38
2484	Synthesis and biological evaluation of novel aliphatic amido-quaternary ammonium salts for anticancer chemotherapy: Part I. European Journal of Medicinal Chemistry, 2011, 46, 2861-2866.	2.6	17
2485	Everolimus for the treatment of advanced renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2011, 12, 1143-1155.	0.9	16
2486	Functional Specificity of Ras Isoforms: So Similar but So Different. Genes and Cancer, 2011, 2, 216-231.	0.6	218
2487	Breaking up is hard to do. Small GTPases, 2011, 2, 329-333.	0.7	10
2488	Evolution of the Ras-like small GTPases and their regulators. Small GTPases, 2011, 2, 4-16.	0.7	54
2489	CaM interaction and Ser181 phosphorylation as new K-Ras signaling modulators. Small GTPases, 2011, 2, 99-103.	0.7	25
2490	Involvement of mitophagy in oncogenic K-Ras-induced transformation. Autophagy, 2011, 7, 1187-1198.	4.3	96
2491	Novel mitogen-activated protein kinase kinase inhibitors. Expert Opinion on Investigational Drugs, 2011, 20, 209-220.	1.9	34
2492	Small-molecule hydrophobic taggingâ€“induced degradation of HaloTag fusion proteins. Nature Chemical Biology, 2011, 7, 538-543.	3.9	322
2493	RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes and Cancer, 2011, 2, 261-274.	0.6	580
2494	C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D. Cancer Discovery, 2011, 1, 128-136.	7.7	126
2495	Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes and Development, 2011, 25, 2147-2157.	2.7	138
2496	miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. Journal of Cell Science, 2011, 124, 2997-3005.	1.2	147

#	Article	IF	Citations
2497	TGF-Î² signaling engages an ATM-CHK2-p53â€“independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8668-8673.	3.3	86
2498	Evolutionary expansion of the Ras switch regulatory module in eukaryotes. Nucleic Acids Research, 2011, 39, 5526-5537.	6.5	18
2499	BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. Journal of Skin Cancer, 2011, 2011, 1-8.	0.5	46
2500	Rapid identification of therapeutic targets in hematologic malignancies via functional genomics. Therapeutic Advances in Hematology, 2011, 2, 83-93.	1.1	1
2501	Genetic and epigenetic changes in lung carcinoma and their clinical implications. Modern Pathology, 2011, 24, 932-943.	2.9	64
2502	Tumor KRAS Status Predicts Responsiveness to Panitumumab in Japanese Patients with Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 210-216.	0.6	10
2503	Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells. Science Signaling, 2011, 4, ra17.	1.6	186
2504	The thyroid hormone receptors as tumor suppressors. Hormone Molecular Biology and Clinical Investigation, 2011, 5, 79-89.	0.3	6
2505	Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma. Digestive Diseases, 2011, 29, 289-302.	0.8	33
2506	KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. Genes and Cancer, 2011, 2, 335-343.	0.6	28
2507	Genetic Alterations in the K-Ras Gene Influence the Prognosis in Patients With Cervical Cancer Treated by Radiotherapy. International Journal of Gynecological Cancer, 2011, 21, 86-91.	1.2	25
2508	Role of MSK1 in the Malignant Phenotype of Ras-transformed Mouse Fibroblasts. Journal of Biological Chemistry, 2011, 286, 42-49.	1.6	30
2509	Poly(ADP-ribose) Polymerase 1 (PARP-1) Binds to 8-Oxoguanine-DNA Glycosylase (OGG1). Journal of Biological Chemistry, 2011, 286, 44679-44690.	1.6	100
2510	Raft Protein Clustering Alters N-Ras Membrane Interactions and Activation Pattern. Molecular and Cellular Biology, 2011, 31, 3938-3952.	1.1	42
2511	BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling. Journal of Biological Chemistry, 2011, 286, 17934-17944.	1.6	23
2512	Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Nonâ€“Small Cell Lung Cancer Treated with Chemotherapy. Clinical Cancer Research, 2011, 17, 3830-3840.	3.2	25
2513	Progressive Genomic Instability in the FVB/KrasLA2 Mouse Model of Lung Cancer. Molecular Cancer Research, 2011, 9, 1339-1345.	1.5	21
2514	Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. British Journal of Cancer, 2011, 105, 246-254.	2.9	23

#	Article	IF	Citations
2515	Sputum-Based Molecular Biomarkers for the Early Detection of Lung Cancer: Limitations and Promise. Cancers, 2011, 3, 2975-2989.	1.7	12
2516	Pharmacogenetics and pharmacogenomics: a clinical reality. Annals of Clinical Biochemistry, 2011, 48, 410-417.	0.8	16
2517	Hunger Artists: Yeast Adapted to Carbon Limitation Show Trade-Offs under Carbon Sufficiency. PLoS Genetics, 2011, 7, e1002202.	1.5	121
2518	The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1498-1507.	1.9	44
2519	Aberrant Signaling Pathways in Glioma. Cancers, 2011, 3, 3242-3278.	1.7	178
2520	Activation of Bmp2-Smad1 Signal and Its Regulation by Coordinated Alteration of H3K27 Trimethylation in Ras-Induced Senescence. PLoS Genetics, 2011, 7, e1002359.	1.5	59
2521	Genetic and Genomic Dissection of Apoptosis Signaling. , 2012, , 181-197.		0
2522	Alternative splicing of the neurofibromatosis typeÂI pre-mRNA. Bioscience Reports, 2012, 32, 131-138.	1.1	41
2523	Rsk-mediated phosphorylation and 14-3-3Îµ binding of Apaf-1 suppresses cytochromec-induced apoptosis. EMBO Journal, 2012, 31, 1279-1292.	3.5	39
2524	Synthesis of Farnesol Analogues Containing Triazoles in Place of Isoprenes through â€˜Click Chemistryâ€™. Synlett, 2012, 23, 2539-2548.	1.0	8
2525	H-Ras isoform modulates extracellular matrix synthesis, proliferation, and migration in fibroblasts. American Journal of Physiology - Cell Physiology, 2012, 302, C686-C697.	2.1	23
2526	Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling. Frontiers in Physiology, 2012, 3, 362.	1.3	24
2527	K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Research, 2012, 22, 399-412.	5.7	257
2528	Potential Biological Functions of Cytochrome P450 Reductase-dependent Enzymes in Small Intestine. Journal of Biological Chemistry, 2012, 287, 17777-17788.	1.6	15
2529	Mouse Tissues that Undergo Neoplastic Progression after K-Ras Activation Are Distinguished by Nuclear Translocation of phospho-Erk1/2 and Robust Tumor Suppressor Responses. Molecular Cancer Research, 2012, 10, 845-855.	1.5	16
2530	Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1315-1326.	0.5	175
2531	KRAS Testing: A Tool for the Implementation of Personalized Medicine. Genes and Cancer, 2012, 3, 459-466.	0.6	45
2532	Regulation of u-PAR gene expression by H2A.Z is modulated by the MEKâ€“ERK/AP-1 pathway. Nucleic Acids Research, 2012, 40, 600-613.	6.5	17

#	Article	IF	Citations
2533	Activated Ras Protein Accelerates Cell Cycle Progression to Perturb Madin-Darby Canine Kidney Cystogenesis*. Journal of Biological Chemistry, 2012, 287, 31703-31711.	1.6	20
2534	RAS, cellular senescence and transformation. Small GTPases, 2012, 3, 163-167.	0.7	7
2535	Escorting Ras. Small GTPases, 2012, 3, 236-239.	0.7	4
2536	K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. Cancer Biology and Therapy, 2012, 13, 1235-1243.	1.5	10
2537	The Syrian hamster embryo (SHE) assay (pH 6.7): mechanisms of cell transformation and application of vibrational spectroscopy to objectively score endpoint alterations. Mutagenesis, 2012, 27, 257-266.	1.0	9
2538	RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. Journal of Clinical Oncology, 2012, 30, 316-321.	0.8	366
2539	Gene of the month: BRAF. Journal of Clinical Pathology, 2012, 65, 986-988.	1.0	12
2540	The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal of Cancer, 2012, 106, 1386-1394.	2.9	67
2541	Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nature Communications, 2012, 3, 1168.	5.8	135
2542	Evidence for type II cells as cells of origin of K-Rasâ€“induced distal lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4910-4915.	3.3	242
2543	Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert Opinion on Biological Therapy, 2012, 12, 1669-1678.	1.4	22
2544	MEK1/2 Inhibition Elicits Regression of Autochthonous Lung Tumors Induced by KRASG12D or BRAFV600E. Cancer Research, 2012, 72, 3048-3059.	0.4	48
2545	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1120-1128.	3.2	57
2546	Detection of KRAS Mutations and Their Associations with Clinicopathological Features and Survival in Chinese Colorectal Cancer Patients. Journal of International Medical Research, 2012, 40, 1589-1598.	0.4	27
2547	MEK genomics in development and disease. Briefings in Functional Genomics, 2012, 11, 300-310.	1.3	62
2548	The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals, 2012, 5, 1236-1264.	1.7	89
2549	Oncolytic Viruses in the Treatment of Bladder Cancer. Advances in Urology, 2012, 2012, 1-11.	0.6	19
2550	Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer. Biochemistry Research International, 2012, 2012, 1-18.	1.5	42

#	Article	IF	Citations
2551	The RASopathies: Syndromes of Ras/MAPK Pathway Dysregulation. , 2012, , 497-511.		2
2552	Interplay between Menin and K-Ras in Regulating Lung Adenocarcinoma. Journal of Biological Chemistry, 2012, 287, 40003-40011.	1.6	36
2553	Transcriptional regulation of the interleukin-11 gene by oncogenic Ras. Carcinogenesis, 2012, 33, 2467-2476.	1.3	33
2554	Ras Stabilization Through Aberrant Activation of Wnt/Î²-Catenin Signaling Promotes Intestinal Tumorigenesis. Science Signaling, 2012, 5, ra30.	1.6	155
2555	Cigarette Smoking and Inflammation. Journal of Dental Research, 2012, 91, 142-149.	2.5	529
2556	Inhibition and Termination of Physiological Responses by GTPase Activating Proteins. Physiological Reviews, 2012, 92, 237-272.	13.1	45
2557	Aberrant Methylation of RASSF2A in Human Pancreatic Ductal Adenocarcinoma and Its Relation to Clinicopathologic Features. Pancreas, 2012, 41, 206-211.	0.5	14
2558	Pharmacogenetic screening for drug therapy: From single gene markers to decision making in the next generation sequencing era. Pathology, 2012, 44, 166-180.	0.3	23
2559	MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance. Oncology Letters, 2012, 4, 783-791.	0.8	60
2560	Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood, 2012, 119, 1032-1035.	0.6	66
2561	ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacological Research, 2012, 66, 105-143.	3.1	1,246
2562	A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Medicinal Chemistry Letters, 2012, 3, 1034-1038.	1.3	104
2563	What We Have Learned About Pancreatic Cancer From Mouse Models. Gastroenterology, 2012, 142, 1079-1092.	0.6	151
2564	Detection of Ras GTPase protein radicals through immuno-spin trapping. Free Radical Biology and Medicine, 2012, 53, 1339-1345.	1.3	10
2565	Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. Modern Pathology, 2012, 25, 1203-1211.	2.9	21
2566	Delving into somatic variation in sporadic melanoma. Pigment Cell and Melanoma Research, 2012, 25, 155-170.	1.5	35
2567	Mitochondria and Reactive Oxygen Species. Which Role in Physiology and Pathology?. Advances in Experimental Medicine and Biology, 2012, 942, 93-136.	0.8	169
2568	Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1909-1917.	1.2	31

#	Article	IF	Citations
2569	AERIO News in brief. Oncologie, 2012, 14, 491-494.	0.2	0
2570	ERK Inhibition Rescues Defects in Fate Specification of Nf1-Deficient Neural Progenitors and Brain Abnormalities. Cell, 2012, 150, 816-830.	13.5	124
2571	Asleep at the Switch: MEK Kinases Control Transit to Gliogenesis in Developing Cortex. Neuron, 2012, 75, 940-942.	3.8	1
2572	Discovery of ferrocene-containing farnesyltransferase inhibitors. Investigation of bulky lipophilic groups for the A2 binding site of farnesyltransferase. MedChemComm, 2012, 3, 1147.	3.5	9
2573	Identification of a novel nanomolar inhibitor of hIcmt via a carboxylate replacement approach. MedChemComm, 2012, 3, 1125.	3.5	2
2574	Electrostatic Effects of Mutations of Ras Glutamine 61 Measured Using Vibrational Spectroscopy of a Thiocyanate Probe. Biochemistry, 2012, 51, 2757-2767.	1.2	31
2575	Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Modern Pathology, 2012, 25, 758-766.	2.9	99
2576	Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E640-7.	3.3	120
2577	p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model. Cancer Research, 2012, 72, 5966-5975.	0.4	102
2578	Reovirus: A Targeted Therapeuticâ€"Progress And Potential. Molecular Cancer Research, 2012, 10, 1514-1525.	1.5	62
2579	Antisense Knockdown of Kras Inhibits Fibrosis in a Rat Model of Unilateral Ureteric Obstruction. American Journal of Pathology, 2012, 180, 82-90.	1.9	19
2580	Transcriptomic fingerprints in human peripheral blood mononuclear cells indicative of genotoxic and non-genotoxic carcinogenic exposure. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 746, 124-134.	0.9	14
2581	Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: A five chemical case study. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 746, 135-143.	0.9	84
2582	New farnesyltransferase inhibitors in the phenothiazine series. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4517-4522.	1.0	32
2583	Phenotypic variability in a family with capillary malformations caused by a mutation in the RASA1 gene. European Journal of Medical Genetics, 2012, 55, 191-195.	0.7	35
2584	Screens, maps & networks: from genome sequences to personalized medicine. Current Opinion in Genetics and Development, 2012, 22, 36-44.	1.5	15
2585	Ras Oncoproteins Transfer from Melanoma Cells to T Cells and Modulate Their Effector Functions. Journal of Immunology, 2012, 189, 4361-4370.	0.4	8
2587	Metalâ€"Bis(2â€picolyl)amine Complexes as Stateâ€...1(T) Inhibitors of Activated Ras Protein. Angewandte Chemie - International Edition, 2012, 51, 10647-10651.	7.2	58

#	Article	IF	Citations
2588	Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BMC Medicine, 2012, 10, 135.	2.3	20
2589	The Helicase HAGE Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor Cell Proliferation in Vivo. Journal of Biological Chemistry, 2012, 287, 13633-13643.	1.6	31
2590	Nanovector delivery of siRNA for cancer therapy. Cancer Gene Therapy, 2012, 19, 367-373.	2.2	156
2591	Vemurafenib. Drugs, 2012, 72, 2207-2222.	4.9	89
2592	Pathways and targets in hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1347-1357.	1.1	55
2593	Update on Turner and Noonan Syndromes. Endocrinology and Metabolism Clinics of North America, 2012, 41, 713-734.	1.2	24
2594	EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?. British Journal of Cancer, 2012, 107, 1864-1868.	2.9	56
2595	Phospho-specific Smad3 signaling. Cell Cycle, 2012, 11, 2443-2451.	1.3	63
2596	Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses. Gastrointestinal Endoscopy, 2012, 76, 702-703.	0.5	0
2597	Dissecting the different biological effects of oncogenic Ras isoforms in cancer cell lines: Could stimulation of oxidative stress be the one more weapon of H-Ras?. Medical Hypotheses, 2012, 79, 731-734.	0.8	3
2598	Some Research Directions. Springer Briefs in Electrical and Computer Engineering, 2012, , 69-80.	0.3	0
2599	Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer. Drugs, 2012, 72, 28-36.	4.9	61
2600	Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology, 2012, 9, 87-97.	12.5	94
2601	Papillary mucinous metaplasia of the endometrium as a possible precursor of endometrial mucinous adenocarcinoma. Modern Pathology, 2012, 25, 1496-1507.	2.9	41
2602	S-Farnesyl-Thiopropionic Acid Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase. ACS Medicinal Chemistry Letters, 2012, 3, 15-19.	1.3	42
2603	The Epigenetics of Gastrointestinal Malignancies. Current Colorectal Cancer Reports, 2012, 8, 254-262.	1.0	2
2604	Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPÎ²-Dependent Suppression of EGFR Expression. Neoplasia, 2012, 14, 190-IN7.	2.3	19
2605	Liquid Chromatographic Analysis and Mass Spectrometric Identification of Farnesylated Peptides. Analytical Chemistry, 2012, 84, 6848-6855.	3.2	16

#	Article	IF	Citations
2606	Lonafarnib for cancer and progeria. Expert Opinion on Investigational Drugs, 2012, 21, 1043-1055.	1.9	21
2607	Histone H3 phosphorylation, immediate-early gene expression, and the nucleosomal response: a historical perspective¹This article is part of Special Issue entitled Asilomar Chromatin and has undergone the Journalâ€™s usual peer review process.. Biochemistry and Cell Biology, 2012, 90, 39-54.	0.9	51
2608	TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation. Nature Cell Biology, 2012, 14, 625-633.	4.6	34
2609	The role of G-domain orientation and nucleotide state on the Ras isoform-specific membrane interaction. European Biophysics Journal, 2012, 41, 801-813.	1.2	64
2610	Age-related and clinicopathological features of colorectal cancer associated with K-ras gene status. Advances in Gerontology, 2012, 2, 306-311.	0.1	1
2611	A Novel Classification of Lung Cancer into Molecular Subtypes. PLoS ONE, 2012, 7, e31906.	1.1	99
2612	Nras Overexpression Results in Granulocytosis, T-Cell Expansion and Early Lethality in Mice. PLoS ONE, 2012, 7, e42216.	1.1	5
2613	Ras GTPases Modulate Morphogenesis, Sporulation and Cellulase Gene Expression in the Cellulolytic Fungus Trichoderma reesei. PLoS ONE, 2012, 7, e48786.	1.1	39
2614	KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells. PLoS ONE, 2012, 7, e50701.	1.1	44
2615	RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally. Frontiers in Genetics, 2011, 2, 100.	1.1	61
2616	Neurogenetics and the molecular biology of human brain tumors. , 2012, , 83-101.		0
2617	CSE1L, a Novel Microvesicle Membrane Protein, Mediates Ras-Triggered Microvesicle Generation and Metastasis of Tumor Cells. Molecular Medicine, 2012, 18, 1269-1280.	1.9	52
2618	Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 163-171.	0.9	113
2619	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. , 2012, 2012, 1-8.		23
2620	Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. OncoTargets and Therapy, 2012, 5, 217.	1.0	5
2621	Mouse models for brain tumor therapy. , 2012, , 316-328.		0
2622	A Comprehensive Survey of Ras Mutations in Cancer. Cancer Research, 2012, 72, 2457-2467.	0.4	1,602
2623	Luminescent Quantum Dots for Molecular Toxicology. Advances in Experimental Medicine and Biology, 2012, 745, 117-137.	0.8	5

#	Article	IF	Citations
2624	Progress of oncolytic viruses in sarcomas. Expert Review of Anticancer Therapy, 2012, 12, 229-242.	1.1	9
2625	Nanofluidic Digital PCR for KRAS Mutation Detection and Quantification in Gastrointestinal Cancer. Clinical Chemistry, 2012, 58, 1332-1341.	1.5	52
2626	Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples. International Journal of Cancer, 2012, 131, 1621-1632.	2.3	20
2627	C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome. European Journal of Human Genetics, 2012, 20, 870-877.	1.4	21
2629	Discovery of Small Molecules that Bind to Kâ€Ras and Inhibit Sosâ€Mediated Activation. Angewandte Chemie - International Edition, 2012, 51, 6140-6143.	7.2	419
2630	Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer, 2012, 118, 5550-5559.	2.0	36
2631	Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer, 2012, 118, 6243-6252.	2.0	20
2632	Organization, dynamics, and segregation of Ras nanoclusters in membrane domains. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8097-8102.	3.3	160
2633	Loss of protein expression and recurrent DNA hypermethylation of the GNG7 gene in squamous cell carcinoma of the head and neck. Journal of Applied Genetics, 2012, 53, 167-174.	1.0	35
2634	Driver mutations as predictive biomarkers in lung cancer. Current Respiratory Care Reports, 2012, 1, 21-29.	0.6	0
2635	RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. International Journal of Hematology, 2012, 95, 509-515.	0.7	33
2636	Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 141-149.	1.4	53
2637	IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Research and Treatment, 2012, 133, 563-573.	1.1	72
2638	DNA Hypermethylation and Histone Modifications Downregulate the Candidate Tumor Suppressor Gene RRP22 on 22q12 in Human Gliomas. Brain Pathology, 2012, 22, 17-25.	2.1	21
2639	KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. Histopathology, 2012, 61, 1036-1042.	1.6	23
2640	Side effects of systemic oncological therapies in dermatology. JDDG - Journal of the German Society of Dermatology, 2012, 10, 475-486.	0.4	20
2641	Kâ€ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma. Apmis, 2012, 120, 459-468.	0.9	20
2642	The atypical PKCs in inflammation: NFâ€ÎºB and beyond. Immunological Reviews, 2012, 246, 154-167.	2.8	106

#	Article	IF	Citations
2643	Changes in actin and E-cadherin expression induced by 5-aminolevulinic acid photodynamic therapy in normal and Ras-transfected human mammary cell lines. Journal of Photochemistry and Photobiology B: Biology, 2012, 106, 47-52.	1.7	11
2644	Small G proteins and their regulators in cellular signalling. Molecular and Cellular Endocrinology, 2012, 353, 10-20.	1.6	32
2645	Ras oncogenes in oral cancer: The past 20 years. Oral Oncology, 2012, 48, 383-392.	0.8	101
2646	Mâ€Ras induces Ral and JNK activation to regulate MEK/ERKâ€independent gene expression in MCFâ€7 breast cancer cells. Journal of Cellular Biochemistry, 2012, 113, 1253-1264.	1.2	19
2647	MicroRNAs in the midst of myeloid signal transduction. Journal of Cellular Physiology, 2012, 227, 525-533.	2.0	2
2648	Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D. American Journal of Medical Genetics, Part A, 2012, 158A, 652-658.	0.7	10
2649	Molecular assessment of c-H-ras p21 expression in Helicobacter pylori-mediated gastric carcinogenesis. Molecular and Cellular Biochemistry, 2012, 362, 169-176.	1.4	3
2650	Ras signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 219-228.	2.2	20
2651	Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors. Journal of Molecular Modeling, 2012, 18, 675-692.	0.8	10
2652	Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells. Journal of Cancer Research and Clinical Oncology, 2012, 138, 537-544.	1.2	4
2653	Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSLâ€Kras^{G12D}â€LSLâ€Trp53^{R172H}â€Pdx1â€Cre mice. Molecular Carcinogenesis, 2013, 52, 739-750.	4.8	42
2654	Mechanisms of RAS/Î²-catenin interactions. Archives of Toxicology, 2013, 87, 611-632.	1.9	33
2655	Lessons from computer simulations of Ras proteins in solution and in membrane. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 5211-5218.	1.1	48
2656	Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. Oncogene, 2013, 32, 2016-2026.	2.6	34
2657	Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. Tumor Biology, 2013, 34, 1901-1911.	0.8	40
2658	Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. BMC Genomics, 2013, 14, 505.	1.2	30
2659	DNA damage activates a complex transcriptional response in murine lymphocytes that includes both physiological and cancer-predisposition programs. BMC Genomics, 2013, 14, 163.	1.2	13
2660	Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). BMC Medicine, 2013, 11, 59.	2.3	23

#	Article	IF	Citations
2661	Leukemias, Lymphomas, and Other Related Disorders. , 2013, , 1-44.		2
2662	Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor. Clinical and Translational Oncology, 2013, 15, 425-433.	1.2	11
2663	Essential genes in thyroid cancers: focus on fascin. Journal of Diabetes and Metabolic Disorders, 2013, 12, 32.	0.8	6
2664	KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Modern Pathology, 2013, 26, 1307-1319.	2.9	102
2665	Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1561-1573.	2.2	16
2666	Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 72, 577-584.	1.1	26
2667	The RASopathies. Annual Review of Genomics and Human Genetics, 2013, 14, 355-369.	2.5	673
2668	Cancer Biology: Some Causes for a Variety of Different Diseases. , 2013, , 121-159.		1
2669	PAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis. Cell Reports, 2013, 5, 314-322.	2.9	41
2670	New monoallelic combination of KRAS gene mutations in codons 12 and 13 in the lung adenocarcinoma. Advances in Medical Sciences, 2013, 58, 83-89.	0.9	8
2671	Pin1 inhibitors: Pitfalls, progress and cellular pharmacology. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4283-4291.	1.0	91
2672	The use of virtual screening and differential scanning fluorimetry for the rapid identification of fragments active against MEK1. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3620-3626.	1.0	22
2673	A 75-Year-Old Man With Progressive Bronchioalveolar Carcinoma. Seminars in Oncology, 2013, 40, e1-e8.	0.8	1
2674	Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes and Development, 2013, 27, 1101-1114.	2.7	113
2675	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Annals of Oncology, 2013, 24, 1267-1273.	0.6	96
2676	HRAS T81C polymorphism modulates risk of urinary bladder cancer and predicts advanced tumors in ethnic Kashmiri population. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 487-492.	0.8	17
2677	Molecular Mechanism of SLC5A8 Inactivation in Breast Cancer. Molecular and Cellular Biology, 2013, 33, 3920-3935.	1.1	27
2678	Ribosomal proteins as novel players in tumorigenesis. Cancer and Metastasis Reviews, 2014, 33, 115-41.	2.7	63

#	Article	IF	Citations
2679	Effect of inhibition of the FGFRâ€“MAPK signaling pathway on the development of ocular toxicities. Cancer Treatment Reviews, 2013, 39, 664-672.	3.4	84
2680	State 1(T) Inhibitors of Activated Ras. The Enzymes, 2013, 33 Pt A, 69-94.	0.7	10
2681	Oral Cavity and Oropharyngeal Squamous Cell Carcinoma Genomics. Otolaryngologic Clinics of North America, 2013, 46, 545-566.	0.5	14
2682	KRAS Mutations in Lung Cancer. Clinical Lung Cancer, 2013, 14, 205-214.	1.1	182
2683	REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (ReolysinÂ®) in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 696-706.	1.2	85
2684	Rapid detection of K-, N-, H-RAS, and BRAF hotspot mutations in thyroid cancer using the multiplex primer extension. Clinical Biochemistry, 2013, 46, 1572-1577.	0.8	6
2686	Sensitive Detection of KRAS Mutations Using Enhanced-ice -COLD-PCR Mutation Enrichment and Direct Sequence Identification. Human Mutation, 2013, 34, 1568-1580.	1.1	41
2687	Intrinsic Allosteric Inhibition of Signaling Proteins by Targeting Rare Interaction States Detected by Highâ€Pressure NMR Spectroscopy. Angewandte Chemie - International Edition, 2013, 52, 14242-14246.	7.2	60
2688	Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS T81C single nucleotide polymorphism (caseâ€“control study). Tumor Biology, 2013, 34, 521-529.	0.8	17
2689	Antigen and cytokine receptor signals guide the development of the naÃ¯ve mature B cell repertoire. Immunologic Research, 2013, 55, 231-240.	1.3	23
2690	KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma. International Journal of Cancer, 2013, 132, 2502-2509.	2.3	13
2691	Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations. Molecular BioSystems, 2013, 9, 361.	2.9	70
2692	Asymmetric total synthesis of (â^')-rasfonin. Tetrahedron, 2013, 69, 1153-1165.	1.0	18
2693	Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Nature Structural and Molecular Biology, 2013, 20, 46-52.	3.6	80
2694	Molecular dynamics analysis of a series of 22 potential farnesyltransferase substrates containing a CaaX-motif. Journal of Molecular Modeling, 2013, 19, 673-688.	0.8	11
2695	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Cell, 2013, 152, 714-726.	13.5	1,202
2696	Why nature really chose phosphate. Quarterly Reviews of Biophysics, 2013, 46, 1-132.	2.4	290
2697	A small-molecule induces apoptosis and suppresses metastasis in pancreatic cancer cells. European Journal of Pharmaceutical Sciences, 2013, 48, 658-667.	1.9	12

#	Article	IF	Citations
2698	Photoaging: New insights into its stimulators, complications, biochemical changes and therapeutic interventions. Biomedicine and Aging Pathology, 2013, 3, 161-169.	0.8	21
2699	Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis. Lung Cancer, 2013, 81, 1-10.	0.9	121
2700	MetÃ¡stasis cutÃ¡neas de origen visceral. Actas Dermo-sifiliogrÃ¡ficas, 2013, 104, 841-853.	0.2	39
2701	Regulator of G protein signaling 19 suppresses Ras-induced neoplastic transformation and tumorigenesis. Cancer Letters, 2013, 339, 33-41.	3.2	23
2702	CSE1L modulates Ras-induced cancer cell invasion: correlation of K-Ras mutation and CSE1L expression in colorectal cancer progression. American Journal of Surgery, 2013, 206, 418-427.	0.9	15
2703	Differential anti-tumor activities of curcumin against Ras- and Src-activated human adenocarcinoma cells. Biochemical and Biophysical Research Communications, 2013, 436, 186-191.	1.0	19
2704	Synthesis and biological evaluation of a new series of N-ylides as protein farnesyltransferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5887-5892.	1.0	12
2705	Cutaneous Metastases of Internal Tumors. Actas Dermo-sifiliogrÃ¡ficas, 2013, 104, 841-853.	0.2	11
2706	Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Critical Reviews in Oncology/Hematology, 2013, 88, 272-283.	2.0	27
2707	Biomarkers and transcription levels of cancer-related genes in cockles Cerastoderma edule from Galicia (NW Spain) with disseminated neoplasia. Aquatic Toxicology, 2013, 136-137, 101-111.	1.9	10
2708	Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway. Biochemical Pharmacology, 2013, 85, 163-172.	2.0	32
2709	Other signalization targets. Targeted Oncology, 2013, 8, 69-77.	1.7	6
2710	Rasosomes originate from the Golgi to dispense Ras signals. Cell Death and Disease, 2013, 4, e496-e496.	2.7	5
2711	Glutathiolated Ras: Characterization and implications for Ras activation. Free Radical Biology and Medicine, 2013, 57, 221-229.	1.3	28
2712	Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVPâ€BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. International Journal of Cancer, 2013, 133, 984-996.	2.3	49
2713	Ras-induced ROS upregulation affecting cell proliferation is connected with cell type-specific alterations of HSF1/SESN3/p21^{Cip1/WAF1}pathways. Cell Cycle, 2013, 12, 826-836.	1.3	46
2714	Prenyltransferase inhibitors: treating human ailments from cancer to parasitic infections. MedChemComm, 2013, 4, 476-492.	3.5	54
2715	Synthesis and biological evaluation of novel aliphatic amido-quaternary ammonium salts for anticancer chemotherapy: Part II. European Journal of Medicinal Chemistry, 2013, 63, 621-628.	2.6	12

#	Article	IF	Citations
2716	Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration. Oncogene, 2013, 32, 352-362.	2.6	54
2717	Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2013, 1829, 239-247.	0.9	81
2718	Oxidative stress and cancer: An overview. Ageing Research Reviews, 2013, 12, 376-390.	5.0	1,106
2719	Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs. Expert Opinion on Biological Therapy, 2013, 13, 51-66.	1.4	13
2720	Development of a Cytokine-Modified Allogeneic Whole Cell Pancreatic Cancer Vaccine. Methods in Molecular Biology, 2013, 980, 175-203.	0.4	11
2721	Role of Par-4 in Prostate Cancer. , 2013, , 481-495.		1
2722	Evidence of a Low Prevalence ofRASMutations in a Large Medullary Thyroid Cancer Series. Thyroid, 2013, 23, 50-57.	2.4	151
2723	Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature, 2013, 497, 633-637.	13.7	1,316
2724	Inhibition of Pancreatitis and Carcinogenesis by Capsaicin. , 2013, , 89-106.		0
2725	Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. Organic and Biomolecular Chemistry, 2013, 11, 3706.	1.5	29
2726	Nuclear receptor-binding protein 1: a novel tumour suppressor and pseudokinase. Biochemical Society Transactions, 2013, 41, 1055-1060.	1.6	23
2727	Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia. International Journal of Hematology, 2013, 98, 549-557.	0.7	4
2728	Implications of Readâ€“Write genomics for cancer biology. Physics of Life Reviews, 2013, 10, 338-340.	1.5	3
2729	P21-activated kinase 1 promotes colorectal cancer survival by up-regulation of hypoxia-inducible factor-1Î±. Cancer Letters, 2013, 340, 22-29.	3.2	27
2730	A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development (Cambridge), 2013, 140, 2354-2364.	1.2	53
2731	Evaluation of everolimus in renal cell cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 1229-1240.	0.9	7
2732	Protein kinase inhibitors in melanoma. Expert Opinion on Pharmacotherapy, 2013, 14, 2195-2201.	0.9	9
2733	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene, 2013, 32, 3009-3018.	2.6	127

#	Article	IF	Citations
2734	Lessons learned from nextâ€generation sequencing in head and neck cancer. Head and Neck, 2013, 35, 454-463.	0.9	58
2735	Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis. Science Signaling, 2013, 6, ra21.	1.6	45
2736	Influence of DNA Repair on Nonlinear Dose-Responses for Mutation. Toxicological Sciences, 2013, 132, 87-95.	1.4	65
2737	A Two-Hybrid Approach to Identify Inhibitors of the RASâ€“RAF Interaction. The Enzymes, 2013, 33 Pt A, 213-248.	0.7	7
2738	Oncogene and non-oncogene addiction in inflammation-associated cancers. Future Oncology, 2013, 9, 561-573.	1.1	10
2739	In TCR-Stimulated T-cells, N-ras Regulates Specific Genes and Signal Transduction Pathways. PLoS ONE, 2013, 8, e63193.	1.1	7
2740	ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma. Experimental and Molecular Medicine, 2013, 45, e3-e3.	3.2	36
2741	Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncology Letters, 2013, 6, 1207-1212.	0.8	23
2742	Ras Chaperones. The Enzymes, 2013, 33 Pt A, 267-289.	0.7	8
2743	Mapping cancer cell metabolism with13C flux analysis: Recent progress and future challenges. Journal of Carcinogenesis, 2013, 12, 13.	2.5	29
2744	Regulation of Ras Exchange Factors and Cellular Localization of Ras Activation by Lipid Messengers in T Cells. Frontiers in Immunology, 2013, 4, 239.	2.2	58
2745	Adrenal incidentaloma and the Janus Kinase 2 V617F mutation: A case-based review of the literature. Indian Journal of Endocrinology and Metabolism, 2013, 17, 153.	0.2	1
2746	Insulin receptor-independent upregulation of cellular glucose uptake. International Journal of Obesity, 2013, 37, 146-153.	1.6	26
2747	ANRIL: Molecular Mechanisms and Implications in Human Health. International Journal of Molecular Sciences, 2013, 14, 1278-1292.	1.8	212
2748	Mouse Models of Gastric Cancer. Cancers, 2013, 5, 92-130.	1.7	78
2749	Oncogenicity of PAKs and Their Substrates. , 2013, , 23-51.		3
2750	Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission. Molecular and Cellular Biology, 2013, 33, 237-251.	1.1	94
2751	Ras, Raf, and MAP Kinase in Melanoma. Advances in Anatomic Pathology, 2013, 20, 217-226.	2.4	60

#	Article	IF	Citations
2752	The Environmental and Human Effects of Ptaquiloside-Induced Enzootic Bovine Hematuria: A Tumorous Disease of Cattle. Reviews of Environmental Contamination and Toxicology, 2013, 224, 53-95.	0.7	11
2753	Identifying the Ubiquitin Ligase Complex That Regulates the NF1 Tumor Suppressor and Ras. Cancer Discovery, 2013, 3, 880-893.	7.7	44
2754	Ras-mutant Cancer Cells Display B-Raf Binding to Ras That Activates Extracellular Signal-regulated Kinase and Is Inhibited by Protein Kinase A Phosphorylation. Journal of Biological Chemistry, 2013, 288, 27646-27657.	1.6	22
2755	The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer. Journal of International Medical Research, 2013, 41, 1473-1483.	0.4	13
2756	Phase II Trial of Cetuximab in Patients With Metastatic or Locally Advanced Soft Tissue or Bone Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 77-82.	0.6	18
2757	Dual effects of Ral-activated pathways on p27 localization and TGF-Î²2 signaling. Molecular Biology of the Cell, 2013, 24, 1812-1824.	0.9	11
2758	Light on the structural communication in Ras GTPases. Journal of Biomolecular Structure and Dynamics, 2013, 31, 142-157.	2.0	19
2759	RAS Mutations in Thyroid Cancer. Oncologist, 2013, 18, 926-932.	1.9	144
2761	Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. Oncologist, 2013, 18, 850-864.	1.9	82
2762	Rotational and Translational Dynamics of Ras Proteins upon Binding to Model Membrane Systems. ChemPhysChem, 2013, 14, 3698-3705.	1.0	23
2763	Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer. Cell Death and Disease, 2013, 4, e728-e728.	2.7	48
2764	Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene, 2013, 32, 4028-4033.	2.6	71
2765	Oligomerization of Rab/Effector Complexes in the Regulation of Vesicle Trafficking. Progress in Molecular Biology and Translational Science, 2013, 117, 579-614.	0.9	7
2766	Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia, 2013, 27, 1943-1946.	3.3	53
2767	Recent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association. The Enzymes, 2013, 34 Pt. B, 181-200.	0.7	12
2768	Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20593-20598.	3.3	86
2769	Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10213-10218.	3.3	70
2770	Ras GTPase activating (RasGAP) activity of the dual specificity GAP protein Rasal requires colocalization and C2 domain binding to lipid membranes. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 111-116.	3.3	41

#	Article	IF	Citations
2771	Not all antibodies are equal. Cancer Biology and Therapy, 2013, 14, 1075-1076.	1.5	0
2772	NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions. Blood, 2013, 121, 5203-5207.	0.6	54
2773	STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood, 2013, 122, 2453-2459.	0.6	128
2774	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. , 2013, , 183-232.		0
2775	Melanoma Mutagenesis and Aberrant Cell Signaling. Cancer Control, 2013, 20, 261-281.	0.7	29
2776	Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients. Experimental and Therapeutic Medicine, 2013, 5, 495-498.	0.8	13
2777	Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications. BMC Genomics, 2013, 14, 731.	1.2	12
2779	Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Management and Research, 2013, 5, 387.	0.9	17
2780	The genetics and biology of KRAS in lung cancer. Chinese Journal of Cancer, 2013, 32, 63-70.	4.9	76
2781	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. OncoTargets and Therapy, 2013, 6, 1761.	1.0	7
2782	Post-Transcriptional Regulation of Connexin43 in H-Ras-Transformed Cells. PLoS ONE, 2013, 8, e58500.	1.1	7
2783	Structural and Logical Analysis of a Comprehensive Hedgehog Signaling Pathway to Identify Alternative Drug Targets for Glioma, Colon and Pancreatic Cancer. PLoS ONE, 2013, 8, e69132.	1.1	23
2784	Study on the Apoptosis Mechanism Induced by T-2 Toxin. PLoS ONE, 2013, 8, e83105.	1.1	37
2785	Genetics of melanoma. Frontiers in Genetics, 2012, 3, 330.	1.1	27
2786	Ras. , 0, , 258-271.		0
2787	Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer. PLoS ONE, 2014, 9, e81126.	1.1	43
2788	Activating the Expression of Human K-rasG12D Stimulates Oncogenic Transformation in Transgenic Goat Fetal Fibroblast Cells. PLoS ONE, 2014, 9, e90059.	1.1	3
2789	Exercise Modulates Redox-Sensitive Small GTPase Activity in the Brain Microvasculature in a Model of Brain Metastasis Formation. PLoS ONE, 2014, 9, e97033.	1.1	15

#	Article	IF	Citations
2790	Long Intergenic Non-Coding RNAs (LincRNAs) Identified by RNA-Seq in Breast Cancer. PLoS ONE, 2014, 9, e103270.	1.1	45
2791	Synthetic Routes to Methylerythritol Phosphate Pathway Intermediates and Downstream Isoprenoids. Current Organic Chemistry, 2014, 18, 1050-1072.	0.9	10
2792	Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World Journal of Gastroenterology, 2014, 20, 9862.	1.4	18
2793	Inhibition of MAPKs, Myc/Max, NFÎºB, and Hypoxia Pathways by Phyllanthus Prevents Proliferation, Metastasis and Angiogenesis in Human Melanoma (MeWo) Cancer Cell Line. International Journal of Medical Sciences, 2014, 11, 564-577.	1.1	16
2794	MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget, 2014, 5, 5416-5427.	0.8	125
2795	The role of the MEK/ERK pathway in regulation of HDACI-induced senescence of transformed rat embryo fibroblasts. Cell and Tissue Biology, 2014, 8, 374-383.	0.2	0
2796	Elevated DDX21 regulates c-Jun activity and rRNA processing in human breast cancers. Breast Cancer Research, 2014, 16, 449.	2.2	57
2797	Ras Regulates SCFÎ²-TrCP Protein Activity and Specificity via Its Effector Protein NORE1A. Journal of Biological Chemistry, 2014, 289, 31102-31110.	1.6	19
2798	Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice. Cell Death and Disease, 2014, 5, e1241-e1241.	2.7	20
2799	Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium. Modern Pathology, 2014, 27, 675-680.	2.9	39
2800	Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death and Disease, 2014, 5, e1018-e1018.	2.7	160
2801	Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells. Cell Death and Disease, 2014, 5, e1548-e1548.	2.7	45
2802	Nanomicellar carriers for targeted delivery of anticancer agents. Therapeutic Delivery, 2014, 5, 53-68.	1.2	38
2803	Molecular Determinants of Congenital Heart Disease. , 2014, , 151-179.		1
2804	O-GlcNAcylation: The Sweet Side of the Cancer. Frontiers in Oncology, 2014, 4, 132.	1.3	97
2805	Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid. International Journal of Endocrinology, 2014, 2014, 1-7.	0.6	23
2806	Regulation of Ras Localization and Cell Transformation by Evolutionarily Conserved Palmitoyltransferases. Molecular and Cellular Biology, 2014, 34, 374-385.	1.1	23
2807	Metabolic vulnerability of KRAS-driven cancer cells. Molecular and Cellular Oncology, 2014, 1, e963445.	0.3	5

#	Article	IF	Citations
2808	Co-occurrence of second primary malignancy in patients with thyroid cancer. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 643-648.	0.2	20
2809	Oncogenic Ras stimulates Eiger/TNF exocytosis to promote growth. Development (Cambridge), 2014, 141, 4729-4739.	1.2	18
2810	The Biology and Clinical Development of MEK Inhibitors for Cancer. Drugs, 2014, 74, 2111-2128.	4.9	35
2811	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer, 2014, 120, 2684-2693.	2.0	105
2812	RNA-Seq Accurately Identifies Cancer Biomarker Signatures to Distinguish Tissue of Origin. Neoplasia, 2014, 16, 918-927.	2.3	37
2813	Thyroid Hormone Receptors and their Role in Cell Proliferation and Cancer. , 2014, , 1-17.		1
2814	Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3401-3406.	3.3	165
2815	<scp>MicroRNA</scp>â€30b functions as a tumour suppressor in human colorectal cancer by targeting <scp>KRAS</scp>, <scp>PIK3CD</scp> and <scp>BCL2</scp>. Journal of Pathology, 2014, 232, 415-427.	2.1	129
2816	Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm. Journal of Experimental and Clinical Cancer Research, 2014, 33, 91.	3.5	10
2817	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Research, 2014, 42, 13557-13572.	6.5	102
2818	Activated K-RAS and its effect on morphological appearance. Journal of Biochemistry, 2014, 156, 137-145.	0.9	5
2819	Phosphorylation at Ser-181 of Oncogenic KRAS Is Required for Tumor Growth. Cancer Research, 2014, 74, 1190-1199.	0.4	54
2820	Reoviral Therapy for Cancer. , 2014, , 185-198.		1
2822	Small G Proteins Dexras1 and RHES and Their Role in Pathophysiological Processes. International Journal of Cell Biology, 2014, 2014, 1-10.	1.0	19
2823	Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1851-7.	1.4	3
2824	Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma. ISRN Oncology, 2014, 2014, 1-4.	2.1	4
2825	Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells. Frontiers in Oncology, 2014, 4, 167.	1.3	56
2826	GI-4000 inKRASmutant cancers. Expert Opinion on Investigational Drugs, 2014, 23, 273-278.	1.9	4

#	Article	IF	Citations
2827	KRAS (G12D) Cooperates with AML1/ETO to Initiate a Mouse Model Mimicking Human Acute Myeloid Leukemia. Cellular Physiology and Biochemistry, 2014, 33, 78-87.	1.1	24
2828	KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. Journal of Thoracic Oncology, 2014, 9, 1513-1522.	0.5	108
2829	A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Science Translational Medicine, 2014, 6, 263ra161.	5.8	47
2830	Crystallization and preliminary X-ray analysis of RabX3, a tandem GTPase fromEntamoeba histolytica. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 933-937.	0.4	8
2831	Peptide chemistry applied to a new family of phenothiazine-containing inhibitors of human farnesyltransferase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3180-3185.	1.0	12
2832	Impeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven Tumorigenesis. Cell Reports, 2014, 7, 871-882.	2.9	66
2833	The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer. European Journal of Pharmaceutical Sciences, 2014, 51, 96-109.	1.9	49
2834	Ï‰-3 Polyunsaturated fatty acids and their metabolites as inhibitors of mammalian tumorigenesis. Phytochemistry Reviews, 2014, 13, 139-156.	3.1	14
2835	Is biomarker research advancing in the era of personalized medicine for head and neck cancer?. International Journal of Clinical Oncology, 2014, 19, 211-219.	1.0	21
2836	Protein Prenylation and Synaptic Plasticity: Implications for Alzheimerâ€™s Disease. Molecular Neurobiology, 2014, 50, 177-185.	1.9	49
2837	Adrenomedullin is a therapeutic target in colorectal cancer. International Journal of Cancer, 2014, 134, 2041-2050.	2.3	22
2838	Characterization of lovastatinâ€“docosahexaenoate anticancer properties against breast cancer cells. Bioorganic and Medicinal Chemistry, 2014, 22, 1899-1908.	1.4	20
2839	Molecular Therapies in Hepatocellular Carcinoma: What Can We Target?. Digestive Diseases and Sciences, 2014, 59, 1688-1697.	1.1	39
2840	Genetics of Adrenal Tumors. , 2014, , 313-321.		0
2841	Interactions between polycyclic aromatic hydrocarbons in complex mixtures and implications for cancer risk assessment. Toxicology, 2014, 321, 27-39.	2.0	132
2842	Fragment N2, a caspase-3-generated RasGAP fragment, inhibits breast cancer metastatic progression. International Journal of Cancer, 2014, 135, 242-247.	2.3	16
2843	Synthesis and Biological Evaluation of Novel Farnesylthiosalicylic Acid Derivatives for Cancer Treatment. Archiv Der Pharmazie, 2014, 347, 327-333.	2.1	5
2844	Genomics and Molecular Profiling of Lung Cancer. , 2014, , 193-211.		0

#	Article	IF	Citations
2845	Polycation-based nanoparticles for RNAi-mediated cancer treatment. Cancer Letters, 2014, 352, 66-80.	3.2	22
2846	Dietary acrylamide intake and the risk of colorectal cancer with specific mutations in KRAS and APC. Carcinogenesis, 2014, 35, 1032-1038.	1.3	31
2847	Therapeutic Targeting of Oncogenic Kâ€Ras by a Covalent Catalytic Site Inhibitor. Angewandte Chemie - International Edition, 2014, 53, 199-204.	7.2	262
2848	An FDA overview of rodent carcinogenicity studies of angiotensin II AT-1 receptor blockers: Pulmonary adenomas and carcinomas. Regulatory Toxicology and Pharmacology, 2014, 70, 555-563.	1.3	9
2849	Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras. Molecular Simulation, 2014, 40, 839-847.	0.9	27
2850	Ras-induced Epigenetic Inactivation of the RRAD (Ras-related Associated with Diabetes) Gene Promotes Glucose Uptake in a Human Ovarian Cancer Model. Journal of Biological Chemistry, 2014, 289, 14225-14238.	1.6	37
2851	Signaling Cascades Driving the Malignant Phenotype of Glioma Cells. , 2014, , 47-75.		2
2852	MicroRNAs 206 and 21 Cooperate To Promote RASâ€“Extracellular Signal-Regulated Kinase Signaling by Suppressing the Translation of RASA1 and SPRED1. Molecular and Cellular Biology, 2014, 34, 4143-4164.	1.1	51
2853	Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer. Advances in Cancer Research, 2014, 121, 331-382.	1.9	28
2854	Rapid Analysis of Protein Farnesyltransferase Substrate Specificity Using Peptide Libraries and Isoprenoid Diphosphate Analogues. ACS Chemical Biology, 2014, 9, 1726-1735.	1.6	30
2855	Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells. Cancer Letters, 2014, 353, 258-263.	3.2	11
2856	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. Gastroenterology, 2014, 147, 882-892.e8.	0.6	56
2857	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	1.9	94
2858	Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 989-992.	1.3	10
2859	Quercetin-3-O-glucuronide inhibits noradrenaline-promoted invasion of MDA-MB-231 human breast cancer cells by blocking Î²2-adrenergic signaling. Archives of Biochemistry and Biophysics, 2014, 557, 18-27.	1.4	64
2860	The impact of TP53 and RAS mutations on cerebellar glioblastomas. Experimental and Molecular Pathology, 2014, 97, 202-207.	0.9	16
2861	Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nature Communications, 2014, 5, 3729.	5.8	72
2864	Pairwise binding competition experiments for sorting hub-protein/effector interaction hierarchy and simultaneous equilibria. Journal of Biomolecular NMR, 2014, 60, 29-36.	1.6	2

#	Article	IF	Citations
2865	A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. Journal of Biomolecular NMR, 2014, 60, 11-14.	1.6	32
2866	Reduction-Sensitive Dual Functional Nanomicelles for Improved Delivery of Paclitaxel. Bioconjugate Chemistry, 2014, 25, 1689-1696.	1.8	26
2867	Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. Annals of Hematology, 2014, 93, 977-982.	0.8	6
2868	Identification of a farnesol analog as a Ras function inhibitor using both an in vivo Ras activation sensor and a phenotypic screening approach. Molecular and Cellular Biochemistry, 2014, 387, 177-186.	1.4	2
2869	Novel signaling axis for ROS generation during K-Ras-induced cellular transformation. Cell Death and Differentiation, 2014, 21, 1185-1197.	5.0	94
2870	Polymeric Micelles: Nanocarriers for Cancer-Targeted Drug Delivery. AAPS PharmSciTech, 2014, 15, 862-871.	1.5	270
2871	Clinicopathology and Genetic Profile of Synchronous Multiple Small Adenocarcinomas: Implication for Surgical Treatment of an Uncommon Lung Malignancy. Annals of Surgical Oncology, 2014, 21, 2555-2562.	0.7	18
2872	Is Targeted Therapy Feasible in Acute Myelogenous Leukemia?. Current Hematologic Malignancy Reports, 2014, 9, 118-127.	1.2	8
2873	Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management. Current Oncology Reports, 2014, 16, 389.	1.8	133
2874	Highly Sensitive KRAS Mutation Detection from Formalin-Fixed Paraffin-Embedded Biopsies and Circulating Tumour Cells Using Wild-Type Blocking Polymerase Chain Reaction and Sanger Sequencing. Molecular Diagnosis and Therapy, 2014, 18, 459-468.	1.6	3
2875	Function of RasGRP3 in the formation and progression of human breast cancer. Molecular Cancer, 2014, 13, 96.	7.9	23
2876	Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array. Journal of Translational Medicine, 2014, 12, 147.	1.8	6
2877	The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. Journal of Translational Medicine, 2014, 12, 55.	1.8	58
2878	Raman spectroscopy as an analytical tool for melanoma research. Clinical and Experimental Dermatology, 2014, 39, 636-645.	0.6	32
2879	Tumor Heterogeneity Revealed byKRAS,BRAF, andPIK3CAPyrosequencing:KRASandPIK3CAIntratumor Mutation Profile Differences and Their Therapeutic Implications. Human Mutation, 2014, 35, 329-340.	1.1	63
2880	Rat strain differences in levels and effects of chronic inflammation due to intratracheal instillation of quartz on lung tumorigenesis induced by DHPN. Experimental and Toxicologic Pathology, 2014, 66, 391-401.	2.1	8
2881	Emerging protein kinase inhibitors for non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2014, 19, 51-65.	1.0	22
2882	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. European Journal of Cancer, 2014, 50, 1819-1828.	1.3	68

#	Article	IF	Citations
2883	Genetics and epigenetics of adrenocortical tumors. Molecular and Cellular Endocrinology, 2014, 386, 67-84.	1.6	88
2884	In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8895-8900.	3.3	193
2885	Molecular targets of aspirin and cancer prevention. British Journal of Cancer, 2014, 111, 61-67.	2.9	167
2886	Permissiveness of Human Cancer Cells to Oncolytic Bovine Herpesvirus 1 Is Mediated in Part by KRAS Activity. Journal of Virology, 2014, 88, 6885-6895.	1.5	21
2887	Antihypertensive Effects of Extract from Flower Buds of Coreopsis tinctoria on Spontaneously Hypertensive Rats. Chinese Herbal Medicines, 2014, 6, 103-109.	1.2	18
2888	Update on Medullary Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2014, 43, 423-442.	1.2	28
2889	Sequenceâ€Specific DNA Alkylation Targeting for Kras Codonâ€...13 Mutation by Pyrroleâ€“Imidazole Polyamide secoâ€CBI Conjugates. Chemistry - A European Journal, 2014, 20, 1310-1317.	1.7	30
2890	Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. Cell Reports, 2014, 7, 86-93.	2.9	266
2891	Targeted therapy for melanoma: rational combinatorial approaches. Oncogene, 2014, 33, 1-9.	2.6	85
2892	Realgar bioleaching solution suppress ras excessive activation by increasing ROS in Caenorhabditis elegans. Archives of Pharmacal Research, 2014, 37, 390-398.	2.7	14
2894	Decoding RAS isoform and codon-specific signalling. Biochemical Society Transactions, 2014, 42, 742-746.	1.6	14
2895	BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies. Cancer Control, 2014, 21, 221-230.	0.7	80
2897	Induction of Ras by <scp>SAF</scp>â€1/<scp>MAZ</scp> through a feedâ€forward loop promotes angiogenesis in breast cancer. Cancer Medicine, 2015, 4, 224-234.	1.3	25
2898	Mouse models of colorectal cancer as preclinical models. BioEssays, 2015, 37, 909-920.	1.2	59
2899	Kinetic Hairpin Oligonucleotide Blockers for Selective Amplification of Rare Mutations. Scientific Reports, 2015, 4, 5921.	1.6	9
2901	Mammalian farnesyltransferase Î± subunit regulates vacuolar protein sorting-associated protein 4A (Vps4A) â€“ dependent intracellular trafficking through recycling endosomes. Biochemical and Biophysical Research Communications, 2015, 468, 580-586.	1.0	5
2903	Activation of MEK2 is sufficient to induce skin papilloma formation in transgenic zebrafish. Journal of Biomedical Science, 2015, 22, 102.	2.6	5
2904	Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecologic Oncology Research and Practice, 2015, 2, 1.	3.6	27

#	Article	IF	Citations
2905	Noonan syndromeâ€like disorder with loose anagen hair: A second case with neuroblastoma. American Journal of Medical Genetics, Part A, 2015, 167, 1902-1907.	0.7	14
2906	Craniosynostosis and Noonan syndrome with KRAS mutations: Expanding the phenotype with a case report and review of the literature. American Journal of Medical Genetics, Part A, 2015, 167, 2657-2663.	0.7	38
2907	MicroRNAâ€Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer. Drug Development Research, 2015, 76, 328-342.	1.4	9
2908	Selective Targeting of the KRAS Codonâ€...12 Mutation Sequence by Pyrroleâ€“Imidazole Polyamide secoâ€CBI Conjugates. Chemistry - A European Journal, 2015, 21, 14996-15003.	1.7	17
2909	Binding hotspots on K-ras: Consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis. Proteins: Structure, Function and Bioinformatics, 2015, 83, 898-909.	1.5	58
2910	Malignant Melanoma of Vulva and Vagina. Journal of Lower Genital Tract Disease, 2015, 19, 350-353.	0.9	58
2911	Characterization of Mouse Models of Early Pancreatic Lesions Induced by Alcohol and Chronic Pancreatitis. Pancreas, 2015, 44, 882-887.	0.5	25
2912	Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer through GTPase Signaling Pathways. Cancer Growth and Metastasis, 2015, 8s1, CGM.S29407.	3.5	14
2913	A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA. Theranostics, 2015, 5, 818-833.	4.6	103
2914	Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience, 2015, 9, 582.	0.6	7
2915	A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation. OncoTargets and Therapy, 2015, 8, 1061.	1.0	17
2917	Cancer Metabolism and Drug Resistance. Metabolites, 2015, 5, 571-600.	1.3	130
2918	Oncolytic virotherapy for head and neck cancer: current research and future developments. Oncolytic Virotherapy, 2015, 4, 83.	6.0	5
2919	pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins. PLoS Computational Biology, 2015, 11, e1004469.	1.5	31
2920	Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PLoS ONE, 2015, 10, e0137595.	1.1	9
2921	Design and Characterization of Bioengineered Cancer-Like Stem Cells. PLoS ONE, 2015, 10, e0141172.	1.1	1
2922	Preclinical Murine Models for Lung Cancer: Clinical Trial Applications. BioMed Research International, 2015, 2015, 1-17.	0.9	113
2923	Oxidative Stress Responses and NRF2 in Human Leukaemia. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-7.	1.9	48

#	Article	IF	Citations
2924	Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy. Critical Reviews in Oncogenesis, 2015, 20, 357-371.	0.2	8
2925	Elucidation of changes in molecular signalling leading to increased cellular transformation in oncogenically progressed human bronchial epithelial cells exposed to radiations of increasing LET. Mutagenesis, 2015, 30, 685-694.	1.0	11
2926	Enhancing FTS (Salirasib) efficiency via combinatorial treatment. Biology of the Cell, 2015, 107, 130-143.	0.7	7
2927	Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. Journal of Investigative Dermatology, 2015, 135, 2475-2483.	0.3	51
2928	RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data. Current Treatment Options in Oncology, 2015, 16, 33.	1.3	2
2929	Emerging roles of hypoxiaâ€inducible factors and reactive oxygen species in cancer and pluripotent stem cells. Kaohsiung Journal of Medical Sciences, 2015, 31, 279-286.	0.8	59
2930	High Pressure NMR Methods for Characterizing Functional Substates of Proteins. Sub-Cellular Biochemistry, 2015, 72, 179-197.	1.0	17
2931	Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 433-438.e2.	0.2	27
2932	Chaperone-mediated specificity in Ras and Rap signaling. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 194-202.	2.3	9
2933	Hematologic toxicity assessment in solid tumor patients treated with cetuximab: A pooled analysis of 18 randomized controlled trials. International Journal of Cancer, 2015, 136, 936-944.	2.3	13
2934	Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nature Genetics, 2015, 47, 142-150.	9.4	101
2935	Erk2 Phosphorylation of Drp1 Promotes Mitochondrial Fission and MAPK-Driven Tumor Growth. Molecular Cell, 2015, 57, 537-551.	4.5	509
2936	The Use of Dipeptide Derivatives of 5-Aminolaevulinic Acid Promotes Their Entry to Tumor Cells and Improves Tumor Selectivity of Photodynamic Therapy. Molecular Cancer Therapeutics, 2015, 14, 440-451.	1.9	15
2937	Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene, 2015, 34, 2672-2680.	2.6	52
2938	Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). Targeted Oncology, 2015, 10, 365-373.	1.7	24
2939	Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK. Clinical Cancer Research, 2015, 21, 739-748.	3.2	121
2940	Spontaneously hyperactive MEK-Erk pathway mediates paradoxical facilitation of cell proliferation in mild hypoxia. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 640-646.	1.1	9
2941	The oncolytic virus, pelareorep, as a novel anticancer agent: a review. Investigational New Drugs, 2015, 33, 761-774.	1.2	52

#	Article	IF	Citations
2942	Caenorhabditis elegansas a model for cancer research. Molecular and Cellular Oncology, 2015, 2, e975027.	0.3	35
2943	Involvement of RalB in the effect of geranylgeranyltransferase I on glioma cell migration and invasion. Clinical and Translational Oncology, 2015, 17, 477-485.	1.2	14
2944	Malignancy in Noonan syndrome and related disorders. Clinical Genetics, 2015, 88, 516-522.	1.0	38
2945	KRAS mutation screening by chip-based DNA hybridization â€“ a further step towards personalized oncology. Analyst, The, 2015, 140, 2747-2754.	1.7	6
2946	Novel Candidate Key Drivers in the Integrative Network of Genes, MicroRNAs, Methylations, and Copy Number Variations in Squamous Cell Lung Carcinoma. BioMed Research International, 2015, 2015, 1-11.	0.9	31
2947	Pancreatic cancer: current management and treatment strategies. Postgraduate Medical Journal, 2015, 91, 601-607.	0.9	22
2948	Molecular Inhibitors of Growth Signals. , 2015, , 163-242.		0
2949	SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in Î²-catenin-mutated tumors. Scientific Reports, 2015, 5, 8155.	1.6	5
2950	KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases. Journal of Vascular and Interventional Radiology, 2015, 26, 1102-1111.	0.2	43
2951	Short-term effects on antioxidant enzymes and long-term genotoxic and carcinogenic potential of CuO nanoparticles compared to bulk CuO and ionic copper in mussels Mytilus galloprovincialis. Marine Environmental Research, 2015, 111, 107-120.	1.1	80
2952	Non-Genomic Androgen Action Regulates Proliferative/Migratory Signaling in Stromal Cells. Frontiers in Endocrinology, 2014, 5, 225.	1.5	30
2953	Quaternized chitosan particles as ion exchange supports for label-free DNA detection using PNA probe and MALDI-TOF mass spectrometry. Carbohydrate Polymers, 2015, 131, 80-89.	5.1	9
2954	The Function of Embryonic Stem Cell-expressed RAS (E-RAS), a Unique RAS Family Member, Correlates with Its Additional Motifs and Its Structural Properties. Journal of Biological Chemistry, 2015, 290, 15892-15903.	1.6	15
2955	Molecular Biology of Urothelial Cancer. , 2015, , 563-590.		0
2956	The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Molecular Cancer Research, 2015, 13, 1265-1273.	1.5	72
2957	Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nature Medicine, 2015, 21, 946-954.	15.2	179
2958	Targeted Therapies for Melanoma. , 2015, , 1529-1541.		0
2959	Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Reports, 2015, 12, 511-524.	2.9	39

#	Article	IF	Citations
2960	Cost Estimates and Economic Implications of Expanded RAS Testing in Metastatic Colorectal Cancer. Oncologist, 2015, 20, 14-18.	1.9	13
2961	Associations of positive epidermal growth factor receptor expression and K-RAS gene mutations with various clinicopathological parameters and survival of colorectal carcinoma patients. Biomarkers and Genomic Medicine, 2015, 7, 1-7.	0.2	2
2962	Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 641-651.	1.2	8
2963	Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic. Current Opinion in Virology, 2015, 13, 11-16.	2.6	19
2964	Expression of KRASG12V in Zebrafish Gills Induces Hyperplasia and CXCL8-Associated Inflammation. Zebrafish, 2015, 12, 221-229.	0.5	7
2965	Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors. Clinical Cancer Research, 2015, 21, 1305-1312.	3.2	40
2966	Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 349-356.	1.2	27
2967	Ras transformation results in cleavage of reticulon protein Nogo-B that is associated with impairment of IFN response. Cell Cycle, 2015, 14, 2301-2310.	1.3	14
2968	Molecularly Targeted Therapies in Nonâ€“Small-Cell Lung Cancer Annual Update 2014. Journal of Thoracic Oncology, 2015, 10, S1-S63.	0.5	119
2969	Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis. Cancer Cell, 2015, 27, 561-573.	7.7	173
2970	Novel In Vivo model for combinatorial fluorescence labeling in mouse prostate. Prostate, 2015, 75, 988-1000.	1.2	5
2971	K-State automaton burst detection model based on KOS: Emerging trends in cancer field. Journal of Information Science, 2015, 41, 16-26.	2.0	3
2972	Detection of Kâ€ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer, 2015, 121, 2271-2280.	2.0	209
2973	Cancer across the tree of life: cooperation and cheating in multicellularity. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140219.	1.8	303
2974	Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nature Medicine, 2015, 21, 1514-1520.	15.2	93
2975	Stereoselective Total Synthesis of (â^')-Depudecin. Organic Letters, 2015, 17, 5558-5561.	2.4	9
2976	The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery. World Journal of Surgery, 2015, 39, 2289-2299.	0.8	16
2977	In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging. Analytical and Bioanalytical Chemistry, 2015, 407, 8321-8331.	1.9	29

#	Article	IF	Citations
2978	Peeling away the layers of ubiquitin signaling complexities with synthetic ubiquitinâ€“protein conjugates. Current Opinion in Chemical Biology, 2015, 28, 57-65.	2.8	20
2979	Ras Transformation Overrides a Proliferation Defect Induced by Tpm3.1 Knockout. Cellular and Molecular Biology Letters, 2015, 20, 626-46.	2.7	9
2980	Exploitation of pleiotropic actions of statins by using tumour-targeted delivery systems. Journal of Microencapsulation, 2015, 32, 619-631.	1.2	15
2981	The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. Future Medicinal Chemistry, 2015, 7, 269-289.	1.1	60
2982	Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. Case Reports in Oncology, 2015, 8, 83-87.	0.3	24
2983	The double trouble of metabolic diseases: the diabetesâ€“cancer link. Molecular Biology of the Cell, 2015, 26, 3129-3139.	0.9	20
2984	Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEÎ´ Inhibitors. Biophysical Journal, 2015, 109, 1163-1168.	0.2	15
2985	Chemical biology of compounds obtained from screening using disease models. Archives of Pharmacal Research, 2015, 38, 1651-1660.	2.7	4
2986	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 2015, 39, 1367-1374.	0.4	48
2987	K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell, 2015, 163, 1237-1251.	13.5	195
2988	Early recognition of lung cancer by integrin targeted imaging in <scp>K</scp>â€ras mouse model. International Journal of Cancer, 2015, 137, 1107-1118.	2.3	10
2989	Defining an optimal surgical strategy for synchronous colorectal liver metastases: staged versus simultaneous resection?. ANZ Journal of Surgery, 2015, 85, 829-833.	0.3	14
2990	An electrochemical method to assay human 8-oxoguanine DNA glycosylase 1. Electrochemistry Communications, 2015, 50, 51-54.	2.3	9
2991	Protein Prenylation: Enzymes, Therapeutics, and Biotechnology Applications. ACS Chemical Biology, 2015, 10, 51-62.	1.6	171
2992	Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	2.3	126
2993	The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?. Critical Reviews in Oncology/Hematology, 2015, 93, 190-202.	2.0	24
2994	Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling. Drug Discovery Today, 2015, 20, 267-276.	3.2	47
2995	The Differential Palmitoylation States of Nâ€Ras and Hâ€Ras Determine Their Distinct Golgi Subcompartment Localizations. Journal of Cellular Physiology, 2015, 230, 610-619.	2.0	42

#	Article	IF	Citations
2996	Autophagy regulates tissue overgrowth in a context-dependent manner. Oncogene, 2015, 34, 3369-3376.	2.6	37
2997	Triple-negative breast cancer: investigating potential molecular therapeutic target. Expert Opinion on Therapeutic Targets, 2015, 19, 55-75.	1.5	44
2998	miR-98 functions as a tumor suppressor in salivary adenoid cystic carcinomas. OncoTargets and Therapy, 2016, 9, 1777.	1.0	20
2999	Kirsten Ras* oncogene: Significance of its discovery in human cancer research. Oncotarget, 2016, 7, 46717-46733.	0.8	57
3000	Chronic Inflammation in Skin Malignancies. Journal of Molecular Signaling, 2016, 11, 2.	0.5	41
3001	Dual-function nanocarriers with interfacial drug-interactive motifs for improved delivery of chemotherapeutic agents. , 2016, , 367-394.		0
3002	Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World Journal of Clinical Oncology, 2016, 7, 340.	0.9	7
3003	RAS and BRAF in metastatic colorectal cancer management. Journal of Gastrointestinal Oncology, 2016, 7, 687-704.	0.6	56
3004	Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World Journal of Methodology, 2016, 6, 25.	1.1	101
3005	Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. ELife, 2016, 5, .	2.8	191
3006	Mapping the functional versatility and fragility of Ras GTPase signaling circuits through in vitro network reconstitution. ELife, 2016, 5, .	2.8	12
3007	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS ONE, 2016, 11, e0149099.	1.1	60
3008	Toxicology of DNA Adducts Formed Upon Human Exposure to Carcinogens. Advances in Molecular Toxicology, 2016, 10, 293-360.	0.4	15
3009	Systems psychopharmacology: A network approach to developing novel therapies. World Journal of Psychiatry, 2016, 6, 66.	1.3	15
3010	Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci. Pediatric Blood and Cancer, 2016, 63, 1704-1712.	0.8	46
3011	Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1). Journal of Biological Chemistry, 2016, 291, 15641-15652.	1.6	14
3012	Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation. Molecular Biology of the Cell, 2016, 27, 1026-1039.	0.9	32
3013	Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2Î± Kinase Levels in NRAS(Q61) Mutant Cells. Journal of Investigative Dermatology, 2016, 136, 2041-2048.	0.3	28

#	Article	IF	Citations
3014	Benign thyroid nodules with <scp>RAS</scp> mutation grow faster. Clinical Endocrinology, 2016, 84, 736-740.	1.2	29
3015	Clinical Report: Cognitive decline in a patient with Cardiofaciocutaneous syndrome. American Journal of Medical Genetics, Part A, 2016, 170, 1251-1256.	0.7	1
3016	Cell type-specific properties and environment shape tissue specificity of cancer genes. Scientific Reports, 2016, 6, 20707.	1.6	64
3017	Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. Scientific Reports, 2016, 6, 38273.	1.6	24
3018	Global proteomic analysis of prenylated proteins in Plasmodium falciparum using an alkyne-modified isoprenoid analogue. Scientific Reports, 2016, 6, 38615.	1.6	63
3019	Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression. Biomarkers, 2016, 22, 1-7.	0.9	18
3021	Biomarker in Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 156-164.	1.0	35
3022	Could drugs inhibiting the mevalonate pathway also target cancer stem cells?. Drug Resistance Updates, 2016, 25, 13-25.	6.5	80
3023	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 2016, 24, 1150-1158.	3.7	114
3024	Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. Pathology Research and Practice, 2016, 212, 598-603.	1.0	12
3025	Insights into K-Ras 4B regulation by post-translational lysine acetylation. Biological Chemistry, 2016, 397, 1071-1085.	1.2	28
3026	Gallic acid as a selective anticancer agent that induces apoptosis in SMMC-7721 human hepatocellular carcinoma cells. Oncology Letters, 2016, 11, 150-158.	0.8	71
3027	The Tumor-suppressive Small GTPase DiRas1 Binds the Noncanonical Guanine Nucleotide Exchange Factor SmgGDS and Antagonizes SmgGDS Interactions with Oncogenic Small GTPases. Journal of Biological Chemistry, 2016, 291, 6534-6545.	1.6	24
3028	Geranylgeranyl Diphosphate Synthase Modulates Fetal Lung Branching Morphogenesis Possibly through Controlling K-Ras Prenylation. American Journal of Pathology, 2016, 186, 1454-1465.	1.9	10
3029	Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis. Leukemia, 2016, 30, 1542-1551.	3.3	40
3030	KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future. Colorectal Cancer, 2016, 5, 73-80.	0.8	0
3031	EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer. Oncology Letters, 2016, 11, 2371-2378.	0.8	14
3032	Prospective analysis of association between statins and pancreatic cancer risk in the Womenâ€™s Health Initiative. Cancer Causes and Control, 2016, 27, 415-423.	0.8	16

#	Article	IF	Citations
3033	Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Science, 2016, 107, 1373-1379.	1.7	527
3034	Selective Gas-Phase Oxidation and Localization of Alkylated Cysteine Residues in Polypeptide Ions via Ion/Ion Chemistry. Journal of Proteome Research, 2016, 15, 3139-3146.	1.8	9
3035	Nutrient restriction in combinatory therapy of tumors. Molecular Biology, 2016, 50, 362-378.	0.4	4
3036	Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy. American Journal of Medical Genetics, Part A, 2016, 170, 195-201.	0.7	30
3037	Review structureâ€•and dynamicsâ€based computational design of anticancer drugs. Biopolymers, 2016, 105, 2-9.	1.2	11
3038	Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14402-14407.	3.3	81
3039	Regulation of K-Ras4B Membrane Binding by Calmodulin. Biophysical Journal, 2016, 111, 113-122.	0.2	44
3040	RASopathien. Medizinische Genetik, 2016, 28, 15-38.	0.1	3
3041	Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prevention Research, 2016, 9, 895-905.	0.7	286
3042	Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. Journal of Molecular Biology, 2016, 428, 4723-4735.	2.0	30
3043	The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therapeutic Advances in Gastroenterology, 2016, 9, 861-886.	1.4	44
3044	Low expression of PKCÎ± and high expression of KRAS predict poor prognosis in patients with colorectal cancer. Oncology Letters, 2016, 12, 1655-1660.	0.8	18
3045	Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. Cancer Informatics, 2016, 15, CIN.S34506.	0.9	13
3046	The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma. Human Genomics, 2016, 10, 40.	1.4	26
3047	Therapeutic Approaches to RAS Mutation. Cancer Journal (Sudbury, Mass), 2016, 22, 165-174.	1.0	14
3048	DNA Repair and Its Influence on Points of Departure for Alkylating Agent Genotoxicity. , 2016, , 67-82.		3
3049	Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell International, 2016, 16, 34.	1.8	8
3050	Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. British Journal of Cancer, 2016, 115, 59-65.	2.9	133

#	Article	IF	Citations
3051	Ras signaling through RASSF proteins. Seminars in Cell and Developmental Biology, 2016, 58, 86-95.	2.3	79
3052	Paper-based microreactor array for rapid screening of cell signaling cascades. Lab on A Chip, 2016, 16, 2911-2920.	3.1	20
3053	Microfluidics in the selection of affinity reagents for the detection of cancer: paving a way towards future diagnostics. Lab on A Chip, 2016, 16, 2759-2774.	3.1	19
3054	Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase). Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1559-1567.	1.9	32
3055	Current targeted therapies in the treatment of advanced colorectal cancer: a review. Therapeutic Advances in Medical Oncology, 2016, 8, 276-293.	1.4	72
3056	TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway. BMC Cancer, 2016, 16, 240.	1.1	46
3057	Hybridization-Induced Aggregation Technology for Practical Clinical Testing. Journal of Molecular Diagnostics, 2016, 18, 546-553.	1.2	2
3058	Heterogeneity of Hepatocellular Carcinoma. Translational Bioinformatics, 2016, , 371-398.	0.0	0
3059	Investigation of MTH1 activity via mismatch-based DNA chain elongation. Analytica Chimica Acta, 2016, 905, 66-71.	2.6	8
3060	Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancerâ˜†. Lung Cancer, 2016, 92, 29-34.	0.9	44
3061	Activating the Adaptive Immune System. , 2016, , 813-848.		0
3062	A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clinical Cancer Research, 2016, 22, 2368-2376.	3.2	17
3063	Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. Journal of Molecular Diagnostics, 2016, 18, 51-67.	1.2	42
3064	Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. Cell Death and Disease, 2016, 7, e2105-e2105.	2.7	45
3065	NRAS mutant melanoma: an overview for the clinician for melanoma management. Melanoma Management, 2016, 3, 47-59.	0.1	12
3066	The use of Gene Ontology terms and KEGG pathways for analysis and prediction of oncogenes. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 2725-2734.	1.1	72
3067	G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology, 2016, 37, 6823-6830.	0.8	38
3068	Crystal Structure Analysis of Wild Type and Fast Hydrolyzing Mutant of EhRabX3, a Tandem Ras Superfamily GTPase from Entamoeba histolytica. Journal of Molecular Biology, 2016, 428, 41-51.	2.0	13

#	Article	IF	Citations
3069	Interplay between Oncogenes and Tumor Suppressor Genes in Human Disease. , 2016, , 411-422.		0
3070	Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis. Biophysical Journal, 2016, 110, 1125-1138.	0.2	122
3071	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine, 2016, 10, 53-68.	1.0	56
3072	Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. Journal of International Medical Research, 2016, 44, 89-98.	0.4	6
3073	Synthetic isoprenoid analogues for the study of prenylated proteins: Fluorescent imaging and proteomic applications. Bioorganic Chemistry, 2016, 64, 59-65.	2.0	11
3074	KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. Molecular Diagnosis and Therapy, 2016, 20, 65-74.	1.6	7
3075	Metastatic melanoma treatment: Combining old and new therapies. Critical Reviews in Oncology/Hematology, 2016, 98, 242-253.	2.0	64
3076	Mechanisms Linking Colorectal Cancer to the Consumption of (Processed) Red Meat: A Review. Critical Reviews in Food Science and Nutrition, 2016, 56, 2747-2766.	5.4	138
3077	Applications of Genetics in Endocrinology. , 2016, , 41-68.e8.		1
3078	Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release. Oncogene, 2016, 35, 771-782.	2.6	35
3079	Twenty-six-week oral carcinogenicity study of 3-monochloropropane-1,2-diol in CB6F1-rasH2 transgenic mice. Archives of Toxicology, 2017, 91, 453-464.	1.9	11
3080	KRAS mutation analysis by nextâ€generation sequencing in endoscopic ultrasoundâ€guided sampling for solid liver masses. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 154-162.	1.4	9
3081	The effect of forced expression of mutated Kâ€RAS gene on gastrointestinal cancer cell lines and the IGFâ€1R targeting therapy. Molecular Carcinogenesis, 2017, 56, 515-526.	1.3	6
3082	KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Medical Oncology, 2017, 34, 26.	1.2	94
3083	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. British Journal of Cancer, 2017, 116, 575-583.	2.9	73
3084	Conformational SERS Classification of Kâ€Ras Point Mutations for Cancer Diagnostics. Angewandte Chemie - International Edition, 2017, 56, 2381-2385.	7.2	46
3085	Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation. Scientific Reports, 2017, 7, 41147.	1.6	19
3086	Quantification of spatiotemporal patterns of Ras isoform expression during development. Scientific Reports, 2017, 7, 41297.	1.6	45

#	Article	IF	Citations
3087	EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth. Nature Communications, 2017, 8, 14688.	5.8	18
3088	Conformational SERS Classification of KâERas Point Mutations for Cancer Diagnostics. Angewandte Chemie, 2017, 129, 2421-2425.	1.6	7
3089	KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer. Clinical and Translational Oncology, 2017, 19, 884-890.	1.2	11
3090	Review of metabolic pathways activated in cancer cells as determined through isotopic labeling and network analysis. Metabolic Engineering, 2017, 43, 113-124.	3.6	52
3091	Underlying Mechanisms for Distant Metastasis - Molecular Biology. Visceral Medicine, 2017, 33, 11-20.	0.5	100
3092	Evaluation of in vivo mutagenesis for assessing the health risk of air pollutants. Genes and Environment, 2017, 39, 16.	0.9	16
3093	Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants. Proteins: Structure, Function and Bioinformatics, 2017, 85, 1618-1632.	1.5	44
3094	Mitochondrial determinants of cancer health disparities. Seminars in Cancer Biology, 2017, 47, 125-146.	4.3	68
3095	Genotype and phenotype spectrum of NRAS germline variants. European Journal of Human Genetics, 2017, 25, 823-831.	1.4	36
3096	MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1. Cell Death and Differentiation, 2017, 24, 1253-1262.	5.0	38
3097	Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Scientific Reports, 2017, 7, 1502.	1.6	20
3098	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. Molecular Cancer Therapeutics, 2017, 16, 2315-2323.	1.9	8
3099	Genetic alterations in Japanese extrahepatic biliary tract cancer. Oncology Letters, 2017, 14, 877-884.	0.8	16
3100	Isoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents. Amino Acids, 2017, 49, 1469-1485.	1.2	16
3101	Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM). Journal of Biological Chemistry, 2017, 292, 11601-11609.	1.6	80
3102	Sensitive detection of cancer gene based on a nicking-mediated RCA of circular DNA nanomachine. Sensors and Actuators B: Chemical, 2017, 251, 692-698.	4.0	23
3103	Anticancer effects of oleuropein. BioFactors, 2017, 43, 517-528.	2.6	76
3104	RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?. Advances in Experimental Medicine and Biology, 2017, 962, 321-332.	0.8	16

#	Article	IF	Citations
3105	Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs. Clinical and Translational Radiation Oncology, 2017, 2, 63-68.	0.9	20
3107	Mixed-Probe Simulation and Probe-Derived Surface Topography Map Analysis for Ligand Binding Site Identification. Journal of Chemical Theory and Computation, 2017, 13, 1851-1861.	2.3	23
3109	KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice. International Journal of Cancer, 2017, 140, 1860-1869.	2.3	24
3110	Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. Critical Reviews in Oncology/Hematology, 2017, 110, 1-12.	2.0	67
3111	Targeting Aberrant Signaling Pathways. , 2017, , 133-150.		1
3112	Ataxia-telangiectasia mutated interactor regulates head and neck cancer metastasis via KRas expression. Oral Oncology, 2017, 66, 100-107.	0.8	4
3113	KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Scientific Reports, 2017, 7, 39721.	1.6	62
3114	HOP expression is regulated by p53 and RAS and characteristic of a cancer gene signature. Cell Stress and Chaperones, 2017, 22, 213-223.	1.2	6
3115	Influence of isoform-specific Ras lipidation motifs on protein partitioning and dynamics in model membrane systems of various complexity. Biological Chemistry, 2017, 398, 547-563.	1.2	25
3116	Re-calculating! Navigating through the osteosarcoma treatment roadblock. Pharmacological Research, 2017, 117, 54-64.	3.1	19
3117	Mechanical mismatch between Ras transformed and untransformed epithelial cells. Soft Matter, 2017, 13, 8483-8491.	1.2	15
3118	Variation and Functional Impact of Neanderthal Ancestry in Western Asia. Genome Biology and Evolution, 2017, 9, 3516-3524.	1.1	14
3119	Molecular Profiling of Odontogenic Tumors - Pilot Study. Balkan Journal of Dental Medicine, 2017, 21, 112-115.	0.2	2
3120	An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nature Communications, 2017, 8, 347.	5.8	151
3121	Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1â€“MAPK Interaction. Cancer Research, 2017, 77, 4328-4341.	0.4	70
3122	Variable expression of molecular markers in juvenile nasopharyngeal angiofibroma. Journal of Laryngology and Otology, 2017, 131, 752-759.	0.4	11
3123	The small G protein RAS2 is involved in the metabolic compensation of the circadian clock in the circadian model Neurospora crassa. Journal of Biological Chemistry, 2017, 292, 14929-14939.	1.6	10
3124	Development of Substrateâ€Derived Sirtuin Inhibitors with Potential Anticancer Activity. ChemMedChem, 2017, 12, 1703-1714.	1.6	16

#	Article	IF	Citations
3125	From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy. European Journal of Medicinal Chemistry, 2017, 142, 229-243.	2.6	26
3126	Cross-generational effects of alcohol dependence in humans on HRAS and TP53 methylation in offspring. Epigenomics, 2017, 9, 1189-1203.	1.0	18
3127	Macrophage-Dependent Cytoplasmic Transfer during Melanoma Invasion InÂVivo. Developmental Cell, 2017, 43, 549-562.e6.	3.1	98
3128	Development of Pyridazinone Chemotypes Targeting the PDEÎ´ Prenyl Binding Site. Chemistry - A European Journal, 2017, 23, 6083-6093.	1.7	26
3129	Reduced risk of apoptosis: mechanisms of stress responses. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 265-283.	2.2	35
3130	Current molecular profile of juvenile nasopharyngeal angiofibroma: First comprehensive study from India. Laryngoscope, 2017, 127, E100-E106.	1.1	19
3131	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene, 2017, 36, 1339-1350.	2.6	39
3132	Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. Cancer Letters, 2017, 384, 86-93.	3.2	27
3133	The sensitivity of head and neck carcinoma cells to statins is related to the expression of their Ras expression status, and statinâ€induced apoptosis is mediated via suppression of the Ras/<scp>ERK</scp> and Ras/<scp>mTOR</scp> pathways. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 222-234.	0.9	34
3134	Role of the HTLV-1 viral factors in the induction of apoptosis. Biomedicine and Pharmacotherapy, 2017, 85, 334-347.	2.5	19
3135	Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies. Clinical Drug Investigation, 2017, 37, 121-134.	1.1	9
3136	Blocking SIAH Proteolysis, an Important K-RAS Vulnerability, to Control and Eradicate K-RAS-Driven Metastatic Cancer. , 2017, , 213-232.		4
3137	K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. European Journal of Medicinal Chemistry, 2017, 125, 299-314.	2.6	39
3138	Oncogenomic disruptions in arsenic-induced carcinogenesis. Oncotarget, 2017, 8, 25736-25755.	0.8	47
3139	NRAS-mutant melanoma: current challenges and future prospect. OncoTargets and Therapy, 2017, Volume 10, 3941-3947.	1.0	122
3140	Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial. Marine Drugs, 2017, 15, 122.	2.2	96
3141	Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Oncotarget, 2017, 8, 36750-36760.	0.8	3
3142	The Interplay between Oncogenic Signaling Networks and Mitochondrial Dynamics. Antioxidants, 2017, 6, 33.	2.2	31

#	Article	IF	Citations
3143	Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells. Frontiers in Immunology, 2017, 8, 799.	2.2	21
3144	The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma. BioMed Research International, 2017, 2017, 1-12.	0.9	9
3145	Chemopreventive Strategies for Inflammation-Related Carcinogenesis: Current Status and Future Direction. International Journal of Molecular Sciences, 2017, 18, 867.	1.8	23
3146	The clinical impact of serrated colorectal polyps. Clinical Epidemiology, 2017, Volume 9, 113-125.	1.5	28
3147	Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa. BMC Evolutionary Biology, 2017, 17, 182.	3.2	14
3148	Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer. Oncotarget, 2017, 8, 35138-35153.	0.8	22
3149	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. Biomedicines, 2017, 5, 10.	1.4	10
3150	Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget, 2017, 8, 3980-4000.	0.8	218
3151	The Molecular Biology of Head and Neck Cancer. , 2017, , 243-256.		1
3152	Targeting Melanoma with Cancer-Killing Viruses. The Open Virology Journal, 2017, 11, 28-47.	1.8	8
3153	ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. , 2018, 187, 45-60.		123
3154	Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. Scientific Reports, 2018, 8, 6076.	1.6	74
3155	Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo. Free Radical Research, 2018, 52, 661-671.	1.5	13
3156	Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. Journal of Immunotherapy, 2018, 41, 141-150.	1.2	21
3157	Transcriptomic approach: A promising tool for rapid screening nanomaterial-mediated toxicity in the marine bivalve Mytilus edulis â€"Application to copper oxide nanoparticles. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2018, 205, 26-33.	1.3	15
3158	Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell, 2018, 172, 578-589.e17.	13.5	834
3159	High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Analytical Biochemistry, 2018, 548, 44-52.	1.1	48
3160	Baicalin induces cellular senescence in human colon cancer cells via upregulation of DEPP and the activation of Ras/Raf/MEK/ERK signaling. Cell Death and Disease, 2018, 9, 217.	2.7	87

#	Article	IF	Citations
3161	Wogonoside induces depalmitoylation and translocation of <scp>PLSCR</scp>1 and Nâ€<scp>RAS</scp> in primary acute myeloid leukaemia cells. Journal of Cellular and Molecular Medicine, 2018, 22, 2117-2130.	1.6	9
3162	Metabolic stress regulates ERK activity by controlling KSRâ€RAF heterodimerization. EMBO Reports, 2018, 19, 320-336.	2.0	11
3163	(Z)-2-(3,4-Dichlorophenyl)-3-(1H-Pyrrol-2-yl)Acrylonitrile Exhibits Selective Antitumor Activity in Breast Cancer Cell Lines via the Aryl Hydrocarbon Receptor Pathway. Molecular Pharmacology, 2018, 93, 168-177.	1.0	20
3164	Ras enhances TGF-Î² signaling by decreasing cellular protein levels of its type II receptor negative regulator SPSB1. Cell Communication and Signaling, 2018, 16, 10.	2.7	14
3165	Mouse Models of Pancreatic Exocrine Cancer. , 2018, , 509-538.		0
3166	Effect of diet and gut environment on the gastrointestinal formation of N -nitroso compounds: A review. Nitric Oxide - Biology and Chemistry, 2018, 73, 66-73.	1.2	81
3167	Biomarker-driven and molecular targeted therapies for colorectal cancers. Seminars in Oncology, 2018, 45, 124-132.	0.8	9
3168	Emerging molecular predictive and prognostic factors in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2021-2039.	0.6	8
3169	PI3K: A Crucial Piece in the RAS Signaling Puzzle. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031450.	2.9	38
3170	Genetics and genomics of breast fibroadenomas. Journal of Clinical Pathology, 2018, 71, 381-387.	1.0	27
3171	Molecular Markers and Mutational Analysis. , 2018, , 295-312.		1
3172	From Ras to Rap and Back, a Journey of 35 Years. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031468.	2.9	16
3173	Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031526.	2.9	3
3174	Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population. Endocrinology, Diabetes and Metabolism, 2018, 1, e00040.	1.0	4
3175	Targeting the BDNF/TrkB pathway for the treatment of tumors (Review). Oncology Letters, 2019, 17, 2031-2039.	0.8	54
3176	Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Annals of Pancreatic Cancer, 2018, 1, 26-26.	1.2	3
3177	Biogenic synthesis of AgNPs using Artemisia oliveriana extract and their biological activities for an effective treatment of lung cancer. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 1047-1058.	1.9	35
3178	Active Kâ€<scp>RAS</scp> induces the coherent rotation of epithelial cells: A model for collective cell invasion in vitro. Cancer Science, 2018, 109, 4045-4055.	1.7	13

#	Article	IF	Citations
3179	Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity. ACS Medicinal Chemistry Letters, 2018, 9, 1230-1234.	1.3	65
3180	KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. Oncotarget, 2018, 9, 26279-26290.	0.8	20
3181	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. Advances in Experimental Medicine and Biology, 2018, 1110, 113-131.	0.8	19
3182	UBIAD1 suppresses the proliferation of bladder carcinoma cells by regulating H-Ras intracellular trafficking via interaction with the C-terminal domain of H-Ras. Cell Death and Disease, 2018, 9, 1170.	2.7	12
3183	Water Distribution within Wild-Type NRas Protein and Q61 Mutants during Unrestrained QM/MM Dynamics. Biophysical Journal, 2018, 115, 1417-1430.	0.2	10
3184	Ionizing Radiation as a Carcinogen. , 2018, , 183-225.		1
3185	Methionine 170 is an Environmentally Sensitive Membrane Anchor in the Disordered HVR of K-Ras4B. Journal of Physical Chemistry B, 2018, 122, 10086-10096.	1.2	22
3186	FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 224.	3.5	31
3187	MEK inhibitors for the treatment of NRAS mutant melanoma. Drug Design, Development and Therapy, 2018, Volume 12, 2553-2565.	2.0	37
3188	N-(3-oxo-acyl) homoserine lactone induced germ cell apoptosis and suppressed the over-activated RAS/MAPK tumorigenesis via mitochondrial-dependent ROS in C. elegans. Apoptosis: an International Journal on Programmed Cell Death, 2018, 23, 626-640.	2.2	21
3189	Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma. Journal of Cancer, 2018, 9, 1-12.	1.2	4
3190	RNAa and Vector-Mediated Overexpression of DIRAS1 Suppresses Tumor Growth and Migration in Renal Cell Carcinoma. Molecular Therapy - Nucleic Acids, 2018, 12, 845-853.	2.3	8
3191	Identification of a novel HRAS variant and its association with papillary thyroid carcinoma. Oncology Letters, 2018, 15, 4511-4516.	0.8	8
3192	Design, Synthesis, and Evaluation of Novel p-(Methylthio)styryl Substituted Quindoline Derivatives as Neuroblastoma RAS (NRAS) Repressors via Specific Stabilizing the RNA G-Quadruplex. Journal of Medicinal Chemistry, 2018, 61, 6629-6646.	2.9	26
3193	Oncogenic N-Ras Stimulates SRF-Mediated Transactivation via H3 Acetylation at Lysine 9. BioMed Research International, 2018, 2018, 1-9.	0.9	7
3194	Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer. Cellular Physiology and Biochemistry, 2018, 47, 1556-1564.	1.1	20
3195	Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia. Tumor Biology, 2018, 40, 101042831877147.	0.8	4
3196	Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 2018, 7, 192.	1.0	27

#	Article	IF	Citations
3197	Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme. Medical Oncology, 2018, 35, 122.	1.2	22
3198	Src Cooperates with Oncogenic Ras in Tumourigenesis via the JNK and PI3K Pathways in Drosophila epithelial Tissue. International Journal of Molecular Sciences, 2018, 19, 1585.	1.8	13
3199	De novo lipogenesis represents a therapeutic target in mutant Kras nonâ€small cell lung cancer. FASEB Journal, 2018, 32, 7018-7027.	0.2	33
3200	Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Cancer Biology and Therapy, 2018, 19, 871-874.	1.5	18
3201	Ras Suppresses TXNIP Expression by Restricting Ribosome Translocation. Molecular and Cellular Biology, 2018, 38, .	1.1	12
3202	Analysis of Gene Expression Variance in Schizophrenia Using Structural Equation Modeling. Frontiers in Molecular Neuroscience, 2018, 11, 192.	1.4	20
3203	Multistage Carcinogenesis: Cell and Animal Models. , 2018, , 11-35.		2
3204	A New Strategy to Control and Eradicate â€œUndruggableâ€•Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers, 2018, 10, 142.	1.7	17
3205	Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEÎ´. Journal of Physical Chemistry B, 2018, 122, 7503-7513.	1.2	12
3206	An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 511-519.	1.1	25
3207	Dissecting the mechanisms and molecules underlying the potential carcinogenicity of red and processed meat in colorectal cancer (CRC): an overview on the current state of knowledge. Infectious Agents and Cancer, 2018, 13, 3.	1.2	63
3208	A highlight on Sonic hedgehog pathway. Cell Communication and Signaling, 2018, 16, 11.	2.7	276
3210	Poorly differentiated osteoclast-like giant cell variant of cutaneous squamous cell carcinoma: Uncovering its mutational landscape through massive parallel sequencing. Pathology Research and Practice, 2018, 214, 1898-1903.	1.0	2
3211	Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC). Wspolczesna Onkologia, 2018, 22, 75-85.	0.7	3
3212	GTPases Rac1 and Ras Signaling from Endosomes. Progress in Molecular and Subcellular Biology, 2018, 57, 65-105.	0.9	10
3213	Mollusca: Disseminated Neoplasia in Bivalves and the p53 Protein Family. , 2018, , 953-979.		5
3214	A multi-functional polymeric carrier for simultaneous positron emission tomography imaging and combination therapy. Acta Biomaterialia, 2018, 75, 312-322.	4.1	30
3215	Im Kampf gegen Krebs: Polyoxometallate als nÃchste Generation metallhaltiger Medikamente. Angewandte Chemie, 2019, 131, 3008-3029.	1.6	48

#	Article	IF	Citations
3216	Polyoxometalates as Potential Nextâ€Generation Metallodrugs in the Combat Against Cancer. Angewandte Chemie - International Edition, 2019, 58, 2980-2999.	7.2	403
3217	Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics. Journal of Chemical Information and Modeling, 2019, 59, 3955-3967.	2.5	23
3218	p21cip1/waf1 Coordinates Autophagy, Proliferation and Apoptosis in Response to Metabolic Stress. Cancers, 2019, 11, 1112.	1.7	31
3219	A Guanidylâ€Based Bivalent Peptidomimetic Inhibits Kâ€Ras Prenylation and Association with câ€Raf. Chemistry - A European Journal, 2019, 25, 13531-13536.	1.7	7
3220	Identification of lysine methylation in the core GTPase domain by GoMADScan. PLoS ONE, 2019, 14, e0219436.	1.1	6
3221	mTOR and other effector kinase signals that impact T cell function and activity. Immunological Reviews, 2019, 291, 134-153.	2.8	53
3222	Perspectives on arsenic toxicity, carcinogenicity and its systemic remediation strategies. Environmental Technology and Innovation, 2019, 16, 100462.	3.0	91
3223	Regulation of CD137 expression through Kâ€Ras signaling in pancreatic cancer cells. Cancer Communications, 2019, 39, 1-11.	3.7	14
3224	CRISPR-Cas9â€“mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15635-15644.	3.3	100
3225	RAS mutations in human cancers: Roles in precision medicine. Seminars in Cancer Biology, 2019, 59, 23-35.	4.3	85
3226	Application of immune repertoire sequencing in cancer immunotherapy. International Immunopharmacology, 2019, 74, 105688.	1.7	7
3227	Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention. F1000Research, 2019, 8, 590.	0.8	6
3228	Oncogenic Ras mutant causes the hyperactivation of NFâ€ÎºB via acceleration of its transcriptional activation. Molecular Oncology, 2019, 13, 2493-2510.	2.1	13
3229	Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas. IScience, 2019, 21, 1-18.	1.9	12
3230	SIRT2 and Lysine Fatty Acylation Regulate the Activity of RalB and Cell Migration. ACS Chemical Biology, 2019, 14, 2014-2023.	1.6	25
3231	In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors. Journal of Controlled Release, 2019, 311-312, 245-256.	4.8	28
3232	KRAS rs7973450 A>G increases neuroblastoma risk in Chinese children: a four-center case-control study . OncoTargets and Therapy, 2019, Volume 12, 7289-7295.	1.0	4
3233	Probing the Conformational and Energy Landscapes of KRAS Membrane Orientation. Journal of Physical Chemistry B, 2019, 123, 8644-8652.	1.2	40

#	Article	IF	Citations
3234	Estimating the Frequency of Single Point Driver Mutations across Common Solid Tumours. Scientific Reports, 2019, 9, 13452.	1.6	6
3235	WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation. Nature Communications, 2019, 10, 295.	5.8	32
3236	Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell, 2019, 176, 1113-1127.e16.	13.5	74
3237	Activated MEK/ERK Pathway Drives Widespread and Coordinated Overexpression of UHRF1 and DNMT1 in Cancer cells. Scientific Reports, 2019, 9, 907.	1.6	26
3238	Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR in Biomedicine, 2019, 32, e4112.	1.6	89
3239	Regulation of RhoB Gene Expression during Tumorigenesis and Aging Process and Its Potential Applications in These Processes. Cancers, 2019, 11, 818.	1.7	19
3240	miRâ€‘338â€‘3p inhibits A549 lung cancer cell proliferation and invasion by targeting AKT and Î²â€‘catenin signaling pathways. Molecular Medicine Reports, 2019, 20, 33-40.	1.1	10
3241	AKT and ERK dual inhibitors: The way forward?. Cancer Letters, 2019, 459, 30-40.	3.2	144
3242	The significance of gene mutations across eight major cancer types. Mutation Research - Reviews in Mutation Research, 2019, 781, 88-99.	2.4	15
3243	Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues. International Journal of Molecular Sciences, 2019, 20, 2167.	1.8	472
3244	Emerging relationships between papillary proliferation of the endometrium and endometrial carcinoma: evidence from an immunohistochemical and molecular analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 201-209.	1.4	7
3245	NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children. Experimental Hematology and Oncology, 2019, 8, 11.	2.0	16
3246	Crystal structure and function of Rbj: A constitutively GTP-bound small G protein with an extra DnaJ domain. Protein and Cell, 2019, 10, 760-763.	4.8	6
3247	Biological Hallmarks of Cancer in Alzheimerâ€™s Disease. Molecular Neurobiology, 2019, 56, 7173-7187.	1.9	42
3248	A 3D Multiscale Model to Explore the Role of EGFR Overexpression in Tumourigenesis. Bulletin of Mathematical Biology, 2019, 81, 2323-2344.	0.9	2
3249	Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. World Journal of Gastroenterology, 2019, 25, 808-823.	1.4	28
3250	Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility. Oncology Reviews, 2019, 13, 389.	0.8	9
3251	High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Reports, 2019, 27, 631-647.e5.	2.9	9

#	Article	IF	Citations
3252	Cancer drug development: The missing links. Experimental Biology and Medicine, 2019, 244, 663-689.	1.1	72
3253	Cancer Genetics. , 2019, , 79-86.		1
3254	Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases. BMC Cancer, 2019, 19, 143.	1.1	21
3255	Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines. Scientific Reports, 2019, 9, 2111.	1.6	14
3256	Targeting epigenetics for cancer therapy. Archives of Pharmacal Research, 2019, 42, 159-170.	2.7	114
3257	Replication stress: Driver and therapeutic target in genomically instable cancers. Advances in Protein Chemistry and Structural Biology, 2019, 115, 157-201.	1.0	15
3258	Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors. Cancers, 2019, 11, 2010.	1.7	38
3259	RAS as Supporting Actor in Breast Cancer. Frontiers in Oncology, 2019, 9, 1199.	1.3	46
3260	Establishment and characterization of transformed goat primary cells by expression of simian virus 40 large T antigen for orf virus propagations. PLoS ONE, 2019, 14, e0226105.	1.1	6
3261	Establishment and Characterization of 10 Human Pancreatic Cancer Cell Lines Including a HER2 Overexpressed Cell Line. Pancreas, 2019, 48, 1285-1293.	0.5	3
3262	Small GTPases: Structure, biological function and its interaction with nanoparticles. Asian Journal of Pharmaceutical Sciences, 2019, 14, 30-39.	4.3	41
3263	Targeting Metalloenzymes for Therapeutic Intervention. Chemical Reviews, 2019, 119, 1323-1455.	23.0	181
3264	Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system. Acta Pharmaceutica Sinica B, 2019, 9, 167-176.	5.7	94
3265	RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis. Clinica Chimica Acta, 2019, 489, 254-260.	0.5	26
3266	Dynamics of Membrane-Bound G12V-KRAS from Simulations and Single-Molecule FRET in Native Nanodiscs. Biophysical Journal, 2019, 116, 179-183.	0.2	56
3267	The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. Molecular Therapy - Nucleic Acids, 2019, 14, 301-317.	2.3	24
3268	A QTL on chromosome 3q23 influences processing speed in humans. Genes, Brain and Behavior, 2019, 18, e12530.	1.1	1
3269	Flavopiridol's effects on metastasis in KRAS mutant lung adenocarcinoma cells. Journal of Cellular Biochemistry, 2019, 120, 5628-5635.	1.2	11

#	Article	IF	Citations
3270	A somatic activating NRAS variant associated with kaposiform lymphangiomatosis. Genetics in Medicine, 2019, 21, 1517-1524.	1.1	85
3271	Molecular features of pleomorphic xanthoastrocytoma. Human Pathology, 2019, 86, 38-48.	1.1	18
3272	Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-Î²) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis. Seminars in Cancer Biology, 2019, 54, 72-79.	4.3	32
3273	Blocking Ras inhibition as an antitumor strategy. Seminars in Cancer Biology, 2019, 54, 91-100.	4.3	35
3274	RAS-mediated oncogenic signaling pathways in human malignancies. Seminars in Cancer Biology, 2019, 54, 1-13.	4.3	115
3275	Statistical methods for genome-wide association studies. Seminars in Cancer Biology, 2019, 55, 53-60.	4.3	59
3276	Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. Wiener Medizinische Wochenschrift, 2019, 169, 314-322.	0.5	5
3277	Characterisation of HRas local signal transduction networks using engineered site-specific exchange factors. Small GTPases, 2020, 11, 371-383.	0.7	9
3278	Targeting Ras signaling in AML: RALB is a small GTPase with big potential. Small GTPases, 2020, 11, 39-44.	0.7	8
3279	Activating MRAS mutations cause Noonan syndrome associated with hypertrophic cardiomyopathy. Human Molecular Genetics, 2020, 29, 1772-1783.	1.4	30
3280	Coptisine suppresses proliferation and inhibits metastasis in human pancreatic cancer PANC-1 cells. Journal of Asian Natural Products Research, 2020, 22, 452-463.	0.7	10
3281	Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene, 2020, 39, 1167-1184.	2.6	61
3282	Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia, 2020, 34, 799-810.	3.3	58
3283	NRAS associated RASopathy and embryonal rhabdomyosarcoma. American Journal of Medical Genetics, Part A, 2020, 182, 195-200.	0.7	9
3284	Ras isoforms selectively regulate antigen-specific immune response. Cytokine, 2020, 126, 154914.	1.4	6
3285	A Real-World Study in Advanced Nonâ€“Small Cell Lung Cancer with KRAS Mutations. Translational Oncology, 2020, 13, 329-335.	1.7	24
3286	Acute PFOA exposure promotes epigenomic alterations in mouse kidney tissues. Toxicology Reports, 2020, 7, 125-132.	1.6	50
3287	An Activating Mutation in ERK Causes Hyperplastic Tumors in a scribble Mutant Tissue in Drosophila. Genetics, 2020, 214, 109-120.	1.2	9

#	Article	IF	Citations
3288	In-silico design of peptide inhibitors of K-Ras target in cancer disease. Journal of Biomolecular Structure and Dynamics, 2020, 38, 5488-5499.	2.0	31
3289	Development and Analytical Validation of a DNA Dual-Strand Approach for the US Food and Drug Administrationâ€“Approved Next-Generation Sequencingâ€“Based Praxis Extended RAS Panel for Metastatic Colorectal Cancer Samples. Journal of Molecular Diagnostics, 2020, 22, 159-178.	1.2	3
3290	Extracellular matrix-cell interactions: Focus on therapeutic applications. Cellular Signalling, 2020, 66, 109487.	1.7	85
3291	Oncogenic K-ras Induces Mitochondrial OPA3 Expression to Promote Energy Metabolism in Pancreatic Cancer Cells. Cancers, 2020, 12, 65.	1.7	18
3292	Therapeutic potential of targeting mitochondrial dynamics in cancer. Biochemical Pharmacology, 2020, 182, 114282.	2.0	78
3293	Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer. Medicine (United States), 2020, 99, e22407.	0.4	10
3294	Enhancement of leukemiaâ€like phenotypes in Drosophila mxc mutant larvae due to activation of the RASâ€MAP kinase cascade possibly via downâ€regulation of DEâ€cadherin. Genes To Cells, 2020, 25, 757-769.	0.5	4
3295	Wound Healing Driver Gene and Therapeutic Development: Political and Scientific Hurdles. Advances in Wound Care, 2021, 10, 415-435.	2.6	9
3296	Molecular Profiling of Advanced Malignancies: A Community Oncology Network Experience and Review of Literature. Frontiers in Medicine, 2020, 7, 314.	1.2	3
3297	Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterology Report, 2020, 8, 179-191.	0.6	60
3298	BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterology Report, 2020, 8, 192-205.	0.6	59
3299	A Dinucleotide Deletion in the CD24 Gene Is a Potential Risk Factor for Colorectal Cancer. American Surgeon, 2020, 86, 480-485.	0.4	3
3300	Photosensitizers Based on G-Quadruplex Ligand for Cancer Photodynamic Therapy. Genes, 2020, 11, 1340.	1.0	25
3301	Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations. Bioinformatics, 2021, 37, 1367-1375.	1.8	6
3302	Cell Motility and Cancer. Cancers, 2020, 12, 2177.	1.7	19
3303	The Plasma Membrane as a Competitive Inhibitor and Positive Allosteric Modulator of KRas4B Signaling. Biophysical Journal, 2020, 118, 1129-1141.	0.2	40
3304	Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer. Cancers, 2020, 12, 2091.	1.7	9
3305	Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy. Frontiers in Oncology, 2020, 10, 1155.	1.3	3

#	Article	IF	Citations
3306	Development of Noonan syndrome by deregulation of allosteric SOS autoactivation. Journal of Biological Chemistry, 2020, 295, 13651-13663.	1.6	6
3307	Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Seminars in Cancer Biology, 2022, 83, 452-471.	4.3	64
3308	Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. MedComm, 2020, 1, 121-128.	3.1	16
3309	Intracellular Iron Concentration and Distribution Have Multiple Effects on Cell Cycle Events. , 2020, , .		0
3310	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. Frontiers in Molecular Biosciences, 2020, 7, 172.	1.6	25
3311	NMR in integrated biophysical drug discovery for RAS: past, present, and future. Journal of Biomolecular NMR, 2020, 74, 531-554.	1.6	9
3312	Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature. Diagnostics, 2020, 10, 582.	1.3	21
3313	A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway. Scientific Reports, 2020, 10, 13978.	1.6	13
3314	Precision medicine for adjuvant chemotherapy of resected colorectal cancer. Annals of Gastroenterological Surgery, 2020, 4, 635-645.	1.2	5
3315	TRP Channels and Small GTPases Interplay in the Main Hallmarks of Metastatic Cancer. Frontiers in Pharmacology, 2020, 11, 581455.	1.6	26
3316	Mutational analysis revealed 97 key cancer metastasis genes from extracellular vesicles associated with patient survival. Meta Gene, 2020, 26, 100781.	0.3	0
3317	Isoprenylcysteine Carboxyl Methyltransferase and Its Substrate Ras Are Critical Players Regulating TLR-Mediated Inflammatory Responses. Cells, 2020, 9, 1216.	1.8	14
3318	Identification of a RAS-activating TMEM87Aâ€“RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4072-4079.	3.2	13
3319	Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nature Communications, 2020, 11, 1800.	5.8	25
3320	Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. Journal of Experimental and Clinical Cancer Research, 2020, 39, 100.	3.5	44
3321	Spontaneous Tumor Regression in Tasmanian Devils Associated with RASL11A Activation. Genetics, 2020, 215, 1143-1152.	1.2	22
3322	Pleiotropic Roles of Calmodulin in the Regulation of KRas and Rac1 GTPases: Functional Diversity in Health and Disease. International Journal of Molecular Sciences, 2020, 21, 3680.	1.8	9
3323	Targeting Kras^{g12c}â€mutant cancer with a mutationâ€specific inhibitor. Journal of Internal Medicine, 2020, 288, 183-191.	2.7	56

#	Article	IF	Citations
3324	The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease. Journal of Biological Chemistry, 2020, 295, 5152-5162.	1.6	19
3325	Personalized Medicineâ€"Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers, 2020, 12, 812.	1.7	30
3326	Lignin-graft-PLGA drug-delivery system improves efficacy of MEK1/2 inhibitors in triple-negative breast cancer cell line. Nanomedicine, 2020, 15, 981-1000.	1.7	19
3327	Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety. Science Signaling, 2020, 13, .	1.6	23
3328	Oncolytic virotherapy in hepatoâ€bilioâ€pancreatic cancer: The key to breaking the log jam?. Cancer Medicine, 2020, 9, 2943-2959.	1.3	12
3329	Insights into the New Cancer Therapy through Redox Homeostasis and Metabolic Shifts. Cancers, 2020, 12, 1822.	1.7	28
3330	FARP1 boosts CDC42 activity from integrin Î±vÎ²5 signaling and correlates with poor prognosis of advanced gastric cancer. Oncogenesis, 2020, 9, 13.	2.1	14
3331	Loss of Histone Locus Bodies in the Mature Hemocytes of Larval Lymph Gland Result in Hyperplasia of the Tissue in mxc Mutants of Drosophila. International Journal of Molecular Sciences, 2020, 21, 1586.	1.8	9
3332	Investigation of possible effects of apigenin, sorafenib and combined applications on apoptosis and cell cycle in hepatocellular cancer cells. Gene, 2020, 737, 144428.	1.0	22
3333	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. Trends in Cancer, 2020, 6, 111-129.	3.8	9
3334	Role of rat sarcoma virus mutations in cancer and potential target for cancer therapy. Future Science OA, 2020, 6, FSO455.	0.9	3
3335	Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS^{G12C}. ChemMedChem, 2020, 15, 827-832.	1.6	20
3336	ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis. Cancers, 2020, 12, 909.	1.7	5
3337	Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS^{G12C} Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 2020, 63, 6679-6693.	2.9	300
3338	In Silico Analysis Identifies Differently Expressed lncRNAs as Novel Biomarkers for the Prognosis of Thyroid Cancer. Computational and Mathematical Methods in Medicine, 2020, 2020, 1-10.	0.7	25
3339	Human Papillomaviruses and Epsteinâ€"Barr Virus Interactions in Colorectal Cancer: A Brief Review. Pathogens, 2020, 9, 300.	1.2	17
3340	Establishment and characterization of 18 human colorectal cancer cell lines. Scientific Reports, 2020, 10, 6801.	1.6	2
3341	Activation of the RAS/ERK signaling pathway by RASAL1 and its clinical significance in squamous cell carcinomas of the tongue. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2020, 32, 400-405.	0.2	0

#	Article	IF	Citations
3342	Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nature Communications, 2020, 11, 1806.	5.8	62
3343	Investigation of EGFR/pi3k/Akt signaling pathway in seminomas. Biotechnic and Histochemistry, 2021, 96, 125-137.	0.7	5
3344	Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 3135-3144.	0.7	15
3345	RasGRP1 induces autophagy and transformation-associated changes in primary human keratinocytes. Translational Oncology, 2021, 14, 100880.	1.7	3
3346	Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway. European Journal of Medicinal Chemistry, 2021, 211, 113006.	2.6	13
3347	NOD-like receptor signaling pathway activation: A potential mechanism underlying negative effects of benzo(Î±)pyrene on zebrafish. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2021, 240, 108935.	1.3	7
3348	Cellâ€permeable CaaXâ€peptides affect Kâ€Ras downstream signaling and promote cell death in cancer cells. FEBS Journal, 2021, 288, 2911-2929.	2.2	10
3349	MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia. Oncotarget, 0, 7, 42683-42697.	0.8	72
3350	Regulation of the Small GTPase Ras and Its Relevance to Human Disease. Methods in Molecular Biology, 2021, 2262, 19-43.	0.4	4
3351	Mechanisms of Cetuximab Resistance and How to Overcome It. , 2021, , 21-51.		1
3352	LAMB1 Is Related to the T Stage and Indicates Poor Prognosis in Gastric Cancer. Technology in Cancer Research and Treatment, 2021, 20, 153303382110049.	0.8	12
3353	Chemical Approach Toward Controlling of Transient Protein Interactions. , 2021, , 77-96.		0
3354	DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer. Clinical Epigenetics, 2021, 13, 38.	1.8	8
3355	Embryonic Expression of NrasG 12 D Leads to Embryonic Lethality and Cardiac Defects. Frontiers in Cell and Developmental Biology, 2021, 9, 633661.	1.8	4
3356	Cigarette smoke-induced alterations in blood: A review of research on DNA methylation and gene expression.. Experimental and Clinical Psychopharmacology, 2021, 29, 116-135.	1.3	23
3357	Bilateral adrenal haematoma complicated by adrenal insufficiency in a patient treated with bevacizumab. BMJ Case Reports, 2021, 14, e239689.	0.2	3
3358	A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. Journal of Pancreatic Cancer, 2021, 7, 8-19.	1.6	8
3359	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica, 2021, , .	1.7	10

#	Article	IF	Citations
3360	Review of 10,11-Dehydrocurvularin: Synthesis, Structural Diversity, Bioactivities and Mechanisms. Mini-Reviews in Medicinal Chemistry, 2022, 22, 836-847.	1.1	3
3361	Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis. Current Drug Targets, 2021, 22, 722-733.	1.0	3
3362	Syntheses and Antitumor Properties of Furoxan Derivatives. Current Organic Chemistry, 2021, 25, 757-778.	0.9	3
3363	Targeting BRAF and RAS in Colorectal Cancer. Cancers, 2021, 13, 2201.	1.7	29
3364	Identification of cancer driver genes using Sleeping Beauty transposon mutagenesis. Cancer Science, 2021, 112, 2089-2096.	1.7	8
3365	40 Years of RASâ€"A Historic Overview. Genes, 2021, 12, 681.	1.0	24
3366	Ras, TrkB, and ShcA Protein Expression Patterns in Pediatric Brain Tumors. Journal of Clinical Medicine, 2021, 10, 2219.	1.0	0
3367	Crystal structure of 3-(2-chloro-benzyl)-7-[4-(2-chloro-benzyl)-piperazin-1-yl]-5,6,8-trifluoro-3H-quinazolin-4-one, C₂₆H₂₁Cl₂F₃N₄O. Zeitschrift Fur Kristallographie - New Crystal Structures, 2021, 236, 815-817.	0.1	1
3368	Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanomaâ€"A Retrospective Single-Institute Study. Cancers, 2021, 13, 3302.	1.7	3
3369	Role of endolysosome function in iron metabolism and brain carcinogenesis. Seminars in Cancer Biology, 2021, 76, 74-85.	4.3	21
3370	Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract. BMC Cancer, 2021, 21, 677.	1.1	6
3371	Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. American Journal of Clinical Dermatology, 2021, 22, 639-651.	3.3	15
3372	Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers, 2021, 13, 2875.	1.7	14
3373	Yorkie drives Ras-induced tumor progression by microRNA-mediated inhibition of cellular senescence. Science Signaling, 2021, 14, .	1.6	6
3374	NF1-Dependent Transcriptome Regulation in the Melanocyte Lineage and in Melanoma. Journal of Clinical Medicine, 2021, 10, 3350.	1.0	2
3375	Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification. Frontiers in Molecular Biosciences, 2021, 8, 707439.	1.6	13
3376	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 3453.	1.7	6
3377	Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations. Saudi Journal of Biological Sciences, 2021, 28, 3735-3740.	1.8	8

#	Article	IF	Citations
3378	Copper nanoparticles green synthesis and characterization as anticancer potential in breast cancer cells (MCF7) derived from Prunus nepalensis phytochemicals. Materials Today: Proceedings, 2022, 49, 3501-3509.	0.9	27
3379	Äá»˜T BIáº¾N KRAS TRONG UNG THÆ¯ PHá»”I KHÃ”NG Táº¾ BÃ€O NHá»Ž Táº¡I Bá»†NH Vlá»†N K. Y Hoc Viet Nam, 2021, 501, .	0.2	1
3380	Inhibition of Calcineurin/NFAT Signaling Blocks Oncogenic H-Ras Induced Autophagy in Primary Human Keratinocytes. Frontiers in Cell and Developmental Biology, 2021, 9, 720111.	1.8	2
3381	Combined intermittent fasting and ERK inhibition enhance the anti-tumor effects of chemotherapy via the GSK3Î²-SIRT7 axis. Nature Communications, 2021, 12, 5058.	5.8	28
3382	Clinical and Cytometric Study of Immune Involvement in a Heterogeneous Cohort of Subjects With RASopathies and mTORopathies. Frontiers in Pediatrics, 2021, 9, 703613.	0.9	5
3383	Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and populationâ€based research. American Journal of Human Biology, 2022, 34, e23665.	0.8	4
3384	Antimetastatic Effects of Curcumin in Oral and Gastrointestinal Cancers. Frontiers in Pharmacology, 2021, 12, 668567.	1.6	18
3385	Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies. Nature Communications, 2021, 12, 5581.	5.8	8
3386	RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball. Genes, 2021, 12, 1556.	1.0	10
3387	Cholangiocarcinoma Therapeutics: An Update. Current Cancer Drug Targets, 2021, 21, 457-475.	0.8	5
3388	Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	6
3389	Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients. Bioengineered, 2021, 12, 5099-5109.	1.4	2
3391	Immunotherapy of cancer. , 2021, , 141-174.		0
3393	Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. Cancer, 1995, 75, 1520-1526.	2.0	53
3395	Multigenic Control of Skin Tumour Development in Mice. Novartis Foundation Symposium, 1996, 197, 156-180.	1.2	3
3397	Cell Cycle Activation in Neurons. , 2005, , 1-21.		1
3398	Structural Principles of Ras Interaction with Regulators and Effectors. , 2006, , 45-66.		1
3399	Global Effects of Ras Signaling on the Genetic Program in Mammalian Cells. , 2006, , 169-198.		7

#	Article	IF	Citations
3400	Ras Signaling in C. Elegans. , 2006, , 199-225.		1
3401	The Origin of Cancer. , 2004, 122, 1-22.		3
3402	Molecular Events in Follicular Thyroid Tumors. , 2004, 122, 85-106.		41
3403	Molecular mechanisms of human carcinogenesis. , 2006, , 321-349.		24
3404	Abnormalities of chromatin in tumor cells. , 2006, , 25-47.		16
3405	Differentiation and De-Differentiationâ€"Neuronal Cell-Cycle Regulation During Development and Age-Related Neurodegenerative Disorders. , 2008, , 157-213.		5
3406	Receptor Tyrosine Kinase Alterations in AML â€“ Biology and Therapy. Cancer Treatment and Research, 2009, 145, 85-108.	0.2	11
3407	The Use of Creâ€"loxP Technology and Inducible Systems to Generate Mouse Models of Cancer. , 2012, , 17-36.		7
3408	Ras-Superfamily GTP-ases in Ovarian Cancer. Cancer Treatment and Research, 2009, 149, 229-240.	0.2	12
3409	Somatic Genetic Development in Epithelial Ovarian Cancer. , 2009, , 215-246.		1
3410	Mechanisms of Dietary Fat-Induced Colon Cancer Promotion. , 1995, , 157-171.		1
3411	PCR and Cancer Diagnostics: Detection and Characterization of Single Point Mutations in Oncogenes and Antioncogenes. , 1994, , 369-394.		3
3412	Molecular Genetics of Pancreatic Carcinoma. , 1998, , 3-20.		3
3413	Role of Polypeptide Growth Factors and Their Receptors in Human Pancreatic Cancer. , 1998, , 21-32.		3
3414	Monoterpenes as Regulators of Malignant Cell Proliferation. Advances in Experimental Medicine and Biology, 1996, 401, 137-146.	0.8	31
3415	Alkylation Repair in Human Tissues. , 1990, 53, 437-452.		5
3416	Mammals II: Downstream of RAS and Actin-Cytoskeleton. , 1996, , 139-180.		2
3417	The c-myb proto-oncogene: a novel target for human gene therapy. Cancer Treatment and Research, 1996, 84, 93-112.	0.2	7

#	Article	IF	Citations
3418	Regulation of the Ras-MAPK Pathway at the Level of Ras and Raf. , 2002, 24, 49-66.		2
3419	Molecular mechanisms of metal toxicity and carcinogenesis. , 2001, , 3-9.		60
3420	Evolution of Secondary Hematologic Disorders: PREMDSâ†'MDSâ†'sAML. Cancer Treatment and Research, 2001, , 185-230.	0.2	8
3421	Biology of Non-Hodgkinâ€™s Lymphoma. Cancer Treatment and Research, 2001, 104, 149-200.	0.2	5
3422	Cholesterol, Cholesterogenesis and Cancer. Advances in Experimental Medicine and Biology, 1995, 369, 155-166.	0.8	17
3423	Oncogene expression in cervical cancer. Cancer Treatment and Research, 1994, 70, 43-51.	0.2	1
3424	Genetic Aspects of Cancer. , 1993, 21, 321-376.		13
3425	Cytokines and myeloid-specific genes: Patterns of expression and possible role in proliferation and differentiation of acute myelogenous leukemia cells. Cancer Treatment and Research, 1993, 64, 171-187.	0.2	1
3426	Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. Cancer Treatment and Research, 1993, 63, 15-60.	0.2	38
3427	Oncogenes and Cell Growth. Advances in Experimental Medicine and Biology, 1992, 321, 45-51.	0.8	6
3428	Relationship between Ras pathways and cell cycle control. , 2000, 4, 1-17.		20
3429	Chemotherapy of advanced colorectal cancer. Cancer Treatment and Research, 1998, 98, 111-152.	0.2	6
3430	Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer Treatment and Research, 1997, 90, 109-125.	0.2	28
3431	Prognostic Implications of ras Oncogene Expression in Head and Neck Squamous Cell Carcinoma. , 1991, , 213-226.		4
3432	Possible Role for Ha-ras Expression in Inducible Steroidogenesis in Immortalized Granulosa Cell Lines. , 1991, , 227-236.		1
3433	ras Proto-Oncogene Activation in Human Malignancy. , 1995, , 17-52.		21
3434	Flavonoids and Gene Expression in Mammalian Cells. Advances in Experimental Medicine and Biology, 2002, 505, 191-200.	0.8	22
3435	Oncogenic Ras Pushes (and Pulls) Cell Cycle Progression Through ERK Activation. Methods in Molecular Biology, 2014, 1170, 155-163.	0.4	13

#	Article	IF	Citations
3436	The MAPK Pathway in Melanoma. , 2016, , 151-163.		1
3437	Cancer Genes. , 2002, , 45-64.		6
3438	Positive Mediators of Cell Proliferation in Neoplastic Transformation. , 2002, , 65-79.		3
3439	The Role of Genomic Instability in the Development of Human Cancer. , 2002, , 115-142.		9
3441	Chemoprevention of Colorectal Cancer. , 2005, , 267-285.		1
3442	Evasion of G1 Checkpoints in Cancer. , 2010, , 3-26.		1
3443	Meats, Protein and Cancer. , 2010, , 195-212.		3
3444	A Review of Post-translational Modifications and Subcellular Localization of Ets Transcription Factors: Possible Connection with Cancer and Involvement in the Hypoxic Response. Methods in Molecular Biology, 2010, 647, 3-30.	0.4	54
3445	Historical Overview of Rho GTPases. Methods in Molecular Biology, 2012, 827, 3-12.	0.4	47
3446	Tomorrowâ€™s anticancer agents: inhibitors of Ras farnesylation. Exs, 2000, 89, 153-179.	1.4	4
3447	Raf-dependent signaling pathways in cell growth and differentiation. , 1998, , 75-95.		3
3448	Role of Oxidative Stress in the Process of Carcinogenesis. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 173-198.	0.4	2
3449	Identifying Critical Signaling Molecules for the Treatment of Cancer. , 2007, 172, 5-24.		3
3450	The Ras Signalling Pathway as a Target in Cancer Therapy. , 2007, 172, 125-153.		9
3451	Chemosensitivity Testing and Test-Directed Chemotherapy in Human Pancreatic Cancer. Recent Results in Cancer Research, 2003, 161, 180-195.	1.8	18
3452	Gut Microbes, Diet, and Cancer. Cancer Treatment and Research, 2014, 159, 377-399.	0.2	108
3453	The DH Protein Family, Exchange Factors for Rho-Like GTPases. Progress in Molecular and Subcellular Biology, 1999, 22, 51-83.	0.9	44
3454	Antisense Oligonucleotides and Their Anticancer Activities. Handbook of Experimental Pharmacology, 1998, , 395-425.	0.9	1

#	Article	IF	Citations
3455	Genetic Alterations in Human Tumors. Current Topics in Microbiology and Immunology, 1997, 221, 149-176.	0.7	8
3456	Influence of c-myc on the Progression of Human Breast Cancer. Current Topics in Microbiology and Immunology, 1996, 213 (Pt 2), 267-283.	0.7	6
3457	The Impact of Cytogenetics and Molecular Genetics on Diagnosis and Treatment. , 1990, , 173-186.		2
3458	The Molecular Biology of Prostate Cancer. , 1991, , 19-26.		1
3459	Conformational Switch and Structural Basis for Oncogenic Mutations of Ras Proteins. Handbook of Experimental Pharmacology, 1993, , 177-194.	0.9	8
3460	Analysis of Ras Structure and Dynamics by Nuclear Magnetic Resonance. Handbook of Experimental Pharmacology, 1993, , 213-234.	0.9	1
3461	Oncogenic Activation of Ras Proteins. Handbook of Experimental Pharmacology, 1993, , 259-287.	0.9	15
3462	Oligonucleotide-Based Therapeutics of Human Malignancies. Nucleic Acids and Molecular Biology, 1994, , 298-326.	0.2	9
3463	Analysis of N-ras Mutations in Human Cutaneous Melanoma: Tumor Heterogeneity Detected by Polymerase Chain Reaction/Single-Stranded Conformation Polymorphism Analysis. Recent Results in Cancer Research, 1995, 139, 57-67.	1.8	43
3464	Discovery and Design of Inhibitors of Oncogenic Tyrosine Kinases. , 1994, , 55-70.		2
3465	Basis and Consequences of Primary and Secondary Prevention of Gastrointestinal Tumors. Recent Results in Cancer Research, 1996, 142, 163-192.	1.8	7
3466	Micrometastasis Detection and Treatment with Monoclonal Antibodies. Current Topics in Microbiology and Immunology, 1996, 213 (Pt 3), 1-18.	0.7	26
3467	Kolon- und Rektumkarzinom. , 2004, , 875-932.		1
3468	On the impact of the molecule structure in chemical carcinogenesis. Exs, 2009, 99, 151-179.	1.4	48
3469	Ribozyme-Mediated Reversal of Human Pancreatic Carcinoma Phenotype. , 1996, , 153-163.		6
3470	Epithelial Cell Signalling in Colorectal Cancer Metastasis. Cancer Metastasis - Biology and Treatment, 2010, , 205-241.	0.1	5
3471	Oncolytic Virotherapy of Cancer. , 2011, , 295-316.		3
3473	Analysis of microsatellite instability in chronic lymphoproliferative disorders. Annals of Hematology, 1996, 72, 67-71.	0.8	6

#	Article	IF	Citations
3474	Early Injury of Cells by External Oxidants and the Consequences of DNA Damage. , 1992, , 21-41.		3
3475	Airborne Toxic Pollutants. Advances in Molecular Toxicology, 2016, 10, 187-233.	0.4	2
3476	Growth Factor Signaling Pathways and Receptor Tyrosine Kinase Inhibitors. , 2006, , 155-172.		2
3477	Antagonists of Rho Family GTPases. , 2002, , 361-377.		1
3478	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. , 2009, , 331-402.		3
3479	Overcoming Resistance to Drugs Targeting KRAS Mutation. Innovation(China), 2020, 1, 100035.	5.2	44
3480	An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin).. Journal of Biological Chemistry, 1994, 269, 23387-23390.	1.6	125
3481	Triplex formation by the human Ha-ras promoter inhibits Sp1 binding and in vitro transcription.. Journal of Biological Chemistry, 1994, 269, 18232-18238.	1.6	61
3482	Biochemical characterization of yeast RAS2 mutants reveals a new region of ras protein involved in the interaction with GTPase-activating proteins.. Journal of Biological Chemistry, 1994, 269, 5322-5327.	1.6	15
3483	Long-term expression of c-H-ras stimulates Na-H and Na(+)-dependent Cl-HCO3 exchange in NIH-3T3 fibroblasts.. Journal of Biological Chemistry, 1994, 269, 4116-4124.	1.6	79
3484	Stimulation of yeast adenylyl cyclase activity by lysophospholipids and fatty acids. Implications for the regulation of Ras/effector function by lipids.. Journal of Biological Chemistry, 1994, 269, 32336-32341.	1.6	22
3485	The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype.. Journal of Biological Chemistry, 1993, 268, 22331-22337.	1.6	42
3486	Characterization and site-directed mutagenesis of a low M(r) GTP-binding protein, ram p25, expressed in Escherichia coli.. Journal of Biological Chemistry, 1992, 267, 19600-19606.	1.6	12
3487	The minimal fragments of c-Raf-1 and NF1 that can suppress v-Ha-Ras-induced malignant phenotype.. Journal of Biological Chemistry, 1994, 269, 30105-30108.	1.6	36
3488	Characterization of the TGF beta 1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence.. Journal of Biological Chemistry, 1994, 269, 26767-26774.	1.6	184
3489	Transforming and c-fos promoter/enhancer-stimulating activities of a stimulatory GDP/GTP exchange protein for small GTP-binding proteins.. Journal of Biological Chemistry, 1992, 267, 926-930.	1.6	32
3490	Insulin-induced p21ras activation does not require protein kinase C, but a protein sensitive to phenylarsine oxide.. Journal of Biological Chemistry, 1991, 266, 21186-21189.	1.6	47
3491	p21 with a phenylalanine 28â€”leucine mutation reacts normally with the GTPase activating protein GAP but nevertheless has transforming properties.. Journal of Biological Chemistry, 1991, 266, 17700-17706.	1.6	94

#	Article	IF	Citations
3492	The human active breakpoint cluster region-related gene encodes a brain protein with homology to guanine nucleotide exchange proteins and GTPase-activating proteins.. Journal of Biological Chemistry, 1993, 268, 27291-27298.	1.6	58
3493	Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides.. Journal of Biological Chemistry, 1992, 267, 19954-19962.	1.6	232
3494	Molecular targets of aspirin and cancer prevention. , 0, .		1
3495	Regulation of choline kinase activity by Ras proteins involves Ralâ€“GDS and PI3K. , 0, .		1
3496	K-ras mutations and RASSF1A promoter methylation in colorectal cancer. , 0, .		2
3497	RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics. Biochemical Journal, 2020, 477, 2893-2919.	1.7	12
3498	RASA1 inhibits the progression of renal cell carcinoma by decreasing the expression of miR-223-3p and promoting the expression of FBXW7. Bioscience Reports, 2020, 40, .	1.1	16
3499	Genetic Abnormalities and Microsatellite Instability in Colorectal Cancer. Cancer Detection and Prevention, 1998, 22, 383-395.	2.1	8
3500	Association of p53, K-ras and Proliferating Cell Nuclear Antigen with Rat Lung Lesions Following Exposure to Simulated Nuclear Fuel Particles. Cancer Detection and Prevention, 1999, 23, 194-203.	2.1	4
3501	EVIDENCE OF A LOW PREVALENCE OF RAS MUTATIONS IN A LARGE MEDULLARY THYROID CANCER SERIES. Thyroid, 0, , 120822105920003.	2.4	3
3502	Mechanism of Activation of the Caenorhabditis elegans ras Homologue let-60 by a Novel, Temperature-Sensitive, Gain-of-Function Mutation. Genetics, 1997, 146, 553-565.	1.2	53
3503	Analysis of Ras-Induced Overproliferation in Drosophila Hemocytes. Genetics, 2003, 163, 203-215.	1.2	262
3504	Synchronous Mucinous Tumors of the Appendix and the Ovary Associated with Pseudomyxoma Peritonei. American Journal of Surgical Pathology, 1996, 20, 739-746.	2.1	103
3505	Comparative Analysis of Histologic Homologues of Endometrial and Ovarian Carcinoma. American Journal of Surgical Pathology, 1998, 22, 319-326.	2.1	51
3506	Prevalence of Activating K-ras Mutations in the Evolutionary Stages of Neoplasia in Intraductal Papillary Mucinous Tumors of the Pancreas. Annals of Surgery, 1997, 226, 491-500.	2.1	183
3507	Meningiomas: Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in Angiogenesis and Peritumoral Edema. Neurosurgery, 1997, 40, 1016-1026.	0.6	189
3509	Signal-Transduction Therapy. A Novel Approach to Disease Management. FEBS Journal, 1994, 226, 1-13.	0.2	159
3510	Oncogenic Ras-Induced Expression of Cytokines: A New Target of Anti-Cancer Therapeutics. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2008, 8, 22-27.	3.4	83

#	Article	IF	Citations
3511	Oncogenicity of AKR mink cell focus-inducing murine leukemia virus correlates with induction of chronic phosphatidylinositol signal transduction. Journal of Virology, 1992, 66, 6125-6132.	1.5	3
3512	The kinetics of simian virus 40-induced progression of quiescent cells into S phase depend on four independent functions of large T antigen. Journal of Virology, 1994, 68, 5496-5508.	1.5	70
3513	Regulation of Collagen I Gene Expression by ras. Molecular and Cellular Biology, 1992, 12, 4714-4723.	1.1	26
3514	Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Molecular and Cellular Biology, 1992, 12, 2050-2056.	1.1	116
3515	Effector Domain Mutations Dissociate p21^{ras} Effector Function and GTPase-Activating Protein Interaction. Molecular and Cellular Biology, 1993, 13, 7311-7320.	1.1	13
3516	Aberrant Function of the Ras-Related Protein TC21/R-Ras2 Triggers Malignant Transformation. Molecular and Cellular Biology, 1994, 14, 4108-4115.	1.1	48
3517	Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues. Molecular and Cellular Biology, 1994, 14, 5318-5325.	1.1	67
3518	Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades. Russian Journal of Bioorganic Chemistry, 2020, 46, 891-902.	0.3	2
3519	Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa.. Journal of Clinical Investigation, 1991, 87, 624-630.	3.9	100
3520	Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. Journal of Clinical Investigation, 2004, 113, 539-550.	3.9	95
3521	Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. Journal of Clinical Investigation, 2004, 113, 539-550.	3.9	147
3522	Progress on new vaccine strategies for the immunotherapy and prevention of cancer. Journal of Clinical Investigation, 2004, 113, 1515-1525.	3.9	175
3523	Autocrine PDGFR signaling promotes mammary cancer metastasis. Journal of Clinical Investigation, 2006, 116, 1561-1570.	3.9	307
3524	Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. Journal of Clinical Investigation, 2008, 118, 3651-3659.	3.9	184
3525	Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. Journal of Clinical Investigation, 2010, 120, 2829-2841.	3.9	61
3526	Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. Journal of Clinical Investigation, 2010, 120, 3940-3952.	3.9	120
3527	Suppression of dual-specificity phosphataseâ€“2 by hypoxia increases chemoresistance and malignancy in human cancer cells. Journal of Clinical Investigation, 2011, 121, 1905-1916.	3.9	88
3528	Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. Journal of Clinical Investigation, 2013, 123, 4681-4694.	3.9	48

#	Article	IF	Citations
3529	Reovirus as a novel oncolytic agent. Journal of Clinical Investigation, 2000, 105, 1035-1038.	3.9	101
3530	Activated H-ras Gene Mutations iN Transitional Cell Carcinoma of Urinary Bladder in a Kashmiri Population. Tumori, 2010, 96, 993-998.	0.6	4
3531	Role of Amplified Genes in the Production of Autoantibodies. Blood, 1999, 93, 2158-2166.	0.6	2
3532	Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood, 2000, 96, 1655-1669.	0.6	11
3533	Biological Markers in the Respiratory Tract. , 1995, , 443-472.		2
3534	Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-Î²1 and Ha-Ras: steps towards invasiveness. Journal of Cell Science, 2002, 115, 1189-1202.	1.2	177
3535	Cytogenetic and Molecular Changes in Leukemia among Atomic Bomb Survivors. Journal of Radiation Research, 1991, 32, 257-265.	0.8	8
3536	Lack of Modifying Effects of Cinnamaldehyde on Development of Lung Proliferative Lesions Induced by Urethane in Transgenic Mice Carrying the Human Prototype c-Ha-ras Gene.. Journal of Toxicologic Pathology, 2000, 13, 249-255.	0.3	3
3537	Thresholds for DNA-Reactive (Genotoxic) Organic Carcinogens. Journal of Toxicologic Pathology, 2005, 18, 69-77.	0.3	25
3538	Phosphatase of Regenerating Liver-3 Localizes to Cyto-Membrane and Is Required for B16F1 Melanoma Cell Metastasis In Vitro and In Vivo. PLoS ONE, 2009, 4, e4450.	1.1	28
3539	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. PLoS ONE, 2009, 4, e7464.	1.1	205
3540	Oncogenic RAS Enables DNA Damage- and p53-Dependent Differentiation of Acute Myeloid Leukemia Cells in Response to Chemotherapy. PLoS ONE, 2009, 4, e7768.	1.1	28
3541	DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset. PLoS ONE, 2010, 5, e13978.	1.1	102
3542	A Systematic Analysis on DNA Methylation and the Expression of Both mRNA and microRNA in Bladder Cancer. PLoS ONE, 2011, 6, e28223.	1.1	35
3543	Constitutive MAP Kinase Activation in Hematopoietic Stem Cells Induces a Myeloproliferative Disorder. PLoS ONE, 2011, 6, e28350.	1.1	21
3544	Temporal Dissection of K-rasG12D Mutant In Vitro and In Vivo Using a Regulatable K-rasG12D Mouse Allele. PLoS ONE, 2012, 7, e37308.	1.1	7
3545	The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome. PLoS ONE, 2012, 7, e45484.	1.1	41
3546	Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts. PLoS ONE, 2013, 8, e73484.	1.1	41

#	Article	IF	Citations
3547	Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation. PLoS ONE, 2014, 9, e86619.	1.1	10
3548	Oncogenic H-Ras Up-Regulates Acid Î²-Hexosaminidase by a Mechanism Dependent on the Autophagy Regulator TFEB. PLoS ONE, 2014, 9, e89485.	1.1	17
3549	Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0101019.	1.1	5
3550	The Role of Hypoxia Inducible Factor-1 Alpha in Bypassing Oncogene-Induced Senescence. PLoS ONE, 2014, 9, e101064.	1.1	31
3551	Validation of a Multiplex Allele-Specific Polymerase Chain Reaction Assay for Detection of KRAS Gene Mutations in Formalin-Fixed, Paraffin-Embedded Tissues from Colorectal Cancer Patients. PLoS ONE, 2016, 11, e0147672.	1.1	13
3552	Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2 in MDCK Cells Expressing Active Ras or Raf. PLoS ONE, 2016, 11, e0167940.	1.1	16
3553	Desethylamiodaroneâ€"A metabolite of amiodaroneâ€"Induces apoptosis on T24 human bladder cancer cells via multiple pathways. PLoS ONE, 2017, 12, e0189470.	1.1	17
3554	Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. PLoS ONE, 2017, 12, e0189651.	1.1	27
3555	L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation. Molecules and Cells, 2017, 40, 363-370.	1.0	6
3556	Tumor suppression by p53: making cells senescent. Histology and Histopathology, 2010, 25, 515-26.	0.5	62
3557	Polymorphism T81C in H-RAS Oncogene Is Associated With Disease Progression in Imatinib (TKI) Treated Chronic Myeloid Leukemia Patients. World Journal of Oncology, 2015, 6, 321-328.	0.6	4
3560	Detection of codon 12 mutation in the k-ras oncogene in pancreatic tumors. Revista Do Hospital Das Clinicas, 1999, 54, 17-20.	0.5	2
3561	Marcadores tumorais no cÃ¢ncer de pulmÃ£o: um caminho para a terapia biolÃ³gica. Jornal De Pneumologia, 2002, 28, 143-149.	0.1	2
3562	Association of KRAS and NRAS gene polymorphisms with Wilms tumor risk: a four-center case-control study. Aging, 2019, 11, 1551-1563.	1.4	28
3563	RALB provides critical survival signals downstream of Ras in acute myeloid leukemia. Oncotarget, 2016, 7, 65147-65156.	0.8	7
3564	SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status. Oncotarget, 2016, 7, 80336-80349.	0.8	35
3565	Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functionalNf1to apoptosis in the absence of protein kinase C. Oncotarget, 2016, 7, 84326-84337.	0.8	5
3566	KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Oncotarget, 2016, 7, 79503-79514.	0.8	11

#	Article	IF	Citations
3567	Marine guanidine alkaloids crambescidins inhibit tumor growth and activate intrinsic apoptotic signaling inducing tumor regression in a colorectal carcinoma zebrafish xenograft model. Oncotarget, 2016, 7, 83071-83087.	0.8	34
3568	The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors. Oncotarget, 2017, 8, 2083-2095.	0.8	16
3569	Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens. Oncotarget, 2017, 8, 34283-34297.	0.8	6
3570	Ras and autophagy in cancer development and therapy. Oncotarget, 2014, 5, 577-586.	0.8	78
3571	Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells. Oncotarget, 2014, 5, 7635-7650.	0.8	21
3572	Mutant NRASQ61 shares signaling similarities across various cancer types - potential implications for future therapies. Oncotarget, 2014, 5, 7936-7944.	0.8	22
3573	A novel suicide gene therapy for the treatment of p16Ink4a-overexpressing tumors. Oncotarget, 2018, 9, 7274-7281.	0.8	9
3574	A lethal synergy induced by phellinus linteus and camptothecin11 in colon cancer cells. Oncotarget, 2018, 9, 6308-6319.	0.8	8
3575	BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications. Oncotarget, 2014, 5, 11752-11777.	0.8	83
3576	RasGRP3 regulates the migration of glioma cells via interaction with Arp3. Oncotarget, 2015, 6, 1850-1864.	0.8	14
3577	Metformin and trametinib have synergistic effects on cell viability and tumor growth inNRASmutant cancer. Oncotarget, 2015, 6, 969-978.	0.8	61
3578	Identification of NDUFAF1 in mediating K-Ras induced mitochondrial dysfunction by a proteomic screening approach. Oncotarget, 2015, 6, 3947-3962.	0.8	21
3579	Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. Oncotarget, 2015, 6, 14472-14487.	0.8	46
3580	Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis. Oncotarget, 2015, 6, 23944-23958.	0.8	21
3581	Ras inhibition by FTS attenuates brain tumor growth in mice directly and by enhancing reactivity of cytotoxic lymphocytes. Oncotarget, 2012, 3, 144-157.	0.8	17
3582	Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling. Oncotarget, 2015, 6, 33091-33105.	0.8	28
3583	HDAC3 mediates smoking-induced pancreatic cancer. Oncotarget, 2016, 7, 7747-7760.	0.8	41
3584	Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. Oncotarget, 2016, 7, 7297-7306.	0.8	29

#	Article	IF	Citations
3585	Comparison of liver oncogenic potential among human RAS isoforms. Oncotarget, 2016, 7, 7354-7366.	0.8	11
3586	Monocarboxylate transporter 1 contributes to growth factor-induced tumor cell migration independent of transporter activity. Oncotarget, 2016, 7, 32695-32706.	0.8	22
3587	A natural small molecule, catechol, induces c-Myc degradation by directly targeting ERK2 in lung cancer. Oncotarget, 2016, 7, 35001-35014.	0.8	32
3588	Inhibitors of Rho kinase (ROCK) signaling revert the malignant phenotype of breast cancer cells in 3D context. Oncotarget, 2016, 7, 31602-31622.	0.8	47
3589	The Potential Use of Anticancer Peptides (ACPs) in the Treatment of Hepatocellular Carcinoma. Current Cancer Drug Targets, 2020, 20, 187-196.	0.8	4
3590	Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. Current Topics in Medicinal Chemistry, 2019, 19, 2128-2142.	1.0	9
3591	Exploring the Lapse in Druggability: Sequence Analysis, Structural Dynamics and Binding Site Characterization of K-RasG12C Variant, a Feasible Oncotherapeutics Target. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1540-1550.	0.9	7
3592	Fluorescent Cascade and Direct Assays for Characterization of RAF Signaling Pathway Inhibitors. Current Chemical Genomics, 2008, 1, 43-53.	2.0	10
3593	Dietary phytate lowers - mutational frequency, decreases DNA-adduct and hydroxyl radical formation in azoxymethane-induced colon cancer. Iranian Journal of Basic Medical Sciences, 2020, 23, 20-29.	1.0	5
3594	Ä Ã¡nh giÃ¡ hoáº¡t tÃnh cá»§a vi khuáº©n Lactobacillus tá»« ruá»™t tÃ´m tháº» chÃ¢n tráº¯ng cÃ³ tiá»m nÄƒng probiotic Ä'á»ƒ bá»• sung Äƒn tÃ´m. Tap Chi Khoa Hoc = Journal of Science, 2020, 56(Aquaculture), 102.	0.1	3
3595	Assessment of Mutations of Ha- and Ki-ras Oncogenes and the p53 Suppressor Gene in Seven Malignant Mesothelioma Patients Exposed to Asbestos. PCR-SSCP and Sequencing Analyses of Paraffin-Embedded Primary Tumors.. Industrial Health, 1998, 36, 52-56.	0.4	15
3596	Assessment of the Mutations of p53 Suppressor Gene and Ha- and Ki-ras Oncogenes in Malignant Mesothelioma in Relation to Asbestos Exposure: A Study of 12 American Patients.. Industrial Health, 2002, 40, 175-181.	0.4	22
3597	Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World Journal of Gastroenterology, 2004, 10, 881.	1.4	22
3598	Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients. World Journal of Gastroenterology, 2006, 12, 1033.	1.4	11
3599	Genetic alterations in pancreatic cancer. World Journal of Gastroenterology, 2007, 13, 4423.	1.4	36
3600	Changes in gene-expression profiles of colon carcinoma cells induced by wild type K-ras2. World Journal of Gastroenterology, 2007, 13, 4620.	1.4	6
3601	Growth inhibitory effect of wild-typeKras2gene on a colonic adenocarcinoma cell line. World Journal of Gastroenterology, 2007, 13, 934.	1.4	11
3602	Circulating microRNAs: Novel biomarkers for esophageal cancer. World Journal of Gastroenterology, 2010, 16, 2348.	1.4	46

#	Article	IF	Citations
3603	MicroRNAs, development of Barrettâ€™s esophagus, and progression to esophageal adenocarcinoma. World Journal of Gastroenterology, 2010, 16, 531.	1.4	41
3604	Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World Journal of Gastroenterology, 2011, 17, 809.	1.4	48
3605	KRAS mutation testing in metastatic colorectal cancer. World Journal of Gastroenterology, 2012, 18, 5171-80.	1.4	166
3606	Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World Journal of Gastroenterology, 2012, 18, 6005.	1.4	39
3607	Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World Journal of Gastroenterology, 2014, 20, 3858.	1.4	44
3608	Standard chemotherapy with cetuximab for treatment of colorectal cancer. World Journal of Gastroenterology, 2015, 21, 7022-7035.	1.4	8
3609	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6345.	1.4	94
3610	Reduced expression of microRNAâ€‘139â€‘5p in hepatocellular carcinoma results in a poor outcome: An exploration the roles of microRNAâ€‘139â€‘5p in tumorigenesis, advancement and prognosis at the molecular biological level using an integrated metaâ€‘analysis and bioinformatic investigation. Oncology Letters, 2019, 18, 6704-6724.	0.8	5
3611	Atonal bHLH transcription factor 1 is an important factor for maintaining the balance of cell proliferation and differentiation in tumorigenesis (Review). Oncology Letters, 2020, 20, 2595-2605.	0.8	8
3612	Clinicopathological features and diagnostic methods of ALK fusionâ€‘positive nonâ€‘small cell lung cancer in Korea. Oncology Reports, 2020, 43, 218-228.	1.2	5
3613	Colorectal carcinoma: Pathologic aspects. Journal of Gastrointestinal Oncology, 2012, 3, 153-73.	0.6	385
3614	The significance of genetics for cholangiocarcinoma development. Annals of Translational Medicine, 2013, 1, 28.	0.7	20
3615	Defining the role of polyamines in colon carcinogenesis using mouse models. Journal of Carcinogenesis, 2011, 10, 10.	2.5	14
3616	KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay. Journal of Pathology and Translational Medicine, 2017, 51, 24-31.	0.4	5
3617	Tumor Angiogenesis: Initiation and Targeting - Therapeutic Targeting of an FGF-Binding Protein, an Angiogenic Switch Molecule, and Indicator of Early Stages of Gastrointestinal Adenocarcinomas -. Cancer Research and Treatment, 2006, 38, 189.	1.3	19
3618	Prospective Development of Small Molecule Targets to Oncogenic Ras Proteins. Open Journal of Biophysics, 2013, 03, 207-211.	0.7	5
3619	Mutations of cancer-related genes in squamous cell carcinomas of the human skin.. Skin Cancer, 2001, 16, 353-356.	0.1	1
3620	Cellular senescence in cancer. BMB Reports, 2019, 52, 42-46.	1.1	32

#	Article	IF	Citations
3621	Antineoplastic effects of mammalian target of rapamycine inhibitors. World Journal of Transplantation, 2012, 2, 74.	0.6	12
3623	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. Journal of Cancer Research Updates, 2013, 2, 265-282.	0.3	53
3624	Oral Leukoplakia. Journal of Japanese Society for Oral Mucous Membrane, 1996, 2, 1-21.	0.0	1
3625	Inhibitory effect of flavonoids on mutant H-Rasp21 protein. Bioinformation, 2010, 5, 11-15.	0.2	7
3626	MicroRNA-203 represses selection and expansion of oncogenic Hras transformed tumor initiating cells. ELife, 2015, 4, .	2.8	17
3627	¹H NMR studies distinguish the water soluble metabolomic profiles of untransformed and RAS-transformed cells. PeerJ, 2016, 4, e2104.	0.9	5
3628	Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death and Disease, 2021, 12, 978.	2.7	9
3629	Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas. Cancers, 2021, 13, 5310.	1.7	4
3630	The Role of Kinase Inhibitors in Cancer Therapies. Biochemistry, 0, , .	0.8	0
3631	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers, 2021, 13, 5059.	1.7	39
3632	Regional Chemotherapy of Cancer of the Pancreas. , 2000, , 101-125.		0
3633	Ets Transcription Factors. , 2000, , 39-65.		1
3634	Oncoproteins as Tumor-Specific Antigens. , 2000, , .		0
3635	Mitogenic Signal Transduction. , 2000, , 75-91.		0
3636	Elements of Signal Transduction in Drug Discovery with Special Reference to Inhibitors of Protein Kinase C. , 2001, , 81-99.		0
3637	Effect of Mutationally Activated Ras on the Ras to MAP Kinase Signaling Pathway and Growth Inhibition of Myeloid Leukemia Cells by Inhibitors of the MAP Kinase Cascade. Hamatologie Und Bluttransfusion, 2001, , 100-108.	0.0	0
3638	Development of Epitope-Specific Immunotherapies for Human Malignancies and Premalignant Lesions Expressing Mutated ras Genes. , 2002, , 145-163.		0
3640	Reovirus Therapy of Ras-Associated Cancers. , 2002, , 31-43.		1

#	Article	IF	Citations
3641	NF1 and Other RAS-Binding Peptides. , 2002, , 169-175.		0
3642	Signalling pathways operated by non-receptor protein tyrosine kinases. , 2002, , 283-297.		1
3643	Molecular Genetics of Gastrointestinal Tract Cancers. , 2002, , 177-192.		0
3644	Kolorektales Karzinom. , 2002, , 231-256.		0
3646	Survival and Follow-up of Colorectal Cancer. , 2002, , 163-179.		0
3647	Zellbiologische Grundlagen. , 2002, , 3-30.		0
3648	Blasenkarzinom. , 2002, , 291-328.		0
3649	Fidelity of DNA synthesis as a molecular biomarker. , 2002, , .		0
3650	Farnesyltransferase Inhibitors. , 2003, , 737-744.		0
3651	Anti-carcinoembryonic antigen immunity. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 299-325.	0.5	0
3652	Ras and Cancer. , 2003, , 671-673.		0
3653	Mouse models in the recognition of tumor antigens. , 2003, , 3-19.		0
3654	Apoptosis and Cancer. , 2003, , 177-199.		0
3656	Redox Regulation of Apoptosis. Oxidative Stress and Disease, 2003, , .	0.3	0
3657	Genetische Grundlagen der Kanzerogenese. , 2004, , 75-145.		1
3658	ras Oncogene Inhibitors. , 2004, , 303-316.		0
3663	Molecular Mechanisms of Carcinogenesis. Chemical and Functional Properties of Food Components Series, 2005, , .	0.1	1
3664	Oncogenes in Thyroid Cancer. , 2006, , 41-53.		0

#	Article	IF	Citations
3665	Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients. World Journal of Gastroenterology, 2006, 12, 1033.	1.4	1
3666	Comparison of the Effects of Ras Effector Mutants and Ras Effectors on Transformed and Tumorigenic Growth of Human and Rodent Cells. , 2006, , 257-272.		0
3667	Genetically Engineered Mice Harboring RAS Mutations as Models of Human Cancer: in Medias RAS. , 2006, , 273-293.		0
3668	Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Science, 2006, .	1.7	0
3670	Cancer genetics. , 2007, , 31-33.		0
3671	Overview of Existing Therapies. , 2007, , 1-17.		0
3672	An Overview of Clinical Trials of Targeted Therapies in Pancreatic Cancer. , 2008, , 565-575.		0
3673	Tumor Suppressor and Pro-progression Roles for TGF-Î² in Breast Cancer. , 2008, , 285-307.		1
3674	Phase 1 Trials Today. , 2008, , 553-570.		0
3675	Genes and metastasis: experimental advances and clinical implications. , 2008, , 33-58.		0
3676	Development of Vaccine Therapy for Pancreas Cancer. , 2008, , 683-704.		0
3677	Molecular Signaling Pathways in Pancreatic Cancer. , 2008, , 181-228.		0
3679	Signal Transduction Inhibitors in the Treatment of Breast Cancer. , 2009, , 177-201.		0
3680	Targeted Approaches to Drug Development. , 2009, , 57-98.		3
3681	Inhibition of Ras Signaling for Brain Tumor Therapy. , 2009, , 919-932.		1
3682	Molecular Targeted Therapies for HCC. , 2009, , 589-614.		0
3683	Molecular Basis of Human Malignancy. , 2009, , 41-55.		1
3684	Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. OncoTargets and Therapy, 2009, 2, 161.	1.0	3

#	Article	IF	Citations
3685	Rho GTPases in Regulation of Cancer Cell Motility, Invasion, and Microenvironment. , 2010, , 67-91.		0
3686	EGFR-Directed Monoclonal Antibodies. , 2010, , 407-436.		0
3687	Aberrant Signalling Complexes in GBMs: Prognostic and Therapeutic Implications. , 2010, , 95-129.		0
3688	RhoB GTPase and FTIs in Cancer. , 2010, , 135-153.		0
3689	Chemotherapy Trials for Colorectal Cancer in Advanced Disease: Whatâ€™s the Current Hypothesis?. , 2010, , 27-54.		0
3691	Molecular Pathogenesis of Myelodysplastic Syndromes. Molecular Pathology Library, 2010, , 417-427.	0.1	0
3692	Cancer of the Pancreas. , 2010, , 801-819.		0
3693	Pharmacogenetics in Colorectal Cancer. , 2010, , 61-86.		0
3694	A Role for eNOS in Oncogenic Ras-Driven Cancer. , 2010, , 23-38.		1
3695	Complete Radiographic Response to Zoledronic Acid Therapy in a Patient With Bony Metastatic Urothelial Carcinoma: A Case Report. World Journal of Oncology, 2010, 1, 208-209.	0.6	3
3696	Atypical PKCs, NF-Î¹B, and Inflammation. , 2010, , 223-244.		0
3697	Molecular Pathology of Myelodysplastic/Myeloproliferative Neoplasms, Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB, and FGFR1, and Mastocytosis. Molecular Pathology Library, 2010, , 405-416.	0.1	0
3698	Gene-Based Therapies for Lung Cancer. , 2010, , 305-330.		1
3699	Farnesyltransferase Inhibitors. , 2010, , 1819-1826.		1
3700	Well-Differentiated Thyroid Follicular Carcinoma. Molecular Pathology Library, 2010, , 73-93.	0.1	0
3701	Applications of Genetics in Endocrinology. , 2010, , 118-143.		0
3702	Insulin and Growth Factor Signaling Pathways. , 2010, , 38-82.		1
3703	The Role of Oncogene Activation in Tumor Progression. , 2010, , 19-41.		0

#	Article	IF	Citations
3704	Interacting Signaling Pathways in Mouse Skin Tumor Initiation and Progression. , 2011, , 149-164.		0
3705	Translational Research in Lung Cancer. Medical Radiology, 2011, , 793-808.	0.0	0
3706	Altered Signal Transduction Pathways in Melanoma. , 2011, , 137-163.		0
3707	Adrenocortical Carcinoma. , 2011, , 195-220.		0
3708	Signaling Cross-Talk of Oncogenic KRAS and Hedgehog Pathways in Pancreatic Cancer. , 2011, , 65-76.		0
3709	Signaling in Congenital Heart Disease. , 2011, , 197-217.		0
3712	Ras/Raf and Their Influence in Glycolysis in Colon Cancer. , 2012, , 131-139.		0
3713	Hematopoietic Malignancies. , 2012, , 1371-1396.		0
3714	Prerequisite Genetic Traits for Metastasis. , 2013, , 403-444.		0
3715	The Biology of K-Ras Signaling Pathways in Pancreatic Cancer. , 2013, , 83-115.		0
3716	Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Research, 2013, 2, 105.	0.8	1
3717	Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics. , 2014, , 29-57.		0
3718	Molecular Pathology and Diagnostics of Gynecologic Malignancies. , 2014, , 365-395.		0
3719	Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. , 2014, , 75-118.		0
3721	KRAS. , 2014, , 1-6.		0
3722	Melanoma. Part II. Personalized Medicine: Using Molecular Tools to Guide Targeted Therapy. , 2014, , 97-131.		1
3723	Melanoma. Part I. Risk Assessment, Diagnosis, and Prognosis: Using Molecular Tools to Diagnose Melanoma, Predict Its Behavior, and Evaluate for Inheritable Forms. , 2014, , 63-96.		1
3724	On the Origin of Oncogenes. , 0, , 61-80.		0

#	Article	IF	Citations
3725	MMTV/N-ras Transgenic Mice as a Model for Altered Capacitation Male Sterility and Tumorigenesis. , 1990, , 939-957.		1
3726	Studies on oncogenes in human oral tumors.. Nihon Koku Geka Gakkai Zasshi, 1990, 36, 2211-2225.	0.0	0
3727	Genetic Alterations During Carcinogenesis in Rodents: Implications for Cancer Risk Assessment. , 1990, , 49-68.		0
3730	Diabetes Induced in Male Transgenic Mice by Expression of Human H-ras Oncoprotein in Pancreatic Î² Cells. Molecular and Cellular Biology, 1990, 10, 1779-1783.	1.1	26
3732	Differential P21 Expression and Point Mutations of ras Gene Family in Human Carcinoma Tissues. , 1991, , 67-79.		0
3733	ras Mutations in Preleukaemia, in Patients Following Cytotoxic Therapy and in Normal Subjects. , 1991, , 89-94.		0
3734	Effects of v-H-ras on Immortalized Non-Tumorigenic Human Mammary Epithelial Cells. , 1991, , 317-326.		0
3735	Suppression of the Phenotype of T24 H-ras1 Transformed Cells. , 1991, , 145-151.		0
3736	Structural and Functional Characteristics of Human Melanoma. , 1991, , 151-176.		1
3737	Immuno scintigram with proto oncogene product as a target.. Japanese Journal of Clinical Immunology, 1991, 14, 522-525.	0.0	0
3738	Search for Genetic Factors in the Etiology of Breast Cancer. , 1991, , 66-77.		0
3739	The Three-Dimensional Structure of P21 in the Catalytically Active Conformation and Analysis of Oncogenic Mutants. , 1991, , 183-193.		0
3740	Molecular Genetic Alterations such as Oncogene Activation as a Tool for the Evaluation of Risks in Chemical Carcinogenesis. , 1991, , 24-32.		0
3741	Lovastatin Selectively Inhibits ras Activation of the 12-O-Tetradecanoylphorbol-13-Acetate Response Element in Mammalian Cells. Molecular and Cellular Biology, 1991, 11, 2307-2310.	1.1	3
3742	Alteration of Homeobox Gene Expression by N-ras Transformation of PA-1 Human Teratocarcinoma Cells. Molecular and Cellular Biology, 1991, 11, 3573-3583.	1.1	9
3743	Pathogenese und Prognose kolorektaler Karzinome â€" molekularbiologische, zytogenetische und zellkinetische Aspekte. , 1992, , 455-460.		0
3744	Growth Factors, Oncogenes and Tumour Suppressor Genes. , 1992, , 27-43.		0
3745	â€˜In Vivoâ€™ Model Systems to Study ras Oncogene Involvement in Carcinogenesis. , 1992, , 111-126.		0

#	Article	IF	Citations
3746	Predictive Value for Cancer Risk Assessment of Cell- and Tissue- Specific Formation of Carcinogen-DNA Adducts. , 1992, , 31-42.		0
3747	MOLECULAR AND CELL BIOLOGY OF LUNG CANCER. , 1992, , 368-374.		0
3748	Growth Factors, Oncogenes and Tumour Suppressor Genes. , 1992, , 27-43.		0
3749	Oncogene Activation and Human Cancer. , 1992, , 61-66.		0
3750	New Experimental Approaches to the Adoptive Immunotherapy of Cancer: Cytokines, Gene Therapy, Oncogenes and Transgenic Mice. , 1992, , 165-188.		1
3751	Isolation of rsp-1, a Novel cDNA Capable of Suppressing v-Ras Transformation. Molecular and Cellular Biology, 1992, 12, 3750-3756.	1.1	50
3752	Practical Applications of Biomarkers in the Study of Environmental Liver Disease. , 1993, , 517-546.		2
3753	IMMUNOHISTOCHEMICAL STAINING OF P21-ONCOPROTEIN IN GASTRIC CARCINOMA. The Journal of the Japanese Practical Surgeon Society, 1993, 54, 600-606.	0.0	0
3754	Molecular Analysis of Fine Needle Aspiration Cytologic Specimens from Suspicious Thyroid Nodules. , 1993, , 223-228.		0
3755	Activation of ras Oncogenes in Human Tumours. , 1993, , 53-64.		0
3756	G-Protein Î± Subunit Chimeras Reveal Specific Regulatory Domains Encoded in the Primary Sequence. Handbook of Experimental Pharmacology, 1993, , 79-97.	0.9	0
3757	Molecular Biology in Epidemiology. , 1993, , 45-78.		1
3758	Bedeutung der medizinischen Molekularbiologie in der Diagnose, Therapie und Prognose von Tumorerkrankungen unter besonderer BerÃ¼cksichtigung der SchilddrÃ¼sentumoren. , 1993, , 21-26.		0
3759	Molecular Biology and Bladder Cancer. , 1994, , 19-45.		1
3760	Hereditary Melanoma and Dysplastic Nevus Syndrome. Recent Results in Cancer Research, 1994, 136, 94-109.	1.8	0
3761	Oxidative Damage and Carcinogenesis. , 1994, , 17-29.		0
3762	Genetic Alterations. , 1994, , 226-237.		0
3763	Signal-transduction therapy. , 1994, , 195-207.		0

#	Article	IF	Citations
3764	Androgen Receptors in Human Prostate Cancer. , 1994, , 239-265.		0
3765	Clinical Application of Oncogene. The Journal of the Japanese Practical Surgeon Society, 1994, 55, 1905-1920.	0.0	0
3766	Suppression of Albumin Enhancer Activity by H-ras and AP-1 in Hepatocyte Cell Lines. Molecular and Cellular Biology, 1994, 14, 1531-1543.	1.1	10
3767	Loss of p53 Protein During Radiation Transformation of Primary Human Mammary Epithelial Cells. Molecular and Cellular Biology, 1994, 14, 2468-2478.	1.1	26
3768	Mechanisms of Mutagenicity and Tumour Formation. , 1995, , 261-302.		0
3769	IRF-1 Functions as a Tumor Suppressor. , 1995, , 77-88.		0
3770	Studies on Sensitivity to ADRIAMYCIN in NIH3T3 Cells Transfected with Several Oncogenes.. Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1995, 11, 110-117.	0.4	0
3772	Tumor Suppressor Genes and Oncogenes in Human Prostate Cancer. , 1996, , 395-414.		0
3773	Androgen Receptors in Human Prostate Cancer: Heterogeneous Expression, Gene Mutations, and Polymorphic Variants. , 1996, , 445-492.		0
3774	Chronological study of genetic alterations during progression of DMBA-induced squamous cell carcinomas of the cheek pouch in golden hamsters.. Nihon Koku Geka Gakkai Zasshi, 1996, 42, 347-362.	0.0	0
3775	The Relationship Between Farnesylation and Carcinogenesis: The Effect of Lovastatin on Fibroblast Proliferation. Advances in Experimental Medicine and Biology, 1997, 400A, 479-486.	0.8	0
3776	A Survey of Diagnosis of Existence and Immunotherapy with Immune Response to ras Oncogenic Proteins in Pancreatic and Colon Cancer Patients.. Japanese Journal of Gastroenterological Surgery, 1997, 30, 901-905.	0.0	0
3777	A Case for ras Targeted Agents as Antineoplastics. , 1997, , 395-415.		2
3778	The Effects of Group II Phospholipase A2 on Ras-Induced Metastasis. Advances in Experimental Medicine and Biology, 1997, 400A, 9-17.	0.8	1
3779	The Role of Small GTPases in Signal Transduction. , 1997, , 63-73.		0
3780	Experimental Carcinogenesis, Exocrine Pancreas, Hamster and Rat. Monographs on Pathology of Laboratory Animals, 1997, , 274-288.	0.0	0
3781	Sequence Analysis of the GAP-Related Domain of the NFI-Gene and All Three RAS Protooncogenes in Patients with Secondary Acute Leukemia. Hamatologie Und Bluttransfusion, 1997, , 111-114.	0.0	0
3782	Experimental Carcinogenesis, Exocrine Pancreas, Hamster and Rat. Monographs on Pathology of Laboratory Animals, 1997, , 274-288.	0.0	1

#	Article	IF	Citations
3783	Ras Peptide Vaccines. , 1997, , 137-146.		0
3784	The use of Genetically Engineered Cells in Drug Discovery. , 1998, 20, 249-266.		0
3785	Contemporary Nonimaging Methods in the Diagnosis and Prognosis of Carcinoma of the Bladder. Medical Radiology, 1998, , 89-92.	0.0	0
3786	Prognostic significance of micrometastatic bone marrow involvement. , 1998, , 291-306.		0
3787	Mechanismen der Entstehung fremdstoffbedingter Krebsformen. , 1998, , 27-49.		0
3788	The c-myb Protooncogene: A Novel Target for Human Gene Therapy. , 1999, , 217-245.		0
3789	K-ras gene mutation in primary lung cancer in Japanese.. The Journal of the Japanese Association for Chest Surgery, 1999, 13, 32-36.	0.0	0
3790	Inhibition of Neurofibromin and p120 GTPASE Activating Protein (GAP) by Dietary Fatty Acids. Advances in Experimental Medicine and Biology, 1999, 469, 391-398.	0.8	0
3791	Molecular Basis of Pancreatic Cancer: Strategies for Genetic Diagnosis and Therapy. , 1999, , 267-280.		0
3792	Onkogenese und Neoplasien. , 1999, , 71-78.		0
3793	Use of Biochemical and Molecular Biomarkers for Cancer Risk Assessment in Humans. , 1999, , 81-182.		4
3794	Principles of Cancer Pathogenesis and Therapies: A Brief Overview. , 2015, , 1-17.		1
3795	Molekulare Grundlagen der malignen Transformation. , 2015, , 1-16.		0
3796	Development of an image-based screening system for inhibitors of the plastidial MEP pathway and of protein geranylgeranylation. F1000Research, 2015, 4, 14.	0.8	3
3797	Dynamical studies of cellular signaling networks in cancers. Wuli Xuebao/Acta Physica Sinica, 2016, 65, 178704.	0.2	4
3798	Developmental Delay: Gene Testing. , 2016, , 101-119.		0
3799	Targeted Therapies for Hepatocellular Carcinoma. , 2016, , 513-529.		0
3800	Genetics and Epigenetics of Head and Neck Cancer. , 2016, , 115-132.		0

#	Article	IF	Citations
3801	An Overview of Cancer Genes. , 2017, , 121-142.		0
3802	Oncogenes and the Initiation and Maintenance of Tumorigenesis. , 2017, , 143-157.		1
3803	Mouse Models of Pancreatic Exocrine Cancer. , 2017, , 1-30.		0
3804	KRAS. , 2017, , 2420-2425.		0
3805	Altered Signal Transduction Pathways in Melanoma. , 2017, , 177-207.		0
3808	Virotherapies in Pancreatic Cancer. , 2018, , 309-322.		0
3809	Chronic Myelomonocytic Leukemia: Clinical and Pathologic Features. Molecular Pathology Library, 2018, , 233-247.	0.1	0
3810	Adverse effects of farnesyltransferase inhibitors on insulin actions. Journal of Biomedical Translational Research, 2017, 18, 113-117.	0.1	0
3813	A novel isolation method for cancer prognostic factors via the p53 pathway by a combination of in vitro and in silico analyses. Oncoscience, 2018, 5, 88-98.	0.9	0
3814	SELECTIVE INHIBITION OF KRAS SIGNALING BY COMBINATION OF LOW DOSE RAPAMYCIN AND PACLITAXEL IN VIVO. Uspehi Molekularnoj Onkologii, 2018, 5, 42-49.	0.1	0
3815	Advances in Preclinical Models of Small Cell Lung Cancer. Med One, 2019, , .	1.5	2
3816	Novel Tumor Suppressive Role of the RAS GTPase-Activating Protein RASA5 to RAS Signaling Perturbation in Human Carcinomas. SSRN Electronic Journal, 0, , .	0.4	0
3817	Targeting the â€œundruggableâ€•RAS - new strategies - new hope?. , 2019, 2, 813-826.		2
3818	The Hippies Were Right: Diet and Cancer Risk. , 2019, , 121-129.		0
3819	Squamous Cell Carcinoma of the Head and Neck. , 2019, , 697-720.		1
3820	Ras-EfektÃ¶r EtkileÅŸimlerinin YapÄ±sal DetaylarÄ±nÄ±n AÃ§Ä±ÄŸa Ã‡Ä±karÄ±lmasÄ±. International Journal of Advances in Engineering and Pure Sciences, 2019, 31, 90-99.	0.2	0
3821	Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia. Journal of Medical Biochemistry, 2019, 39, 72-82.	0.7	0
3823	Genetics and Pathway in Neurofibromatosis Type 1. , 2020, , 5-14.		1

#	Article	IF	Citations
3824	Genetics of Colorectal Cancer: Role of p53. Journal of Drug Delivery and Therapeutics, 2020, 10, 183-185.	0.2	0
3825	What does â€œResearchâ€•mean to Neurosurgeons?. Japanese Journal of Neurosurgery, 2020, 29, 768-776.	0.0	0
3826	Mechanisms of CaaX Protein Processing: Protein Prenylation by FTase and GGTase-I. , 2020, , 497-527.		0
3827	PhÃ¢n tÃch má»‘i liÃªn quan giá»¯a bá»‡nh ung thÆ° vÃ¹ng thá»©c Ä‚n. Tap Chi Khoa Hoc = Journal of Science, 2020, 56(1), 110.		0
3829	NMR 1H, 13C, 15N backbone resonance assignments of the T35S and oncogenic T35S/Q61L mutants of human KRAS4b in the active, GppNHp-bound conformation. Biomolecular NMR Assignments, 2022, 16, 1-8.	0.4	1
3830	The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer. Current Cancer Drug Targets, 2021, 21, 932-943.	0.8	21
3831	Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1. Oncogene, 2022, 41, 280-292.	2.6	10
3834	Molekulare Prognosemarker des Harnblasenkarzinoms. , 2005, , 27-65.		0
3836	The mode of action of organic carcinogens on cellular structures. , 2006, , 65-95.		10
3839	Smoking and Lung Cancer. , 2008, , 219-239.		0
3840	The Seed of Selfishness. , 2008, , 9-26.		0
3841	Apoptosis in Colorectal Tumorigenesis and Chemotherapy. , 2009, , 75-109.		0
3842	Reovirus as an Oncolytic Agent. , 2005, , 249-260.		0
3843	Oncogenes and Tumor Suppressor Genes in Tumorigenesis of the Endocrine System. , 2005, , 301-309.		1
3844	Principles of Medical Management. , 2006, , 93-100.		0
3845	Transformation of Normal Astrocytes Into a Tumor Phenotype. , 2006, , 433-447.		0
3847	Signal Transduction by the Rasâ€“MAP Kinase Pathway in Prostate Cancer Progression. , 2008, , 223-256.		1
3849	Automated synthesis of 18F radiolabelled indole containing Oncrasin-like molecules; a comparison of iodonium salts and boronic ester chemistry. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 23.	1.8	0

#	Article	IF	Citations
3851	The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. Journal of Gastrointestinal Oncology, 2013, 4, 264-84.	0.6	22
3855	Solution structure of GAP SH3 domain by 1H NMR and spatial arrangement of essential Ras signaling-involved sequence. EMBO Journal, 1994, 13, 1270-9.	3.5	14
3856	Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. EMBO Journal, 1993, 12, 1923-7.	3.5	38
3857	Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO Journal, 1991, 10, 1111-8.	3.5	28
3858	The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid. EMBO Journal, 1991, 10, 2897-903.	3.5	6
3859	Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO Journal, 1992, 11, 569-74.	3.5	175
3860	Isolation of multiple mouse cDNAs with coding homology to Saccharomyces cerevisiae CDC25: identification of a region related to Bcr, Vav, Dbl and CDC24. EMBO Journal, 1992, 11, 4007-15.	3.5	37
3861	p21ras mediates control of IL-2 gene promoter function in T cell activation. EMBO Journal, 1992, 11, 4549-56.	3.5	52
3863	The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. Journal of the Royal Society of Medicine, 1995, 88, 35P-39P.	1.1	4
3865	Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix. American Journal of Pathology, 1998, 152, 1057-63.	1.9	21
3866	Single somatic ras gene point mutation in soft tissue malignant fibrous histiocytomas. American Journal of Pathology, 1996, 148, 731-8.	1.9	20
3867	Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. American Journal of Pathology, 1996, 149, 883-93.	1.9	111
3868	Activated ras. Yet another player in melanoma?. American Journal of Pathology, 1996, 149, 739-44.	1.9	44
3869	Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy. American Journal of Pathology, 1996, 149, 237-45.	1.9	54
3870	Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. American Journal of Pathology, 1996, 149, 1553-64.	1.9	136
3871	Mutations of the Ki-ras oncogene in carcinoma of the endometrium. American Journal of Pathology, 1995, 146, 182-8.	1.9	67
3872	Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes. American Journal of Pathology, 1991, 138, 349-58.	1.9	33
3873	K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. American Journal of Pathology, 1991, 139, 777-85.	1.9	144

#	Article	IF	Citations
3874	Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. American Journal of Pathology, 1993, 142, 1051-60.	1.9	66
3875	K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. American Journal of Pathology, 1993, 143, 545-54.	1.9	487
3876	Cathepsin B and other proteases in human colorectal carcinoma. American Journal of Pathology, 1994, 145, 253-62.	1.9	17
3877	Further evidence that one of the earliest alterations in colorectal carcinogenesis involves APC. American Journal of Pathology, 1994, 145, 531-4.	1.9	25
3878	Ras gene mutation-independent tumours in the intestine of the rat by a single dose of N-methyl-N-nitrosourea. International Journal of Experimental Pathology, 1992, 73, 435-47.	0.6	5
3879	Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer. Cancer Therapy, 2007, 5B, 331-344.	2.9	4
3880	The scientific challenge of Langerhans cell histiocytosis. The British Journal of Cancer Supplement, 1994, 23, S61-3.	0.1	1
3881	Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Molecular Medicine, 1995, 1, 789-94.	1.9	31
3883	Tipifarnib in the treatment of acute myeloid leukemia. Biologics: Targets and Therapy, 2007, 1, 415-24.	3.0	13
3884	CAAX-box protein, prenylation process and carcinogenesis. American Journal of Translational Research (discontinued), 2009, 1, 312-25.	0.0	55
3885	Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope. Gastrointestinal Cancer Research: GCR, 2009, 3, 208-11.	0.8	9
3887	BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis. Cancer Growth and Metastasis, 2010, 2009, 45-55.	3.5	24
3889	Tnk1/Kos1: a novel tumor suppressor. Transactions of the American Clinical and Climatological Association, 2010, 121, 281-92; discussion 292-3.	0.9	14
3891	Systemic activation of K-ras rapidly induces gastric hyperplasia and metaplasia in mice. American Journal of Cancer Research, 2011, 1, 432-445.	1.4	12
3892	New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. Acta Naturae, 2009, 1, 44-60.	1.7	3
3894	Gene mutations and molecularly targeted therapies in acute myeloid leukemia. American Journal of Blood Research, 2013, 3, 29-51.	0.6	36
3896	Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples. International Journal of Clinical and Experimental Pathology, 2014, 7, 1667-76.	0.5	4
3897	Oncogenic NRAS hyper-activates multiple pathways in human cord blood stem/progenitor cells and promotes myelomonocytic proliferation in vivo. American Journal of Translational Research (discontinued), 2015, 7, 1963-73.	0.0	4

#	Article	IF	Citations
3898	A preliminary study on ras protein expression in human esophageal cancer and precancerous lesions. World Journal of Gastroenterology, 2000, 6, 278-280.	1.4	10
3899	MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras. American Journal of Cancer Research, 2017, 7, 982-998.	1.4	21
3902	Signal transduction by Ras-like GTPases: a potential target for anticancer drugs. Gene Expression, 1995, 4, 345-56.	0.5	22
3903	Changes in levels of normal ML-1 gene transcripts associated with the conversion of human nontumorigenic to tumorigenic phenotypes. Gene Expression, 1999, 8, 129-39.	0.5	6
3904	KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. Caspian Journal of Internal Medicine, 2020, 11, 355-369.	0.1	0
3905	Lung cancer: microRNA and target database. Chinese Journal of Lung Cancer, 2012, 15, 429-34.	0.7	4
3906	Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by <scp>RAS</scp>/<scp>RAF</scp> mutations. Genes Chromosomes and Cancer, 2022, 61, 131-137.	1.5	8
3907	Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. Targeted Oncology, 2022, 17, 35-41.	1.7	3
3908	Altered Glycan Expression on Breast Cancer Cells Facilitates Infection by T3 Seroptype Oncolytic Reovirus. Nano Letters, 2021, 21, 9720-9728.	4.5	3
3909	Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer. International Journal of Molecular Sciences, 2021, 22, 12402.	1.8	8
3910	Determinants of Membrane Orientation Dynamics in Lipid-Modified Small GTPases. Jacs Au, 2022, 2, 128-135.	3.6	6
3911	Effect of the altered codon position and encoded amino acid on transformation by point mutation in ras genes. , 2002, 4, 58-67.		0
3913	Methylation-Driven Gene PLAU as a Potential Prognostic Marker for Differential Thyroid Carcinoma. Frontiers in Cell and Developmental Biology, 2022, 10, 819484.	1.8	4
3914	Equilibria between conformational states of the Ras oncogene protein revealed by high pressure crystallography. Chemical Science, 2022, 13, 2001-2010.	3.7	17
3916	Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics. Computational and Structural Biotechnology Journal, 2022, 20, 117-127.	1.9	4
3917	Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway. Molecular Psychiatry, 2022, 27, 1542-1551.	4.1	4
3918	Molecular Genetic Investigation of Digital Melanoma in Dogs. Veterinary Sciences, 2022, 9, 56.	0.6	6
3919	Defining RASopathy. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	26

#	Article	IF	Citations
3920	Rapid Multiplex Strip Test for the Detection of Circulating Tumor DNA Mutations for Liquid Biopsy Applications. Biosensors, 2022, 12, 97.	2.3	11
3921	Shifting the Focus of Signaling Abnormalities in Colon Cancer. Cancers, 2022, 14, 784.	1.7	3
3922	Characterization of the promoter of the human farnesyltransferase beta subunit and the impact of the transcription factor OCT-1 on its expression. Genomics, 2022, 114, 110314.	1.3	2
3923	Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility?. Central European Journal of Public Health, 2021, 29, 247-258.	0.4	0
3924	Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS^{G12D} Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 3123-3133.	2.9	243
3925	Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Signal Transduction and Targeted Therapy, 2021, 6, 422.	7.1	57
3926	Molecular mechanisms of metal toxicity and carcinogenesis. Molecular and Cellular Biochemistry, 2001, 222, 3-9.	1.4	48
3927	KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis. Sub-Cellular Biochemistry, 2022, 98, 189-204.	1.0	1
3928	Lovastatin Inhibits RhoA to Suppress Canonical Wnt/Î²-Catenin Signaling and Alternative Wnt-YAP/TAZ Signaling in Colon Cancer. Cell Transplantation, 2022, 31, 096368972210757.	1.2	15
3929	New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. International Journal of Molecular Sciences, 2022, 23, 3887.	1.8	16
3930	Gene Expression over Time during Cell Transformation Due to Non-Genotoxic Carcinogen Treatment of Bhas 42 Cells. International Journal of Molecular Sciences, 2022, 23, 3216.	1.8	9
3932	Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers. Targeted Oncology, 2022, 17, 177-185.	1.7	1
3933	Genetic Background of Polycythemia Vera. Genes, 2022, 13, 637.	1.0	6
3934	Diagnostic yield using wholeâ€genome sequencing and inâ€silico panel of 281 genes associated with nonâ€immune hydrops fetalis in clinical setting. Ultrasound in Obstetrics and Gynecology, 2022, 60, 487-493.	0.9	11
3935	Untangling the KRAS mutated lung cancer subsets and its therapeutic implications. Molecular Biomedicine, 2021, 2, 40.	1.7	3
3936	Association of a Novel Prognosis Model with Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Thyroid Carcinoma. Frontiers in Genetics, 2021, 12, 744304.	1.1	9
3937	Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review. Npj Precision Oncology, 2022, 6, 27.	2.3	19
3938	Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects. Blood Cancer Journal, 2022, 12, 64.	2.8	3

#	Article	IF	Citations
3939	Aloperine: A Potent Modulator of Crucial Biological Mechanisms in Multiple Diseases. Biomedicines, 2022, 10, 905.	1.4	6
3952	Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma. Oncogene, 2022, 41, 2973-2983.	2.6	9
3958	Papillary mucinous metaplasia: a distinct precursor of mucinous adenocarcinoma of the endometrium.. International Journal of Clinical and Experimental Pathology, 2022, 15, 83-87.	0.5	0
3959	Establishing the mutational effect on the binding susceptibility of AMG510 to KRAS switch II binding pocket: Computational insights. Informatics in Medicine Unlocked, 2022, 30, 100952.	1.9	9
3960	Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment. Journal of Biomolecular Structure and Dynamics, 2022, , 1-13.	2.0	4
3961	Multiple Aspects of the Phenotype of Mammary Epithelial Cells Transformed by Expression of Activated M-Ras Depend on an Autocrine Mechanism Mediated by Hepatocyte Growth Factor/Scatter Factor. Molecular Cancer Research, 2004, 2, 242-255.	1.5	15
3962	At the Crossroads of Life and Death: The Proteins That Influence Cell Fate Decisions. Cancers, 2022, 14, 2745.	1.7	5
3963	Bioorthogonal Light-Up Fluorescent Probe Enables Wash-Free Real-Time Dynamic Monitoring of Cellular Glucose Uptake. Analytical Chemistry, 2022, 94, 8293-8301.	3.2	5
3964	Multidisciplinary Management of Costello Syndrome: Current Perspectives. Journal of Multidisciplinary Healthcare, 0, Volume 15, 1277-1296.	1.1	7
3967	Perioperative anaphylaxis to fibrin sealants in children with Noonan syndrome. Annals of Allergy, Asthma and Immunology, 2022, 129, 11-12.	0.5	0
3969	A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions. Molecular and Cellular Proteomics, 2022, 21, 100268.	2.5	4
3970	Ras Inhibition in Glioblastoma Down-regulates Hypoxia-Inducible Factor-1Î±, Causing Glycolysis Shutdown and Cell Death. Cancer Research, 2005, 65, 999-1006.	0.4	142
3971	Parental Exposure to Medications and Hydrocarbons and ras Mutations in Children with Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1230-1235.	1.1	44
3972	Germinal and somatic genetic variants of NF1 in neuroblastoma: own experience and literature review. Russian Journal of Pediatric Hematology and Oncology, 2022, 9, 29-38.	0.1	0
3973	Translational Research in Lung Cancer. Medical Radiology, 2022, , .	0.0	0
3974	Molecular Genetics of Cancer. , 2022, , 871-952.		0
3975	Targeting K-Ras Mutations Show Promise Towards Ending Rasâ€™s â€œUndruggableâ€•Era. Protein and Peptide Letters, 2022, 29, 1007-1015.	0.4	0
3976	The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis. Nature Medicine, 2022, 28, 2017-2018.	15.2	14

#	Article	IF	Citations
3977	Transcription Factor Sp1 in the Expression of Genes Encoding Components of Mapk, JAK/STAT, and PI3K/Akt Signaling Pathways. Molecular Biology, 2022, 56, 756-769.	0.4	6
3978	Qualification and quantification of plasma cell-free DNA after long-term storage conditions in patients with benign prostatic hyperplasia (BPH): a pilot study. Journal of Laboratory Medicine, 2022, .	1.1	0
3981	Identification of Peptide Superagonists for a Self-K-ras-Reactive CD4+ T Cell Clone Using Combinatorial Peptide Libraries and Mass Spectrometry. Journal of Immunology, 1999, 162, 7155-7161.	0.4	10
3983	Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy. Research, 2023, 6, .	2.8	12
3984	Ras protein abundance correlates with Ras isoform mutation patterns in cancer. Oncogene, 2023, 42, 1224-1232.	2.6	12
3985	Molecular Pathology of Lung Cancer. , 0, , .		0